{"dd9db6a3d1abe70b58525fbbd7bca449217221cd": [["Deutschland hat sich als Vertragsstaat des Internationalen Paktes \u00fcber wirtschaftliche, soziale und kulturelle Rechte verpflichtet, \"das Recht eines jeden auf das f\u00fcr ihn erreichbare H\u00f6chstma\u00df an k\u00f6rperlicher und geistiger Gesundheit\" anzuerkennen und die Voraussetzungen zu schaffen, \"die f\u00fcr jedermann im Krankheitsfall den Genuss medizinischer Einrichtungen und \u00e4rztlicher Betreuung sicherstellen\" (Art. 12 Abs.", [["Deutschland hat sich als Vertragsstaat des Internationalen Paktes \u00fcber wirtschaftliche, soziale und kulturelle Rechte verpflichtet, \"das Recht eines jeden auf das f\u00fcr ihn erreichbare H\u00f6chstma\u00df an k\u00f6rperlicher und geistiger Gesundheit\" anzuerkennen und die Voraussetzungen zu schaffen, \"die f\u00fcr jedermann im Krankheitsfall den Genuss medizinischer Einrichtungen und \u00e4rztlicher Betreuung sicherstellen", "SPECIES", 0, 399]]], ["Weitere Konkretisierungen der Zug\u00e4nglichkeit in die Gesundheitsversorgung finden sich f\u00fcr diskriminierungsgef\u00e4hrdete Gruppen in Art. 25 der UN-Behindertenrechtskonvention (CRPD), in Art. 12 der UN-Frauenrechtskonvention (CEDAW) und in Art. 24 der UN-Kinderrechtskonvention (CRC).", [["CRC", "DISEASE", 274, 277], ["CRC", "CANCER", 274, 277], ["Weitere Konkretisierungen der Zug\u00e4nglichkeit", "TREATMENT", 0, 44]]], ["So ist sicherzustellen, \"dass keinem Kind das Recht auf Zugang zu derartigen Gesundheitsdiensten vorenthalten wird\" (Art. 24 Absatz 1).", [["dass keinem Kind das Recht auf Zugang zu derartigen Gesundheitsdiensten vorenthalten wird\" (Art. 24 Absatz 1", "SPECIES", 25, 133]]], ["In Deutschland ist aber bei Fl\u00fcchtlingen und ihren Familienangeh\u00f6rigen eine starke Diskrepanz zwischen dem Anspruch der universellen Menschenrechte und der (Nicht-)Gew\u00e4hrung von Krankenhilfen auf Grundlage der Asylgesetze zu konstatieren [1, 2] .", [["Deutschland ist aber bei Fl\u00fcchtlingen und ihren Familienangeh\u00f6rigen eine starke Diskrepanz zwischen dem Anspruch der universellen Menschenrechte und der (Nicht-)Gew\u00e4hrung von Krankenhilfen auf Grundlage der Asylgesetze zu konstatieren", "SPECIES", 3, 237]]], ["Bei der Gesundheitsversorgung von Asylbewerbern werden in Deutschland gro\u00dfe Versorgungsl\u00fccken in vielen Analysen \u00fcbereinstimmend beobachtet [3] [4] [5] [6] [7] [8] .", [["beobachtet [3] [4] [5] [6] [7]", "CHEMICAL", 129, 159], ["4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 145, 163], ["Bei der Gesundheitsversorgung von Asylbewerbern werden", "SPECIES", 0, 54]]], ["Der Ausschuss f\u00fcr wirtschaftliche, soziale und kulturelle Rechte der Vereinten Nationen dr\u00fcckt seine Besorgnis aus, dass \"asylum-seekers' access to health care is restricted to acute and painful conditions for the first 15 months of their stay in Germany and that their access to health care is further limited . . . \" [9] .EinleitungDie Versorgung von Fl\u00fcchtlingen ist aufgrund der f\u00f6deralen Struktur in Deutschland durch verschiedene Zust\u00e4ndigkeiten auf der Bundes-, L\u00e4nderund kommunalen Ebene gepr\u00e4gt.", [["acute and painful conditions", "PROBLEM", 177, 205], ["EinleitungDie", "PROBLEM", 324, 337]]], ["F\u00fcr die Durchf\u00fchrung des Asylverfahrens ist der Bund bzw. das Bundesamt f\u00fcr Migration und Fl\u00fcchtlinge (BAMF) zust\u00e4ndig.", [["F\u00fcr die Durchf\u00fchrung des Asylverfahrens ist der Bund bzw", "SPECIES", 0, 56]]], ["Die Verteilung der ankommenden Fl\u00fcchtlinge auf die Bundesl\u00e4nder orientiert sich an dem K\u00f6nigsteiner Schl\u00fcssel und damit nach Steueraufkommen und Bev\u00f6lkerungszahlen.", [["Die Verteilung der ankommenden Fl\u00fcchtlinge auf die Bundesl\u00e4nder orientiert sich an dem K\u00f6nigsteiner Schl\u00fcssel und damit nach Steueraufkommen und Bev\u00f6lkerungszahlen", "SPECIES", 0, 163]]], ["Die L\u00e4nder sind nach dem Asylverfahrensgesetz verpflichtet, f\u00fcr die Unterbringung von Asylsuchenden zu sorgen und die Geld-und Sachleistungen zu ihrer Existenzsicherung zu gew\u00e4hrleisten.", [["Die L\u00e4nder sind nach dem Asylverfahrensgesetz verpflichtet, f\u00fcr die Unterbringung von Asylsuchenden zu sorgen und die Geld-und Sachleistungen zu ihrer Existenzsicherung zu gew\u00e4hrleisten", "SPECIES", 0, 185]]], ["Nach der Entlassung aus der Aufnahmeeinrichtung folgt die Verteilung innerhalb des Landes in Gemeinschaftsunterk\u00fcnfte und dezentrale Unterbringungsformen.", [["Nach der Entlassung aus der Aufnahmeeinrichtung folgt", "TREATMENT", 0, 53]]], ["Asylbewerber und sonstige ausl\u00e4ndische Fl\u00fcchtlinge, die keinen dauerhaften Aufenthaltsstatus besitzen, erhalten im Falle der Hilfsbe-d\u00fcrftigkeit soziale Leistungen nach Ma\u00dfgabe des vorrangigen Asylbewerberleistungsgesetzes (AsylbLG).", [["Hilfsbe", "TEST", 125, 132]]], ["Zu den leistungsberechtigten Gruppen z\u00e4hlen auch Personen, die \u00fcber einen Flughafen einreisen wollen und denen die Einreise noch nicht gestattet ist.", [["Zu den leistungsberechtigten Gruppen z\u00e4hlen auch Personen, die \u00fcber einen Flughafen einreisen wollen und denen die Einreise noch nicht gestattet", "SPECIES", 0, 144]]], ["F\u00fcr den Arztbesuch ben\u00f6tigen die Leistungsberechtigungen meist einen Berechtigungsoder Behandlungsschein, dessen Voraussetzungen zur Ausstellung die zust\u00e4ndige Beh\u00f6rde selbst pr\u00fcft und entscheidet.", [["F\u00fcr den Arztbesuch ben\u00f6tigen die Leistungsberechtigungen meist einen Berechtigungsoder Behandlungsschein, dessen Voraussetzungen zur Ausstellung die zust\u00e4ndige Beh\u00f6rde selbst pr\u00fcft und entscheidet", "SPECIES", 0, 196]]], ["Der \u00dcbergang von einzelfallbezogenen Krankenscheinausgaben auf ein modernes Gesundheitskartensystem ist allerdings in einem Gro\u00dfteil der Bundesl\u00e4nder in Kooperation mit der gesetzlichen Krankenversicherung gelungen (Landesrahmenvereinbarungen nach \u00a7264 Abs.", [["Der \u00dcbergang von einzelfallbezogenen", "TREATMENT", 0, 36], ["auf ein modernes", "TREATMENT", 59, 75]]], ["1 Sozialgesetzbuch (SGB) V aktuell in Berlin, Brandenburg, Bremen, Hamburg, Niedersachsen, Nordrhein-Westfalen, Rheinland-Pfalz, Schleswig-Holstein und Th\u00fcringen).", [["Niedersachsen", "TREATMENT", 76, 89], ["Nordrhein", "TREATMENT", 91, 100], ["Westfalen", "TREATMENT", 101, 110], ["Rheinland", "TREATMENT", 112, 121], ["Pfalz", "TREATMENT", 122, 127], ["Schleswig", "TREATMENT", 129, 138]]], ["In der Umsetzung der gesetzlichen Vorgaben des AsylbLG werden im Verwaltungsvollzug die Ermessensspielr\u00e4ume unterschiedlich genutzt.", [["der Umsetzung der gesetzlichen Vorgaben des", "TREATMENT", 3, 46]]], ["Als verbesserungsbed\u00fcrftig wurden die Standardisierung in den Abl\u00e4ufen, z\u00fcgige Durchf\u00fchrung von Impfungen, standardisierte Erhebung und \u00dcbermittlung gesundheitsbezogener Informationen sowie Konzentration auf wichtige Infektionskrankheiten erachtet [6] .", [["Als verbesserungsbed\u00fcrftig wurden", "PROBLEM", 0, 33]]], ["Empirischen Arbeiten zur medizinischen Versorgung von Asylsuchenden kommt daher besondere Wichtigkeit zu [12] .", [["Empirischen", "TREATMENT", 0, 11]]], ["As of 31 December 2018, 423,201 persons in Germany were receiving benefits according to the AsylbLG.", [["AsylbLG", "CHEMICAL", 92, 99], ["persons", "ORGANISM", 32, 39], ["AsylbLG", "GENE_OR_GENE_PRODUCT", 92, 99], ["AsylbLG", "PROTEIN", 92, 99], ["persons", "SPECIES", 32, 39]]], ["A good third of these were women.", [["women", "ORGANISM", 27, 32], ["women", "SPECIES", 27, 32], ["good", "OBSERVATION_MODIFIER", 2, 6]]], ["More than one-third of all benefit recipients were in outpatient (33.5%) or inpatient treatment (1.3%).", [["recipients", "ORGANISM", 35, 45], ["inpatient treatment", "TREATMENT", 76, 95]]], ["Among the federal states, benefits for assistance in the case of illness as well as the health-related per capita gross expenditure varied considerably.", [["illness", "DISEASE", 65, 72], ["illness", "PROBLEM", 65, 72]]], ["The provision of illness benefits in reception facilities was relatively low.", [["illness", "DISEASE", 17, 24]]], ["With the health card, the use of inpatient treatment was higher.", [["inpatient treatment", "TREATMENT", 33, 52]]], ["The standard healthrelated provision of assistance in special cases ( \u00a72 AsylbLG analogous to SGB XII) reached a higher share of people entitled to benefits at the end of the year (42.7%) than the minimum provision according to \u00a73 AsylbLG (29.0%).", [["people", "ORGANISM", 129, 135], ["SGB XII", "PROTEIN", 94, 101], ["people", "SPECIES", 129, 135]]], ["It is recommended to apply \u00a72 AsylbLG for a prestay period of three months or longer in order to be able to grant assistance analogous to Chapters 5 to 9 SGB XII earlier.", [["AsylbLG", "CHEMICAL", 30, 37], ["XII", "GENE_OR_GENE_PRODUCT", 158, 161], ["SGB XII", "PROTEIN", 154, 161]]], ["[14] .KeywordsF\u00fcr die vorliegende Arbeit wurden an einem Gastwissenschaftsarbeitsplatz im Forschungsdatenzentrum der Statistischen \u00c4mter des Bundes und der L\u00e4nder die beiden Scientific Use Files zu den \"Empf\u00e4ngern von Asylbewerberregelleistungen\" und den \"Empf\u00e4ngern von besonderen Asylbewerberleistungen\" unter Geheimhaltungsvorschriften ausgewertet.", [["F\u00fcr die vorliegende Arbeit wurden an einem Gastwissenschaftsarbeitsplatz im Forschungsdatenzentrum der Statistischen \u00c4mter des Bundes und der L\u00e4nder die beiden Scientific Use Files zu den \"Empf\u00e4ngern von Asylbewerberregelleistungen\" und den \"Empf\u00e4ngern von besonderen Asylbewerberleistungen\" unter Geheimhaltungsvorschriften ausgewertet", "SPECIES", 14, 350], ["an einem Gastwissenschaftsarbeitsplatz im Forschungsdatenzentrum der Statistischen \u00c4mter des", "TREATMENT", 48, 140]]], ["Die \"Statistik der Ausgaben und Einnahmen f\u00fcr Asylbewerberleistungen\" steht nicht als Datensatz auf der Mikroebene, sondern in Tabellenform", [["Die \"Statistik der Ausgaben und Einnahmen f\u00fcr Asylbewerberleistungen\" steht nicht als Datensatz auf der Mikroebene", "SPECIES", 0, 114]]]], "d7f625a8d2dc886b2ec4e6af3f93518f263ffb59": [["INTRODUCTIONPendant longtemps on a pens\u00e9 que les diarrh\u00e9es infectieuses des jeunes enfants et des animaux \u00e9taient limit\u00e9es aux bact\u00e9ries et aux protozoaires avant l'arriv\u00e9e de nouvelles techniques telles que de la microscopie \u00e9lectronique et la biologie mol\u00e9culaire.", [["a pens\u00e9 que les diarrh\u00e9es", "TREATMENT", 33, 58]]], ["C'est en m\u00e9decine v\u00e9t\u00e9rinaire que l'on a d\u00e9montr\u00e9 pour la premi\u00e8re fois en 1969 qu'une diarrh\u00e9e pouvait reconna\u00eetre une origine virale, ceci par l'observation d'un virus \u00ab r\u00e9o-like \u00bb en microscopie \u00e9lectronique dans les selles d'un veau diarrh\u00e9ique [1] .", [["virale", "TEST", 128, 134], ["ceci", "TEST", 136, 140], ["virus", "TEST", 164, 169]]], ["Il s'agissait d'un rotavirus et ce n'est que quatre ann\u00e9es plus tard que l'on a d\u00e9couvert qu'il \u00e9tait aussi \u00e0 l'origine des diarrh\u00e9es s\u00e9v\u00e8res observ\u00e9es chez les jeunes enfants [2] .", [["Il s'agissait d", "TREATMENT", 0, 15], ["rotavirus et ce n'est que quatre ann\u00e9es", "TREATMENT", 19, 58], ["l'origine des", "TREATMENT", 110, 123]]], ["A la m\u00eame p\u00e9riode les norovirus, en particulier le virus Norwalk humain, ont \u00e9t\u00e9 d\u00e9couverts puis, selon les esp\u00e8ces, les coronavirus, les sapovirus, les pestivirus, les astrovirus, les ad\u00e9novirus ent\u00e9ritiques, les torovirus, les picobirnavirus...", [["A la m\u00eame p\u00e9riode les norovirus", "PROBLEM", 0, 31], ["selon les esp\u00e8ces", "PROBLEM", 98, 115], ["les coronavirus", "PROBLEM", 117, 132], ["les sapovirus", "PROBLEM", 134, 147], ["les pestivirus", "PROBLEM", 149, 163], ["les astrovirus", "PROBLEM", 165, 179], ["les ad\u00e9novirus ent\u00e9ritiques", "PROBLEM", 181, 208], ["les torovirus", "PROBLEM", 210, 223], ["les picobirnavirus", "PROBLEM", 225, 243], ["les coronavirus", "ANATOMY", 117, 132], ["les sapovirus", "ANATOMY", 134, 147], ["les pestivirus", "ANATOMY", 149, 163], ["les", "ANATOMY", 210, 213]]], ["Certains de ces virus rencontr\u00e9s chez l'animal pourraient jouer un r\u00f4le zoonotique.", [["ces virus", "ORGANISM", 12, 21]]], ["Il s'agit principalement des rotavirus, responsables de la majorit\u00e9 des diarrh\u00e9es d'origine virale rencontr\u00e9es aussi bien chez l'Homme que chez les animaux.", [["des rotavirus", "PROBLEM", 25, 38]]], ["Chez les animaux, le taux de morbidit\u00e9 des rotaviroses est important mais le taux de mortalit\u00e9 est faible.", [["Chez les animaux", "TEST", 0, 16], ["le", "ANATOMY", 18, 20]]], ["Il n'en est pas de m\u00eame pour les diarrh\u00e9es dues aux coronavirus.", [["aux coronavirus", "PROBLEM", 48, 63], ["aux coronavirus", "OBSERVATION", 48, 63]]], ["Mais on peut remarquer que, contrairement \u00e0 l'esp\u00e8ce humaine, les diarrh\u00e9es animales dues au coronavirus s'accompagnent de sympt\u00f4mes aigus s\u00e9v\u00e8res avec des taux de mortalit\u00e9 parfois importants dans de nombreuses esp\u00e8ces domestiques (ruminants, porcs, chevaux et volailles) alors que la seule zoonose connue avec cette classe de virus n'a \u00e9t\u00e9 observ\u00e9e qu'avec le syndrome respiratoire aigu s\u00e9v\u00e8re (SRAS) dont le r\u00e9servoir animal est principalement la chauve-souris.Rotaviroses des animaux domestiquesLes rotavirus du principal groupe s\u00e9rologique, le Groupe A (GARVs), sont responsables de pr\u00e8s d'un million de d\u00e9c\u00e8s chez les enfants par an.", [["coronavirus s'accompagnent", "DISEASE", 93, 119], ["rotavirus", "SPECIES", 503, 512], ["au coronavirus s'accompagnent", "PROBLEM", 90, 119], ["chevaux et volailles", "TREATMENT", 251, 271], ["que la seule zoonose", "TREATMENT", 279, 299], ["le syndrome", "PROBLEM", 359, 370], ["Rotaviroses", "TEST", 464, 475], ["rotavirus", "PROBLEM", 503, 512]]], ["Ces virus repr\u00e9sentent aussi un probl\u00e8me majeur lors d'ent\u00e9rites chez les veaux et les porcelets (au sevrage et au post-sevrage), les poulains ou les volailles.", [["Ces virus", "ORGANISM", 0, 9], ["Ces virus repr\u00e9sentent aussi un probl\u00e8me majeur lors d'ent\u00e9rites chez les veaux et les porcelets (au sevrage et au post-sevrage", "SPECIES", 0, 127], ["Ces virus", "TEST", 0, 9]]], ["Ils ont \u00e9t\u00e9 aussi identifi\u00e9s chez d'autres esp\u00e8ces animales domestiques telles que le chat, le chien ou le lapin ou non domestiques comme le singe, le rat et la souris.", [["rat", "ORGANISM", 151, 154], ["rat", "SPECIES", 151, 154]]], ["En r\u00e8gle g\u00e9n\u00e9rale, les infections \u00e0 rotavirus surviennent par \u00e9pid\u00e9mies saisonni\u00e8res (saison hivernale dans les pays temp\u00e9r\u00e9s, saison humide dans les pays tropicaux).", [["les infections", "PROBLEM", 19, 33], ["rotavirus", "PROBLEM", 36, 45], ["les", "ANATOMY_MODIFIER", 19, 22], ["infections", "OBSERVATION", 23, 33]]], ["Classiquement la diarrh\u00e9e due au rotavirus a \u00e9t\u00e9 consid\u00e9r\u00e9e comme une diarrh\u00e9e osmotique par malabsorption en raison de l'abrasion des villosit\u00e9s intestinales associ\u00e9e \u00e0 une diminution de la production de lactase mais (plus r\u00e9cemment) il a \u00e9t\u00e9 montr\u00e9 qu'une toxine pouvait aussi intervenir car il n'y avait pas toujours une corr\u00e9lation entre les l\u00e9sions intestinales et la diarrh\u00e9e La diarrh\u00e9e \u00e0 rotavirus comporte \u00e9galement une hypers\u00e9cr\u00e9tion mod\u00e9r\u00e9e du chlore dans la lumi\u00e8re intestinale.", [["malabsorption en raison", "DISEASE", 93, 116], ["lumi\u00e8re intestinale", "ORGANISM", 470, 489], ["Classiquement la diarrh\u00e9e", "PROBLEM", 0, 25], ["par malabsorption", "PROBLEM", 89, 106], ["une diminution", "PROBLEM", 170, 184], ["lactase mais (plus r\u00e9cemment)", "TREATMENT", 205, 234], ["qu'une toxine", "TREATMENT", 251, 264], ["et la diarrh\u00e9e", "PROBLEM", 367, 381], ["La diarrh\u00e9e", "PROBLEM", 382, 393], ["rotavirus", "PROBLEM", 396, 405]]], ["La glycoprot\u00e9ine non structurale NSP4 du rotavirus est la premi\u00e8re ent\u00e9rotoxine virale connue [3] , capable d'induire une diarrh\u00e9e s\u00e9cr\u00e9toire.", [["La glycoprot\u00e9ine non structurale NSP4", "TREATMENT", 0, 37], ["rotavirus est la premi\u00e8re ent\u00e9rotoxine virale connue", "TREATMENT", 41, 93]]], ["NSP4 pourrait agir en augmentant le calcium intracellulaire par l'interm\u00e9diaire du syst\u00e8me nerveux ent\u00e9rique (SNE) [4] .Rotaviroses des animaux domestiquesEn raison de l'importance de l'excr\u00e9tion virale (aussi bien chez les animaux atteints cliniquement que lors d'infection subclinique ou asymptomatique) et de la forte r\u00e9sistance des rotavirus dans le milieu ext\u00e9rieur, le risque infectieux augmente progressivement dans l'environnement des troupeaux atteints.", [["calcium", "CHEMICAL", 36, 43], ["infection subclinique", "DISEASE", 265, 286], ["aussi bien chez les animaux atteints cliniquement que lors d'infection subclinique ou asymptomatique) et de la forte r\u00e9sistance des rotavirus dans le milieu ext\u00e9rieur, le risque infectieux augmente progressivement dans l'environnement des troupeaux", "SPECIES", 204, 452], ["NSP4", "PROBLEM", 0, 4], ["agir", "TEST", 14, 18], ["en augmentant le calcium intracellulaire par l'interm\u00e9diaire du syst\u00e8me nerveux ent\u00e9rique (SNE)", "TREATMENT", 19, 114], ["Rotaviroses des", "TREATMENT", 120, 135], ["'infection", "PROBLEM", 264, 274], ["ou asymptomatique", "PROBLEM", 287, 304], ["et de la forte r\u00e9sistance des", "TREATMENT", 306, 335]]], ["L'abondance de l'excr\u00e9tion f\u00e9cale au cours d'une rotavirose peut expliquer la d\u00e9couverte pr\u00e9coce de ces virus par l'utilisation de la microscopie \u00e9lectronique et des premiers outils de la biologie mol\u00e9culaire ayant permis d'aborder l'analyse du g\u00e9nome directement \u00e0 partir du pr\u00e9l\u00e8vement sans la n\u00e9cessit\u00e9 d'une purification, d'une concentration ou d'une amplification pr\u00e9alable.Les maladies animalesRuminants C'est chez les bovins que l'on a observ\u00e9 le premier rotavirus dans un cas de diarrh\u00e9e chez le veau [1] , d\u00e9nomm\u00e9e de virus de la diarrh\u00e9e n\u00e9onatale du veau.", [["la d\u00e9couverte pr\u00e9coce de ces virus par l'utilisation de la microscopie \u00e9lectronique et des", "TREATMENT", 75, 165], ["la n\u00e9cessit\u00e9 d'une purification", "TREATMENT", 293, 324], ["d'une concentration", "TREATMENT", 326, 345], ["Les maladies", "PROBLEM", 379, 391], ["chez les", "TEST", 416, 424]]], ["Alors que 90 % des bovins ont pu \u00eatre contamin\u00e9s, on observe une diarrh\u00e9e dans 20 % des cas, surtout pendant les deux premi\u00e8res semaines de vie : le veau est surtout sensible avant l'\u00e2ge de trois semaines, avec un pic \u00e0 l'\u00e2ge de six jours [5] .", [["Alors", "TEST", 0, 5], ["ont pu \u00eatre contamin\u00e9s", "TREATMENT", 26, 48], ["le", "ANATOMY", 146, 148]]], ["Les pertes \u00e9conomiques li\u00e9es principalement au co\u00fbt des traitements et \u00e0 la perte de poids varient en fonction des facteurs associ\u00e9s \u00e0 la diarrh\u00e9e : co-infections (virus, bact\u00e9ries, protozoaires), conduite d'\u00e9levage, environnement, statut immunologique du veau.", [["co-infections", "DISEASE", 149, 162], ["au co\u00fbt des traitements", "TREATMENT", 44, 67], ["co-infections (virus", "PROBLEM", 149, 169], ["co-infections", "OBSERVATION", 149, 162]]], ["Du fait de la contagiosit\u00e9 le virus se propage chez tous les animaux et l'excr\u00e9tion virale va en croissant dans la ferme.", [["Du fait de la contagiosit\u00e9 le virus", "TEST", 0, 35]]], ["En France il existe des vaccins pour la pr\u00e9vention des diarrh\u00e9es n\u00e9onatales dues aux rotavirus chez les bovins (souvent associ\u00e9s \u00e0 un vaccin destin\u00e9 aux coronavirus).", [["En France il existe des vaccins pour la pr\u00e9vention des diarrh\u00e9es n\u00e9onatales dues aux rotavirus chez les bovins (souvent associ\u00e9s \u00e0 un vaccin destin\u00e9 aux coronavirus", "SPECIES", 0, 164], ["En France il existe des vaccins", "TREATMENT", 0, 31], ["pour la pr\u00e9vention des", "TREATMENT", 32, 54], ["n\u00e9onatales", "TEST", 65, 75]]], ["Ces vaccins sont administr\u00e9s aux vaches en fin de gestation (vaccins inactiv\u00e9s ou vivants att\u00e9nu\u00e9s) pour permettre la protection passive du veau nouveau-n\u00e9, en particulier par l'apport du colostrum.", [["colostrum", "ORGANISM_SUBSTANCE", 188, 197], ["Ces vaccins", "TREATMENT", 0, 11], ["aux vaches en fin de gestation (vaccins", "TREATMENT", 29, 68], ["ou vivants att\u00e9nu\u00e9s", "TREATMENT", 79, 98], ["du colostrum", "OBSERVATION", 185, 197]]], ["D'autres pays utilisent aussi des vaccins vivants att\u00e9nu\u00e9s administr\u00e9s aux veaux d\u00e8s la naissance.PorcinsComme chez les bovins les rotavirus sont pr\u00e9sents dans tous les \u00e9levages porcins chez des animaux diarrh\u00e9iques ou asymptomatiques et sont le plus souvent du groupe A. Depuis 1975 on sait qu'ils sont impliqu\u00e9s surtout chez les porcelets entre l'\u00e2ge de une et huit semaines, dans les ent\u00e9rites du sevrage et du post-sevrage.", [["PorcinsComme chez les bovins les rotavirus sont pr\u00e9sents dans tous les \u00e9levages porcins chez des animaux diarrh\u00e9iques ou asymptomatiques et sont le plus souvent du groupe A. Depuis 1975 on sait qu'ils sont impliqu\u00e9s surtout chez les porcelets entre l'\u00e2ge de une et huit semaines", "SPECIES", 98, 376], ["Porcins", "TREATMENT", 98, 105], ["rotavirus", "PROBLEM", 131, 140]]], ["Comme chez les veaux la maladie peut \u00eatre multifactorielle pouvant accentuer sa gravit\u00e9 \u00e9conomique, en particulier lors de surinfection par les colibacilles ent\u00e9rotoxinog\u00e8nes et/ou par les coccidies (Isospora suis) [6] .", [["Isospora suis", "DISEASE", 200, 213], ["Isospora suis", "SPECIES", 200, 213], ["colibacilles ent\u00e9rotoxinog\u00e8nes et/ou par les coccidies (Isospora suis", "SPECIES", 144, 213], ["ent\u00e9rotoxinog\u00e8nes", "TEST", 157, 174]]], ["Les infections virales peuvent \u00eatre mixtes.", [["infections", "DISEASE", 4, 14], ["Les infections", "PROBLEM", 0, 14], ["infections", "OBSERVATION", 4, 14]]], ["Ainsi, Martella et al ont montr\u00e9 que, dans douze \u00e9levages porcins atteints de diarrh\u00e9e o\u00f9 70.8 % des porcs \u00e2g\u00e9s de un \u00e0 trois mois \u00e9taient positifs pour le rotavirus, 50,7 % des animaux positifs sont aussi positifs pour les calicivirus et les rotavirus du groupe C mais il reste \u00e0 d\u00e9montrer le r\u00f4le pathog\u00e8ne de ces derniers [7] .", [["pour le rotavirus", "PROBLEM", 148, 165], ["pour les calicivirus", "PROBLEM", 215, 235]]], ["Il n'existe pas de vaccin en France pour lutter contre la rotavirose porcine.ChevauxLes rotavirus sont le plus souvent en cause dans les diarrh\u00e9es du poulain \u00e2g\u00e9 de moins de deux mois (surtout entre l'\u00e2ge de 5 \u00e0 35 jours) mais il existe peu de donn\u00e9es sur les s\u00e9rotypes en cause.", [["ChevauxLes rotavirus", "ORGANISM", 77, 97], ["rotavirus", "SPECIES", 88, 97], ["ChevauxLes rotavirus sont le plus souvent en cause dans les diarrh\u00e9es du poulain \u00e2g\u00e9 de moins de deux mois (surtout entre l'\u00e2ge", "SPECIES", 77, 204], ["vaccin en France pour lutter contre la rotavirose porcine", "TREATMENT", 19, 76], ["ChevauxLes rotavirus", "TREATMENT", 77, 97]]], ["Comme chez les bovins et les porcins, la pr\u00e9sence d'anticorps s\u00e9riques chez la plupart des chevaux adultes montre que la rotavirose \u00e9quine peut \u00eatre ubiquitaire.LapinsParmi les virus isol\u00e9s chez le lapin, les rotavirus semblent les plus fr\u00e9quents.", [["lapin", "ORGANISM", 198, 203], ["rotavirus", "ORGANISM", 209, 218], ["virus isol\u00e9s", "SPECIES", 177, 189], ["LapinsParmi les virus", "TEST", 161, 182], ["les", "ANATOMY_MODIFIER", 205, 208]]], ["Chez le lapereau \u00e2g\u00e9 de une \u00e0 trois semaines, les rotaviroses provoquent une morbidit\u00e9 et une mortalit\u00e9 \u00e9lev\u00e9es.OiseauxDepuis 1977, les rotavirus sont rencontr\u00e9s chez des nombreux oiseaux domestiques, causant une diarrh\u00e9e b\u00e9nigne \u00e0 s\u00e9v\u00e8re, une d\u00e9shydratation, un amaigrissement et une augmentation du taux de mortalit\u00e9.", [["Chez le lapereau", "TEST", 0, 16], ["une d\u00e9shydratation", "PROBLEM", 240, 258]]], ["Il s'agit surtout de virus diff\u00e9rents des virus des mammif\u00e8res.Chiens et chatContrairement aux esp\u00e8ces animales domestiques de rente, les rotaviroses des chiens et des chats ne repr\u00e9sentent pas un probl\u00e8me de sant\u00e9 majeur.Rotavirus et risque zoonotiqueLes rotavirus sont g\u00e9n\u00e9ralement sp\u00e9cifiques de l'esp\u00e8ce h\u00f4te.", [["rotavirus", "SPECIES", 256, 265], ["Il s'agit surtout", "TREATMENT", 0, 17], ["Rotavirus et risque zoonotiqueLes rotavirus", "TREATMENT", 222, 265]]], ["Leur g\u00e9nome est compos\u00e9 de onze segments \u00e0 double brin d'ARN.", [["ARN", "DISEASE", 57, 60]]], ["Ce g\u00e9nome code pour six prot\u00e9ines structurales (VP) et, selon la souche virale, cinq ou six prot\u00e9ines non structurales (NSP).", [["Ce", "CHEMICAL", 0, 2], ["Ce", "TEST", 0, 2]]], ["A et C ont \u00e9t\u00e9 identifi\u00e9s \u00e0 la fois chez l'Homme et diverses esp\u00e8ces animales domestiques et de ce fait suspects d'\u00eatre \u00e0 risque zoonotique, le groupe E n'ayant \u00e9t\u00e9 observ\u00e9 que chez le porc alors que les groupes D, F et G n'ont \u00e9t\u00e9 identifi\u00e9s que chez les oiseaux.", [["A et C ont \u00e9t\u00e9", "TREATMENT", 0, 14]]], ["Les prot\u00e9ines structurales de la capside interne VP7 et de la capside externe VP4 correspondent aux antig\u00e8nes G (Glycoprot\u00e9ine) et P (sensible aux prot\u00e9ases) respectivement induisant la production d'anticorps neutralisants.", [["Les prot\u00e9ines structurales", "PROBLEM", 0, 26], ["VP4 correspondent aux antig\u00e8nes G (Glycoprot\u00e9ine)", "TREATMENT", 78, 127], ["sensible aux prot\u00e9ases)", "TREATMENT", 134, 157]]], ["Ainsi, ces antig\u00e8nes ont permis de d\u00e9finir les types G et P des souches virales et ainsi de mieux conna\u00eetre d'une part les souches pr\u00e9dominantes dans les diarrh\u00e9es humaines et d'autre part de les comparer aux souches isol\u00e9es chez les animaux en vue d'identifier un \u00e9ventuel risque zoonotique.", [["Ainsi", "TEST", 0, 5], ["et P des", "TREATMENT", 55, 63], ["et ainsi", "PROBLEM", 80, 88]]], ["Depuis le nouveau syst\u00e8me de classification des virus d\u00e9fini par Matthunssens et al [8, 9] , on comprend mieux les interactions complexes entre les rotavirus humains et animaux.", [["Depuis le nouveau syst\u00e8me", "PROBLEM", 0, 25]]], ["Actuellement il y a au moins 23 g\u00e9notypes G (VP7) et 32 g\u00e9notypes P (VP4) identifi\u00e9s [9] .", [["Actuellement", "TEST", 0, 12], ["a au moins", "TEST", 18, 28], ["g\u00e9notypes", "TEST", 32, 41], ["G", "TEST", 42, 43], ["VP7", "TEST", 45, 48], ["et", "TEST", 50, 52]]], ["Dans le groupe A les s\u00e9rotypes G1, G2, G3 et G4 repr\u00e9sentent \u00e0 eux seuls 95 % des souches isol\u00e9es chez l'Homme, avec une pr\u00e9dominance du type G1P[8] [10] .Rotavirus et risque zoonotiqueOn a identifi\u00e9 trois groupes g\u00e9niques chez les rotavirus humains du groupe A : Wa-like, DS-1-like et AU-1-like [11] .", [["rotavirus", "ORGANISM", 232, 241], ["eux", "TEST", 63, 66], ["seuls", "TEST", 67, 72], ["Rotavirus et risque zoonotiqueOn", "TREATMENT", 155, 187], ["DS", "TEST", 273, 275], ["et AU", "TEST", 283, 288]]], ["La nouvelle classification a permis de montrer l'\u00e9volution d'une \u00e9troite parent\u00e9 d'une part entre la souche humaine Wa-like et les souches de rotavirus porcins et d'autre part entre la souche humaine DS-1-like et les souches de rotavirus bovins, sugg\u00e9rant ainsi que les rotavirus humains majeurs G et P pourraient reconna\u00eetre une origine animale [8] .", [["rotavirus bovins", "DISEASE", 228, 244], ["DS", "TEST", 200, 202], ["et les souches", "PROBLEM", 210, 224], ["rotavirus bovins", "TREATMENT", 228, 244], ["rotavirus humains", "TREATMENT", 270, 287]]], ["Une troisi\u00e8me famille de rotavirus, AU-1-like, est compos\u00e9e de nombreux segments retrouv\u00e9s dans les rotavirus circulant chez les animaux (tableau 3).", [["rotavirus", "PROBLEM", 25, 34], ["AU", "TEST", 36, 38]]], ["La fr\u00e9quente co-existence d'infections mixtes (par deux souches diff\u00e9rentes de rotavirus), surtout not\u00e9e lors d'un pic \u00e9pid\u00e9mique, sera \u00e0 l'origine d'\u00e9changes de g\u00e8nes entre les virus (r\u00e9assortiments) qui expliquent la diversit\u00e9 des souches, en particulier dans certains pays en voie de d\u00e9veloppement.", [["infections mixtes", "DISEASE", 28, 45], ["'infections mixtes", "PROBLEM", 27, 45]]], ["Enfin, l'\u00e9mergence de s\u00e9rotypes P et G inhabituels chez l'Homme t\u00e9moigne des nombreuses variations possibles li\u00e9es \u00e0 des r\u00e9assortiments entre des rotavirus de groupes diff\u00e9rents ou entre des rotavirus de m\u00eame groupe et de m\u00eame s\u00e9rotype.Rotavirus et risque zoonotiqueDans le groupe A comparant les souches de rotavirus rencontr\u00e9es chez l'Homme et les animaux domestiques, le s\u00e9rotype G3 est pr\u00e9dominant (ce s\u00e9rotype est aussi fr\u00e9quent chez le singe, animal non domestique) [12] .", [["Rotavirus et risque zoonotiqueDans le groupe A comparant les souches de rotavirus rencontr\u00e9es chez l'Homme et les animaux domestiques, le s\u00e9rotype G3 est pr\u00e9dominant (ce s\u00e9rotype est aussi fr\u00e9quent chez le singe", "SPECIES", 236, 447], ["Enfin", "TREATMENT", 0, 5], ["l'\u00e9mergence de s\u00e9rotypes", "TREATMENT", 7, 31], ["et G inhabituels chez", "TREATMENT", 34, 55], ["Homme t\u00e9moigne des", "TREATMENT", 58, 76], ["Rotavirus et risque zoonotiqueDans", "TREATMENT", 236, 270], ["domestiques", "TEST", 358, 369], ["le s\u00e9rotype", "TEST", 371, 382], ["ce s\u00e9rotype est", "TEST", 403, 418]]], ["Au sein du s\u00e9rotype G3, on a pu noter diff\u00e9rents types de r\u00e9assortiments t\u00e9moignant des multiples possibilit\u00e9s de transmission de g\u00e8nes d'origine animale (tableau 3).", [["Au", "CHEMICAL", 0, 2]]], ["Le rotavirus est en constante \u00e9volution, soit par mutation ponctuelle ou \u00e0 la suite d'un r\u00e9assortiment g\u00e9n\u00e9tique et de nombreuses souches inhabituelles humaines et/ou animales ont \u00e9merg\u00e9 dans de nombreux pays [13] et la liste des souches humaines de rotavirus pouvant reconna\u00eetre un segment g\u00e9nomique d'origine animale est loin d'\u00eatre compl\u00e8te.", [["rotavirus", "SPECIES", 3, 12], ["Le rotavirus est", "PROBLEM", 0, 16], ["et la liste des souches humaines", "TREATMENT", 214, 246]]], ["Ainsi de Grazia et al [14] ont d\u00e9couvert r\u00e9cemment en Italie chez des enfants atteints de diarrh\u00e9e deux nouvelles souches humaines G3P [9] reconnaissant un assortiment entre des g\u00e8nes f\u00e9lins, bovins et humains.", [["ont d\u00e9couvert r\u00e9cemment en Italie chez des", "TREATMENT", 27, 69]]], ["Cependant, on ne sait pas si un nouveau rotavirus transmis de l'animal \u00e0 l'Homme sera un \u00ab cul de sac \u00e9pid\u00e9miologique \u00bb ou un virus \u00e9mergent capable de se transmettre secondairement au sein de l'esp\u00e8ce humaine pour provoquer une nouvelle \u00e9pid\u00e9mie.Rotavirus et risque zoonotiqueDe nombreux exemples ont permis de montrer la transmission inter-esp\u00e8ce des rotavirus ou de sugg\u00e9rer la possibilit\u00e9 une origine zoonotique des rotavirus humains, principalement dans le groupe A selon les donn\u00e9es de la litt\u00e9rature, mais \u00e9galement le groupe C pour les souches porcines.", [["rotavirus humains", "DISEASE", 420, 437], ["sera", "ORGANISM_SUBSTANCE", 81, 85], ["rotavirus", "SPECIES", 40, 49], ["Rotavirus et risque zoonotiqueDe", "TREATMENT", 247, 279], ["ont permis de montrer la transmission", "TREATMENT", 298, 335]]], ["De nombreuses esp\u00e8ces domestiques sont concern\u00e9es, animaux de rente comme animaux de compagnie) (tableau 3) :Rotavirus et risque zoonotiquePorcins -D\u00e8s 1996, on a montr\u00e9 exp\u00e9rimentalement que la souche Wa du rotavirus humain G1P [8] \u00e9tait pathog\u00e8ne chez le porc gnotobiotique [15] .", [["Wa du rotavirus humain", "SPECIES", 202, 224], ["Rotavirus et risque zoonotiquePorcins", "TREATMENT", 109, 146], ["du rotavirus humain G1P", "TREATMENT", 205, 228], ["\u00e9tait pathog\u00e8ne chez le porc gnotobiotique", "TREATMENT", 233, 275]]], ["De plus, seules les souches humaines pathog\u00e8nes provoquent une diarrh\u00e9e chez le porc alors que ce n'est pas le cas pour les souches humaines att\u00e9nu\u00e9es [16] , ce qui permet d'utiliser le mod\u00e8le porcin dans les \u00e9preuves destin\u00e9es \u00e0 v\u00e9rifier l'efficacit\u00e9 des vaccins contre les rotavirus humains. -En Europe, les souches humaines de rotavirus ressemblant aux souches porcines du groupe P [6] VP4 ont \u00e9t\u00e9 souvent identifi\u00e9es et d'autres s\u00e9rotypes d'origine porcine ont \u00e9t\u00e9 not\u00e9es dans des diarrh\u00e9es infantiles observ\u00e9es dans des pays non europ\u00e9ens (Br\u00e9sil, Argentine, Paraguay, Inde, Tha\u00eflande) [12] . -On a montr\u00e9 la pr\u00e9sence d'un rotavirus porcin du groupe C chez un enfant br\u00e9silien atteint de diarrh\u00e9e [17] .", [["rotavirus", "SPECIES", 628, 637], ["ce qui permet", "TREATMENT", 158, 171], ["le mod\u00e8le porcin dans les", "TREATMENT", 183, 208], ["v\u00e9rifier l'efficacit\u00e9 des", "TREATMENT", 230, 255], ["VP4 ont \u00e9t\u00e9 souvent", "TREATMENT", 389, 408], ["et d'autres s\u00e9rotypes", "TREATMENT", 421, 442], ["porcine ont \u00e9t\u00e9 not\u00e9es dans des", "TREATMENT", 453, 484], ["a montr\u00e9 la pr\u00e9sence d'un rotavirus porcin", "TREATMENT", 602, 644]]], ["On peut d'ailleurs noter le contraste frappant entre la faible diversit\u00e9 g\u00e9n\u00e9tique des souches humaines isol\u00e9es dans le groupe C (responsable des cas de diarrh\u00e9e avec hospitalisation chez moins de 5 % des enfants) et la grande variabilit\u00e9 des souches porcines de ce groupe.Bovins-Certaines souches de rotavirus bovins ont pu pr\u00e9senter un risque zoonotique par transmission directe sans r\u00e9assortiment g\u00e9n\u00e9tique \u00e0 des jeunes enfants pr\u00e9sentant une diarrh\u00e9e telle que la souche G 10 [P11] en Inde [17] ou la souche G8P [1] au Nicaragua en 1969 [18] .Bovins-La souche de rotavirus G6P [6] B1711 peut \u00eatre le r\u00e9sultat d'un r\u00e9assortiment entre la souche humaine du rotavirus DS-1-like et des rotavirus bovins [19] . -Les souches humaines P [14] peuvent \u00eatre le r\u00e9sultat de multiples transmissions interesp\u00e8ces avec certains r\u00e9assortiments du mouton et d'autres ruminants vers l'Homme [20] .Lapins-D\u00e8s 1997, Ciarlet et al [21] ont montr\u00e9 les parent\u00e9s existant entre quatre souches de rotavirus comportant le s\u00e9rotype P [14] chez le lapin et des souches humines isol\u00e9es en Italie, en Finlande ou en Tha\u00eflande. -La souche humaine B4106 du groupe G3P [14] , d\u00e9tect\u00e9e dans une diarrh\u00e9e infantile, est tr\u00e8s proche de la souche lapine 30/96. -Bien que les souches G3P [14] aient \u00e9t\u00e9 souvent isol\u00e9es chez les lapins, et plus sporadiquement chez les humains, il a \u00e9t\u00e9 montr\u00e9 ult\u00e9rieurement que les prot\u00e9ines VP4 des souches humaines P [14] \u00e9taient plus apparent\u00e9es aux souches isol\u00e9es chez les esp\u00e8ces d'ongul\u00e9s de l'ordre des artiodactyles que chez les lapins, sugg\u00e9rant que le principal r\u00e9servoir de ces souches de rotaviroses humaines dans le monde pouvaient \u00eatre des ruminants, en particulier le mouton [22] .Chien et chat-Les infections sont souvent subcliniques mais on a pu montrer exp\u00e9rimentalement la sensibilit\u00e9 du chien d\u00e8s 1978 au rotavirus humain [23] . -Plusieurs cas ont indiqu\u00e9 la possibilit\u00e9 d'une contamination de l'Homme par des animaux de compagnie porteur de rotavirus G3, soit avec une souche f\u00e9line isol\u00e9e d'un enfant et de son chat de compagnie [24] ou chez un b\u00e9b\u00e9 \u00e2g\u00e9 de 3 semaines infect\u00e9 par le chiot de la maison [25] . -Puis, en 1982, Engleberg et al [26] ont montr\u00e9 que les cas de diarrh\u00e9e infantile \u00e0 rotavirus dans une r\u00e9serve indienne am\u00e9ricaine pouvaient \u00eatre associ\u00e9s \u00e0 la possession d'un chien de fa\u00e7on significative (P = 0,05). -Les souches humaines Ro1845 et HCR3A du groupe G3P [3] sont \u00e9troitement apparent\u00e9es aux souches canines CU-1, K9 et A79-10 ainsi qu'\u00e0 la souche f\u00e9line Cat97 dans tous les segments du g\u00e9nome [27] .Modes de transmission de l'animal \u00e0 l'HommeLes ruminants et les porcins ont souvent \u00e9t\u00e9 mis en cause dans l'\u00e9tiologie des rotaviroses humaines.", [["infantile", "DISEASE", 1175, 1184], ["infections", "DISEASE", 1716, 1726], ["rotavirus", "ORGANISM", 301, 310], ["rotavirus", "ORGANISM", 567, 576], ["rotavirus", "ORGANISM", 686, 695], ["rotavirus", "SPECIES", 301, 310], ["sensibilit\u00e9 du chien d\u00e8s 1978 au rotavirus humain", "SPECIES", 1795, 1844], ["-Les souches humaines Ro1845 et HCR3A du groupe G3P", "SPECIES", 2351, 2402], ["Bovins", "TEST", 273, 279], ["G", "TEST", 475, 476], ["Bovins", "TEST", 547, 553], ["B1711", "TEST", 585, 590], ["peut", "TEST", 591, 595], ["\u00eatre", "TEST", 596, 600], ["entre la", "TEST", 632, 640], ["humaine", "TEST", 648, 655], ["du rotavirus DS", "TEST", 656, 671], ["et des rotavirus bovins", "PROBLEM", 679, 702], ["peuvent \u00eatre le r\u00e9sultat", "TREATMENT", 739, 763], ["Lapins", "TEST", 884, 890], ["Ciarlet et al", "TREATMENT", 901, 914], ["ont montr\u00e9 les", "TREATMENT", 920, 934], ["entre quatre souches", "TREATMENT", 953, 973], ["rotavirus comportant le s\u00e9rotype P", "TREATMENT", 977, 1011], ["chez le lapin et des", "TREATMENT", 1017, 1037], ["aient", "TEST", 1260, 1265], ["chez les lapins", "TREATMENT", 1286, 1301], ["et plus sporadiquement chez les humains", "TREATMENT", 1303, 1342], ["VP4 des", "TREATMENT", 1393, 1400], ["\u00e9taient", "TREATMENT", 1425, 1432], ["chez les", "PROBLEM", 1470, 1478], ["d'ongul\u00e9s de l'ordre des", "TREATMENT", 1487, 1511], ["Les infections", "PROBLEM", 1712, 1726], ["Plusieurs cas", "PROBLEM", 1853, 1866], ["ou chez un b\u00e9b\u00e9", "TREATMENT", 2059, 2074], ["\u00e9troitement", "TEST", 2412, 2423], ["CU", "TEST", 2456, 2458], ["K9 et A79", "TEST", 2462, 2471], ["ainsi", "TEST", 2475, 2480], ["la souche", "TEST", 2486, 2495]]], ["Ainsi, une estimation du risque d'exposition d'un fermier au rotavirus bovin a \u00e9t\u00e9 r\u00e9alis\u00e9e au Royaume-Uni en comptant le nombre de fermes laiti\u00e8res (18 000) ayant en moyenne quatre-vingts vaches par troupeau et le nombre de jours de contact veau-Homme par an (6 570 000) [29] .", [["rotavirus", "SPECIES", 61, 70]]], ["Un veau excr\u00e9tant 1x10 6 particules virales par millilitre de f\u00e8ces, les auteurs ont estim\u00e9 qu'un fermier peut ing\u00e9rer 1 \u03bcl de f\u00e8ces par jour soit 1x10 3 virus s'il est en contact avec un veau excr\u00e9teur.", [["les", "ANATOMY_MODIFIER", 69, 72]]], ["Une \u00e9tude effectu\u00e9e chez des volontaires [30] ayant d\u00e9termin\u00e9 que 1 000 particules virales suffisent pour infecter 85 % des personnes contamin\u00e9es par la voie orale, Cook et al [29] concluent au risque non n\u00e9gligeable d'une contamination des fermiers anglais par les rotavirus.", [["Une \u00e9tude effectu\u00e9e chez des volontaires", "PROBLEM", 0, 40], ["virales", "TEST", 83, 90], ["pour infecter", "TEST", 101, 114]]], ["Celles-ci peuvent \u00eatre asymptomatiques mais une propagation de ces virus est possible secondairement au sein de leur famille.", [["Celles", "TEST", 0, 6], ["mais une propagation", "PROBLEM", 39, 59]]], ["Ce type de contamination directe \u00e0 l'\u00e9table est aussi possible dans d'autres circonstances, en particulier avec l'acc\u00e8s des enfants aux fermes p\u00e9dagogiques en saison de v\u00ealage.", [["Ce", "CHEMICAL", 0, 2]]], ["Ce risque f\u00e9cal est surtout connu avec les colibacilles ent\u00e9rotoxinog\u00e8nes et les cryptosporidies et a justifi\u00e9 de nombreuses recommandations pour limiter un tel risque chez les enfants [31] .", [["Ce", "CHEMICAL", 0, 2], ["Ce risque", "TEST", 0, 9], ["f\u00e9cal est", "TEST", 10, 19], ["connu", "TEST", 28, 33], ["et les cryptosporidies", "PROBLEM", 74, 96]]], ["D'autres modes de contamination de l'Homme sont possibles avec les rotavirus animaux :Modes de transmission de l'animal \u00e0 l'Homme-contamination de l'environnement par les lisiers du b\u00e9tail ; -contamination f\u00e9cale de l'eau voire de l'eau de boisson comme l'ont observ\u00e9 Gratacap-Cavaillier et al [32] en Is\u00e8re en identifiant des rotavirus d'origine porcine et bovine dans l'eau de boisson de cinquante-six enfants atteints de gastroent\u00e9rite \u00e0 rotavirus ; -contamination des v\u00e9g\u00e9taux consomm\u00e9s crus o\u00f9 les virus peuvent survivre jusqu'\u00e0 trente jours \u00e0 + 4\u00b0C [33] ; -la contamination par a\u00e9rosols est \u00e9galement sugg\u00e9r\u00e9e pour les rotavirus, surtout dans les \u00e9levages porcins [29] . -enfin, les chiens et les chats peuvent aussi \u00eatre \u00e0 l'origine d'une exposition f\u00e9cale de l'Homme aux rotavirus.Autres virus animaux responsables de gastroent\u00e9rites et risque zoonotiqueQuelques souches animales de norovirus, de sapovirus, de picobirnavirus ou d'astrovirus peuvent pr\u00e9senter des similitudes g\u00e9n\u00e9tiques avec des souches humaines mais le risque de zoonose n'a jamais \u00e9t\u00e9 d\u00e9montr\u00e9.", [["bovine", "SPECIES", 358, 364], ["Gratacap", "TEST", 268, 276], ["Cavaillier et al [32] en Is\u00e8re en identifiant des rotavirus d'origine porcine et bovine dans", "TREATMENT", 277, 369], ["rotavirus", "PROBLEM", 441, 450], ["contamination des", "TREATMENT", 454, 471], ["crus o\u00f9 les virus", "TEST", 491, 508], ["peuvent", "TEST", 509, 516], ["jusqu", "TEST", 526, 531], ["la contamination par a\u00e9rosols", "TEST", 563, 592], ["est \u00e9galement", "TEST", 593, 606], ["pour les rotavirus", "PROBLEM", 616, 634], ["enfin", "TREATMENT", 678, 683], ["Autres virus animaux", "TREATMENT", 789, 809], ["animales de norovirus", "PROBLEM", 879, 900], ["sapovirus", "PROBLEM", 905, 914]]], ["Enfin, la d\u00e9tection relativement r\u00e9cente de s\u00e9quences apparent\u00e9es aux g\u00e9nogroupe II.4 humain dans les f\u00e8ces et la viande de porcs et de bovins au Canada pourrait modifier cette \u00e9valuation du risque zoonotique [40] .CONCLUSIONL'\u00e9tude des rotavirus a b\u00e9n\u00e9fici\u00e9 des outils de la biologie mol\u00e9culaire tr\u00e8s pr\u00e9cocement du fait de l'importance de l'excr\u00e9tion virale dans les f\u00e8ces et de la facilit\u00e9 de l'analyse directe du double brin d'ARN de son g\u00e9nome, insensible aux RNases.", [["humain dans les", "TREATMENT", 86, 101], ["et la viande de porcs et de bovins au Canada pourrait modifier cette", "TREATMENT", 108, 176], ["du risque zoonotique", "TREATMENT", 188, 208], ["'\u00e9tude des", "TREATMENT", 226, 236], ["a b\u00e9n\u00e9fici\u00e9 des", "TREATMENT", 247, 262], ["insensible aux RNases", "PROBLEM", 450, 471]]], ["Si le lien entre les rotavirus des animaux domestiques semble bien \u00e9tabli, il reste \u00e0 d\u00e9terminer les facteurs de virulence en cause dans les s\u00e9quences sp\u00e9cifiques de ces virus pour une meilleure pr\u00e9vention de ces maladies.", [["dans les s\u00e9quences", "PROBLEM", 132, 150]]], ["L'\u00e9volution permanente des rotavirus, notamment par r\u00e9assortiment et/ou par l'\u00e9mergence de nouveaux s\u00e9rotypes G, sera \u00e0 l'origine de nouvelles mosa\u00efques virales justifiant l'importance d'une \u00e9pid\u00e9miosurveillance constante en m\u00e9decine humaine et v\u00e9t\u00e9rinaire de ce p\u00e9ril f\u00e9cal pr\u00e9sent dans notre environnement (lisier, air, sol et eau).", [["L'\u00e9volution permanente des rotavirus, notamment par r\u00e9assortiment et/ou par l'\u00e9mergence", "SPECIES", 0, 87], ["L'\u00e9volution permanente des rotavirus", "TREATMENT", 0, 36], ["sera", "TEST", 113, 117]]], ["Le ph\u00e9nom\u00e8ne de r\u00e9assortiment est la cause principale des \u00e9checs \u00e0 la vaccination que nous connaissons en m\u00e9decine v\u00e9t\u00e9rinaire mais permet aussi l'emploi de souches animales att\u00e9nu\u00e9es pour la vaccination en m\u00e9decine humaine.CONCLUSIONEnfin, il reste \u00e0 d\u00e9montrer le r\u00f4le zoonotique des autres virus rencontr\u00e9s dans les gastroent\u00e9rites des animaux domestiques.", [["CONCLUSIONEnfin", "TEST", 224, 239], ["le r\u00f4le zoonotique des", "TREATMENT", 262, 284]]]], "PMC7505606": [["High skill labour is especially important to cities that are home to a large portion of the world\u2019s population.1According to Bettencourt et al. (2007) and Schlapfer et al. (2014) global cities have higher rates of innovation in terms of patents and scientific production and, more recently, Belderbos et al. (2020) have found that half of all inventions have their origin in global cities.", [["skill labour", "OBSERVATION", 5, 17], ["higher", "OBSERVATION_MODIFIER", 198, 204], ["patents", "OBSERVATION", 237, 244]]], ["High rates of mobility are not a new phenomenon (Cardwell, 1972, Mokyr, 2016, Serafinelli, Tabellini, 2017), but its size has increased in a globalized market for advanced human capital (Culotta, 2017, Geuna, 2015, OECD, 2017).IntroductionThe confluence of these two trends: the superior innovation performance of global cities and sustained mobility of scientists begs the questions if and to what extent the latter boosts the former.", [["human", "ORGANISM", 172, 177], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["High rates of mobility", "PROBLEM", 0, 22], ["mobility", "OBSERVATION_MODIFIER", 14, 22], ["new", "OBSERVATION_MODIFIER", 33, 36], ["size", "OBSERVATION_MODIFIER", 117, 121], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["confluence", "OBSERVATION_MODIFIER", 243, 253], ["superior", "OBSERVATION_MODIFIER", 279, 287], ["global", "OBSERVATION_MODIFIER", 314, 320]]], ["Many factors might reasonably enhance knowledge production in large urban areas ranging from localized knowledge spillovers (Boschma, 2005, Cantwell, Piscitello, 2005, Feldman, 1999, Jaffe, Trajtenberg, Henderson, 1993) to network effects (Agrawal, Cockburn, McHale, 2006, Almeida, Kogut, 1999, Alnuaimi, Opsahl, George, 2012, Breschi, Lenzi, 2016, Breschi, Lissoni, 2009).", [["large", "OBSERVATION_MODIFIER", 62, 67]]], ["The main challenge is to trace individual movements of scientists in space and time on a global scale.", [["a global scale", "TEST", 87, 101], ["main", "OBSERVATION_MODIFIER", 4, 8], ["trace", "OBSERVATION_MODIFIER", 25, 30], ["individual", "OBSERVATION_MODIFIER", 31, 41], ["movements", "OBSERVATION_MODIFIER", 42, 51]]], ["We observe an increase in the mobility of scientists over the past decade on a global scale, with significant differences across scientific fields (e.g., physicists are more mobile than physicians), countries (see also Verginer and Riccaboni (2020) on this) and career phases (similarly to Azoulay et al. (2017)).", [["a global scale", "TREATMENT", 77, 91], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["mobility", "OBSERVATION_MODIFIER", 30, 38], ["significant", "OBSERVATION_MODIFIER", 98, 109]]], ["Then in Section 3 we describe the dataset we use as well as the methodology we developed to trace the mobility of scientists based on bibliometric data.", [["bibliometric data", "TEST", 134, 151]]], ["Section 4 illustrates the results of the empirical analysis, and finally in Section 5 we discuss our contribution to the literature and the policy implications of our findings.Theoretical background and research hypothesesCities are central to national economic activity and are part of a global network of interconnected urban areas.", [["the empirical analysis", "TEST", 37, 59], ["Theoretical background and research hypotheses", "PROBLEM", 176, 222], ["central", "OBSERVATION_MODIFIER", 233, 240]]], ["The celebrated works by Jacobs, 1969, Jacobs, 1984 illustrate how cities function as cauldrons of culture, creativity and economic activity (Sassen, 2016, Taylor, Derudder, 2015).", [["culture", "TEST", 98, 105]]], ["Cities collaborate and compete in various fields for resources and human capital (Belderbos et al., 2020).", [["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72]]], ["The widely cited work by Bathelt et al. (2004) outlines that local activities are essential for innovation (\u201clocal buzz\u201d) but are moderated by global interactions (\u201cglobal pipelines\u201d, i.e., long-distance connections).", [["widely", "OBSERVATION_MODIFIER", 4, 10]]], ["The observation that cities are hubs of scientific production embedded in a global network, or ecosystem, of cities, is the central theme of this work.Theoretical background and research hypotheses", [["Theoretical background and research hypotheses", "PROBLEM", 151, 197]]]], "d28578e7c6a4ce66dae59039adf07b4d16eaac90": [["Persistent symptoms are those lasting longer than 10-14 days but less than 30 days [ 8 ] .", [["Persistent symptoms", "PROBLEM", 0, 19], ["symptoms", "OBSERVATION", 11, 19]]], ["Severe symptoms include a temperature of at least 39 \u00b0C and purulent nasal discharge which present concurrently for at least 3-4 consecutive days in an ill-appearing child [ 8 ] .", [["nasal", "ANATOMY", 69, 74], ["nasal", "ORGANISM_SUBDIVISION", 69, 74], ["Severe symptoms", "PROBLEM", 0, 15], ["a temperature", "TEST", 24, 37], ["purulent nasal discharge", "PROBLEM", 60, 84], ["purulent", "OBSERVATION_MODIFIER", 60, 68], ["nasal", "ANATOMY", 69, 74]]]], "78d13d43caf690a21819ee86f556afd863c42984": [["Our study was conducted from January 10th to February 8th, 2020 when China was in severe outbreak.", [["Our study", "TEST", 0, 9], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["outbreak", "OBSERVATION", 89, 97]]], ["At that time, either doctors or scientists knew little about COVID-19, testing capacity was limited and false-negative results existed.", [["COVID", "TEST", 61, 66], ["testing capacity", "TEST", 71, 87], ["false", "TEST", 104, 109]]], ["That is why we mentioned \"we suggested CT and epidemiological history as the primary clues and clinical symptoms and routine laboratory tests as the secondary clues for the early clinical diagnosis of suspicious patients to implement isolation and then wait for the nucleic acid results\" [1] .", [["nucleic acid", "CHEMICAL", 266, 278], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["CT", "TEST", 39, 41], ["clinical symptoms", "PROBLEM", 95, 112], ["routine laboratory tests", "TEST", 117, 141], ["the nucleic acid results", "TEST", 262, 286]]], ["A basic premise was that CT results could be known within 1 h; however, RT-PCR results were reported after 12-48 h at that time.", [["CT", "TEST", 25, 27], ["RT-PCR", "TEST", 72, 78]]], ["CT results could be a faster measure to identify suspected cases.", [["CT", "TEST", 0, 2]]]], "PMC7228218": [["INTRODUCTIONCoronaviruses (CoVs) are found in humans and a wide variety of wild and domestic animals, causing mild or severe respiratory, enteric, hepatic and neurological diseases, and resulting in substantial impact on human and animal health (Cheng, Lau, Woo, & Yuen, 2007; Guan et al., 2003; Marra et al., 2003; Peiris et al., 2003; Rota et al., 2003; Rota et al., 2003; Snijder et al., 2003; Woo et al., 2004, 2009).", [["respiratory", "ANATOMY", 125, 136], ["hepatic", "ANATOMY", 147, 154], ["neurological", "ANATOMY", 159, 171], ["respiratory, enteric, hepatic and neurological diseases", "DISEASE", 125, 180], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["humans", "ORGANISM", 46, 52], ["hepatic", "MULTI-TISSUE_STRUCTURE", 147, 154], ["human", "ORGANISM", 221, 226], ["CoVs", "PROTEIN", 27, 31], ["humans", "SPECIES", 46, 52], ["human", "SPECIES", 221, 226], ["humans", "SPECIES", 46, 52], ["human", "SPECIES", 221, 226], ["mild or severe respiratory, enteric, hepatic and neurological diseases", "PROBLEM", 110, 180], ["wide", "OBSERVATION_MODIFIER", 59, 63], ["mild", "OBSERVATION_MODIFIER", 110, 114], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["respiratory", "OBSERVATION", 125, 136], ["enteric", "ANATOMY", 138, 145], ["hepatic", "ANATOMY", 147, 154], ["neurological diseases", "OBSERVATION", 159, 180], ["substantial", "OBSERVATION_MODIFIER", 199, 210]]], ["The severe acute respiratory syndrome (SARS) CoV caused an epidemic in 2003 which resulted in 775 human deaths (Woo et al., 2004).", [["acute respiratory syndrome", "DISEASE", 11, 37], ["SARS", "DISEASE", 39, 43], ["deaths", "DISEASE", 104, 110], ["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["severe acute respiratory syndrome (SARS) CoV", "SPECIES", 4, 48], ["human", "SPECIES", 98, 103], ["The severe acute respiratory syndrome", "PROBLEM", 0, 37], ["SARS) CoV", "PROBLEM", 39, 48], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory syndrome", "OBSERVATION", 17, 37], ["epidemic", "OBSERVATION_MODIFIER", 59, 67]]], ["The novel coronavirus SARS\u2010CoV\u20102 emerging in Wuhan, China, in 2019 has spread to dozens of countries and caused thousands of human deaths till the present (WHO, 2020).INTRODUCTIONCoVs belong to the subfamily Orthocoronavirinae in the family Coronaviridae.", [["SARS", "DISEASE", 22, 26], ["deaths", "DISEASE", 131, 137], ["coronavirus", "ORGANISM", 10, 21], ["human", "ORGANISM", 125, 130], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 208, 226], ["coronavirus", "SPECIES", 10, 21], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["coronavirus", "OBSERVATION_MODIFIER", 10, 21]]], ["Orthocoronavirinae covers four genera, namely Alpha\u2010, Beta\u2010, Gamma\u2010 and Deltacoronavirus (de Groot et al., 2012).", [["Orthocoronavirinae", "TREATMENT", 0, 18], ["Alpha\u2010", "TREATMENT", 46, 52], ["Beta\u2010", "TREATMENT", 54, 59]]], ["SARS CoV and MERS CoV belong to the genus Betacoronavirus.", [["SARS", "DISEASE", 0, 4], ["SARS CoV", "ORGANISM", 0, 8], ["MERS CoV", "ORGANISM", 13, 21], ["SARS CoV", "SPECIES", 0, 8], ["MERS CoV", "SPECIES", 13, 21], ["SARS CoV", "PROBLEM", 0, 8], ["MERS CoV", "PROBLEM", 13, 21], ["genus Betacoronavirus", "OBSERVATION", 36, 57]]], ["All the CoVs detected from domestic fowls and some CoVs detected from wild birds belong to the genus Gammacoronavirus, while some other CoVs detected from wild birds have constituted the genus Deltacoronavirus (de Groot et al., 2012; Jordan, Hilt, Poulson, Stallknecht, & Jackwood, 2015).INTRODUCTIONThe genus Gammacoronavirus covers two subgenera, Igacovirus which is represented by the species of Avian coronavirus including infectious bronchitis virus (IBV) circulating in chickens (Chen et al., 2013; de Groot et al., 2012) and Cegacovirus which is represented by CoVs isolated from whales and dolphins (Mihindukulasuriya, Wu, St Leger, Nordhausen, & Wang, 2008; Woo et al., 2014).", [["Avian coronavirus", "DISEASE", 399, 416], ["infectious bronchitis virus", "DISEASE", 427, 454], ["CoVs", "GENE_OR_GENE_PRODUCT", 8, 12], ["CoVs", "GENE_OR_GENE_PRODUCT", 51, 55], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 101, 117], ["CoVs", "GENE_OR_GENE_PRODUCT", 136, 140], ["birds", "ORGANISM", 160, 165], ["Avian coronavirus", "ORGANISM", 399, 416], ["infectious bronchitis virus", "ORGANISM", 427, 454], ["IBV", "ORGANISM", 456, 459], ["chickens", "ORGANISM", 476, 484], ["CoVs", "GENE_OR_GENE_PRODUCT", 568, 572], ["whales", "ORGANISM_SUBDIVISION", 587, 593], ["dolphins", "ORGANISM_SUBDIVISION", 598, 606], ["CoVs", "DNA", 8, 12], ["CoVs", "DNA", 136, 140], ["Avian coronavirus", "SPECIES", 399, 416], ["infectious bronchitis virus", "SPECIES", 427, 454], ["chickens", "SPECIES", 476, 484], ["fowls", "SPECIES", 36, 41], ["Avian coronavirus", "SPECIES", 399, 416], ["infectious bronchitis virus", "SPECIES", 427, 454], ["IBV", "SPECIES", 456, 459], ["chickens", "SPECIES", 476, 484], ["All the CoVs", "PROBLEM", 0, 12], ["domestic fowls", "PROBLEM", 27, 41], ["some CoVs", "PROBLEM", 46, 55], ["some other CoVs", "PROBLEM", 125, 140], ["The genus Gammacoronavirus", "PROBLEM", 300, 326], ["two subgenera", "PROBLEM", 334, 347], ["Igacovirus", "PROBLEM", 349, 359], ["Avian coronavirus", "PROBLEM", 399, 416], ["infectious bronchitis virus", "PROBLEM", 427, 454], ["Cegacovirus", "PROBLEM", 532, 543], ["CoVs", "OBSERVATION", 8, 12], ["genus Gammacoronavirus", "ANATOMY", 95, 117], ["genus Gammacoronavirus", "OBSERVATION", 304, 326], ["infectious", "OBSERVATION_MODIFIER", 427, 437]]], ["Infectious bronchitis virus circulates worldwide and causes acute and highly contagious respiratory diseases in chickens of all ages and diminish egg production in hens (Chen et al., 2013; Cook, Jackwood, & Jones, 2012).", [["respiratory", "ANATOMY", 88, 99], ["egg", "ANATOMY", 146, 149], ["Infectious bronchitis virus", "DISEASE", 0, 27], ["respiratory diseases", "DISEASE", 88, 108], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["chickens", "ORGANISM", 112, 120], ["egg", "ORGANISM_SUBDIVISION", 146, 149], ["chickens", "SPECIES", 112, 120], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["chickens", "SPECIES", 112, 120], ["Infectious bronchitis virus circulates", "PROBLEM", 0, 38], ["acute and highly contagious respiratory diseases", "PROBLEM", 60, 108], ["diminish egg production", "PROBLEM", 137, 160], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["highly", "OBSERVATION_MODIFIER", 70, 76], ["contagious", "OBSERVATION_MODIFIER", 77, 87], ["respiratory diseases", "OBSERVATION", 88, 108]]], ["Additionally, some CoVs detected from turkeys, peafowls and other birds were highly homologous to IBV (Cook et al., 2012; Day et al., 2014; Liu et al., 2005).INTRODUCTIONRecombination and mutation are frequent in the genomes of CoVs (Liu et al., 2014).", [["peafowls", "ANATOMY", 47, 55], ["CoVs", "GENE_OR_GENE_PRODUCT", 19, 23], ["turkeys", "ORGANISM", 38, 45], ["birds", "ORGANISM", 66, 71], ["IBV", "ORGANISM", 98, 101], ["CoVs", "PATHOLOGICAL_FORMATION", 228, 232], ["CoVs", "PROTEIN", 19, 23], ["turkeys", "SPECIES", 38, 45], ["turkeys", "SPECIES", 38, 45], ["IBV", "SPECIES", 98, 101], ["some CoVs", "PROBLEM", 14, 23], ["INTRODUCTIONRecombination", "PROBLEM", 158, 183], ["mutation", "PROBLEM", 188, 196], ["some", "OBSERVATION_MODIFIER", 14, 18], ["CoVs", "OBSERVATION", 19, 23]]], ["Some CoVs distinct from IBVs and mainly circulating in birds other than chickens have been identified (Chen et al., 2013; de Groot et al., 2012).", [["CoVs", "GENE_OR_GENE_PRODUCT", 5, 9], ["IBVs", "GENE_OR_GENE_PRODUCT", 24, 28], ["birds", "ORGANISM", 55, 60], ["chickens", "ORGANISM", 72, 80], ["CoVs", "PROTEIN", 5, 9], ["chickens", "SPECIES", 72, 80], ["chickens", "SPECIES", 72, 80], ["Some CoVs distinct from IBVs", "PROBLEM", 0, 28], ["CoVs", "OBSERVATION_MODIFIER", 5, 9], ["distinct", "OBSERVATION_MODIFIER", 10, 18], ["IBVs", "OBSERVATION_MODIFIER", 24, 28], ["mainly", "OBSERVATION_MODIFIER", 33, 39], ["circulating", "OBSERVATION_MODIFIER", 40, 51]]], ["In 2013, we found that CoVs dominant (i.e. mainly circulating) in ducks were phylogenetically distinct from IBVs and may represent a potential novel species within the genus Gammacoronavirus, as indicated by the sequences of three regions in the viral 1ab gene (Chen et al., 2013).", [["CoVs", "GENE_OR_GENE_PRODUCT", 23, 27], ["ducks", "ORGANISM", 66, 71], ["IBVs", "CANCER", 108, 112], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 174, 190], ["viral 1ab gene", "DNA", 246, 260], ["ducks", "SPECIES", 66, 71], ["CoVs dominant", "PROBLEM", 23, 36], ["a potential novel species within the genus Gammacoronavirus", "PROBLEM", 131, 190], ["CoVs dominant", "OBSERVATION", 23, 36], ["may represent", "UNCERTAINTY", 117, 130], ["species", "OBSERVATION", 149, 156], ["genus Gammacoronavirus", "OBSERVATION", 168, 190]]], ["Then, we sequenced the genomic sequence of the duck\u2010dominant CoV and conducted a surveillance of CoVs in chickens and ducks and found solid evidences to support that the duck\u2010dominant CoVs are distinct from common IBVs and should represent a novel species in the genus Gammacoronavirus (Zhuang et al., 2015).INTRODUCTIONThe genetic distances in the following seven Coronaviridae\u2010wide conserved domains in the viral replicase polyprotein pp1ab: ADP\u2010ribose\u20101\u2033\u2010phosphatase (ADRP) in nsp3, nsp5, nsp12, nsp13, nsp14, nsp15 and nsp16 are crucial for newly identified CoVs to be assigned to a species within Coronaviridae according to the ninth report of International Committee on Taxonomy of Viruses (ICTV) (de Groot et al., 2012; Woo et al., 2006).", [["duck\u2010dominant CoV", "ORGANISM", 47, 64], ["CoVs", "GENE_OR_GENE_PRODUCT", 97, 101], ["chickens", "ORGANISM", 105, 113], ["ducks", "ORGANISM", 118, 123], ["CoVs", "GENE_OR_GENE_PRODUCT", 184, 188], ["IBVs", "CANCER", 214, 218], ["ADP\u2010ribose\u20101\u2033\u2010phosphatase", "GENE_OR_GENE_PRODUCT", 444, 469], ["ADRP", "GENE_OR_GENE_PRODUCT", 471, 475], ["nsp3", "GENE_OR_GENE_PRODUCT", 480, 484], ["nsp5", "GENE_OR_GENE_PRODUCT", 486, 490], ["nsp12", "GENE_OR_GENE_PRODUCT", 492, 497], ["nsp13", "GENE_OR_GENE_PRODUCT", 499, 504], ["nsp14", "GENE_OR_GENE_PRODUCT", 506, 511], ["nsp15", "GENE_OR_GENE_PRODUCT", 513, 518], ["nsp16", "GENE_OR_GENE_PRODUCT", 523, 528], ["CoVs", "GENE_OR_GENE_PRODUCT", 562, 566], ["duck\u2010dominant CoVs", "DNA", 170, 188], ["Coronaviridae\u2010wide conserved domains", "DNA", 365, 401], ["viral replicase polyprotein pp1ab", "PROTEIN", 409, 442], ["ADP\u2010ribose\u20101\u2033\u2010phosphatase", "PROTEIN", 444, 469], ["ADRP", "PROTEIN", 471, 475], ["nsp3", "PROTEIN", 480, 484], ["nsp5", "PROTEIN", 486, 490], ["nsp12", "PROTEIN", 492, 497], ["nsp13", "PROTEIN", 499, 504], ["nsp14", "PROTEIN", 506, 511], ["nsp15", "PROTEIN", 513, 518], ["nsp16", "PROTEIN", 523, 528], ["CoVs", "PROTEIN", 562, 566], ["chickens", "SPECIES", 105, 113], ["ducks", "SPECIES", 118, 123], ["duck\u2010dominant CoV", "SPECIES", 47, 64], ["chickens", "SPECIES", 105, 113], ["CoVs in chickens", "TREATMENT", 97, 113], ["the duck\u2010dominant CoVs", "PROBLEM", 166, 188], ["common IBVs", "PROBLEM", 207, 218], ["a novel species", "PROBLEM", 240, 255], ["the viral replicase polyprotein", "TEST", 405, 436], ["ADP\u2010ribose", "TEST", 444, 454], ["nsp3", "TEST", 480, 484], ["nsp5", "TEST", 486, 490], ["nsp12", "TEST", 492, 497], ["nsp13", "TEST", 499, 504], ["nsp14", "TREATMENT", 506, 511], ["nsp15", "TREATMENT", 513, 518], ["nsp16", "TREATMENT", 523, 528], ["newly identified CoVs", "PROBLEM", 545, 566], ["a species", "PROBLEM", 585, 594], ["Coronaviridae", "TREATMENT", 602, 615], ["duck\u2010dominant CoVs", "OBSERVATION", 170, 188]]], ["According to the ICTV demarcation of CoV species, CoVs that share an overall amino acid (aa) identity of more than 90% in these seven Coronaviridae\u2010wide conserved domains should be regarded as the same species (de Groot et al., 2012).INTRODUCTIONIn this study, we conducted a large\u2010scale surveillance of CoVs in chickens, ducks, geese, pigeons and other birds (quails, sparrows and partridges) and sequenced the aforementioned seven Coronaviridae\u2010wide conserved domains in replicase polyprotein pp1ab of multiple CoVs, to further investigate the genetic diversity, distribution and taxonomy of CoVs circulating in poultry, especially those circulating in pigeons.Ethics Statement ::: METHODSThis study was conducted according to the animal welfare guidelines of the World Organization for Animal Health (Thiermann, 2015) and approved by the Animal Welfare Committee of China Animal Health and Epidemiology Center.", [["amino acid", "CHEMICAL", 77, 87], ["CoVs", "CHEMICAL", 304, 308], ["amino acid", "CHEMICAL", 77, 87], ["CoV", "ORGANISM", 37, 40], ["CoVs", "GENE_OR_GENE_PRODUCT", 50, 54], ["amino acid", "AMINO_ACID", 77, 87], ["CoVs", "GENE_OR_GENE_PRODUCT", 304, 308], ["chickens", "ORGANISM", 312, 320], ["ducks", "ORGANISM", 322, 327], ["geese", "ORGANISM", 329, 334], ["pigeons", "ORGANISM", 336, 343], ["quails", "ORGANISM_SUBDIVISION", 361, 367], ["CoVs", "GENE_OR_GENE_PRODUCT", 513, 517], ["CoVs", "GENE_OR_GENE_PRODUCT", 594, 598], ["CoVs", "PROTEIN", 50, 54], ["Coronaviridae\u2010wide conserved domains", "PROTEIN", 134, 170], ["Coronaviridae\u2010wide conserved domains", "DNA", 433, 469], ["replicase polyprotein pp1ab", "PROTEIN", 473, 500], ["CoVs", "PROTEIN", 513, 517], ["chickens", "SPECIES", 312, 320], ["ducks", "SPECIES", 322, 327], ["pigeons", "SPECIES", 336, 343], ["chickens", "SPECIES", 312, 320], ["poultry", "SPECIES", 614, 621], ["CoV species", "PROBLEM", 37, 48], ["CoVs", "PROBLEM", 50, 54], ["an overall amino acid", "TEST", 66, 87], ["this study", "TEST", 249, 259], ["CoVs", "PROBLEM", 304, 308], ["multiple CoVs", "PROBLEM", 504, 517], ["CoVs circulating in poultry", "PROBLEM", 594, 621], ["METHODSThis study", "TEST", 684, 701], ["CoV species", "OBSERVATION", 37, 48], ["amino acid", "OBSERVATION", 77, 87], ["multiple CoVs", "OBSERVATION", 504, 517]]], ["The faeces samples, drinking\u2010water samples and swab samples, from poultry farms, backyard flocks and live bird markets, were all collected with permission given by multiple relevant parties, including China Ministry of Agriculture and Rural Affairs, China Animal Health and Epidemiology Center and the relevant veterinary section in the provincial and county government.Designation of lineages and viruses ::: METHODSViruses were assigned into lineages based on phylogenetic analysis, and the CoVs dominant in pigeons, chickens, ducks and geese were designated as pigeon\u2010dominant coronavirus (PdCoV), chicken\u2010dominant coronavirus (CdCoV), duck\u2010dominant coronavirus (DdCoV) and geese\u2010dominant coronavirus (GdCoV), respectively.", [["faeces samples", "ANATOMY", 4, 18], ["samples", "ANATOMY", 35, 42], ["swab samples", "ANATOMY", 47, 59], ["faeces samples", "ORGANISM_SUBSTANCE", 4, 18], ["swab samples", "ORGANISM_SUBSTANCE", 47, 59], ["CoVs", "GENE_OR_GENE_PRODUCT", 493, 497], ["pigeons", "ORGANISM", 510, 517], ["chickens", "ORGANISM", 519, 527], ["ducks", "ORGANISM", 529, 534], ["geese", "ORGANISM", 539, 544], ["pigeon\u2010dominant coronavirus", "ORGANISM", 564, 591], ["PdCoV", "ORGANISM", 593, 598], ["chicken\u2010dominant coronavirus", "ORGANISM", 601, 629], ["CdCoV", "ORGANISM", 631, 636], ["duck\u2010dominant coronavirus", "ORGANISM", 639, 664], ["DdCoV", "ORGANISM", 666, 671], ["geese\u2010dominant coronavirus", "ORGANISM", 677, 703], ["GdCoV", "ORGANISM", 705, 710], ["CoVs", "DNA", 493, 497], ["pigeons", "SPECIES", 510, 517], ["chickens", "SPECIES", 519, 527], ["ducks", "SPECIES", 529, 534], ["pigeon\u2010dominant coronavirus", "SPECIES", 564, 591], ["chicken\u2010dominant coronavirus", "SPECIES", 601, 629], ["duck\u2010dominant coronavirus", "SPECIES", 639, 664], ["geese\u2010dominant coronavirus", "SPECIES", 677, 703], ["chickens", "SPECIES", 519, 527], ["geese", "SPECIES", 539, 544], ["pigeon\u2010dominant coronavirus", "SPECIES", 564, 591], ["PdCoV", "SPECIES", 593, 598], ["chicken\u2010dominant coronavirus", "SPECIES", 601, 629], ["CdCoV", "SPECIES", 631, 636], ["duck\u2010dominant coronavirus", "SPECIES", 639, 664], ["DdCoV", "SPECIES", 666, 671], ["geese\u2010dominant coronavirus", "SPECIES", 677, 703], ["GdCoV", "SPECIES", 705, 710], ["The faeces samples", "TEST", 0, 18], ["swab samples", "TEST", 47, 59], ["backyard flocks", "TREATMENT", 81, 96], ["METHODSViruses", "TREATMENT", 410, 424], ["phylogenetic analysis", "TEST", 462, 483], ["the CoVs dominant in pigeons", "PROBLEM", 489, 517], ["pigeon\u2010dominant coronavirus (PdCoV)", "PROBLEM", 564, 599], ["chicken\u2010dominant coronavirus (CdCoV)", "PROBLEM", 601, 637], ["duck\u2010dominant coronavirus (DdCoV)", "PROBLEM", 639, 672], ["geese\u2010dominant coronavirus (GdCoV)", "PROBLEM", 677, 711], ["backyard flocks", "OBSERVATION", 81, 96], ["lineages", "OBSERVATION_MODIFIER", 385, 393], ["viruses", "OBSERVATION", 398, 405], ["CoVs", "OBSERVATION_MODIFIER", 493, 497], ["dominant", "OBSERVATION_MODIFIER", 498, 506], ["duck\u2010dominant coronavirus", "ANATOMY", 639, 664], ["geese\u2010dominant coronavirus", "ANATOMY", 677, 703]]], ["It should be noted that PdCoVs may cover some CoVs isolated from the birds other than pigeons, and not all CoVs isolated from pigeons are PdCoVs, and this is the same with CdCoVs and DdCoVs.", [["PdCoVs", "CHEMICAL", 24, 30], ["PdCoVs", "SIMPLE_CHEMICAL", 24, 30], ["CoVs", "GENE_OR_GENE_PRODUCT", 46, 50], ["birds", "ORGANISM", 69, 74], ["CoVs", "GENE_OR_GENE_PRODUCT", 107, 111], ["pigeons", "ORGANISM", 126, 133], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 138, 144], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 172, 178], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 183, 189], ["CdCoVs", "PROTEIN", 172, 178], ["DdCoVs", "PROTEIN", 183, 189], ["PdCoVs", "TREATMENT", 24, 30], ["some CoVs", "PROBLEM", 41, 50], ["all CoVs", "PROBLEM", 103, 111], ["PdCoVs", "TREATMENT", 138, 144], ["CdCoVs", "TREATMENT", 172, 178], ["DdCoVs", "TREATMENT", 183, 189]]], ["Virus strains were designated in the format of lineage/host/place/number/year, and hosts were abbreviated as \u2018PG\u2019 for pigeon, \u2018CK\u2019 for chicken, \u2018DK\u2019 for duck and \u2018GS\u2019 for goose in the designations, for example PdCoV/PG/Guangdong/1507/2014.Sample collection for surveillance ::: METHODSA total of 5,249 samples were collected from seventeen provinces (Anhui, Fujian, Guangdong, Guizhou, Hainan, Hebei, Henan, Hubei, Hunan, Jilin, Jiangsu, Jiangxi, Shanxi, Shanghai, Sichuan, Zhejiang and Chongqing) of China, including 4,539 swab samples (2,496 from chickens, 1,187 from ducks, 437 from geese, 403 from pigeons, 11 from partridges and 5 from quails), 605 faeces samples (264 from pigeons, 201 from ducks, 66 from chickens, 40 from geese, 10 from sparrows, 14 from partridges and 10 from quails) and 105 drinking\u2010water samples (63 from ducks, 20 from pigeons, 17 from geese and 5 from chickens).", [["samples", "ANATOMY", 302, 309], ["swab samples", "ANATOMY", 524, 536], ["faeces samples", "ANATOMY", 654, 668], ["samples", "ANATOMY", 817, 824], ["PG", "CHEMICAL", 110, 112], ["PdCoV", "CHEMICAL", 210, 215], ["PG", "CHEMICAL", 216, 218], ["Virus", "ORGANISM", 0, 5], ["pigeon", "ORGANISM", 118, 124], ["CK", "GENE_OR_GENE_PRODUCT", 127, 129], ["chicken", "ORGANISM", 135, 142], ["duck", "ORGANISM", 153, 157], ["samples", "CANCER", 302, 309], ["swab samples", "CANCER", 524, 536], ["chickens", "ORGANISM", 549, 557], ["ducks", "ORGANISM", 570, 575], ["geese", "ORGANISM", 586, 591], ["pigeons", "ORGANISM", 602, 609], ["quails", "ORGANISM", 641, 647], ["pigeons", "ORGANISM", 679, 686], ["ducks", "ORGANISM", 697, 702], ["chickens", "ORGANISM", 712, 720], ["quails", "ORGANISM", 786, 792], ["ducks", "ORGANISM", 834, 839], ["geese", "ORGANISM", 866, 871], ["chickens", "ORGANISM", 883, 891], ["pigeon", "SPECIES", 118, 124], ["chicken", "SPECIES", 135, 142], ["duck", "SPECIES", 153, 157], ["chickens", "SPECIES", 549, 557], ["ducks", "SPECIES", 570, 575], ["pigeons", "SPECIES", 679, 686], ["ducks", "SPECIES", 697, 702], ["chickens", "SPECIES", 712, 720], ["ducks", "SPECIES", 834, 839], ["chickens", "SPECIES", 883, 891], ["pigeon", "SPECIES", 118, 124], ["chicken", "SPECIES", 135, 142], ["goose", "SPECIES", 171, 176], ["chickens", "SPECIES", 549, 557], ["chickens", "SPECIES", 712, 720], ["chickens", "SPECIES", 883, 891], ["Virus strains", "PROBLEM", 0, 13], ["CK", "TEST", 127, 129], ["duck and \u2018GS", "TEST", 153, 165], ["faeces samples", "TEST", 654, 668]]], ["These 5,249 samples were collected from 66 LPMs, 14 duck farms and 22 backyard flocks, for surveillance of avian influenza viruses, Newcastle disease viruses and CoVs circulating in poultry in China in these 3 years, 2013 (n = 737), 2014 (n = 4,309) and 2018 (n = 93).The swab samples were collected through gently taking smears at both cloacal and oropharyngeal tracts of a bird.", [["samples", "ANATOMY", 12, 19], ["LPMs", "ANATOMY", 43, 47], ["swab samples", "ANATOMY", 272, 284], ["cloacal", "ANATOMY", 337, 344], ["oropharyngeal tracts", "ANATOMY", 349, 369], ["avian influenza viruses", "DISEASE", 107, 130], ["Newcastle disease viruses", "DISEASE", 132, 157], ["samples", "CANCER", 12, 19], ["duck", "ORGANISM", 52, 56], ["avian influenza viruses", "ORGANISM", 107, 130], ["Newcastle disease viruses", "ORGANISM", 132, 157], ["CoVs", "GENE_OR_GENE_PRODUCT", 162, 166], ["swab samples", "CANCER", 272, 284], ["cloacal", "ORGANISM_SUBDIVISION", 337, 344], ["oropharyngeal tracts", "MULTI-TISSUE_STRUCTURE", 349, 369], ["duck", "SPECIES", 52, 56], ["avian influenza viruses", "SPECIES", 107, 130], ["avian influenza viruses", "SPECIES", 107, 130], ["Newcastle disease viruses", "SPECIES", 132, 157], ["LPMs", "TEST", 43, 47], ["22 backyard flocks", "PROBLEM", 67, 85], ["surveillance", "TEST", 91, 103], ["avian influenza viruses", "PROBLEM", 107, 130], ["Newcastle disease viruses", "PROBLEM", 132, 157], ["CoVs", "PROBLEM", 162, 166], ["The swab samples", "TEST", 268, 284], ["smears", "TEST", 322, 328], ["backyard flocks", "OBSERVATION", 70, 85], ["influenza viruses", "OBSERVATION", 113, 130], ["poultry", "OBSERVATION_MODIFIER", 182, 189], ["oropharyngeal tracts", "ANATOMY", 349, 369]]], ["The faeces samples were collected through taking approximately 0.5 ml wet and fresh faeces on the ground or cages.", [["faeces samples", "ANATOMY", 4, 18], ["faeces", "ANATOMY", 84, 90], ["faeces samples", "ORGANISM_SUBSTANCE", 4, 18], ["The faeces samples", "TEST", 0, 18]]], ["The drinking\u2010water samples were collected through taking approximately 3.5 ml drinking water from the water trough for a group of birds in LPMs.", [["\u2010water samples", "ANATOMY", 12, 26], ["birds", "ORGANISM", 130, 135], ["The drinking\u2010water samples", "TREATMENT", 0, 26]]], ["The swab samples were stored in 1.5 ml phosphate\u2010buffered saline (pH 7.2) containing 10% glycerol, and the faeces samples were stored in 3.5 ml phosphate\u2010buffered saline (pH 7.2) containing 10% glycerol, and the drinking\u2010water samples were stored with 0.4 ml glycerol.", [["swab samples", "ANATOMY", 4, 16], ["faeces samples", "ANATOMY", 107, 121], ["samples", "ANATOMY", 227, 234], ["phosphate", "CHEMICAL", 39, 48], ["glycerol", "CHEMICAL", 89, 97], ["phosphate", "CHEMICAL", 144, 153], ["glycerol", "CHEMICAL", 194, 202], ["glycerol", "CHEMICAL", 259, 267], ["phosphate", "CHEMICAL", 39, 48], ["glycerol", "CHEMICAL", 89, 97], ["phosphate", "CHEMICAL", 144, 153], ["glycerol", "CHEMICAL", 194, 202], ["glycerol", "CHEMICAL", 259, 267], ["swab samples", "ORGANISM_SUBSTANCE", 4, 16], ["saline", "SIMPLE_CHEMICAL", 58, 64], ["glycerol", "SIMPLE_CHEMICAL", 89, 97], ["faeces samples", "ORGANISM_SUBSTANCE", 107, 121], ["phosphate\u2010buffered saline", "SIMPLE_CHEMICAL", 144, 169], ["glycerol", "SIMPLE_CHEMICAL", 194, 202], ["glycerol", "SIMPLE_CHEMICAL", 259, 267], ["The swab samples", "TEST", 0, 16], ["phosphate\u2010buffered saline", "TREATMENT", 39, 64], ["pH", "TEST", 66, 68], ["10% glycerol", "TREATMENT", 85, 97], ["the faeces samples", "TEST", 103, 121], ["phosphate\u2010buffered saline", "TREATMENT", 144, 169], ["pH", "TEST", 171, 173], ["10% glycerol", "TREATMENT", 190, 202], ["the drinking\u2010water samples", "TREATMENT", 208, 234], ["0.4 ml glycerol", "TREATMENT", 252, 267]]], ["The samples were stored at 4\u00b0C and detected in three days after collection.", [["samples", "ANATOMY", 4, 11], ["C", "GENE_OR_GENE_PRODUCT", 29, 30], ["The samples", "TEST", 0, 11], ["collection", "PROBLEM", 64, 74]]], ["The samples were stored at \u201380\u00b0C after detection.", [["samples", "ANATOMY", 4, 11], ["C", "GENE_OR_GENE_PRODUCT", 31, 32], ["The samples", "TEST", 0, 11], ["detection", "TEST", 39, 48]]], ["The surveillance data of 3,583 of the 4,309 samples collected in 2014 have been published with the focus on DdCoVs rather than on PdCoVs in this study (Zhuang et al., 2015).Detection of swab samples ::: METHODSThe swab samples were clarified by centrifugated at 10,000 g for 5 min, and the supernatants were inoculated in 10\u2010day\u2010old specific\u2010pathogen\u2010free (SPF) chicken embryonated eggs via the allantoic sac route.", [["samples", "ANATOMY", 44, 51], ["swab samples", "ANATOMY", 186, 198], ["swab samples", "ANATOMY", 214, 226], ["supernatants", "ANATOMY", 290, 302], ["eggs", "ANATOMY", 382, 386], ["allantoic sac", "ANATOMY", 395, 408], ["DdCoVs", "SIMPLE_CHEMICAL", 108, 114], ["PdCoVs", "SIMPLE_CHEMICAL", 130, 136], ["swab samples", "CANCER", 214, 226], ["chicken", "ORGANISM", 362, 369], ["allantoic sac", "MULTI-TISSUE_STRUCTURE", 395, 408], ["chicken", "SPECIES", 362, 369], ["chicken", "SPECIES", 362, 369], ["The surveillance data", "TEST", 0, 21], ["DdCoVs", "TREATMENT", 108, 114], ["this study", "TEST", 140, 150], ["swab samples", "TEST", 186, 198], ["METHODSThe swab samples", "TEST", 203, 226], ["chicken embryonated eggs", "TREATMENT", 362, 386], ["the allantoic sac route", "TREATMENT", 391, 414], ["allantoic sac", "ANATOMY", 395, 408]]], ["The SPF embryonated eggs were purchased from Shandong Healthtec Laboratory Animal Breeding Company (Jinan, China).", [["eggs", "ANATOMY", 20, 24], ["The SPF embryonated eggs", "PROBLEM", 0, 24]]], ["The inoculated eggs were further incubated for 2 days and checked twice each day during the incubation period.", [["eggs", "ANATOMY", 15, 19], ["The inoculated eggs", "TREATMENT", 0, 19]]], ["Dead ones were picked out and stored in a refrigerator.", [["Dead ones", "PROBLEM", 0, 9]]], ["After the incubation period, the allantoic fluids of live embryos were examined using the routine haemagglutination assay.", [["allantoic fluids", "ANATOMY", 33, 49], ["embryos", "ANATOMY", 58, 65], ["allantoic fluids", "ORGANISM_SUBSTANCE", 33, 49], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 58, 65], ["the allantoic fluids of live embryos", "TREATMENT", 29, 65], ["the routine haemagglutination assay", "TEST", 86, 121]]], ["All the haemagglutination\u2010positive allantoic fluids of live embryos and the allantoic fluids of all dead eggs were investigated by RT\u2010PCR for detection of avian influenza virus (AIV) and Newcastle disease virus (NDV) (data not shown).", [["allantoic fluids", "ANATOMY", 35, 51], ["embryos", "ANATOMY", 60, 67], ["allantoic fluids", "ANATOMY", 76, 92], ["eggs", "ANATOMY", 105, 109], ["avian influenza virus", "DISEASE", 155, 176], ["Newcastle disease", "DISEASE", 187, 204], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 60, 67], ["allantoic fluids", "MULTI-TISSUE_STRUCTURE", 76, 92], ["eggs", "ORGANISM_SUBSTANCE", 105, 109], ["avian influenza virus", "ORGANISM", 155, 176], ["AIV", "ORGANISM", 178, 181], ["Newcastle disease virus", "ORGANISM", 187, 210], ["NDV", "ORGANISM", 212, 215], ["avian influenza virus", "SPECIES", 155, 176], ["Newcastle disease virus", "SPECIES", 187, 210], ["avian influenza virus", "SPECIES", 155, 176], ["AIV", "SPECIES", 178, 181], ["Newcastle disease virus", "SPECIES", 187, 210], ["NDV", "SPECIES", 212, 215], ["All the haemagglutination\u2010positive allantoic fluids", "TREATMENT", 0, 51], ["live embryos", "TREATMENT", 55, 67], ["the allantoic fluids", "TREATMENT", 72, 92], ["all dead eggs", "TREATMENT", 96, 109], ["RT\u2010PCR", "TEST", 131, 137], ["avian influenza virus", "PROBLEM", 155, 176], ["Newcastle disease virus", "PROBLEM", 187, 210]]], ["They were also examined further by a conserved RT\u2010PCR assay for detection of CoVs, as described below.Detection of faeces and drinking\u2010water samples ::: METHODSThe faeces and drinking\u2010water samples were clarified by centrifugated at 10,000 g for 5 min, and then, the supernatants were detected through two ways.", [["faeces", "ANATOMY", 115, 121], ["faeces", "ANATOMY", 164, 170], ["\u2010water samples", "ANATOMY", 183, 197], ["supernatants", "ANATOMY", 267, 279], ["CoVs", "GENE_OR_GENE_PRODUCT", 77, 81], ["faeces", "ORGANISM_SUBSTANCE", 115, 121], ["faeces", "ORGANISM_SUBSTANCE", 164, 170], ["CoVs", "PROTEIN", 77, 81], ["a conserved RT\u2010PCR assay", "TEST", 35, 59], ["CoVs", "PROBLEM", 77, 81], ["METHODSThe faeces", "TREATMENT", 153, 170], ["CoVs", "OBSERVATION", 77, 81]]], ["One was as the same as the detection for swab samples, and the other was detected directly using the following conserved RT\u2010PCR assay for detection of CoVs.Detection of CoVs using a conserved RT\u2010PCR assay ::: METHODSThe RNA in the collected faeces and drinking\u2010water samples or in the allantoic fluids was extracted using an RNeasy Mini Kit (Qiagen) and amplified with the One Step RT\u2010PCR Kit (Qiagen), using a conserved RT\u2010PCR assay designed by ourselves with the primers 5\u2032\u2010GGTTGGGAYTAYCCYAAGTGTGA\u20103\u2032 (upper) and 5\u2032\u2010GAATCIGCCATAWAAACATTRTT\u20103\u2032 (down) (Zhuang et al., 2015).", [["swab samples", "ANATOMY", 41, 53], ["faeces", "ANATOMY", 241, 247], ["\u2010water samples", "ANATOMY", 260, 274], ["allantoic fluids", "ANATOMY", 285, 301], ["CoVs", "GENE_OR_GENE_PRODUCT", 151, 155], ["CoVs", "GENE_OR_GENE_PRODUCT", 169, 173], ["faeces", "ORGANISM_SUBSTANCE", 241, 247], ["\u2010water samples", "ORGANISM_SUBSTANCE", 260, 274], ["allantoic fluids", "ORGANISM_SUBSTANCE", 285, 301], ["CoVs", "PROTEIN", 151, 155], ["CoVs", "DNA", 169, 173], ["swab samples", "TEST", 41, 53], ["RT\u2010PCR assay", "TEST", 121, 133], ["CoVs", "PROBLEM", 151, 155], ["CoVs", "PROBLEM", 169, 173], ["a conserved RT\u2010PCR assay", "TEST", 180, 204], ["METHODSThe RNA", "TREATMENT", 209, 223], ["drinking\u2010water samples", "TREATMENT", 252, 274], ["the allantoic fluids", "TREATMENT", 281, 301], ["an RNeasy Mini Kit (Qiagen)", "TREATMENT", 322, 349], ["a conserved RT\u2010PCR assay", "TEST", 409, 433], ["the primers", "TEST", 461, 472], ["GGTTGGGAYTAYCCYAAGTGTGA", "TEST", 476, 499], ["upper", "ANATOMY_MODIFIER", 504, 509]]], ["The assay amplifies a 545\u2010nucleotide region in the viral 1ab gene, and we have found that the conserved RT\u2010PCR assay can detect some CoVs circulating in humans, pigs, chickens, ducks, geese and pigeons.", [["CoVs", "GENE_OR_GENE_PRODUCT", 133, 137], ["humans", "ORGANISM", 153, 159], ["pigs", "ORGANISM", 161, 165], ["chickens", "ORGANISM", 167, 175], ["ducks", "ORGANISM", 177, 182], ["geese", "ORGANISM", 184, 189], ["545\u2010nucleotide region", "DNA", 22, 43], ["viral 1ab gene", "DNA", 51, 65], ["humans", "SPECIES", 153, 159], ["pigs", "SPECIES", 161, 165], ["chickens", "SPECIES", 167, 175], ["ducks", "SPECIES", 177, 182], ["humans", "SPECIES", 153, 159], ["pigs", "SPECIES", 161, 165], ["chickens", "SPECIES", 167, 175], ["The assay", "TEST", 0, 9], ["RT\u2010PCR assay", "TEST", 104, 116], ["some CoVs circulating in humans", "PROBLEM", 128, 159]]], ["The RT\u2010PCR detection was performed in a 25\u2010\u00b5l reaction system with incubation at 42\u00b0C for 30 min and denaturation at 94\u00b0C for 60 s, followed by 30 cycles at 94\u00b0C for 30 s, 50\u00b0C for 30 s and 72\u00b0C for 1 min.", [["The RT\u2010PCR detection", "TEST", 0, 20], ["denaturation", "TEST", 101, 113]]], ["RT\u2010PCR products were purified with an agarose gel DNA extraction kit (Sangon) and sequenced directly using the ABI 3730xl DNA Analyzer for the following phylogenetic analysis.Phylogenetic analysis ::: METHODSSequences were aligned using the software MUSCLE (Edgar, 2004).", [["DNA", "CELLULAR_COMPONENT", 50, 53], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["ABI 3730xl DNA", "DNA", 111, 125], ["RT\u2010PCR products", "TREATMENT", 0, 15], ["an agarose gel DNA extraction", "TREATMENT", 35, 64], ["the ABI", "TEST", 107, 114], ["DNA Analyzer", "TEST", 122, 134], ["phylogenetic analysis", "TEST", 153, 174], ["Phylogenetic analysis", "TEST", 175, 196], ["MUSCLE", "ANATOMY", 250, 256]]], ["Bayesian Information Criterion scores of substitution models and phylogenetic relationships were calculated using the software package MEGA 7.0 (Hall, 2013; Kumar, Stecher, & Tamura, 2016).", [["substitution models", "TEST", 41, 60]]], ["Gaps were handled by partial deletion, and bootstrap values were calculated out of 1,000 replicates (Hall, 2013).Genome sequencing in seven conserved regions and genome analysis ::: METHODSSeven conserved regions in genomes of the three PdCoVs were amplified through RT\u2010PCR with a series of primers (Table 1).", [["PdCoVs", "GENE_OR_GENE_PRODUCT", 237, 243], ["PdCoVs", "DNA", 237, 243], ["partial deletion", "PROBLEM", 21, 37], ["bootstrap values", "TEST", 43, 59], ["the three PdCoVs", "TREATMENT", 227, 243], ["RT\u2010PCR", "TEST", 267, 273], ["a series of primers", "TREATMENT", 279, 298], ["partial deletion", "OBSERVATION", 21, 37]]], ["The primers were designed according to the conserved regions in the genomes of the CoVs in genus Gammacoronavirus (Chen et al., 2013).", [["CoVs", "GENE_OR_GENE_PRODUCT", 83, 87], ["conserved regions", "DNA", 43, 60], ["CoVs", "DNA", 83, 87], ["CoVs", "ANATOMY", 83, 87], ["genus Gammacoronavirus", "ANATOMY", 91, 113]]], ["The RT\u2010PCR reactions were performed in a 50\u2010\u00b5l reaction system with incubation at 42\u00b0C for 30 min and denaturation at 94\u00b0C for 60 s, followed by 30 cycles at 94\u00b0C for 30 s, 50\u201355\u00b0C (largely depending on the Tm values of the primers) for 30 s and 72\u00b0C for 1\u20134 min (depending on the length of the amplicons).", [["The RT\u2010PCR reactions", "TEST", 0, 20], ["denaturation", "TEST", 102, 114]]], ["RT\u2010PCR products were purified with an agarose gel DNA extraction kit (Sangon).", [["DNA", "CELLULAR_COMPONENT", 50, 53], ["RT\u2010PCR products", "TREATMENT", 0, 15], ["an agarose gel DNA extraction", "TREATMENT", 35, 64]]], ["The amplicons were purified using an agarose gel DNA extraction kit (Takara) and ligated into the pEASY\u2010T1 cloning vector (TransGen).", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["T1 cloning vector", "DNA", 104, 121], ["TransGen", "DNA", 123, 131], ["The amplicons", "TREATMENT", 0, 13], ["an agarose gel DNA extraction kit (Takara)", "TREATMENT", 34, 76]]], ["Positive clones were sequenced by the ABI 3730xl DNA Analyzer using the pair of M13 primers from both senses.", [["clones", "ANATOMY", 9, 15], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["ABI 3730xl DNA", "DNA", 38, 52], ["M13 primers", "DNA", 80, 91], ["Positive clones", "PROBLEM", 0, 15], ["the ABI", "TEST", 34, 41], ["DNA Analyzer", "TEST", 49, 61], ["the pair of M13 primers", "TREATMENT", 68, 91], ["clones", "OBSERVATION", 9, 15]]], ["Sequences were assembled and edited manually to generate the whole genome sequence which was further compared with those of IBVs and were annotated manually.Nucleotide sequences ::: METHODSA total of 725 sequences were used for phylogenetic analysis of this study including 306 original sequences of the 1ab gene of CoVs (MK983498\u2013MK983520, MK983524\u2013MK983531, KP032646\u2013KP032664, KP033041\u2013KP033042, KP033080\u2013KP033137, KT222456\u2013KT222651), 49 original sequences of the seven conserved domains of PdCoVs (KT254267\u2013KT254269, KT254272\u2013KT254274, KT254277\u2013KT254279, KT254282\u2013KT254284, KT254287\u2013KT254289, KT254292\u2013KT254294, KT254297\u2013KT254299, MN025297\u2013MN025324), and 468 reference sequences (KM454473, KP006677\u2013KP006687, KP032640\u2013KP032645, KP032665\u2013KP033040, DQ834384, FJ888351, KP033043\u2013KP033079, NC_010800, AY641576, KT254265\u2013KT254266, KT254270\u2013KT254271, KT254275\u2013KT254276, KT254280\u2013KT254281, KT254285\u2013KT254286, KT254290\u2013KT254291, KT254295\u2013KT254296, NC_001451, JQ977698, DQ001339, JQ977697, JQ088078, DQ646405, KF574761, FN430415, GU396668\u2013GU396671, GU396674\u2013GU396679, GU396681, GU396683, GU396685, GU396687\u2013GU396689, NC_010646, KF793824 and KF793826.Surveillance of CoVs in poultry ::: RESULTSA total of 736 CoV positive samples were identified through the conserved RT\u2010PCR assay from the 5,249 samples collected in the 3 years.", [["samples", "ANATOMY", 1215, 1222], ["samples", "ANATOMY", 1289, 1296], ["KT254295\u2013KT254296", "CHEMICAL", 924, 941], ["NC_001451", "CHEMICAL", 943, 952], ["JQ977698", "CHEMICAL", 954, 962], ["DQ001339", "CHEMICAL", 964, 972], ["JQ977697", "CHEMICAL", 974, 982], ["JQ088078", "CHEMICAL", 984, 992], ["DQ646405", "CHEMICAL", 994, 1002], ["KF574761", "CHEMICAL", 1004, 1012], ["FN430415", "CHEMICAL", 1014, 1022], ["GU396671", "CHEMICAL", 1033, 1041], ["GU396679", "CHEMICAL", 1052, 1060], ["GU396681", "CHEMICAL", 1062, 1070], ["GU396683", "CHEMICAL", 1072, 1080], ["GU396685", "CHEMICAL", 1082, 1090], ["GU396689", "CHEMICAL", 1101, 1109], ["NC_010646", "CHEMICAL", 1111, 1120], ["KF793824", "CHEMICAL", 1122, 1130], ["KF793826", "CHEMICAL", 1135, 1143], ["KP032646\u2013KP032664", "CHEMICAL", 360, 377], ["KM454473", "CHEMICAL", 683, 691], ["KP006677\u2013KP006687", "CHEMICAL", 693, 710], ["KP032640\u2013KP032645", "CHEMICAL", 712, 729], ["KP032665\u2013KP033040", "CHEMICAL", 731, 748], ["DQ834384", "CHEMICAL", 750, 758], ["FJ888351", "CHEMICAL", 760, 768], ["KP033043\u2013KP033079", "CHEMICAL", 770, 787], ["NC_010800", "CHEMICAL", 789, 798], ["AY641576", "CHEMICAL", 800, 808], ["KT254266", "CHEMICAL", 819, 827], ["KT254270\u2013KT254271", "CHEMICAL", 829, 846], ["KT254276", "CHEMICAL", 857, 865], ["KT254280\u2013KT254281", "CHEMICAL", 867, 884], ["KT254285\u2013KT254286", "CHEMICAL", 886, 903], ["KT254290\u2013KT254291", "CHEMICAL", 905, 922], ["KT254295\u2013KT254296", "CHEMICAL", 924, 941], ["NC_001451", "CHEMICAL", 943, 952], ["JQ977698", "CHEMICAL", 954, 962], ["DQ001339", "CHEMICAL", 964, 972], ["JQ977697", "CHEMICAL", 974, 982], ["JQ088078", "CHEMICAL", 984, 992], ["DQ646405", "CHEMICAL", 994, 1002], ["KF574761", "CHEMICAL", 1004, 1012], ["FN430415", "CHEMICAL", 1014, 1022], ["GU396671", "CHEMICAL", 1033, 1041], ["GU396679", "CHEMICAL", 1052, 1060], ["GU396681", "CHEMICAL", 1062, 1070], ["GU396683", "CHEMICAL", 1072, 1080], ["GU396685", "CHEMICAL", 1082, 1090], ["GU396689", "CHEMICAL", 1101, 1109], ["NC_010646", "CHEMICAL", 1111, 1120], ["KF793824", "CHEMICAL", 1122, 1130], ["KF793826", "CHEMICAL", 1135, 1143], ["IBVs", "CANCER", 124, 128], ["1ab", "GENE_OR_GENE_PRODUCT", 304, 307], ["CoVs", "GENE_OR_GENE_PRODUCT", 316, 320], ["CoVs", "CANCER", 1160, 1164], ["CoV", "ORGANISM", 1202, 1205], ["whole genome sequence", "DNA", 61, 82], ["IBVs", "DNA", 124, 128], ["1ab gene", "DNA", 304, 312], ["IBVs", "TREATMENT", 124, 128], ["Nucleotide sequences", "TEST", 157, 177], ["phylogenetic analysis", "TEST", 228, 249], ["this study", "TEST", 253, 263], ["CoVs", "TEST", 316, 320], ["KP032646\u2013KP032664", "TEST", 360, 377], ["KP033041\u2013KP033042", "TEST", 379, 396], ["KP033080\u2013KP033137", "TEST", 398, 415], ["KT222456\u2013", "TEST", 417, 426], ["KT222651", "TEST", 426, 434], ["original sequences", "TEST", 440, 458], ["PdCoVs", "TEST", 493, 499], ["KT254272\u2013KT254274", "TEST", 520, 537], ["KT254277\u2013KT254279", "TEST", 539, 556], ["KT254282\u2013KT254284", "TEST", 558, 575], ["KT254287\u2013KT254289", "TEST", 577, 594], ["KT254292\u2013KT254294", "TEST", 596, 613], ["KT254297\u2013KT254299", "TEST", 615, 632], ["KM454473", "TEST", 683, 691], ["KP006677\u2013KP006687", "TEST", 693, 710], ["KP032640\u2013KP032645", "TEST", 712, 729], ["KP032665\u2013KP033040", "TEST", 731, 748], ["DQ834384", "TEST", 750, 758], ["KP033043\u2013KP033079", "TEST", 770, 787], ["NC_010800", "TEST", 789, 798], ["KT254265\u2013", "TEST", 810, 819], ["KT254266", "TEST", 819, 827], ["KT254270\u2013KT254271", "TEST", 829, 846], ["KT254275\u2013", "TEST", 848, 857], ["KT254276", "TEST", 857, 865], ["KT254280\u2013KT254281", "TEST", 867, 884], ["KT254285\u2013KT254286", "TEST", 886, 903], ["KT254290\u2013KT254291", "TEST", 905, 922], ["JQ977698", "TEST", 954, 962], ["JQ977697", "TEST", 974, 982], ["KF574761", "TEST", 1004, 1012], ["KF793824", "TEST", 1122, 1130], ["KF793826", "TEST", 1135, 1143], ["CoV positive samples", "TEST", 1202, 1222], ["the conserved RT\u2010PCR assay", "TEST", 1247, 1273], ["CoVs", "OBSERVATION", 1160, 1164]]], ["The corresponding RT\u2010PCR amplicons were sequenced, and 725 sequences corresponding to 725 CoVs were clearly revealed, and they were used for further analysis regarding the viral diversity, distribution and phylogenetic relationships.Surveillance of CoVs in poultry ::: RESULTSAs shown in Figure 1, phylogenetic analysis of the RT\u2010PCR amplicons suggested that these 725 viruses could be classified into four lineages corresponding to CdCoVs (n = 446), DdCoVs (n = 107), PdCoVs (n = 170) and GdCoVs (n = 2), respectively.Surveillance of CoVs in poultry ::: RESULTSThe positive rate of CdCoVs in the samples of chickens, 15.43% (396/2567), was significantly higher than that in the samples of pigeons (2.77%, 19/687), geese (2.23%, 11/494), ducks (1.31%, 19/1451) and other birds (1.08%, 1/93), with p < .01 by the chi\u2010square test.", [["samples", "ANATOMY", 597, 604], ["samples", "ANATOMY", 679, 686], ["CdCoVs", "CHEMICAL", 583, 589], ["CoVs", "GENE_OR_GENE_PRODUCT", 90, 94], ["CoVs", "CANCER", 249, 253], ["CoVs", "CANCER", 535, 539], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 583, 589], ["chickens", "ORGANISM", 608, 616], ["pigeons", "ORGANISM", 690, 697], ["ducks", "ORGANISM", 738, 743], ["RT\u2010PCR amplicons", "DNA", 18, 34], ["725 CoVs", "DNA", 86, 94], ["RT\u2010PCR amplicons", "DNA", 327, 343], ["CdCoVs", "PROTEIN", 583, 589], ["chickens", "SPECIES", 608, 616], ["pigeons", "SPECIES", 690, 697], ["ducks", "SPECIES", 738, 743], ["chickens", "SPECIES", 608, 616], ["The corresponding RT\u2010PCR amplicons", "TEST", 0, 34], ["CoVs", "TEST", 90, 94], ["further analysis", "TEST", 141, 157], ["phylogenetic analysis", "TEST", 298, 319], ["the RT\u2010PCR amplicons", "TEST", 323, 343], ["these 725 viruses", "PROBLEM", 359, 376], ["CdCoVs", "TEST", 433, 439], ["DdCoVs", "TEST", 451, 457], ["PdCoVs", "TEST", 469, 475], ["GdCoVs (n", "TREATMENT", 490, 499], ["chickens", "TEST", 608, 616], ["ducks", "TEST", 738, 743], ["p", "TEST", 797, 798], ["the chi\u2010square test", "TEST", 808, 827], ["viral diversity", "OBSERVATION", 172, 187], ["CoVs", "OBSERVATION", 249, 253], ["CoVs", "OBSERVATION", 535, 539], ["significantly", "OBSERVATION_MODIFIER", 641, 654], ["higher", "OBSERVATION_MODIFIER", 655, 661]]], ["These data suggested that CdCoVs mainly circulate in chickens and circulate in other birds at a much lower prevalence.Surveillance of CoVs in poultry ::: RESULTSThe positive rate of DdCoVs in the samples of ducks (6.82%, 99/1451) was significantly higher than that in the samples of pigeons (0.87%, 6/687), geese (0.40%, 2/494) and chickens (0.04%, 1/2567), with p < .01 by the chi\u2010square test, suggesting that DdCoVs mainly circulate in ducks and circulate in other birds at a much lower prevalence.Surveillance of CoVs in poultry ::: RESULTSAs shown in Figure 2, the positive rate of PdCoVs in the samples of pigeons, 23.14% (159/687), was significantly higher than that in the samples of ducks (0.55%, 8/1451), geese (0.20%, 1/494) and chickens (0.08%, 2/2567), with p < .01 by the chi\u2010square test.", [["samples", "ANATOMY", 196, 203], ["samples", "ANATOMY", 272, 279], ["samples", "ANATOMY", 600, 607], ["samples", "ANATOMY", 680, 687], ["CdCoVs", "CHEMICAL", 26, 32], ["DdCoVs", "CHEMICAL", 411, 417], ["PdCoVs", "CHEMICAL", 586, 592], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 26, 32], ["chickens", "ORGANISM", 53, 61], ["birds", "ORGANISM", 85, 90], ["CoVs", "CANCER", 134, 138], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 182, 188], ["ducks", "ORGANISM", 207, 212], ["pigeons", "ORGANISM", 283, 290], ["chickens", "ORGANISM", 332, 340], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 411, 417], ["ducks", "ORGANISM", 438, 443], ["CoVs", "CANCER", 516, 520], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 586, 592], ["pigeons", "ORGANISM", 611, 618], ["ducks", "ORGANISM", 691, 696], ["chickens", "ORGANISM", 739, 747], ["CdCoVs", "PROTEIN", 26, 32], ["DdCoVs", "PROTEIN", 182, 188], ["DdCoVs", "PROTEIN", 411, 417], ["PdCoVs", "PROTEIN", 586, 592], ["chickens", "SPECIES", 53, 61], ["ducks", "SPECIES", 207, 212], ["pigeons", "SPECIES", 283, 290], ["chickens", "SPECIES", 332, 340], ["ducks", "SPECIES", 438, 443], ["ducks", "SPECIES", 691, 696], ["chickens", "SPECIES", 739, 747], ["chickens", "SPECIES", 53, 61], ["ducks", "SPECIES", 207, 212], ["chickens", "SPECIES", 332, 340], ["ducks", "SPECIES", 438, 443], ["chickens", "SPECIES", 739, 747], ["These data", "TEST", 0, 10], ["CdCoVs", "PROBLEM", 26, 32], ["ducks", "TEST", 207, 212], ["the chi\u2010square test", "TEST", 374, 393], ["DdCoVs", "PROBLEM", 411, 417], ["the chi\u2010square test", "TEST", 781, 800], ["CoVs", "OBSERVATION", 134, 138], ["significantly", "OBSERVATION_MODIFIER", 234, 247], ["higher", "OBSERVATION_MODIFIER", 248, 254], ["CoVs", "OBSERVATION", 516, 520], ["significantly", "OBSERVATION_MODIFIER", 642, 655], ["higher", "OBSERVATION_MODIFIER", 656, 662]]], ["These data suggested that PdCoVs mainly circulate in pigeons and circulate in other birds at a much lower prevalence.Surveillance of CoVs in poultry ::: RESULTSThe positive rate of GdCoVs in the samples of geese, 0.40% (2/494), was significantly higher than that in other avian samples (0.00%, 0/4882) in this study, with p < .01 by the chi\u2010square test.", [["samples", "ANATOMY", 195, 202], ["samples", "ANATOMY", 278, 285], ["PdCoVs", "CHEMICAL", 26, 32], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 26, 32], ["pigeons", "ORGANISM", 53, 60], ["birds", "ORGANISM", 84, 89], ["CoVs", "CANCER", 133, 137], ["GdCoVs", "GENE_OR_GENE_PRODUCT", 181, 187], ["geese", "ORGANISM", 206, 211], ["PdCoVs", "PROTEIN", 26, 32], ["GdCoVs", "PROTEIN", 181, 187], ["These data", "TEST", 0, 10], ["PdCoVs", "TREATMENT", 26, 32], ["this study", "TEST", 305, 315], ["the chi\u2010square test", "TEST", 333, 352], ["CoVs", "OBSERVATION", 133, 137], ["GdCoVs", "OBSERVATION_MODIFIER", 181, 187], ["geese", "OBSERVATION_MODIFIER", 206, 211], ["higher", "OBSERVATION_MODIFIER", 246, 252]]], ["These data suggested that GdCoVs mainly circulate in geese.Surveillance of CoVs in poultry ::: RESULTSPdCoVs were found in 62.5% (10/17) of the provinces, 46.97% (31/66) of the LPMs and 9.09% (2/22) of the backyard flocks where the samples were collected.", [["samples", "ANATOMY", 232, 239], ["GdCoVs", "CHEMICAL", 26, 32], ["LPMs", "DISEASE", 177, 181], ["GdCoVs", "GENE_OR_GENE_PRODUCT", 26, 32], ["geese", "ORGANISM", 53, 58], ["CoVs", "CANCER", 75, 79], ["LPMs", "CANCER", 177, 181], ["samples", "CANCER", 232, 239], ["GdCoVs", "PROTEIN", 26, 32], ["These data", "TEST", 0, 10], ["RESULTSPdCoVs", "TEST", 95, 108], ["the LPMs", "TEST", 173, 181], ["the samples", "TEST", 228, 239], ["CoVs", "OBSERVATION", 75, 79], ["backyard flocks", "OBSERVATION", 206, 221]]], ["CdCoVs were found in 76.47% (13/17) of the provinces, 59.09% (39/66) of the LPMs and 36.36% (8/22) of the backyard flocks where the samples were collected.", [["LPMs", "ANATOMY", 76, 80], ["samples", "ANATOMY", 132, 139], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 0, 6], ["LPMs", "CANCER", 76, 80], ["samples", "CANCER", 132, 139], ["CdCoVs", "TEST", 0, 6], ["the LPMs", "TEST", 72, 80], ["the samples", "TEST", 128, 139], ["backyard flocks", "OBSERVATION", 106, 121]]], ["DdCoVs were found in 64.71% (11/17) of the provinces, 42.42 (28/66) of the LPMs, 9.09% (2/22) of the backyard flocks and 7.14% (1/14) of the duck farms where the samples were collected.", [["LPMs", "ANATOMY", 75, 79], ["samples", "ANATOMY", 162, 169], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 0, 6], ["LPMs", "PATHOLOGICAL_FORMATION", 75, 79], ["duck", "ORGANISM", 141, 145], ["samples", "CANCER", 162, 169], ["duck", "SPECIES", 141, 145], ["duck", "SPECIES", 141, 145], ["DdCoVs", "TEST", 0, 6], ["the LPMs", "TEST", 71, 79], ["the backyard flocks", "TEST", 97, 116], ["the samples", "TEST", 158, 169], ["duck", "ANATOMY", 141, 145]]], ["These data suggested that PdCoVs, CdCoVs and DdCoVs were significantly more prevalent in LPMs than in backyard flocks and/or poultry farms in some regions in China with p < .01 by the chi\u2010square test.Surveillance of CoVs in poultry ::: RESULTSOf the aforementioned 170 PdCoVs, 159 were from pigeon samples, and 11 were from non\u2010pigeon samples.", [["LPMs", "ANATOMY", 89, 93], ["pigeon samples", "ANATOMY", 291, 305], ["samples", "ANATOMY", 335, 342], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 26, 32], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 34, 40], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 45, 51], ["LPMs", "PATHOLOGICAL_FORMATION", 89, 93], ["CoVs", "CANCER", 216, 220], ["PdCoVs", "CANCER", 269, 275], ["pigeon", "ORGANISM", 291, 297], ["samples", "CANCER", 298, 305], ["non\u2010pigeon samples", "CANCER", 324, 342], ["PdCoVs", "PROTEIN", 26, 32], ["CdCoVs", "PROTEIN", 34, 40], ["DdCoVs", "PROTEIN", 45, 51], ["PdCoVs", "DNA", 269, 275], ["pigeon", "SPECIES", 291, 297], ["pigeon", "SPECIES", 291, 297], ["These data", "TEST", 0, 10], ["PdCoVs", "PROBLEM", 26, 32], ["CdCoVs", "TREATMENT", 34, 40], ["DdCoVs", "TREATMENT", 45, 51], ["the chi\u2010square test", "TEST", 180, 199], ["PdCoVs", "TEST", 269, 275], ["pigeon samples", "TEST", 291, 305], ["CoVs", "OBSERVATION", 216, 220]]], ["The prevalence of PdCoVs in pigeon swab, faeces and drinking\u2010water samples was 4.96% (20/403), 50.00% (132/264) and 35.00% (7/20).", [["pigeon swab", "ANATOMY", 28, 39], ["faeces", "ANATOMY", 41, 47], ["\u2010water samples", "ANATOMY", 60, 74], ["PdCoVs", "CHEMICAL", 18, 24], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 18, 24], ["pigeon", "ORGANISM", 28, 34], ["swab", "ORGANISM_SUBSTANCE", 35, 39], ["faeces", "ORGANISM_SUBSTANCE", 41, 47], ["PdCoVs", "PROTEIN", 18, 24], ["pigeon", "SPECIES", 28, 34], ["pigeon", "SPECIES", 28, 34], ["pigeon swab", "TREATMENT", 28, 39]]], ["All the collected pigeon faeces and drinking\u2010water samples were found to be CoV negative when they were detected through inoculation in chicken embryonated eggs followed by the conserved RT\u2010PCR assay.", [["faeces", "ANATOMY", 25, 31], ["\u2010water samples", "ANATOMY", 44, 58], ["eggs", "ANATOMY", 156, 160], ["pigeon", "ORGANISM", 18, 24], ["faeces", "ORGANISM_SUBDIVISION", 25, 31], ["\u2010water samples", "ORGANISM_SUBSTANCE", 44, 58], ["CoV", "ORGANISM", 76, 79], ["chicken", "ORGANISM", 136, 143], ["pigeon", "SPECIES", 18, 24], ["chicken", "SPECIES", 136, 143], ["pigeon", "SPECIES", 18, 24], ["chicken", "SPECIES", 136, 143], ["drinking\u2010water samples", "TEST", 36, 58], ["CoV", "TEST", 76, 79], ["chicken embryonated eggs", "TREATMENT", 136, 160], ["the conserved RT\u2010PCR assay", "TEST", 173, 199]]], ["This indicates that PdCoVs replicate poorly in chicken embryonated eggs.", [["eggs", "ANATOMY", 67, 71], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 20, 26], ["chicken", "ORGANISM", 47, 54], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 67, 71], ["PdCoVs", "PROTEIN", 20, 26], ["chicken", "SPECIES", 47, 54], ["chicken", "SPECIES", 47, 54]]], ["As for the eleven non\u2010pigeon\u2010origin PdCoVs, 2 were from chicken swab samples, 8 from duck faeces samples and 1 from goose drinking\u2010water samples.Surveillance of CoVs in poultry ::: RESULTSThe positive rates of CdCoVs, DdCoVs, PdCoVs and GdCoVs in the faeces samples collected in the 3 years were given in Table 2.", [["swab samples", "ANATOMY", 64, 76], ["samples", "ANATOMY", 97, 104], ["samples", "ANATOMY", 137, 144], ["faeces samples", "ANATOMY", 251, 265], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 36, 42], ["chicken", "ORGANISM", 56, 63], ["swab samples", "ORGANISM_SUBSTANCE", 64, 76], ["duck", "ORGANISM", 85, 89], ["faeces samples", "ORGANISM_SUBSTANCE", 90, 104], ["goose", "ORGANISM", 116, 121], ["CoVs", "CANCER", 161, 165], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 210, 216], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 218, 224], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 226, 232], ["GdCoVs", "GENE_OR_GENE_PRODUCT", 237, 243], ["CdCoVs", "PROTEIN", 210, 216], ["DdCoVs", "PROTEIN", 218, 224], ["PdCoVs", "PROTEIN", 226, 232], ["GdCoVs", "PROTEIN", 237, 243], ["chicken", "SPECIES", 56, 63], ["duck", "SPECIES", 85, 89], ["goose", "SPECIES", 116, 121], ["chicken", "SPECIES", 56, 63], ["goose", "SPECIES", 116, 121], ["the eleven non\u2010pigeon\u2010origin PdCoVs", "PROBLEM", 7, 42], ["chicken swab samples", "TEST", 56, 76], ["duck faeces samples", "TEST", 85, 104], ["CdCoVs", "PROBLEM", 210, 216], ["DdCoVs", "PROBLEM", 218, 224], ["PdCoVs", "TREATMENT", 226, 232], ["GdCoVs", "TREATMENT", 237, 243], ["the faeces samples", "TEST", 247, 265], ["CoVs", "OBSERVATION", 161, 165]]], ["This table suggested that CdCoVs, DdCoVs and PdCoVs were all prevalent in their dominant hosts in the 3 years, while GdCoVs were not that prevalent in geese in these 3 years.Surveillance of CoVs in poultry ::: RESULTSOf the detected 5,249 samples, 4,667 were collected from LPMs, 153 were from backyard flocks, and 429 were from poultry farms.", [["samples", "ANATOMY", 239, 246], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 26, 32], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 34, 40], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 45, 51], ["GdCoVs", "GENE_OR_GENE_PRODUCT", 117, 123], ["CoVs", "CANCER", 190, 194], ["LPMs", "CANCER", 274, 278], ["CdCoVs", "PROTEIN", 26, 32], ["DdCoVs", "PROTEIN", 34, 40], ["PdCoVs", "PROTEIN", 45, 51], ["CdCoVs", "PROBLEM", 26, 32], ["PdCoVs", "TREATMENT", 45, 51], ["LPMs", "TEST", 274, 278], ["backyard flocks", "TEST", 294, 309], ["CoVs", "OBSERVATION", 190, 194]]], ["Due\u2010species infections of the CoVs, namely that infections of CdCoVs in chickens, infections of DdCoVs in ducks, infections of PdCoVs in pigeons and infections of GdCoVs in geese, were identified in numerous samples collected in all the three types of poultry sites (Table 3).", [["samples", "ANATOMY", 208, 215], ["infections", "DISEASE", 12, 22], ["infections", "DISEASE", 48, 58], ["CdCoVs", "CHEMICAL", 62, 68], ["infections", "DISEASE", 82, 92], ["DdCoVs", "DISEASE", 96, 102], ["infections", "DISEASE", 113, 123], ["PdCoVs", "CHEMICAL", 127, 133], ["infections", "DISEASE", 149, 159], ["GdCoVs", "CHEMICAL", 163, 169], ["CoVs", "GENE_OR_GENE_PRODUCT", 30, 34], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 62, 68], ["chickens", "ORGANISM", 72, 80], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 96, 102], ["ducks", "ORGANISM", 106, 111], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 127, 133], ["GdCoVs", "GENE_OR_GENE_PRODUCT", 163, 169], ["geese", "ORGANISM", 173, 178], ["chickens", "SPECIES", 72, 80], ["ducks", "SPECIES", 106, 111], ["pigeons", "SPECIES", 137, 144], ["chickens", "SPECIES", 72, 80], ["the CoVs", "PROBLEM", 26, 34], ["CdCoVs in chickens", "PROBLEM", 62, 80], ["infections", "PROBLEM", 82, 92], ["DdCoVs in ducks", "PROBLEM", 96, 111], ["infections", "PROBLEM", 113, 123], ["PdCoVs", "PROBLEM", 127, 133], ["infections of GdCoVs", "PROBLEM", 149, 169], ["CoVs", "OBSERVATION_MODIFIER", 30, 34], ["infections", "OBSERVATION", 48, 58], ["infections", "OBSERVATION", 82, 92], ["infections", "OBSERVATION", 113, 123], ["infections", "OBSERVATION_MODIFIER", 149, 159], ["numerous", "OBSERVATION_MODIFIER", 199, 207], ["three types", "OBSERVATION_MODIFIER", 237, 248], ["poultry sites", "OBSERVATION", 252, 265]]], ["In contrast, cross\u2010species infections of the CoVs, namely that infections of CdCoVs in birds other than chickens, infections of DdCoVs in birds other than ducks, infections of PdCoVs in birds other than pigeons and infections of GdCoVs in birds other than geese, were identified in 68 of the 5,249 samples from LPMs (49 with CdCoVs, 8 with DdCoVs and 11 with PdCoVs), and in none of the 153 samples from backyard flocks and the 429 samples from poultry farms.Analysis of the sequences of seven conserved domains ::: RESULTSWe detected in this study the sequences of the seven conserved domains in the viral replicase gene (namely ADRP in nsp3, nsp5, nsp12, nsp13, nsp14, nsp15 and nsp16) of seven PdCoVs: PdCoV/PG/Guangdong/1418/2014, PdCoV/PG/Guangdong/1068/2014, PdCoV/PG/Guangdong/1507/2014, PdCoV/PG/Jiangsu/9\u20101\u20103/2018, PdCoV/PG/Jiangsu/9\u20104\u20106/2018, PdCoV/PG/Jiangsu/9\u20107\u20109/2018 and PdCoV/PG/Hebei/15\u20104\u20106/2018.Analysis of the sequences of seven conserved domains ::: RESULTSAs compared to CdCoV and DdCoV sequences, thousands of substitutions and dozens of insertions or deletions occurred in PdCoVs in the seven conserved domains.", [["samples", "ANATOMY", 298, 305], ["LPMs", "ANATOMY", 311, 315], ["samples", "ANATOMY", 391, 398], ["samples", "ANATOMY", 432, 439], ["infections", "DISEASE", 27, 37], ["infections", "DISEASE", 63, 73], ["CdCoVs", "CHEMICAL", 77, 83], ["infections", "DISEASE", 114, 124], ["DdCoVs", "DISEASE", 128, 134], ["infections", "DISEASE", 162, 172], ["PdCoVs", "CHEMICAL", 176, 182], ["infections", "DISEASE", 215, 225], ["GdCoVs", "CHEMICAL", 229, 235], ["LPMs", "DISEASE", 311, 315], ["PG", "CHEMICAL", 711, 713], ["PG", "CHEMICAL", 741, 743], ["PG", "CHEMICAL", 771, 773], ["CoVs", "GENE_OR_GENE_PRODUCT", 45, 49], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 77, 83], ["birds", "ORGANISM", 87, 92], ["chickens", "ORGANISM", 104, 112], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 128, 134], ["ducks", "ORGANISM", 155, 160], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 176, 182], ["GdCoVs", "GENE_OR_GENE_PRODUCT", 229, 235], ["LPMs", "CANCER", 311, 315], ["ADRP", "GENE_OR_GENE_PRODUCT", 630, 634], ["nsp3", "GENE_OR_GENE_PRODUCT", 638, 642], ["nsp5", "GENE_OR_GENE_PRODUCT", 644, 648], ["nsp12", "GENE_OR_GENE_PRODUCT", 650, 655], ["nsp13", "GENE_OR_GENE_PRODUCT", 657, 662], ["nsp14", "GENE_OR_GENE_PRODUCT", 664, 669], ["nsp15", "GENE_OR_GENE_PRODUCT", 671, 676], ["nsp16", "GENE_OR_GENE_PRODUCT", 681, 686], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 697, 703], ["PdCoV", "GENE_OR_GENE_PRODUCT", 705, 710], ["PdCoV", "GENE_OR_GENE_PRODUCT", 735, 740], ["CdCoV", "GENE_OR_GENE_PRODUCT", 991, 996], ["viral replicase gene", "DNA", 601, 621], ["ADRP", "DNA", 630, 634], ["nsp3", "DNA", 638, 642], ["nsp5", "DNA", 644, 648], ["nsp12", "DNA", 650, 655], ["nsp13", "DNA", 657, 662], ["nsp14", "DNA", 664, 669], ["nsp15", "DNA", 671, 676], ["nsp16", "DNA", 681, 686], ["PdCoV", "DNA", 885, 890], ["PG", "DNA", 891, 893], ["Hebei", "DNA", 894, 899], ["15\u20104\u20106/2018", "DNA", 900, 911], ["CdCoV and DdCoV sequences", "DNA", 991, 1016], ["PdCoVs", "DNA", 1095, 1101], ["chickens", "SPECIES", 104, 112], ["ducks", "SPECIES", 155, 160], ["chickens", "SPECIES", 104, 112], ["Guangdong/1418/2014, PdCoV/PG/Guangdong/1068/2014, PdCoV/PG/Guangdong/1507/2014, PdCoV/PG/Jiangsu/9\u20101\u20103/2018, PdCoV/PG/Jiangsu/9\u20104\u20106/2018, PdCoV/PG/Jiangsu/9\u20107\u20109/2018 and PdCoV/PG/Hebei/15\u20104\u20106/2018", "SPECIES", 714, 911], ["the CoVs", "PROBLEM", 41, 49], ["CdCoVs", "PROBLEM", 77, 83], ["DdCoVs", "PROBLEM", 128, 134], ["infections of PdCoVs", "PROBLEM", 162, 182], ["infections of GdCoVs", "PROBLEM", 215, 235], ["LPMs", "TEST", 311, 315], ["CdCoVs", "TEST", 325, 331], ["DdCoVs", "TEST", 340, 346], ["PdCoVs", "TEST", 359, 365], ["backyard flocks", "TEST", 404, 419], ["the sequences", "TEST", 471, 484], ["this study", "TEST", 538, 548], ["the viral replicase gene", "TEST", 597, 621], ["ADRP", "TEST", 630, 634], ["nsp3", "TEST", 638, 642], ["nsp5", "TEST", 644, 648], ["nsp12", "TEST", 650, 655], ["nsp13", "TEST", 657, 662], ["nsp14", "TEST", 664, 669], ["nsp15", "TEST", 671, 676], ["nsp16", "TEST", 681, 686], ["PdCoV", "TEST", 853, 858], ["PdCoV", "TEST", 885, 890], ["the sequences", "TEST", 924, 937], ["RESULTSAs", "TEST", 969, 978], ["CdCoV", "TEST", 991, 996], ["DdCoV sequences", "TEST", 1001, 1016], ["substitutions", "PROBLEM", 1031, 1044], ["dozens of insertions", "TREATMENT", 1049, 1069], ["deletions", "PROBLEM", 1073, 1082], ["PdCoVs", "TREATMENT", 1095, 1101], ["infections", "OBSERVATION", 63, 73], ["infections", "OBSERVATION", 114, 124], ["infections", "OBSERVATION", 162, 172], ["infections", "OBSERVATION", 215, 225], ["viral replicase", "OBSERVATION", 601, 616]]], ["For example, as shown in Figure 3, two obvious insertions or deletions were found in the Nsp12 domain of PdCoVs as compared with the sequences of CdCoVs and DdCoVs.Analysis of the sequences of seven conserved domains ::: RESULTSPhylogenetic analysis of the sequences of the seven domains combined together, as shown in Figure 4, suggested that the PdCoVs, DdCoVs and CdCoVs belong to different lineages.", [["PdCoVs", "GENE_OR_GENE_PRODUCT", 105, 111], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 146, 152], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 157, 163], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 348, 354], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 356, 362], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 367, 373], ["Nsp12 domain", "DNA", 89, 101], ["PdCoVs", "PROTEIN", 105, 111], ["CdCoVs", "DNA", 146, 152], ["DdCoVs", "DNA", 157, 163], ["PdCoVs", "DNA", 348, 354], ["DdCoVs", "DNA", 356, 362], ["CdCoVs", "DNA", 367, 373], ["two obvious insertions or deletions", "PROBLEM", 35, 70], ["PdCoVs", "TREATMENT", 105, 111], ["CdCoVs", "TREATMENT", 146, 152], ["DdCoVs", "TREATMENT", 157, 163], ["the sequences", "TEST", 176, 189], ["RESULTSPhylogenetic analysis", "TEST", 221, 249], ["the sequences", "TEST", 253, 266], ["the PdCoVs", "PROBLEM", 344, 354], ["DdCoVs", "PROBLEM", 356, 362], ["CdCoVs", "TREATMENT", 367, 373], ["obvious", "OBSERVATION_MODIFIER", 39, 46], ["insertions", "OBSERVATION", 47, 57]]], ["The PdCoVs, DdCoVs and CdCoVs also belong to different lineages based on each of these seven conserved domains, with the exceptions that DdCoV/DK/Guangdong/2014 is located in the same lineage with the 12 CdCoVs based on the nsp5 gene sequences and the nsp16 gene sequences (Zhuang et al., 2015).", [["PdCoVs", "GENE_OR_GENE_PRODUCT", 4, 10], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 12, 18], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 23, 29], ["DdCoV", "GENE_OR_GENE_PRODUCT", 137, 142], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 204, 210], ["nsp5", "GENE_OR_GENE_PRODUCT", 224, 228], ["nsp16", "GENE_OR_GENE_PRODUCT", 252, 257], ["PdCoVs", "PROTEIN", 4, 10], ["DdCoVs", "PROTEIN", 12, 18], ["CdCoVs", "PROTEIN", 23, 29], ["DdCoV", "PROTEIN", 137, 142], ["2014", "PROTEIN", 156, 160], ["CdCoVs", "DNA", 204, 210], ["nsp5 gene sequences", "DNA", 224, 243], ["nsp16 gene sequences", "DNA", 252, 272], ["The PdCoVs", "TREATMENT", 0, 10], ["DdCoVs", "TREATMENT", 12, 18], ["CdCoVs", "TREATMENT", 23, 29], ["the nsp5 gene sequences", "TEST", 220, 243]]], ["The exceptions might be caused by genomic recombination (Zhuang et al., 2015).Analysis of the sequences of seven conserved domains ::: RESULTSAs given in Table 4, the identity between seven PdCoVs reported herein and twelve randomly selected CdCoVs (ten from chickens, one from turkeys and one from peafowl) and three DdCoVs in the combined amino acid sequences of the seven conserved domains in the viral replicase gene is 83.6%\u201385.1% between PdCoVs and CdCoVs, 86.7%\u201389.8% between PdCoVs and DdCoVs and 85.5%\u201389.0% between CdCoVs and DdCoVs.", [["amino acid", "CHEMICAL", 341, 351], ["amino acid", "CHEMICAL", 341, 351], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 190, 196], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 242, 248], ["chickens", "ORGANISM", 259, 267], ["turkeys", "ORGANISM", 278, 285], ["peafowl", "CANCER", 299, 306], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 318, 324], ["amino acid", "AMINO_ACID", 341, 351], ["PdCoVs", "CANCER", 444, 450], ["CdCoVs", "CANCER", 455, 461], ["PdCoVs", "CANCER", 483, 489], ["DdCoVs", "CANCER", 494, 500], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 525, 531], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 536, 542], ["PdCoVs", "DNA", 190, 196], ["CdCoVs", "PROTEIN", 242, 248], ["DdCoVs", "PROTEIN", 318, 324], ["viral replicase gene", "DNA", 400, 420], ["CdCoVs", "PROTEIN", 525, 531], ["DdCoVs", "PROTEIN", 536, 542], ["chickens", "SPECIES", 259, 267], ["turkeys", "SPECIES", 278, 285], ["chickens", "SPECIES", 259, 267], ["the sequences", "TEST", 90, 103], ["the combined amino acid sequences", "TEST", 328, 361], ["the viral replicase gene", "TEST", 396, 420], ["PdCoVs", "TEST", 444, 450], ["CdCoVs", "TEST", 455, 461], ["PdCoVs", "TEST", 483, 489], ["DdCoVs", "TEST", 494, 500], ["CdCoVs", "TEST", 525, 531], ["DdCoVs", "PROBLEM", 536, 542], ["might be caused", "UNCERTAINTY", 15, 30], ["viral replicase", "OBSERVATION", 400, 415]]], ["In contrast, the corresponding amino acid identity is 97.0%\u201398.5% among the seven PdCoVs, 94.7%\u201397.3% among the twelve CdCoVs and 94.6%\u201398.9% among the three DdCoVs.", [["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "AMINO_ACID", 31, 41], ["PdCoVs", "CANCER", 82, 88], ["CdCoVs", "CANCER", 119, 125], ["CdCoVs", "PROTEIN", 119, 125], ["DdCoVs", "PROTEIN", 158, 164], ["the corresponding amino acid identity", "TEST", 13, 50], ["PdCoVs", "TEST", 82, 88], ["the twelve CdCoVs", "TEST", 108, 125]]], ["Therefore, according to the sole species demarcation criterion for CoVs that the viruses sharing more than 90% amino acid sequence identity in these seven conserved domains belong to the same species (de Groot et al., 2012), the PdCoVs, DdCoVs and CdCoVs should belong to three different species.DISCUSSIONThe large\u2010scale surveillance of this study revealed that PdCoVs, DdCoVs and CdCoVs mainly circulate in pigeons, ducks and chickens, respectively, and they belong to different phylogenetic lineages.", [["amino acid", "CHEMICAL", 111, 121], ["amino acid", "CHEMICAL", 111, 121], ["CoVs", "GENE_OR_GENE_PRODUCT", 67, 71], ["amino acid", "AMINO_ACID", 111, 121], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 229, 235], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 237, 243], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 248, 254], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 363, 369], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 371, 377], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 382, 388], ["pigeons", "ORGANISM", 409, 416], ["ducks", "ORGANISM", 418, 423], ["chickens", "ORGANISM", 428, 436], ["CoVs", "PROTEIN", 67, 71], ["PdCoVs", "PROTEIN", 229, 235], ["DdCoVs", "PROTEIN", 237, 243], ["CdCoVs", "PROTEIN", 248, 254], ["PdCoVs", "PROTEIN", 363, 369], ["DdCoVs", "PROTEIN", 371, 377], ["CdCoVs", "PROTEIN", 382, 388], ["ducks", "SPECIES", 418, 423], ["chickens", "SPECIES", 428, 436], ["chickens", "SPECIES", 428, 436], ["CoVs", "PROBLEM", 67, 71], ["the viruses", "PROBLEM", 77, 88], ["amino acid sequence identity", "PROBLEM", 111, 139], ["the PdCoVs, DdCoVs and CdCoVs", "PROBLEM", 225, 254], ["this study", "TEST", 338, 348], ["PdCoVs", "PROBLEM", 363, 369], ["DdCoVs", "TREATMENT", 371, 377], ["CdCoVs", "TREATMENT", 382, 388], ["phylogenetic lineages", "OBSERVATION", 481, 502]]], ["According to the official criteria of ICTV definition for demarcation of CoV species, the genetic distances between PdCoVs, DdCoVs and CdCoVs in the seven conserved domains are large enough to separate them into different species in the genus Gammacoronavirus (de Groot et al., 2012).", [["CoV", "ORGANISM", 73, 76], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 116, 122], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 124, 130], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 135, 141], ["PdCoVs", "PROTEIN", 116, 122], ["DdCoVs", "PROTEIN", 124, 130], ["CdCoVs", "PROTEIN", 135, 141], ["CoV species", "PROBLEM", 73, 84], ["PdCoVs", "TREATMENT", 116, 122], ["DdCoVs and CdCoVs in the seven conserved domains", "PROBLEM", 124, 172], ["CoV species", "OBSERVATION", 73, 84], ["large", "OBSERVATION", 177, 182], ["different", "OBSERVATION_MODIFIER", 212, 221], ["species", "OBSERVATION_MODIFIER", 222, 229], ["genus Gammacoronavirus", "ANATOMY", 237, 259]]], ["Classifying PdCoVs, DdCoVs and CdCoVs into different species also meets the definition of virus species that a virus species is a polythetic class of viruses that constitutes a replicating lineage and occupies a particular ecological niche (de Groot et al., 2012).DISCUSSIONCurrently, the subgenus Igacovirus of the genus Gammacoronavirus is represented by the species of Avian coronavirus covering IBVs in chickens and related CoVs in turkeys and other birds (de Groot et al., 2012).", [["Avian coronavirus", "DISEASE", 372, 389], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 12, 18], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 20, 26], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 31, 37], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 322, 338], ["Avian coronavirus", "ORGANISM", 372, 389], ["IBVs", "CANCER", 399, 403], ["chickens", "ORGANISM", 407, 415], ["CoVs", "GENE_OR_GENE_PRODUCT", 428, 432], ["turkeys", "ORGANISM", 436, 443], ["PdCoVs", "PROTEIN", 12, 18], ["DdCoVs", "PROTEIN", 20, 26], ["CdCoVs", "PROTEIN", 31, 37], ["Avian coronavirus", "SPECIES", 372, 389], ["chickens", "SPECIES", 407, 415], ["turkeys", "SPECIES", 436, 443], ["Avian coronavirus", "SPECIES", 372, 389], ["chickens", "SPECIES", 407, 415], ["turkeys", "SPECIES", 436, 443], ["PdCoVs", "PROBLEM", 12, 18], ["DdCoVs", "PROBLEM", 20, 26], ["CdCoVs into different species", "PROBLEM", 31, 60], ["virus species", "PROBLEM", 90, 103], ["a virus species", "PROBLEM", 109, 124], ["the genus Gammacoronavirus", "PROBLEM", 312, 338], ["Avian coronavirus", "TREATMENT", 372, 389], ["IBVs", "TREATMENT", 399, 403], ["genus Gammacoronavirus", "OBSERVATION", 316, 338], ["CoVs", "OBSERVATION_MODIFIER", 428, 432]]], ["The designation has become questionable because some CoVs in wild birds have been identified to be members of another genus Deltacoronavirus (Woo et al., 2012).", [["CoVs", "GENE_OR_GENE_PRODUCT", 53, 57], ["wild birds", "ORGANISM", 61, 71], ["CoVs", "PROTEIN", 53, 57], ["some CoVs in wild birds", "PROBLEM", 48, 71]]], ["In this report, we further challenged the designation of Avian coronavirus as we provided evidence in supporting that the CoVs dominant, respectively, in pigeons, ducks and chickens likely belong to different species.DISCUSSIONThis study indicates that PdCoVs likely replicate poorly in embryonated chicken eggs, and this is consistent with a previous report which showed no replication in embryonated chicken eggs could be achieved for pigeon or goose coronaviruses (Jonassen et al., 2005).", [["eggs", "ANATOMY", 307, 311], ["eggs", "ANATOMY", 410, 414], ["Avian coronavirus", "DISEASE", 57, 74], ["Avian coronavirus", "ORGANISM", 57, 74], ["CoVs", "GENE_OR_GENE_PRODUCT", 122, 126], ["pigeons", "ORGANISM", 154, 161], ["ducks", "ORGANISM", 163, 168], ["chickens", "ORGANISM", 173, 181], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 253, 259], ["chicken", "ORGANISM", 299, 306], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 307, 311], ["chicken", "ORGANISM", 402, 409], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 410, 414], ["pigeon", "ORGANISM", 437, 443], ["goose coronaviruses", "ORGANISM", 447, 466], ["PdCoVs", "PROTEIN", 253, 259], ["Avian coronavirus", "SPECIES", 57, 74], ["pigeons", "SPECIES", 154, 161], ["ducks", "SPECIES", 163, 168], ["chickens", "SPECIES", 173, 181], ["chicken", "SPECIES", 299, 306], ["chicken", "SPECIES", 402, 409], ["pigeon", "SPECIES", 437, 443], ["goose", "SPECIES", 447, 452], ["Avian coronavirus", "SPECIES", 57, 74], ["chickens", "SPECIES", 173, 181], ["chicken", "SPECIES", 299, 306], ["chicken", "SPECIES", 402, 409], ["pigeon", "SPECIES", 437, 443], ["goose coronaviruses", "SPECIES", 447, 466], ["Avian coronavirus", "PROBLEM", 57, 74], ["the CoVs dominant", "PROBLEM", 118, 135], ["DISCUSSIONThis study", "TEST", 217, 237], ["replication", "PROBLEM", 375, 386], ["embryonated chicken eggs", "TREATMENT", 390, 414]]], ["Therefore, the detection procedure with inoculation in chicken embryonated eggs used in this study is not suitable for the detection of PdCoVs, although it is suitable for surveillance of AIVs, NDVs and CdCoVs.", [["eggs", "ANATOMY", 75, 79], ["chicken", "ORGANISM", 55, 62], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 136, 142], ["AIVs", "GENE_OR_GENE_PRODUCT", 188, 192], ["NDVs", "GENE_OR_GENE_PRODUCT", 194, 198], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 203, 209], ["CdCoVs", "PROTEIN", 203, 209], ["chicken", "SPECIES", 55, 62], ["chicken", "SPECIES", 55, 62], ["the detection procedure", "TREATMENT", 11, 34], ["inoculation", "TREATMENT", 40, 51], ["chicken embryonated eggs", "TREATMENT", 55, 79], ["this study", "TEST", 88, 98], ["PdCoVs", "PROBLEM", 136, 142], ["AIVs", "PROBLEM", 188, 192], ["NDVs", "TREATMENT", 194, 198], ["CdCoVs", "TREATMENT", 203, 209], ["AIVs", "OBSERVATION", 188, 192]]], ["Consequently, the prevalence of PdCoVs in pigeon swab samples detected in this study with inoculation in chicken embryonated eggs could be underestimated.DISCUSSIONOur surveillance results suggest that PdCoVs, CdCoVs and DdCoVs are significantly more prevalent at LPMs than in backyard flocks and farms in some regions in China.", [["swab samples", "ANATOMY", 49, 61], ["eggs", "ANATOMY", 125, 129], ["PdCoVs", "CHEMICAL", 32, 38], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 32, 38], ["pigeon", "ORGANISM", 42, 48], ["swab samples", "ORGANISM_SUBSTANCE", 49, 61], ["chicken", "ORGANISM", 105, 112], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 202, 208], ["CdCoVs", "GENE_OR_GENE_PRODUCT", 210, 216], ["DdCoVs", "GENE_OR_GENE_PRODUCT", 221, 227], ["PdCoVs", "PROTEIN", 32, 38], ["PdCoVs", "PROTEIN", 202, 208], ["CdCoVs", "PROTEIN", 210, 216], ["DdCoVs", "PROTEIN", 221, 227], ["pigeon", "SPECIES", 42, 48], ["chicken", "SPECIES", 105, 112], ["pigeon", "SPECIES", 42, 48], ["chicken", "SPECIES", 105, 112], ["PdCoVs", "PROBLEM", 32, 38], ["pigeon swab samples", "TEST", 42, 61], ["this study", "TEST", 74, 84], ["inoculation in chicken embryonated eggs", "TREATMENT", 90, 129], ["PdCoVs", "TREATMENT", 202, 208], ["CdCoVs", "TREATMENT", 210, 216], ["DdCoVs", "TREATMENT", 221, 227], ["significantly", "OBSERVATION_MODIFIER", 232, 245], ["more prevalent", "OBSERVATION_MODIFIER", 246, 260], ["farms", "OBSERVATION", 297, 302], ["China", "ANATOMY", 322, 327]]], ["Cross\u2010species infections of the CoVs were only identified in some samples from LPMs, and none were identified from backyard flocks and poultry farms.", [["samples", "ANATOMY", 66, 73], ["LPMs", "ANATOMY", 79, 83], ["infections", "DISEASE", 14, 24], ["CoVs", "GENE_OR_GENE_PRODUCT", 32, 36], ["LPMs", "CANCER", 79, 83], ["CoVs", "DNA", 32, 36], ["Cross\u2010species infections", "PROBLEM", 0, 24], ["the CoVs", "PROBLEM", 28, 36], ["LPMs", "TEST", 79, 83], ["CoVs", "ANATOMY", 32, 36], ["backyard flocks", "OBSERVATION", 115, 130], ["poultry farms", "OBSERVATION", 135, 148]]], ["Therefore, LPMs likely play an important role in the circulation of a diversity of CoVs in poultry, as they do in the circulation of AIVs (Jiang et al., 2012).DISCUSSIONRecently, researchers identified a CoV from pigeons which has been regarded as a member of Deltacoronavirus (Lau et al., 2018), and this CoV was phylogenetically distinct from all avian CoVs within Gammacoronavirus.", [["LPMs", "GENE_OR_GENE_PRODUCT", 11, 15], ["CoVs", "GENE_OR_GENE_PRODUCT", 83, 87], ["CoV", "ORGANISM", 204, 207], ["pigeons", "ORGANISM", 213, 220], ["Deltacoronavirus", "ORGANISM", 260, 276], ["CoV", "ORGANISM", 306, 309], ["avian", "ORGANISM", 349, 354], ["CoVs", "CANCER", 355, 359], ["Gammacoronavirus", "CANCER", 367, 383], ["LPMs", "TREATMENT", 11, 15], ["CoVs", "PROBLEM", 83, 87], ["this CoV", "PROBLEM", 301, 309], ["all avian CoVs within Gammacoronavirus", "PROBLEM", 345, 383], ["avian CoVs", "OBSERVATION", 349, 359]]], ["It remains unknown whether this CoV is prevalent in pigeons or other birds.DISCUSSIONPigeons are widely distributed in many countries mainly for pigeon racing and food consumption (Ashton, 1984; Stenzel, Pestka, Tykalowski, Smialek, & Koncicki, 2012).", [["CoV", "ORGANISM", 32, 35], ["pigeons", "ORGANISM", 52, 59], ["pigeon", "ORGANISM", 145, 151], ["food", "ORGANISM_SUBDIVISION", 163, 167], ["pigeon", "SPECIES", 145, 151], ["pigeon", "SPECIES", 145, 151], ["this CoV", "PROBLEM", 27, 35]]], ["Although we identified in this study that PdCoVs are prevalent in pigeons in China, it remains unknown about pathogenicity of PdCoVs which is worth studying in the future.DISCUSSIONIn conclusion, this study shed novel insight into the genetic diversity, distribution, evolution and taxonomy of avian CoVs.", [["PdCoVs", "GENE_OR_GENE_PRODUCT", 42, 48], ["PdCoVs", "GENE_OR_GENE_PRODUCT", 126, 132], ["avian", "ORGANISM", 294, 299], ["CoVs", "GENE_OR_GENE_PRODUCT", 300, 304], ["PdCoVs", "PROTEIN", 42, 48], ["this study", "TEST", 26, 36], ["PdCoVs", "PROBLEM", 126, 132], ["this study", "TEST", 196, 206], ["avian CoVs", "OBSERVATION", 294, 304]]], ["Continuous surveillance and studies on avian CoVs will help to better understand the diversity, distribution, cross\u2010species transmission and clinical significance of these viruses.CONFLICT OF INTERESTAll the authors declare that they have no conflict of interest.AUTHOR CONTRIBUTIONSJiming Chen and Qingye Zhuang conceived and designed the study; Qingye Zhuang, Shuo Liu, Guangyu Hou, Suchun Wang, Jinping Li, Xiaochun Zhang and Jingjing Wang performed the experiment; Qingye Zhuang, Jiming Chen, Hualei Liu, Wenming Jiang, Kaicheng Wang, Cheng Peng, Xiaohui Yu, Liping Yuan and Yang Li conducted data analysis; Qingye Zhuang and Jiming Chen wrote and revised the paper.ETHICAL APPROVALAll applicable international, national and/or institutional guidelines for the care and use of animals were followed.", [["avian", "ORGANISM", 39, 44], ["CoVs", "MULTI-TISSUE_STRUCTURE", 45, 49], ["animals", "ORGANISM", 781, 788], ["avian", "SPECIES", 39, 44], ["Continuous surveillance and studies", "TEST", 0, 35], ["avian CoVs", "TREATMENT", 39, 49], ["these viruses", "PROBLEM", 166, 179], ["the study", "TEST", 336, 345], ["viruses", "OBSERVATION", 172, 179]]]], "296ac973286df20a9f9a5e5374f37998654d5c8a": [["Strengths and limitations of this study\uf0b7 Childhood maltreatment and domestic abuse are global public health issues associated with substantial morbidity and mortality.", [["Childhood maltreatment", "DISEASE", 41, 63], ["domestic abuse", "DISEASE", 68, 82], ["this study", "TEST", 29, 39], ["Childhood maltreatment", "PROBLEM", 41, 63], ["global public health issues", "PROBLEM", 87, 114], ["substantial morbidity", "PROBLEM", 131, 152], ["substantial", "OBSERVATION_MODIFIER", 131, 142], ["morbidity", "OBSERVATION", 143, 152]]], ["Public sector bodies, such as those working in healthcare, are in a position to identify and support those who have experienced such traumatic experiences in order to prevent the development of subsequent negative consequences \uf0b7 To our knowledge this is the first study to describe the incidence and prevalence of domestic abuse using UK primary care data and to update evidence regarding the occurrence of childhood maltreatment in the last two decades \uf0b7 The study was able to examine patients by age, gender, deprivation and ethnicity.Strengths and limitations of this studyHowever, for ethnicity there was missing data. \uf0b7 There is a substantial under-recording of Read codes relating to childhood maltreatment and domestic abuse within this dataset \uf0b7 There are several explanations for the possible under-recording, these need to be further studied in detail.INTRODUCTIONChildhood maltreatment (physical, sexual or emotional abuse and neglect against those under the age of 18 years) 1 and domestic abuse (controlling, coercive, threatening behaviour, violence or abuse between those who are, or have been, intimate partners or family members) 2 are global public health problems.", [["domestic abuse", "DISEASE", 314, 328], ["maltreatment", "DISEASE", 417, 429], ["maltreatment", "DISEASE", 700, 712], ["domestic abuse", "DISEASE", 717, 731], ["maltreatment", "DISEASE", 884, 896], ["physical, sexual or emotional abuse and neglect", "DISEASE", 898, 945], ["domestic abuse", "DISEASE", 993, 1007], ["violence", "DISEASE", 1055, 1063], ["patients", "ORGANISM", 486, 494], ["patients", "SPECIES", 486, 494], ["The study", "TEST", 456, 465], ["this study", "TEST", 566, 576], ["global public health problems", "PROBLEM", 1153, 1182], ["substantial", "OBSERVATION_MODIFIER", 636, 647]]], ["Approximately one third of women and one third of children globally are estimated to have been survivors of domestic abuse and childhood maltreatment respectively.", [["domestic abuse", "DISEASE", 108, 122], ["maltreatment", "DISEASE", 137, 149], ["women", "ORGANISM", 27, 32], ["children", "ORGANISM", 50, 58], ["women", "SPECIES", 27, 32], ["children", "SPECIES", 50, 58]]], ["3, 4 The negative downstream social, psychological and physical health effects of childhood maltreatment and domestic abuse bear a substantial societal cost.", [["maltreatment", "DISEASE", 92, 104], ["domestic abuse", "DISEASE", 109, 123], ["substantial", "OBSERVATION_MODIFIER", 131, 142]]], ["[5] [6] [7] [8] [9] [10] Therefore, a public health approach is urgently needed to prevent both the occurrence of childhood maltreatment and domestic abuse as well as their secondary consequences.", [["maltreatment", "DISEASE", 124, 136], ["domestic abuse", "DISEASE", 141, 155], ["[5] [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 0, 24], ["a public health approach", "TREATMENT", 36, 60]]], ["In order to support a public health approach, high quality data recording relating to these exposures plays an important role.", [["a public health approach", "TREATMENT", 20, 44]]], ["Exploring the role of routinely collected data (which due its repeatable nature can be used for surveillance) is crucial in both the estimation of the societal burden of disease as well as the identification of risk and protective factors.", [["routinely collected data", "TEST", 22, 46], ["surveillance", "TEST", 96, 108], ["disease", "PROBLEM", 170, 177], ["disease", "OBSERVATION", 170, 177]]], ["11 Exposure to domestic abuse and childhood maltreatment remain taboo topics in many cultures, despite the adverse consequences in terms of health and wellbeing, with significant stigma around disclosure of traumatic events.", [["domestic abuse", "DISEASE", 15, 29], ["maltreatment", "DISEASE", 44, 56], ["childhood maltreatment", "PROBLEM", 34, 56], ["many cultures", "TEST", 80, 93], ["significant stigma", "PROBLEM", 167, 185], ["traumatic events", "PROBLEM", 207, 223], ["significant", "OBSERVATION_MODIFIER", 167, 178], ["stigma", "OBSERVATION", 179, 185], ["traumatic", "OBSERVATION", 207, 216]]], ["12, 13 As a result, survivors of such traumatic experiences often find it difficult to attend and seek support from public sector authorities such as healthcare staff.", [["such traumatic experiences", "PROBLEM", 33, 59]]], ["14, 15 There are also challenges for healthcare staff to routinely enquire or ask about such experiences in their patients' lives.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122]]], ["16 The combination of barriers to disclosure and enquiry are likely to lead to a hidden burden of domestic abuse and childhood maltreatment not captured in administrative public sector data.", [["domestic abuse", "DISEASE", 98, 112], ["maltreatment", "DISEASE", 127, 139]]], ["However, since introductions of new guidelines in the UK (National Institute of Health and Care Excellence in 2016 and 2017), the hope has been that administrative recording will have improved.", [["improved", "OBSERVATION_MODIFIER", 184, 192]]], ["17, 18 This drive towards improved reporting is spurred on by UK media and governmental interest in these topics (Examples of high profile events leading to media and governmental interest includes: the death of Baby P, the Jimmy Savile inquiry, Operation Yewtree, the death of Daniel Pelka, the identification and referral to improve safety (IRIS) trial and the consideration of the domestic abuse bill), administrative recording will have improved.", [["death", "DISEASE", 203, 208], ["death", "DISEASE", 269, 274], ["IRIS", "DISEASE", 343, 347], ["high profile events", "PROBLEM", 126, 145], ["improved", "OBSERVATION_MODIFIER", 441, 449]]], ["[19] [20] [21] [22] [23] Current UK national estimates of domestic abuse are largely derived from self-reported surveys in conjunction with administrative data, where suitable, to overcome the challenge of estimating the hidden burden of abuse which may not be visible to public sector bodies.", [["[19] [20] [21] [22", "SIMPLE_CHEMICAL", 0, 18], ["may not be", "UNCERTAINTY", 250, 260]]], ["The crime survey for England and Wales (CSEW) provides useful self-reported information and used in conjunction with police records of the number of recorded domestic abuse incidents to define epidemiological estimates of domestic abuse.", [["domestic abuse", "DISEASE", 158, 172], ["domestic abuse", "DISEASE", 222, 236]]], ["In women, the reported prevalence from the CSEW (for those aged 16-59 years old) was 7.9% in the financial year 2017/2018 while the crude estimate derived from police data for the year ending 2017 (not yet available for 2018 for those aged 16 and over) across England was 24.0/1,000 population (in men and women).", [["women", "ORGANISM", 3, 8], ["men", "ORGANISM", 298, 301], ["women", "ORGANISM", 306, 311], ["women", "SPECIES", 3, 8], ["men", "SPECIES", 298, 301], ["women", "SPECIES", 306, 311]]], ["There is no specific international classification of disease code that are specific to domestic abuse: The closest matches are T74.1 (physical abuse, confirmed), Y07.0 (spouse or partner, perpetrator of maltreatment and neglect) and Z63.0 (and problems in a relationship with spouse or partner) which when specified in adults relate to physical abuse, maltreatment.", [["domestic abuse", "DISEASE", 87, 101], ["maltreatment", "DISEASE", 203, 215], ["neglect", "DISEASE", 220, 227], ["physical abuse", "DISEASE", 336, 350], ["maltreatment", "DISEASE", 352, 364], ["neglect", "PROBLEM", 220, 227], ["no", "UNCERTAINTY", 9, 11], ["disease", "OBSERVATION", 53, 60]]], ["26 However, there are substantial limitations to utilising these codes to describe the epidemiology of domestic abuse, due to low numbers of such codes being recorded and also ambiguities in coding practice between hospital trusts.", [["domestic abuse", "DISEASE", 103, 117], ["substantial", "OBSERVATION_MODIFIER", 22, 33]]], ["26 The state of epidemiological estimates when exploring childhood maltreatment suffers from similar challenges.", [["maltreatment", "DISEASE", 67, 79]]], ["A recent observational study utilised data from 1858-2016 that was derived from child mortality records, police recorded-homicides, crimes against children, child protection data, children in care and data taken from the National Society for the Prevention of Cruelty to Children (NSPCC) to study long term trends of child maltreatment.", [["maltreatment", "DISEASE", 323, 335], ["children", "ORGANISM", 147, 155], ["children", "ORGANISM", 180, 188], ["children", "SPECIES", 147, 155], ["children", "SPECIES", 180, 188], ["Children", "SPECIES", 271, 279], ["A recent observational study", "TEST", 0, 28]]], ["The study found a decreasing long-term trend in child maltreatment until the year 2000 but reported an increase thereafter.", [["maltreatment", "DISEASE", 54, 66], ["The study", "TEST", 0, 9], ["decreasing", "OBSERVATION_MODIFIER", 18, 28], ["long-term", "OBSERVATION_MODIFIER", 29, 38], ["increase", "OBSERVATION_MODIFIER", 103, 111]]], ["27 However child mortality continued to decrease.", [["child mortality", "PROBLEM", 11, 26], ["decrease", "OBSERVATION_MODIFIER", 40, 48]]], ["27 A recommendation of the report was to further research and establish whether child maltreatment is continuing to increase.", [["maltreatment", "DISEASE", 86, 98]]], ["27 However, once again when taken from the CSEW, the estimated prevalence of experiencing childhood maltreatment was 18.9% (financial year end 2016).", [["maltreatment", "DISEASE", 100, 112], ["childhood maltreatment", "PROBLEM", 90, 112]]], ["28 The information relating to the incidence rate for those at risk of childhood maltreatment or domestic abuse is low.", [["maltreatment", "DISEASE", 81, 93], ["domestic abuse", "DISEASE", 97, 111], ["low", "OBSERVATION_MODIFIER", 115, 118]]], ["A previous study using GP recorded data between 1995 to 2010 explored the incidence rates and prevalence of childhood maltreatment related concerns (includes information relating to suspected and possible maltreatment) and identified an increase in incidence and prevalence of maltreatment related concerns between this time.", [["maltreatment", "DISEASE", 118, 130], ["maltreatment", "DISEASE", 205, 217], ["maltreatment", "DISEASE", 277, 289], ["A previous study", "TEST", 0, 16], ["GP recorded data", "TEST", 23, 39], ["increase", "OBSERVATION_MODIFIER", 237, 245]]], ["29 Considering the limitations which exist in current approaches estimating the burden of childhood maltreatment and domestic abuse, there is a need to explore the incidence and prevalence of childhood maltreatment and domestic abuse within general practice records to 1) gain further insight into the epidemiology of these traumatic exposures 2) identify the strengths and limitations of using such records to monitor rates of childhood maltreatment and domestic abuse.", [["maltreatment", "DISEASE", 100, 112], ["domestic abuse", "DISEASE", 117, 131], ["maltreatment", "DISEASE", 202, 214], ["domestic abuse", "DISEASE", 219, 233], ["traumatic", "DISEASE", 324, 333], ["maltreatment", "DISEASE", 438, 450], ["domestic abuse", "DISEASE", 455, 469]]], ["Therefore, our aim was to investigate how the incidence and prevalence of childhood maltreatment and domestic abuse have changed between 1996-2017 using 'The Health Improvement Network' (THIN) primary care database.Study design and data sourceYearly cohort and cross-sectional studies were conducted between 1 st January 1995 and 31 st December 2018 to describe the yearly incidence rate (IR) and prevalence of childhood maltreatment and domestic abuse.", [["maltreatment", "DISEASE", 84, 96], ["domestic abuse", "DISEASE", 101, 115], ["maltreatment", "DISEASE", 421, 433], ["domestic abuse", "DISEASE", 438, 452], ["Study design", "TEST", 215, 227], ["cross-sectional studies", "TEST", 261, 284]]], ["A retrospective cohort study between 1 st January 1995 and 31 st December 2018 was conducted to describe the cumulative IR broken down by age group, gender (in childhood maltreatment), deprivation and ethnicity.Study design and data sourceDuring the study period, the dataset consisted of medical records taken from 787 UK general practices and deemed to be representative of the UK population.", [["maltreatment", "DISEASE", 170, 182], ["A retrospective cohort study", "TEST", 0, 28], ["Study design", "TEST", 211, 223], ["the study", "TEST", 246, 255]]], ["30 information relating to demographics, disease progression and management.", [["disease progression", "PROBLEM", 41, 60], ["management", "TREATMENT", 65, 75]]], ["31 Information relating to symptoms, examinations, and diagnoses are documented using a hierarchical clinical coding system called Read codes.", [["symptoms", "PROBLEM", 27, 35], ["examinations", "TEST", 37, 49]]], ["During the study period from 1 st January 1995 and 31 st December 2018, there were 11,831,850 eligible patient records following this inclusion criteria.Population, exposure and outcomesThe outcomes of interest (childhood maltreatment or domestic abuse) were both defined by presence of a relevant Read code relating to patient exposure.", [["maltreatment", "DISEASE", 222, 234], ["domestic abuse", "DISEASE", 238, 252], ["patient", "ORGANISM", 103, 110], ["patient", "ORGANISM", 320, 327], ["patient", "SPECIES", 103, 110], ["patient", "SPECIES", 320, 327]]], ["As the aim of this study was to examine incidence and prevalence, the code list used to define incidence and prevalence varied to account for codes that mention a history of the exposure (for the calculation of prevalence but not for incidence rate).", [["this study", "TEST", 14, 24]]], ["The list of Read codes used in this study to describe childhood maltreatment/domestic abuse (varied by incidence and prevalence) are documented in the supplementary (supplementary read code lists) and selection of such codes are described in previous published work.", [["maltreatment/domestic abuse", "DISEASE", 64, 91], ["this study", "TEST", 31, 41]]], ["9, [35] [36] [37] Domestic abuse exposure in this study was limited to only female patients as comparatively very low numbers of men had recorded incidents of domestic abuse during the study period.", [["domestic abuse", "DISEASE", 159, 173], ["patients", "ORGANISM", 83, 91], ["men", "ORGANISM", 129, 132], ["patients", "SPECIES", 83, 91], ["men", "SPECIES", 129, 132], ["this study", "TEST", 45, 55]]], ["The annual incidence rate and prevalence of domestic abuse experienced by men between 2005-2017 is displayed on supplementary tables 1-2.Population, exposure and outcomesDependent on the outcome of interest, there were further inclusion criteria on the study population which was eligible for inclusion.", [["domestic abuse", "DISEASE", 44, 58], ["men", "ORGANISM", 74, 77], ["men", "SPECIES", 74, 77], ["the study population", "TEST", 249, 269]]], ["To calculate the IR and prevalence of childhood maltreatment, we only included patients under the age of 18 at cohort entry.", [["maltreatment", "DISEASE", 48, 60], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]], ["We enforced a study criterion that patients would have to exit the study by their 18 th birthday as they would no longer be contributing child-years (CY) at risk.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["a study criterion", "TEST", 12, 29], ["the study", "TEST", 63, 72]]], ["During the study period the total population amounted to 3,045,456 children.", [["children", "ORGANISM", 67, 75], ["children", "SPECIES", 67, 75], ["the study", "TEST", 7, 16]]], ["In order to calculate the IR and prevalence of domestic abuse, a female adult cohort was selected who had an eligible cohort entry date from the age of 18 years onwards (4,982,781 eligible patients).", [["domestic abuse", "DISEASE", 47, 61], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197]]], ["Additionally, there is debate about whether children living in a household where there is domestic abuse overlaps with the definition of child maltreatment as a form of adverse childhood experience (ACEs).", [["maltreatment", "DISEASE", 143, 155], ["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52]]], ["38 Therefore, to avoid confusion in definition between childhood maltreatment and experiencing ACEs which include other markers of household adversity, we have restricted our domestic abuse population to only those over the age of 18 years.Statistical analysis and follow upFor annual point prevalence, the numerator was the cumulative count of eligible individuals with any record of domestic abuse (occurred over 18 years) or childhood maltreatment (occurred under 18 years) identified at the 1 st January each year from 1996 to 2017 who were then divided by the total eligible population on the same date (denominator).", [["confusion", "DISEASE", 23, 32], ["maltreatment", "DISEASE", 65, 77], ["ACEs", "DISEASE", 95, 99], ["domestic abuse", "DISEASE", 385, 399], ["maltreatment", "DISEASE", 438, 450], ["confusion", "PROBLEM", 23, 32], ["ACEs", "PROBLEM", 95, 99], ["Statistical analysis", "TEST", 240, 260]]], ["The prevalence is described per 100,000 population (in the domestic abuse cohort per 100,000 A series of yearly cohort studies were performed to calculate the crude IR of domestic abuse and childhood maltreatment for each year from 1996 to 2017.", [["domestic abuse", "DISEASE", 171, 185], ["maltreatment", "DISEASE", 200, 212], ["yearly cohort studies", "TEST", 105, 126]]], ["The numerator was the new number of cases in that calendar year, divided by the total number of person-years at risk (denominator) for the given year.", [["person", "SPECIES", 96, 102], ["new", "OBSERVATION_MODIFIER", 22, 25]]], ["In each annual cohort study to determine IR, the period of follow up was defined as:Statistical analysis and follow upEntry date: The latest date of either study start date (1 st of January each year), one year after electronic medical records were implemented, one year after the practice reached acceptable mortality recording date or when the patient met the age inclusion criteria if one was present (e.g. patients had to reach 18 years before they were eligible for entry into the domestic abuse study population).Statistical analysis and follow upExit date: The earliest date of either study end date (31 st of December each year), outcome date (new incident of childhood maltreatment or domestic abuse), death date, transfer date (when patient moved practice and were censored from the dataset), collection date (last date the practice contributed to the dataset) and the date when patient's age crosses the age inclusion criteria (e.g. patients will exit the cohort when they turn 18 for the IR calculation of childhood maltreatment).Statistical analysis and follow upGraphical representations of the incidence and prevalence was conducted from years where there were 5 or more incident cases of domestic abuse (2005) or childhood maltreatment (1997).", [["maltreatment", "DISEASE", 678, 690], ["domestic abuse", "DISEASE", 694, 708], ["death", "DISEASE", 711, 716], ["maltreatment", "DISEASE", 1028, 1040], ["domestic abuse", "DISEASE", 1204, 1218], ["maltreatment", "DISEASE", 1239, 1251], ["patient", "ORGANISM", 346, 353], ["patients", "ORGANISM", 410, 418], ["patient", "ORGANISM", 743, 750], ["patient", "ORGANISM", 889, 896], ["patients", "ORGANISM", 944, 952], ["patient", "SPECIES", 346, 353], ["patients", "SPECIES", 410, 418], ["patient", "SPECIES", 743, 750], ["patient", "SPECIES", 889, 896], ["patients", "SPECIES", 944, 952], ["Statistical analysis", "TEST", 519, 539], ["Statistical analysis", "TEST", 1042, 1062]]], ["The annual IR and prevalence are also stratified by sex (male or female) for childhood maltreatment.Statistical analysis and follow upAdditionally, the cumulative IR for the whole time period from the 1 st January 1995 to 31 st December 2018 was stratified by age category of outcome incidence (defined using categories used by the Department of Education to allow for comparison), 39 Townsend deprivation quintile, 40 ethnicity and sex when using data for the whole time period from the 1 st January 1995 to 31 st December 2018.Statistical analysis and follow upTo discern differences between ethnic groups and deprivation quintiles (in the child cohort) a multivariate (adjusting for each other, sex and age at cohort entry) Poisson regression offsetting for person years of follow-up was used to calculate an adjusted incidence rate ratio (aIRR).", [["maltreatment", "DISEASE", 87, 99], ["person", "SPECIES", 761, 767], ["Statistical analysis", "TEST", 100, 120], ["Statistical analysis", "TEST", 529, 549]]], ["Significance was set at p<0.05.Statistical analysis and follow upStatistical analysis was conducted using STATA MP/4 v15.1 (Statacorp 2017).", [["Statistical analysis", "TEST", 31, 51], ["follow upStatistical analysis", "TEST", 56, 85], ["STATA MP", "TEST", 106, 114]]], ["Wherever IR, IRR and prevalence are presented, associated 95% confidence intervals (CI) are given in conjunction.", [["CI", "TEST", 84, 86]]], ["In the multivariate analysis following adjustment for age at cohort entry, sex and deprivation quintile, the increased risk apparent in South Asians compared to White children was not evident (aIRR 1.06; 95% CI 0.89-1.26).", [["children", "ORGANISM", 167, 175], ["children", "SPECIES", 167, 175], ["aIRR", "TEST", 193, 197], ["CI", "TEST", 208, 210], ["increased", "OBSERVATION_MODIFIER", 109, 118]]], ["However, the Black (aIRR 1.25; 95% CI 1.04-1.49) and other (aIRR 1.45; 95% CI 1.15-1.82) populations were at a greater risk.", [["aIRR", "TEST", 20, 24], ["CI", "TEST", 35, 37], ["aIRR", "TEST", 60, 64], ["CI", "TEST", 75, 77], ["Black", "OBSERVATION_MODIFIER", 13, 18]]], ["In the above analysis there was a gradient increase observed in the risk of childhood maltreatment with worsening deprivation.", [["maltreatment", "DISEASE", 86, 98], ["the above analysis", "TEST", 3, 21], ["a gradient increase", "PROBLEM", 32, 51], ["childhood maltreatment", "PROBLEM", 76, 98], ["worsening deprivation", "PROBLEM", 104, 125], ["gradient", "OBSERVATION_MODIFIER", 34, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["childhood", "OBSERVATION_MODIFIER", 76, 85], ["maltreatment", "OBSERVATION", 86, 98], ["worsening", "OBSERVATION_MODIFIER", 104, 113], ["deprivation", "OBSERVATION", 114, 125]]], ["The most deprived quintile had a five-fold increased risk of childhood maltreatment (aIRR 5.14; 95% CI 4.57-5.77).", [["maltreatment", "DISEASE", 71, 83], ["childhood maltreatment", "PROBLEM", 61, 83], ["aIRR", "TEST", 85, 89], ["CI", "TEST", 100, 102]]], ["Further details are seen in supplementary table 10.Domestic abuseThe IR of domestic abuse increased from 0.3 per 100,000 AY (95% CI 0.0-0.", [["abuse", "DISEASE", 60, 65], ["domestic abuse", "DISEASE", 75, 89], ["CI", "TEST", 129, 131], ["abuse", "OBSERVATION", 60, 65], ["domestic", "OBSERVATION_MODIFIER", 75, 83], ["abuse", "OBSERVATION", 84, 89]]], ["6Summary of key findingsThe IR of both childhood maltreatment and domestic abuse increased until 2017 (60.1 (95% CI 54.3-66.0) per 100,000 CY and 34.6 (95% CI 31.4.1-37.7) per 100,000 AY respectively in 2017).", [["maltreatment", "DISEASE", 49, 61], ["domestic abuse", "DISEASE", 66, 80], ["CY", "CHEMICAL", 139, 141], ["CI", "TEST", 113, 115], ["CY", "TEST", 139, 141], ["CI", "TEST", 156, 158]]], ["Additionally, the prevalence of both childhood maltreatment and domestic abuse continued to increase in a linear fashion until 2017.", [["maltreatment", "DISEASE", 47, 59], ["domestic abuse", "DISEASE", 64, 78]]], ["For both childhood maltreatment and domestic abuse, there was a substantially increased aIRR seen in those from a more deprived background when compared to the least deprived, and a greater incidence rate of new cases of both childhood maltreatment and domestic abuse in those from an ethnic minority background despite taking into account other co-variates.", [["maltreatment and domestic abuse", "DISEASE", 19, 50], ["maltreatment", "DISEASE", 236, 248], ["domestic abuse", "DISEASE", 253, 267], ["a substantially increased aIRR", "PROBLEM", 62, 92], ["substantially", "OBSERVATION_MODIFIER", 64, 77], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["aIRR", "OBSERVATION", 88, 92]]], ["The IR was also highest in the 0-1-year group and in females for childhood maltreatment and the 18-24-year group for those experiencing domestic abuse.", [["maltreatment", "DISEASE", 75, 87], ["domestic abuse", "DISEASE", 136, 150]]], ["The most notable finding is the high level of under-recording of childhood maltreatment and domestic abuse in the dataset in comparison to those reported in selfreported surveys including the CSEW and NSPCC survey.Comparison to current literatureAs this was the first cohort to the authors' knowledge to explore the annual incidence and prevalence of domestic abuse (in women) using UK primary care records, it is difficult to compare the incidence rates directly with other studies.", [["maltreatment", "DISEASE", 75, 87], ["domestic abuse", "DISEASE", 92, 106], ["domestic abuse", "DISEASE", 351, 365], ["women", "ORGANISM", 370, 375], ["women", "SPECIES", 370, 375], ["childhood maltreatment", "PROBLEM", 65, 87], ["other studies", "TEST", 469, 482], ["most notable", "OBSERVATION_MODIFIER", 4, 16], ["high", "OBSERVATION_MODIFIER", 32, 36], ["domestic abuse", "OBSERVATION", 92, 106]]], ["However for childhood maltreatment, one previous study (including data from 1995-2010) reported the IR of childhood maltreatment related concerns using THIN.", [["maltreatment", "DISEASE", 22, 34], ["maltreatment", "DISEASE", 116, 128], ["one previous study", "TEST", 36, 54]]], ["29 The maltreatment related concern codes included cases of suspected or probable maltreatment which would explain why their documented IR and prevalence are substantially higher than those reported in our study.", [["maltreatment", "DISEASE", 7, 19], ["maltreatment", "DISEASE", 82, 94], ["maltreatment", "PROBLEM", 82, 94], ["our study", "TEST", 202, 211], ["substantially", "OBSERVATION_MODIFIER", 158, 171], ["higher", "OBSERVATION_MODIFIER", 172, 178]]], ["29 However, of note in that study they demonstrated an increased IR of childhood maltreatment related concerns in those in the under one group, those who are female and almost a five times increased risk in those from the most deprived group when compared to the lowest group, all of which are similar to our findings.", [["maltreatment", "DISEASE", 81, 93], ["that study", "TEST", 23, 33], ["increased", "OBSERVATION_MODIFIER", 55, 64]]], ["29 Of particular note, a key finding of our study was the prevalence and IR were much lower than estimates derived from currently existing sources of childhood maltreatment and domestic abuse epidemiology.", [["maltreatment", "DISEASE", 160, 172], ["domestic abuse", "DISEASE", 177, 191], ["our study", "TEST", 40, 49]]], ["When examining UK police reports of domestic abuse, although for both genders, the prevalence in England was 24.0 per 1,000 population, much higher than in our study even though we only included a female denominator population.", [["domestic abuse", "DISEASE", 36, 50], ["our study", "TEST", 156, 165]]], ["24 When compared to the CSEW data which showed a prevalence of 7.9% in women, our figure seems even lower.", [["women", "ORGANISM", 71, 76], ["women", "SPECIES", 71, 76], ["the CSEW data", "TEST", 20, 33], ["lower", "OBSERVATION_MODIFIER", 100, 105]]], ["25 Similarly, although no combined child maltreatment figure exists for police reports, if we examine the estimated prevalence from the CSEW which suggested 18.9% of all adults have experienced some form of childhood maltreatment our figure of 4.2 per 1,000 population (2017) is substantially lower.", [["maltreatment", "DISEASE", 41, 53], ["maltreatment", "DISEASE", 217, 229], ["adults", "ORGANISM", 170, 176], ["the CSEW", "TEST", 132, 140], ["no", "UNCERTAINTY", 23, 25], ["lower", "OBSERVATION_MODIFIER", 293, 298]]], ["28 When compared to other administrative data such as children in need data, which contains the rate of children on Child protection plans, GP recorded prevalence still remains low, which has also been shown in previous literature on maltreatment related concerns.", [["maltreatment", "DISEASE", 234, 246], ["children", "ORGANISM", 54, 62], ["children", "ORGANISM", 104, 112], ["children", "SPECIES", 54, 62], ["children", "SPECIES", 104, 112], ["Child protection plans", "TREATMENT", 116, 138], ["GP recorded prevalence", "TEST", 140, 162]]], ["29, 41 The low values of incidence and prevalence of childhood maltreatment and domestic abuse and other interesting findings resonate and build on known literature.", [["maltreatment", "DISEASE", 63, 75], ["domestic abuse", "DISEASE", 80, 94], ["childhood maltreatment", "PROBLEM", 53, 75], ["low values", "OBSERVATION_MODIFIER", 11, 21]]], ["There have been national policy reports highlighting inconsistencies in data collected relating domestic abuse and childhood maltreatment to poverty and ethnicity.", [["domestic abuse", "DISEASE", 96, 110], ["maltreatment", "DISEASE", 125, 137], ["poverty", "DISEASE", 141, 148]]], ["42, 43 However, we clearly demonstrate a linear relationship between IR and socio-economic deprivation following adjustment for ethnicity.", [["IR and socio-economic deprivation", "TREATMENT", 69, 102], ["ethnicity", "PROBLEM", 128, 137]]], ["When adjusting for deprivation, GP data still highlights the burden of maltreatment and abuse experienced in ethnic minorities (although South Asians were not at a higher risk of childhood maltreatment, and mixed raced individuals were not at a higher risk of either childhood maltreatment or domestic abuse).", [["maltreatment", "DISEASE", 71, 83], ["maltreatment", "DISEASE", 189, 201], ["maltreatment", "DISEASE", 277, 289], ["domestic abuse", "DISEASE", 293, 307], ["deprivation", "TREATMENT", 19, 30], ["GP data", "TEST", 32, 39], ["mixed raced individuals", "PROBLEM", 207, 230]]], ["It has been previously highlighted that black and minority ethnic children are over-represented in child protection records within the UK, but this may be related to poverty (a form of which we have been able to adjust for in our study), isolation and willingness to seek help due to stigma in some communities.", [["children", "ORGANISM", 66, 74], ["children", "SPECIES", 66, 74], ["our study", "TEST", 226, 235], ["stigma", "PROBLEM", 284, 290], ["black", "OBSERVATION_MODIFIER", 40, 45]]], ["44 In contrast to our findings, the prevalence reported for domestic abuse exposure CSEW was highest in those from a mixed race background, and lower in those from the South Asian, Black or Other community.", [["lower", "OBSERVATION_MODIFIER", 144, 149]]], ["25 There are clear messages that need to be taken from this study relating to the underrecording of domestic abuse and childhood maltreatment in GP records.", [["domestic abuse", "DISEASE", 100, 114], ["maltreatment", "DISEASE", 129, 141], ["this study", "TEST", 55, 65], ["clear", "OBSERVATION", 13, 18]]], ["Although approaches and intervention have been implemented and evaluated to record both of these traumatic experiences, more needs to be done.", [["intervention", "TREATMENT", 24, 36], ["traumatic", "OBSERVATION", 97, 106]]], ["23, 45 Healthcare professionals should be aware of the morbidity burden caused by such exposures and also the referral tools at their disposal highlighted in recent national guidelines.", [["the morbidity burden", "PROBLEM", 51, 71]]], ["17, 18 Attempts to overcome barriers in asking about domestic abuse and childhood maltreatment such as the use of short question proformas are options to be trialled more broadly.", [["domestic abuse", "DISEASE", 53, 67], ["maltreatment", "DISEASE", 82, 94]]], ["46 Although recording of domestic abuse and childhood maltreatment do not yet fall under the incentivised payment system for GPs, it should be strongly encouraged to improve our recording and implementation of appropriate referral mechanisms.", [["domestic abuse", "DISEASE", 25, 39], ["maltreatment", "DISEASE", 54, 66]]], ["47Strengths and limitationsAlthough our data are derived from a large population-based cohort, the results demonstrate substantial under-recording of childhood maltreatment and domestic abuse.", [["maltreatment", "DISEASE", 160, 172], ["domestic abuse", "DISEASE", 177, 191], ["large", "OBSERVATION_MODIFIER", 64, 69], ["substantial", "OBSERVATION_MODIFIER", 119, 130]]], ["Therefore, our results are likely to underestimate the burden of childhood maltreatment and domestic abuse by GPs.", [["maltreatment", "DISEASE", 75, 87], ["domestic abuse", "DISEASE", 92, 106]]], ["The increasing trends in IR and prevalence suggest that recording is improving and with the introduction of national guidelines and standards, this will continue to improve.", [["increasing", "OBSERVATION_MODIFIER", 4, 14], ["trends", "OBSERVATION_MODIFIER", 15, 21]]], ["17, 18 Before this dataset can be used for surveillance purposes or tracking of long term trends in childhood maltreatment or domestic abuse, there need to be further improvements in the rate or recording and reporting.", [["maltreatment", "DISEASE", 110, 122], ["domestic abuse", "DISEASE", 126, 140], ["surveillance purposes", "TEST", 43, 64], ["the rate", "TEST", 183, 191], ["long term", "OBSERVATION_MODIFIER", 80, 89]]], ["Although this study was not designed to assess the impact of public policy or media attention at certain time points, it is also possible that spikes in IR seen in the dataset such as in 2012-2013 in the childhood maltreatment cohort may be related to high profile news events such as the exposure of Jimmy Savile which was shown to result in an increase of reports of childhood maltreatment to UK statutory bodies.", [["maltreatment", "DISEASE", 214, 226], ["maltreatment", "DISEASE", 379, 391], ["this study", "TEST", 9, 19], ["public policy", "TREATMENT", 61, 74], ["spikes", "PROBLEM", 143, 149], ["high profile news events", "PROBLEM", 252, 276], ["increase", "OBSERVATION_MODIFIER", 346, 354]]], ["48 In our IR subgroup analysis, we also have limitations in the recorded ethnicity of patients (highlighted in table 1).", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["our IR subgroup analysis", "TEST", 6, 30]]], ["Ethnicity recording has historically been poor, although improving in primary care data, with missing rates of around 50%.", [["poor", "OBSERVATION_MODIFIER", 42, 46]]], ["1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 F o r p e e r r e v i e w o n l y In conclusion, our study showed an in-depth exploration of the incidence rate and prevalence trends of childhood maltreatment and domestic abuse using UK primary care records.", [["maltreatment", "DISEASE", 318, 330], ["domestic abuse", "DISEASE", 335, 349], ["our study", "TEST", 220, 229]]], ["It is clear that there is a severe under-reporting of both of these important exposures which relate to substantial morbidity and mortality burdens.", [["substantial morbidity", "PROBLEM", 104, 125], ["mortality burdens", "PROBLEM", 130, 147], ["clear", "OBSERVATION", 6, 11], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["substantial", "OBSERVATION_MODIFIER", 104, 115], ["morbidity", "OBSERVATION", 116, 125]]], ["Therefore, approaches to improve recording of abuse and strategies to detect and prevent negative consequences of childhood maltreatment and domestic abuse should be implemented.AcknowledgementsThe study team would like to thank Dr Anuradhaa Subramanian for her support with the statistical analysis.Data statementThe original data can be requested from the study team.", [["maltreatment", "DISEASE", 124, 136], ["domestic abuse", "DISEASE", 141, 155], ["childhood maltreatment", "PROBLEM", 114, 136], ["the statistical analysis", "TEST", 275, 299]]], ["However, ethics approval may need to be sought by the data provider prior to release of data.Author contributionsThis study contributed to the PhD thesis for the main author JSC.", [["This study", "TEST", 113, 123]]], ["JSC, JT, SB and KN were responsible for initial conception of the study.", [["the study", "TEST", 62, 71], ["JT", "ANATOMY", 5, 7], ["SB", "ANATOMY", 9, 11]]], ["JSC was responsible for data extraction, analysis and first draft of the manuscript.", [["data extraction", "TEST", 24, 39], ["analysis", "TEST", 41, 49]]], ["The final manuscript was authorised by all the authors with JT providing expert knowledge on childhood maltreatment, whereas SB and KN provided methodological expertise.FundingThere is no funding to declare in this study.Declaration of InterestsAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.", [["maltreatment", "DISEASE", 103, 115], ["this study", "TEST", 210, 220], ["no", "UNCERTAINTY", 185, 187]]], ["Neglected appearance R037.00Declaration of Interests[D]Insufficient intake of food and water due to self neglect R2y3.", [["self neglect R2y3", "PROBLEM", 100, 117]]], ["11 [D] Self neglect Ry18.00Declaration of Interests[D]Self neglect SN42000Declaration of InterestsDeprivation of food, unspecified SN43000Declaration of InterestsDeprivation of water SN55.00Declaration of InterestsChild maltreatment syndrome SN55000Declaration of InterestsEmotional maltreatment of child SN55011Declaration of InterestsEmotional deprivation of child SN55012Declaration of InterestsEmotional abuse of child SN55100Declaration of InterestsNutritional maltreatment of child SN55111Declaration of InterestsNutritional deprivation of child SN55112Declaration of InterestsMalnutrition in child maltreatment syndrome SN55200Declaration of InterestsNon-accidental injury to child SN55211Declaration of InterestsNAI -non-accidental injury to child SN55212Declaration of InterestsPhysical injury to child SN55300Declaration of InterestsBattered baby or child syndrome NOS SN55311Declaration of InterestsBattered baby syndrome NOS SN55312Declaration of InterestsBattered child syndrome NOS SN55400Declaration of InterestsMultiple deprivation of child SN55500Declaration of InterestsPhysical abuse of child SN55600Declaration of InterestsNon-accidental traumatic head injury to child SN55z00Declaration of InterestsChild maltreatment syndrome NOS SN55z11Declaration of InterestsChild abuse NEC SN55z12Declaration of InterestsChild deprivation syndrome SN55z13Declaration of InterestsNeglect affecting child NEC SN56000Declaration of InterestsBattered person unspecified, syndrome SN57.00 Maltreatment syndromes SN57000Declaration of InterestsNeglect or abandonment SN57100Declaration of InterestsSexual abuse SN57200Declaration of InterestsChild affected by Munchausen's by proxy SyuH500Declaration of Interests[X]Other maltreatment syndromes TE40.00 Accidents due to abandonment or neglect of helpless person TL7..00Declaration of InterestsChild battering and other maltreatment TL70.00Declaration of InterestsChild battering or other maltreatment by parent TL7y Child abuse investigation Z787.00Declaration of InterestsSelf-neglect Z787200Declaration of InterestsNeglect of clothes Z787400Declaration of InterestsNeglect of personal hygiene Z787500Declaration of InterestsNeglect of physical health Z787600Declaration of InterestsNeglect of dental care Z787700Declaration of InterestsNeglect of physical illness Z787800Declaration of InterestsNeglect of common dangers ZV1B400Declaration of Interests[V]Personal history of neglect ZV4H300Declaration of Interests[V]Emotional neglect of child ZV4H400Declaration of Interests[V]Other problems related to neglect in upbringing ZV61200Declaration of Interests[V]Child abuse ZV61211Declaration of Interests[V]Child battering ZV61212Declaration of Interests[V]Child neglect ZV61213Declaration of Interests[V]Parent -child conflict ZVu4B00Declaration of Interests[X]Other problems related to neglect in upbringing Neglected appearance R037.00Childhood maltreatment-Prevalent codes[D]Insufficient intake of food and water due to self neglect R2y3.", [["head", "ANATOMY", 1168, 1172], ["maltreatment syndrome", "DISEASE", 220, 241], ["Emotional maltreatment", "DISEASE", 273, 295], ["Emotional abuse", "DISEASE", 398, 413], ["Nutritional maltreatment", "DISEASE", 454, 478], ["Malnutrition", "DISEASE", 583, 595], ["maltreatment syndrome", "DISEASE", 605, 626], ["Non-accidental injury", "DISEASE", 658, 679], ["accidental injury", "DISEASE", 729, 746], ["Physical injury", "DISEASE", 787, 802], ["Battered baby syndrome", "DISEASE", 910, 932], ["Physical abuse", "DISEASE", 1088, 1102], ["traumatic head injury", "DISEASE", 1158, 1179], ["maltreatment syndrome", "DISEASE", 1226, 1247], ["abuse NEC", "DISEASE", 1289, 1298], ["Child deprivation syndrome", "DISEASE", 1330, 1356], ["Neglect", "DISEASE", 1388, 1395], ["NEC", "DISEASE", 1412, 1415], ["Neglect", "DISEASE", 1547, 1554], ["Sexual abuse", "DISEASE", 1601, 1613], ["Munchausen", "DISEASE", 1663, 1673], ["maltreatment syndromes", "DISEASE", 1725, 1747], ["Accidents", "DISEASE", 1756, 1765], ["maltreatment", "DISEASE", 1872, 1884], ["maltreatment", "DISEASE", 1941, 1953], ["Neglect", "DISEASE", 2120, 2127], ["Neglect", "DISEASE", 2179, 2186], ["Neglect", "DISEASE", 2237, 2244], ["Neglect", "DISEASE", 2291, 2298], ["physical illness", "DISEASE", 2302, 2318], ["Neglect", "DISEASE", 2350, 2357], ["Emotional neglect", "DISEASE", 2472, 2489], ["neglect", "DISEASE", 2559, 2566], ["neglect", "DISEASE", 2842, 2849], ["R037.00", "CHEMICAL", 2885, 2892], ["maltreatment", "DISEASE", 2902, 2914], ["head", "ORGANISM_SUBDIVISION", 1168, 1172], ["person", "SPECIES", 1456, 1462], ["person", "SPECIES", 1808, 1814], ["Self neglect", "PROBLEM", 7, 19], ["Self neglect", "PROBLEM", 54, 66], ["Child maltreatment syndrome", "PROBLEM", 214, 241], ["maltreatment syndrome", "PROBLEM", 605, 626], ["Non-accidental injury", "PROBLEM", 658, 679], ["accidental injury", "PROBLEM", 729, 746], ["child syndrome", "PROBLEM", 860, 874], ["NOS", "PROBLEM", 992, 995], ["Non-accidental traumatic head injury", "PROBLEM", 1143, 1179], ["Child maltreatment syndrome", "PROBLEM", 1220, 1247], ["NEC", "PROBLEM", 1295, 1298], ["Child deprivation syndrome", "PROBLEM", 1330, 1356], ["InterestsNeglect", "PROBLEM", 1379, 1395], ["NEC", "PROBLEM", 1412, 1415], ["syndrome", "PROBLEM", 1476, 1484], ["Maltreatment syndromes", "PROBLEM", 1493, 1515], ["InterestsNeglect", "PROBLEM", 1538, 1554], ["Other maltreatment syndromes", "PROBLEM", 1719, 1747], ["dental care", "TREATMENT", 2248, 2259], ["neglect", "PROBLEM", 2430, 2437], ["Other problems", "PROBLEM", 2533, 2547], ["neglect", "PROBLEM", 2559, 2566], ["Other problems", "PROBLEM", 2816, 2830], ["neglect", "PROBLEM", 2842, 2849], ["self neglect R2y3", "PROBLEM", 2978, 2995], ["neglect", "OBSERVATION", 1788, 1795], ["neglect", "OBSERVATION", 2430, 2437], ["neglect", "OBSERVATION", 2842, 2849]]], ["11 [D] Self neglect Ry18.00Childhood maltreatment-Prevalent codes[D]Self neglect SN42000Childhood maltreatment-Prevalent codesDeprivation of food, unspecified SN43000Childhood maltreatment-Prevalent codesDeprivation of water SN55.00Childhood maltreatment-Prevalent codesChild maltreatment syndrome SN55000Childhood maltreatment-Prevalent codesEmotional maltreatment of child SN55011Childhood maltreatment-Prevalent codesEmotional deprivation of child SN55012Childhood maltreatment-Prevalent codesEmotional abuse of child SN55100Childhood maltreatment-Prevalent codesNutritional maltreatment of child SN55111Childhood maltreatment-Prevalent codesNutritional deprivation of child SN55112Childhood maltreatment-Prevalent codesMalnutrition in child maltreatment syndrome SN55200Childhood maltreatment-Prevalent codesNon-accidental injury to child SN55211 NAI -non-accidental injury to child SN55212Childhood maltreatment-Prevalent codesPhysical injury to child Child abuse investigation Z787.00Childhood maltreatment-Prevalent codesSelf-neglect Z787200Childhood maltreatment-Prevalent codesNeglect of clothes Z787400Childhood maltreatment-Prevalent codesNeglect of personal hygiene Z787500Childhood maltreatment-Prevalent codesNeglect of physical health Z787600Childhood maltreatment-Prevalent codesNeglect of dental care Neglect of physical illness Z787800Childhood maltreatment-Prevalent codesNeglect of common dangers ZV1B400Childhood maltreatment-Prevalent codes[V]Personal history of neglect ZV4H300Childhood maltreatment-Prevalent codes[V]Emotional neglect of child ZV4H400Childhood maltreatment-Prevalent codes[V]Other problems related to neglect in upbringing ZV61200Childhood maltreatment-Prevalent codes[V]Child abuse ZV61211Childhood maltreatment-Prevalent codes[V]Child battering ZV61212Childhood maltreatment-Prevalent codes[V]Child neglect ZV61213Childhood maltreatment-Prevalent codes[V]Parent -child conflict ZVu4B00Childhood maltreatment-Prevalent codes[X]Other problems related to neglect in upbringingINTRODUCTIONChildhood maltreatment (physical, sexual or emotional abuse and neglect against those under the age of 18 years) 1 and domestic abuse (controlling, coercive, threatening behaviour, violence or abuse between those who are, or have been, intimate partners or family members) 2 are global public health problems.", [["maltreatment", "DISEASE", 37, 49], ["maltreatment", "DISEASE", 98, 110], ["maltreatment", "DISEASE", 176, 188], ["maltreatment", "DISEASE", 242, 254], ["maltreatment syndrome", "DISEASE", 276, 297], ["SN55000", "CHEMICAL", 298, 305], ["maltreatment", "DISEASE", 315, 327], ["Emotional maltreatment", "DISEASE", 343, 365], ["SN55011", "CHEMICAL", 375, 382], ["maltreatment", "DISEASE", 392, 404], ["SN55012Childhood maltreatment", "DISEASE", 451, 480], ["codesEmotional abuse", "DISEASE", 491, 511], ["SN55100", "CHEMICAL", 521, 528], ["maltreatment", "DISEASE", 538, 550], ["Nutritional maltreatment", "DISEASE", 566, 590], ["SN55111", "CHEMICAL", 600, 607], ["maltreatment", "DISEASE", 617, 629], ["SN55112", "CHEMICAL", 678, 685], ["maltreatment", "DISEASE", 695, 707], ["Malnutrition", "DISEASE", 723, 735], ["maltreatment syndrome", "DISEASE", 745, 766], ["SN55200", "CHEMICAL", 767, 774], ["maltreatment", "DISEASE", 784, 796], ["Non-accidental injury", "DISEASE", 812, 833], ["NAI", "CHEMICAL", 851, 854], ["non-accidental injury", "DISEASE", 856, 877], ["SN55212", "CHEMICAL", 887, 894], ["maltreatment", "DISEASE", 904, 916], ["Physical injury", "DISEASE", 932, 947], ["Child abuse", "DISEASE", 957, 968], ["Z787.00", "CHEMICAL", 983, 990], ["maltreatment", "DISEASE", 1000, 1012], ["maltreatment", "DISEASE", 1058, 1070], ["Neglect", "DISEASE", 1086, 1093], ["Z787400", "CHEMICAL", 1105, 1112], ["maltreatment", "DISEASE", 1122, 1134], ["Neglect", "DISEASE", 1150, 1157], ["Z787500", "CHEMICAL", 1178, 1185], ["maltreatment", "DISEASE", 1195, 1207], ["Neglect", "DISEASE", 1223, 1230], ["Z787600", "CHEMICAL", 1250, 1257], ["maltreatment", "DISEASE", 1267, 1279], ["Neglect", "DISEASE", 1295, 1302], ["Neglect", "DISEASE", 1318, 1325], ["physical illness", "DISEASE", 1329, 1345], ["Z787800", "CHEMICAL", 1346, 1353], ["maltreatment", "DISEASE", 1363, 1375], ["Neglect", "DISEASE", 1391, 1398], ["neglect ZV4H300Childhood maltreatment", "DISEASE", 1485, 1522], ["Emotional neglect", "DISEASE", 1541, 1558], ["ZV4H400Childhood maltreatment", "DISEASE", 1568, 1597], ["neglect", "DISEASE", 1642, 1649], ["maltreatment", "DISEASE", 1681, 1693], ["ZV61211", "CHEMICAL", 1724, 1731], ["maltreatment", "DISEASE", 1741, 1753], ["ZV61212Childhood maltreatment", "DISEASE", 1788, 1817], ["ZV61213Childhood maltreatment", "DISEASE", 1850, 1879], ["ZVu4B00Childhood maltreatment", "DISEASE", 1921, 1950], ["neglect", "DISEASE", 1995, 2002], ["upbringingINTRODUCTIONChildhood maltreatment", "DISEASE", 2006, 2050], ["physical, sexual or emotional abuse and neglect", "DISEASE", 2052, 2099], ["domestic abuse", "DISEASE", 2147, 2161], ["violence or abuse", "DISEASE", 2209, 2226], ["SN43000", "CHEMICAL", 159, 166], ["SN55112", "CHEMICAL", 678, 685], ["SN55212", "CHEMICAL", 887, 894], ["Z787.00", "CHEMICAL", 983, 990], ["Z787400", "CHEMICAL", 1105, 1112], ["Z787600", "CHEMICAL", 1250, 1257], ["Z787800", "CHEMICAL", 1346, 1353], ["ZV61211", "CHEMICAL", 1724, 1731], ["Self neglect Ry", "PROBLEM", 7, 22], ["Self neglect", "PROBLEM", 68, 80], ["Child maltreatment syndrome", "PROBLEM", 270, 297], ["Malnutrition", "PROBLEM", 723, 735], ["maltreatment syndrome", "PROBLEM", 745, 766], ["non-accidental injury", "PROBLEM", 856, 877], ["neglect", "PROBLEM", 1033, 1040], ["neglect", "PROBLEM", 1485, 1492], ["Other problems", "PROBLEM", 1616, 1630], ["neglect", "PROBLEM", 1642, 1649], ["Other problems", "PROBLEM", 1969, 1983], ["neglect", "PROBLEM", 1995, 2002], ["global public health problems", "PROBLEM", 2307, 2336], ["Malnutrition", "OBSERVATION", 723, 735], ["neglect", "OBSERVATION", 1033, 1040], ["neglect", "OBSERVATION", 1485, 1492], ["neglect", "OBSERVATION", 1642, 1649], ["neglect", "OBSERVATION", 1995, 2002]]], ["The negative downstream social, psychological and physical health effects of childhood maltreatment and domestic abuse bear a substantial societal cost.", [["maltreatment", "DISEASE", 87, 99], ["domestic abuse", "DISEASE", 104, 118], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["downstream", "OBSERVATION_MODIFIER", 13, 23]]], ["[3] [4] [5] [6] [7] [8] [9] [10] [11] Therefore, a public health approach is urgently needed to prevent both the occurrence of childhood maltreatment and domestic abuse as well as their secondary consequences.", [["[3] [4] [5] [6", "CHEMICAL", 0, 14], ["maltreatment", "DISEASE", 137, 149], ["domestic abuse", "DISEASE", 154, 168], ["[3] [4] [5] [6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 37], ["a public health approach", "TREATMENT", 49, 73]]], ["In order to support a public health approach, high quality data recording relating to these exposures plays an important role.", [["a public health approach", "TREATMENT", 20, 44]]], ["Exploring the role of routinely collected data (which due its repeatable nature can be used for surveillance) in the UK as well as other countries is crucial in both the estimation of the societal burden of disease as well as the identification of risk and protective factors.", [["surveillance", "TEST", 96, 108], ["disease", "PROBLEM", 207, 214], ["disease", "OBSERVATION", 207, 214]]], ["12 Exposure to domestic abuse and childhood maltreatment remain taboo topics in many cultures, despite the adverse consequences in terms of health and wellbeing, with significant stigma around disclosure of traumatic events.", [["domestic abuse", "DISEASE", 15, 29], ["maltreatment", "DISEASE", 44, 56], ["childhood maltreatment", "PROBLEM", 34, 56], ["many cultures", "TEST", 80, 93], ["significant stigma", "PROBLEM", 167, 185], ["traumatic events", "PROBLEM", 207, 223], ["significant", "OBSERVATION_MODIFIER", 167, 178], ["stigma", "OBSERVATION", 179, 185], ["traumatic", "OBSERVATION", 207, 216]]], ["13, 14 As a result, survivors of such traumatic experiences often find it difficult to attend and seek support from public sector authorities such as healthcare staff.", [["such traumatic experiences", "PROBLEM", 33, 59]]], ["15, 16 There are also challenges for healthcare staff to routinely enquire or ask about such experiences in their patients' lives.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122]]], ["17 The combination of barriers to disclosure and enquiry are likely to lead to a hidden burden of domestic abuse and childhood maltreatment not captured in administrative public sector data.", [["domestic abuse", "DISEASE", 98, 112], ["maltreatment", "DISEASE", 127, 139]]], ["However, since introductions of new guidelines in the UK (National Institute of Health and Care Excellence in 2016 and 2017), the hope has been that administrative recording will have improved.", [["improved", "OBSERVATION_MODIFIER", 184, 192]]], ["18, 19 This drive towards improved reporting is spurred on by UK media and governmental interest in these topics (high profile events leading to media and governmental interest include: the death of Baby P, the Jimmy Savile inquiry, Operation Yewtree, the death of Daniel Pelka, the identification and referral to improve safety (IRIS) trial and the consideration of the domestic abuse bill), and the consequent expectation that administrative recording will have improved.", [["death", "DISEASE", 190, 195], ["death", "DISEASE", 256, 261], ["IRIS", "DISEASE", 330, 334], ["high profile events", "PROBLEM", 114, 133], ["improved", "OBSERVATION_MODIFIER", 464, 472]]], ["[20] [21] [22] [23] [24] Current UK national estimates of domestic abuse are largely derived from self-reported surveys in conjunction with administrative data.", [["[20] [21] [22] [23", "SIMPLE_CHEMICAL", 0, 18]]], ["The crime survey for England and Wales (CSEW) provides self-reported information and used in conjunction with police records of the number of recorded domestic abuse incidents to define epidemiological estimates of domestic abuse.", [["domestic abuse", "DISEASE", 151, 165], ["domestic abuse", "DISEASE", 215, 229]]], ["In women, the reported prevalence from the CSEW (for those aged 16-59 years old) was 7.9% in the financial year 2017/2018 while the crude estimate derived from 16 and over) across England was 24.0/1,000 population (in men and women).", [["women", "ORGANISM", 3, 8], ["men", "ORGANISM", 218, 221], ["women", "ORGANISM", 226, 231], ["women", "SPECIES", 3, 8], ["men", "SPECIES", 218, 221], ["women", "SPECIES", 226, 231], ["the crude estimate", "TEST", 128, 146]]], ["There is no specific international classification of disease code that are specific to domestic abuse: The closest matches are T74.1 (physical abuse, confirmed), Y07.0 (spouse or partner, perpetrator of maltreatment and neglect) and Z63.0 (and problems in a relationship with spouse or partner) which when specified in adults relate to physical abuse, maltreatment.", [["domestic abuse", "DISEASE", 87, 101], ["maltreatment", "DISEASE", 203, 215], ["neglect", "DISEASE", 220, 227], ["physical abuse", "DISEASE", 336, 350], ["maltreatment", "DISEASE", 352, 364], ["neglect", "PROBLEM", 220, 227], ["no", "UNCERTAINTY", 9, 11], ["disease", "OBSERVATION", 53, 60]]], ["27 However, there are substantial limitations to utilising these codes to describe the epidemiology of domestic abuse, due to low numbers of such codes being recorded and also ambiguities in coding practice between hospital trusts.", [["domestic abuse", "DISEASE", 103, 117], ["substantial", "OBSERVATION_MODIFIER", 22, 33]]], ["27 The state of epidemiological estimates when exploring childhood maltreatment suffers from similar challenges.", [["maltreatment", "DISEASE", 67, 79]]], ["A recent observational study utilised data from 1858-2016 that was derived from child mortality records, police recorded-homicides, crimes against children, child protection data, children in care and data taken from the National Society for the Prevention of Cruelty to Children (NSPCC) to study long term trends of child maltreatment.", [["maltreatment", "DISEASE", 323, 335], ["children", "ORGANISM", 147, 155], ["children", "ORGANISM", 180, 188], ["children", "SPECIES", 147, 155], ["children", "SPECIES", 180, 188], ["Children", "SPECIES", 271, 279], ["A recent observational study", "TEST", 0, 28]]], ["The study found a decreasing long-term trend in child maltreatment until the year 2000 but reported an increase thereafter.", [["maltreatment", "DISEASE", 54, 66], ["The study", "TEST", 0, 9], ["decreasing", "OBSERVATION_MODIFIER", 18, 28], ["long-term", "OBSERVATION_MODIFIER", 29, 38], ["increase", "OBSERVATION_MODIFIER", 103, 111]]], ["28 However child mortality continued to decrease.", [["child mortality", "PROBLEM", 11, 26], ["decrease", "OBSERVATION_MODIFIER", 40, 48]]], ["28 A recommendation of the report was to further research and establish whether child maltreatment is continuing to increase.", [["maltreatment", "DISEASE", 86, 98]]], ["28 However, once again when taken from the CSEW, the estimated prevalence of experiencing childhood maltreatment was 18.9% (financial year end 2016).", [["maltreatment", "DISEASE", 100, 112], ["childhood maltreatment", "PROBLEM", 90, 112]]], ["29 The information relating to the incidence rate for those at risk of childhood maltreatment or domestic abuse is low.", [["maltreatment", "DISEASE", 81, 93], ["domestic abuse", "DISEASE", 97, 111], ["low", "OBSERVATION_MODIFIER", 115, 118]]], ["A previous study using GP recorded data between 1995 to 2010 explored the incidence rates and prevalence of childhood maltreatment related concerns (includes information relating to suspected and possible maltreatment) and identified an increase in incidence and prevalence of maltreatment related concerns between this time.", [["maltreatment", "DISEASE", 118, 130], ["maltreatment", "DISEASE", 205, 217], ["maltreatment", "DISEASE", 277, 289], ["A previous study", "TEST", 0, 16], ["GP recorded data", "TEST", 23, 39], ["increase", "OBSERVATION_MODIFIER", 237, 245]]], ["30 In summary, the limitations of existing estimates relate to challenges with: 1) continuous recording of survey data to allow for active surveillance and examination of trends; 2) social desirability bias 31 leading to an under-estimation in survey estimates; 3) selection bias 32 leading to an under-estimation in administrative datasets; 4) an appropriate denominator population to describe prevalence in administrative data.INTRODUCTIONPrimary care data from sources such as 'The Health Improvement Network' (THIN) database have previously been shown to representative of the UK population in terms of age structure and can provide a suitable denominator population to examine the epidemiology of public health risk factors.", [["survey data", "TEST", 107, 118], ["active surveillance", "TEST", 132, 151], ["examination", "TEST", 156, 167]]], ["33 Additionally, new guidelines and interventions have been put in place to improve recording of childhood maltreatment and domestic abuse.", [["maltreatment", "DISEASE", 107, 119], ["domestic abuse", "DISEASE", 124, 138], ["interventions", "TREATMENT", 36, 49]]], ["Therefore, there is a need to describe the current estimates of childhood maltreatment and domestic abuse from primary care data and compare these to existing estimates to describe the possibility of further use of primary care data to support Our aim was to investigate how the incidence and prevalence of childhood maltreatment and domestic abuse have changed between 1996-2017 using 'The Health Improvement Network' (THIN) primary care database.Study design and data sourceA cohort was extracted of eligible patients who contributed to the dataset between 1 st January 1995 and 31 st December 2018.", [["maltreatment", "DISEASE", 74, 86], ["domestic abuse", "DISEASE", 91, 105], ["maltreatment", "DISEASE", 317, 329], ["domestic abuse", "DISEASE", 334, 348], ["patients", "ORGANISM", 511, 519], ["patients", "SPECIES", 511, 519], ["primary care data", "TREATMENT", 215, 232], ["Study design", "TEST", 448, 460]]], ["Using this cohort, it was possible to describe the yearly incidence rate (IR) and prevalence of childhood maltreatment and domestic abuse.", [["maltreatment", "DISEASE", 106, 118], ["domestic abuse", "DISEASE", 123, 137]]], ["Using the cohort it was also possible to describe the cumulative IR broken down by age group, gender (in childhood maltreatment), deprivation and ethnicity.Study design and data sourceDuring the study period, the dataset consisted of medical records taken from 787 UK general practices and deemed to be representative of the UK population.", [["maltreatment", "DISEASE", 115, 127], ["Study design", "TEST", 156, 168], ["the study", "TEST", 191, 200]]], ["35 THIN records information relating to demographics, disease progression and management.", [["disease progression", "PROBLEM", 54, 73], ["management", "TREATMENT", 78, 88]]], ["36 Information relating to symptoms, examinations, and diagnoses are documented using a hierarchical clinical coding system called Read codes.", [["symptoms", "PROBLEM", 27, 35], ["examinations", "TEST", 37, 49]]], ["During the study period from 1 st January 1995 and 31 st December 2018, there were 11,831,850 eligible patient records following this inclusion criteria.Population, exposure and outcomesThe outcomes of interest (childhood maltreatment or domestic abuse) were both defined by presence of a relevant Read code relating to patient exposure.", [["maltreatment", "DISEASE", 222, 234], ["domestic abuse", "DISEASE", 238, 252], ["patient", "ORGANISM", 103, 110], ["patient", "ORGANISM", 320, 327], ["patient", "SPECIES", 103, 110], ["patient", "SPECIES", 320, 327]]], ["As the aim of this study was to examine incidence and prevalence, the code list used to define incidence and prevalence varied to account for codes that mention a history of the exposure (for the calculation of prevalence but not for incidence rate).", [["this study", "TEST", 14, 24]]], ["The list of Read codes used in this study to describe childhood maltreatment/domestic abuse (varied by incidence and prevalence) are documented in the supplementary (supplementary read code lists) and selection of such codes are described in previous published work.", [["maltreatment/domestic abuse", "DISEASE", 64, 91], ["this study", "TEST", 31, 41]]], ["7, 9, 40, 41 Domestic abuse exposure in this study was limited to only female patients as comparatively very low numbers of men had recorded incidents of domestic abuse during the study period (displayed in table 1).", [["domestic abuse", "DISEASE", 154, 168], ["patients", "ORGANISM", 78, 86], ["men", "ORGANISM", 124, 127], ["patients", "SPECIES", 78, 86], ["men", "SPECIES", 124, 127], ["this study", "TEST", 40, 50]]], ["The annual incidence rate and prevalence of domestic abuse experienced by men between 2005-2017 is displayed on supplementary tables 1-2.Population, exposure and outcomesDependent on the outcome of interest, there were further inclusion criteria on the study population which was eligible for inclusion.", [["domestic abuse", "DISEASE", 44, 58], ["men", "ORGANISM", 74, 77], ["men", "SPECIES", 74, 77], ["the study population", "TEST", 249, 269]]], ["To calculate the IR and prevalence of childhood maltreatment, we only included patients under the age of 18 at cohort entry.", [["maltreatment", "DISEASE", 48, 60], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]], ["We enforced a study criterion that patients would have to exit the study by their 18 th birthday as they would no longer be contributing child-years (CY) at risk.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["a study criterion", "TEST", 12, 29], ["the study", "TEST", 63, 72]]], ["During the study period the total F o r p e e r r e v i e w o n l y population amounted to 3,045,456 children.", [["children", "ORGANISM", 101, 109], ["children", "SPECIES", 101, 109], ["the study", "TEST", 7, 16]]], ["In order to calculate the IR and prevalence of domestic abuse, a female adult cohort was selected who had an eligible cohort entry date from the age of 18 years onwards (4,982,781 eligible patients).", [["domestic abuse", "DISEASE", 47, 61], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197]]], ["Additionally, there is debate about whether children living in a household where there is domestic abuse overlaps with the definition of child maltreatment as a form of adverse childhood experience (ACEs).", [["maltreatment", "DISEASE", 143, 155], ["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52]]], ["42 Therefore, to avoid confusion in definition between childhood maltreatment and experiencing ACEs which include other markers of household adversity, we have restricted our domestic abuse population to only those over the age of 18 years.Statistical analysis and follow upFor annual point prevalence, the numerator was the cumulative count of eligible individuals with any record of domestic abuse (occurred over 18 years) or childhood maltreatment (occurred under 18 years) identified at the 1 st January each year from 1996 to 2017 who were then divided by the total eligible population on the same date (denominator).", [["confusion", "DISEASE", 23, 32], ["maltreatment", "DISEASE", 65, 77], ["ACEs", "DISEASE", 95, 99], ["domestic abuse", "DISEASE", 385, 399], ["maltreatment", "DISEASE", 438, 450], ["confusion", "PROBLEM", 23, 32], ["ACEs", "PROBLEM", 95, 99], ["Statistical analysis", "TEST", 240, 260]]], ["The prevalence is described per 100,000 population (in the domestic abuse cohort per 100,000 adult population and childhood maltreatment cohort per 100,000 child population) with their associated confidence intervals (CI).Statistical analysis and follow upA series of yearly cohort studies were performed to calculate the crude IR of domestic abuse and childhood maltreatment for each year from 1996 to 2017.", [["maltreatment", "DISEASE", 124, 136], ["domestic abuse", "DISEASE", 334, 348], ["maltreatment", "DISEASE", 363, 375], ["Statistical analysis", "TEST", 222, 242], ["follow upA series", "TEST", 247, 264], ["yearly cohort studies", "TEST", 268, 289]]], ["The numerator was the new number of cases in that calendar year, divided by the total number of person-years at risk (denominator) for the given year.", [["person", "SPECIES", 96, 102], ["new", "OBSERVATION_MODIFIER", 22, 25]]], ["In each annual cohort study to determine IR, the period of follow up was defined as:Statistical analysis and follow upEntry date: The latest date of either study start date (1 st of January each year), one year after electronic medical records were implemented, one year after the practice reached acceptable mortality recording date or when the patient met the age inclusion criteria if one was present (e.g. patients had to reach 18 years before they were eligible for entry into the domestic abuse study population).Statistical analysis and follow upExit date: The earliest date of either study end date (31 st of December each year), outcome date (new incident of childhood maltreatment or domestic abuse), death date, transfer date (when patient moved practice and were censored from the dataset), collection date (last date the practice contributed to the dataset) and the date when patient's age crosses the age inclusion criteria (e.g. patients will exit the cohort when they turn 18 for the IR calculation of childhood maltreatment).Statistical analysis and follow upGraphical representations of the incidence and prevalence was conducted from years where there were 5 or more incident cases of domestic abuse (2005) or childhood maltreatment (1997).", [["maltreatment", "DISEASE", 678, 690], ["domestic abuse", "DISEASE", 694, 708], ["death", "DISEASE", 711, 716], ["maltreatment", "DISEASE", 1028, 1040], ["domestic abuse", "DISEASE", 1204, 1218], ["maltreatment", "DISEASE", 1239, 1251], ["patient", "ORGANISM", 346, 353], ["patients", "ORGANISM", 410, 418], ["patient", "ORGANISM", 743, 750], ["patient", "ORGANISM", 889, 896], ["patients", "ORGANISM", 944, 952], ["patient", "SPECIES", 346, 353], ["patients", "SPECIES", 410, 418], ["patient", "SPECIES", 743, 750], ["patient", "SPECIES", 889, 896], ["patients", "SPECIES", 944, 952], ["Statistical analysis", "TEST", 519, 539], ["Statistical analysis", "TEST", 1042, 1062]]], ["The annual IR and prevalence are also stratified by sex (male or female) for childhood maltreatment.Statistical analysis and follow upAdditionally, the cumulative IR for the whole time period from the 1 st January 1995 to 31 st December 2018 was stratified by age category of outcome incidence (defined using categories used by the Department of Education to allow for comparison), 43 Townsend To discern differences between ethnic groups and deprivation quintiles (in the child cohort) a multivariate (adjusting for each other, sex and age at cohort entry) Poisson regression offsetting for person years of follow-up was used to calculate an adjusted incidence rate ratio (aIRR).", [["maltreatment", "DISEASE", 87, 99], ["person", "SPECIES", 592, 598], ["Statistical analysis", "TEST", 100, 120]]], ["Significance was set at p<0.05.Statistical analysis and follow upStatistical analysis was conducted using STATA MP/4 v15.1 (Statacorp 2017).", [["Statistical analysis", "TEST", 31, 51], ["follow upStatistical analysis", "TEST", 56, 85], ["STATA MP", "TEST", 106, 114]]], ["Wherever IR, IRR and prevalence are presented, associated 95% confidence intervals (CI) are given in conjunction.Patient and public involvementNo patients were actively involved in setting the research question, outcome measures, study design, results interpretation of write up of the results.", [["patients", "ORGANISM", 146, 154], ["Patient", "SPECIES", 113, 120], ["patients", "SPECIES", 146, 154], ["CI", "TEST", 84, 86]]], ["There are plans for the results to be disseminated to the community affected by this research through childhood maltreatment and domestic abuse charities and social media channels.Ethical ApprovalAnonymised data were used throughout the study provided by the data provider to the University of Birmingham.", [["maltreatment", "DISEASE", 112, 124], ["domestic abuse charities", "DISEASE", 129, 153], ["the study", "TEST", 233, 242]]], ["The Scientific Review Committee (IQVIA) approved the study protocol (SRC Reference Number: SRC18THIN034) prior to its undertaking.RESULTSDuring the study period there was a total of 4,603 incident episodes of childhood maltreatment cohort in a cohort of 3,045,456 children (aged under 18).", [["maltreatment", "DISEASE", 219, 231], ["children", "ORGANISM", 264, 272], ["children", "SPECIES", 264, 272], ["the study", "TEST", 144, 153]]], ["In the adult female cohort (aged over 18), there were 5,598 incident recorded episodes of domestic abuse in the total female population of 4,982,781 patients.", [["domestic abuse", "DISEASE", 90, 104], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["domestic abuse", "OBSERVATION", 90, 104]]], ["Table 1 outlines the characteristics of both cohorts at cohort entry as well as the patients who were incident cases of childhood maltreatment and domestic abuse.Childhood maltreatmentThe IR of childhood maltreatment increased from 22.5 per 100,000 CY (95% CI 11.8-33.", [["maltreatment", "DISEASE", 130, 142], ["domestic abuse", "DISEASE", 147, 161], ["maltreatment", "DISEASE", 172, 184], ["maltreatment", "DISEASE", 204, 216], ["CY", "CHEMICAL", 249, 251], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Childhood maltreatment", "PROBLEM", 162, 184], ["childhood maltreatment", "PROBLEM", 194, 216], ["CI", "TEST", 257, 259], ["maltreatment", "OBSERVATION", 172, 184]]], ["When broken down by sex, a similar temporal trend is noted between both males and females.", [["temporal", "OBSERVATION_MODIFIER", 35, 43], ["trend", "OBSERVATION", 44, 49], ["females", "OBSERVATION", 82, 89]]], ["However, the cumulative IR was higher in the female cohort ( figure 1 b-c and supplementary tables 4-5.Childhood maltreatmentThe age range was broken down into the categories 0-1, 1-4, 5-9, 10-15 and 16-17 years.", [["maltreatment", "DISEASE", 113, 125], ["Childhood maltreatment", "PROBLEM", 103, 125], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["maltreatment", "OBSERVATION", 113, 125]]], ["The group with the highest IR was the 0-1-year cohort (IR 52.7; 95% CI 47.9-58.0 per 100,000 CY) and whereas the 16-17 group (IR 21.2; 95% CI 19.0-23.5 per 100,000 CY) had the lowest IR ( figure 1d and supplementary table 6 ).", [["IR", "TEST", 55, 57], ["CI", "TEST", 68, 70], ["IR", "TEST", 126, 128], ["CI", "TEST", 139, 141]]], ["Lastly, the IR was higher in the ethnic minority groups (Black (IR In the multivariate analysis following adjustment for age at cohort entry, sex and deprivation quintile, the increased risk apparent in South Asians compared to White children was not evident (aIRR 1.06; 95% CI 0.89-1.26).", [["children", "ORGANISM", 234, 242], ["children", "SPECIES", 234, 242], ["the IR", "TEST", 8, 14], ["aIRR", "TEST", 260, 264], ["CI", "TEST", 275, 277], ["higher", "OBSERVATION_MODIFIER", 19, 25], ["increased", "OBSERVATION_MODIFIER", 176, 185]]], ["However, the Black (aIRR 1.25; 95% CI 1.04-1.49) and other (aIRR 1.45; 95% CI 1.15-1.82) populations were at a greater risk.", [["aIRR", "TEST", 20, 24], ["CI", "TEST", 35, 37], ["aIRR", "TEST", 60, 64], ["CI", "TEST", 75, 77], ["Black", "OBSERVATION_MODIFIER", 13, 18]]], ["In the above analysis there was a gradient increase observed in the risk of childhood maltreatment with worsening deprivation.", [["maltreatment", "DISEASE", 86, 98], ["the above analysis", "TEST", 3, 21], ["a gradient increase", "PROBLEM", 32, 51], ["childhood maltreatment", "PROBLEM", 76, 98], ["worsening deprivation", "PROBLEM", 104, 125], ["gradient", "OBSERVATION_MODIFIER", 34, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["childhood", "OBSERVATION_MODIFIER", 76, 85], ["maltreatment", "OBSERVATION", 86, 98], ["worsening", "OBSERVATION_MODIFIER", 104, 113], ["deprivation", "OBSERVATION", 114, 125]]], ["The most deprived quintile had a five-fold increased risk of childhood maltreatment (aIRR 5.14; 95% CI 4.57-5.77).", [["maltreatment", "DISEASE", 71, 83], ["childhood maltreatment", "PROBLEM", 61, 83], ["aIRR", "TEST", 85, 89], ["CI", "TEST", 100, 102]]], ["1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 F o r p e e r r e v i e w o n l y AY)) had a higher incidence rate when compared with those who had a White (IR 21.5; 95% CI 20.7-22.3 per 100,000 AY)) or mixed ethnic (IR 36.8; 95% CI 29.4-44.2 per 100,000 AY) background.", [["r", "TEST", 175, 176], ["p", "TEST", 177, 178], ["e", "TEST", 179, 180], ["a higher incidence rate", "PROBLEM", 214, 237], ["IR", "TEST", 280, 282], ["CI", "TEST", 293, 295], ["IR", "TEST", 340, 342], ["CI", "TEST", 353, 355]]], ["Figure 3d and supplementary table 14 contain additional detail.Childhood maltreatmentThe prevalence of domestic abuse increased in an almost linear manner from 16.0 (95% CI 14.0-17.9) per 100,000 adult population to 368.7 (95% CI 358.7-378.9) per 100,000 adult population in 2017.", [["maltreatment", "DISEASE", 73, 85], ["domestic abuse", "DISEASE", 103, 117], ["Childhood maltreatment", "PROBLEM", 63, 85], ["CI", "TEST", 170, 172], ["CI", "TEST", 227, 229], ["maltreatment", "OBSERVATION", 73, 85], ["domestic", "OBSERVATION_MODIFIER", 103, 111], ["abuse", "OBSERVATION", 112, 117], ["increased", "OBSERVATION_MODIFIER", 118, 127]]], ["This can be seen in figure 4 and from supplementary table 15.Childhood maltreatmentIn the multivariate regression analysis, it was evident that ethnicity played a factor in the risk of domestic abuse.", [["maltreatment", "DISEASE", 71, 83], ["domestic abuse", "DISEASE", 185, 199], ["Childhood maltreatment", "PROBLEM", 61, 83], ["the multivariate regression analysis", "TEST", 86, 122], ["maltreatment", "OBSERVATION", 71, 83], ["domestic abuse", "OBSERVATION", 185, 199]]], ["South Asians (aIRR 2.14; 95% CI 1.92-2.39), Black (aIRR 1.64; 95% CI 1.42-1.89) and Other (aIRR 2.19; 95% CI 1.75-2.73) populations were all at a greater risk than the White cohort.", [["aIRR", "TEST", 14, 18], ["CI", "TEST", 29, 31], ["Black", "TEST", 44, 49], ["aIRR", "TEST", 51, 55], ["CI", "TEST", 66, 68], ["aIRR", "TEST", 91, 95], ["CI", "TEST", 106, 108], ["populations", "PROBLEM", 120, 131]]], ["Similar to childhood maltreatment there was a gradient increase between worsening deprivation and the risk of domestic abuse.", [["maltreatment", "DISEASE", 21, 33], ["domestic abuse", "DISEASE", 110, 124], ["a gradient increase", "PROBLEM", 44, 63], ["worsening deprivation", "PROBLEM", 72, 93], ["gradient", "OBSERVATION_MODIFIER", 46, 54], ["increase", "OBSERVATION_MODIFIER", 55, 63], ["worsening", "OBSERVATION_MODIFIER", 72, 81], ["deprivation", "OBSERVATION", 82, 93], ["domestic abuse", "OBSERVATION", 110, 124]]], ["The most deprived quintile had an aIRR of 2.30; 95%CI 2.71-3.30.", [["an aIRR", "TEST", 31, 38], ["CI", "TEST", 51, 53]]], ["Further details contained within supplementary table 16 .Summary of key findingsThe IR of both childhood maltreatment and domestic abuse increased until 2017 (60.1 (95% CI 54.3-66.0) per 100,000 CY and 34.6 (95% CI 31.4.1-37.7) per 100,000 AY respectively in 2017).", [["maltreatment", "DISEASE", 105, 117], ["domestic abuse", "DISEASE", 122, 136], ["CY", "CHEMICAL", 195, 197], ["CI", "TEST", 169, 171], ["CY", "TEST", 195, 197], ["CI", "TEST", 212, 214]]], ["Additionally, the prevalence of both childhood maltreatment and domestic abuse continued to increase in a linear fashion until 2017.", [["maltreatment", "DISEASE", 47, 59], ["domestic abuse", "DISEASE", 64, 78]]], ["For both childhood maltreatment and domestic abuse, there was a substantially increased aIRR seen in those from a more deprived background when compared to the least deprived, and a greater incidence rate of new cases of both childhood maltreatment and domestic abuse in those from an ethnic minority background despite taking into account other co-variates.", [["maltreatment and domestic abuse", "DISEASE", 19, 50], ["maltreatment", "DISEASE", 236, 248], ["domestic abuse", "DISEASE", 253, 267], ["a substantially increased aIRR", "PROBLEM", 62, 92], ["substantially", "OBSERVATION_MODIFIER", 64, 77], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["aIRR", "OBSERVATION", 88, 92]]], ["The IR was also highest in the 0-1-year group and in females for childhood maltreatment and the 18-24-year group for those experiencing domestic abuse.", [["maltreatment", "DISEASE", 75, 87], ["domestic abuse", "DISEASE", 136, 150]]], ["The most notable finding is the high level of under-recording of childhood maltreatment and domestic abuse in the dataset in comparison to those reported in selfreported surveys including the CSEW and NSPCC survey.Comparison to current literatureAs this was the first cohort to the authors' knowledge to explore the annual incidence and prevalence of domestic abuse (in women) using UK primary care records, it is difficult to compare the incidence rates directly with other studies.", [["maltreatment", "DISEASE", 75, 87], ["domestic abuse", "DISEASE", 92, 106], ["domestic abuse", "DISEASE", 351, 365], ["women", "ORGANISM", 370, 375], ["women", "SPECIES", 370, 375], ["childhood maltreatment", "PROBLEM", 65, 87], ["other studies", "TEST", 469, 482], ["most notable", "OBSERVATION_MODIFIER", 4, 16], ["high", "OBSERVATION_MODIFIER", 32, 36], ["domestic abuse", "OBSERVATION", 92, 106]]], ["However for childhood maltreatment, one previous study (including data from 1995-2010) reported the IR of childhood maltreatment related concerns using THIN.", [["maltreatment", "DISEASE", 22, 34], ["maltreatment", "DISEASE", 116, 128], ["one previous study", "TEST", 36, 54]]], ["30 The maltreatment related concern codes included cases of suspected or probable maltreatment which would explain why their documented IR and prevalence are substantially higher than those reported in our study.", [["maltreatment", "DISEASE", 7, 19], ["maltreatment", "DISEASE", 82, 94], ["maltreatment", "PROBLEM", 82, 94], ["our study", "TEST", 202, 211], ["substantially", "OBSERVATION_MODIFIER", 158, 171], ["higher", "OBSERVATION_MODIFIER", 172, 178]]], ["30 However, of note in that study they demonstrated an increased IR of childhood maltreatment related concerns in those in the under one group, those who are female and almost a five times increased risk in those from the most deprived group when compared to the lowest group, all of which are similar to our findings.", [["maltreatment", "DISEASE", 81, 93], ["that study", "TEST", 23, 33], ["increased", "OBSERVATION_MODIFIER", 55, 64]]], ["30Page 11 of 50For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 F o r p e e r r e v i e w o n l y Of particular note, a key finding of our study was the prevalence and IR were much lower than estimates derived from currently existing sources of childhood maltreatment and domestic abuse epidemiology.", [["maltreatment", "DISEASE", 459, 471], ["domestic abuse", "DISEASE", 476, 490], ["p", "TEST", 274, 275], ["e", "TEST", 276, 277], ["our study", "TEST", 339, 348]]], ["When examining UK police reports of domestic abuse, although for both genders, the prevalence in England was 24.0 per 1,000 population, much higher than in our study even though we only included a female denominator population.", [["domestic abuse", "DISEASE", 36, 50], ["our study", "TEST", 156, 165]]], ["25 When compared to the CSEW data which showed a prevalence of 7.9% in women, our figure seems even lower.", [["women", "ORGANISM", 71, 76], ["women", "SPECIES", 71, 76], ["the CSEW data", "TEST", 20, 33], ["lower", "OBSERVATION_MODIFIER", 100, 105]]], ["26 Similarly, although no combined child maltreatment figure exists for police reports, if we examine the estimated prevalence from the CSEW which suggested 18.9% of all adults have experienced some form of childhood maltreatment our figure of 4.2 per 1,000 population (2017) is substantially lower.", [["maltreatment", "DISEASE", 41, 53], ["maltreatment", "DISEASE", 217, 229], ["adults", "ORGANISM", 170, 176], ["the CSEW", "TEST", 132, 140], ["no", "UNCERTAINTY", 23, 25], ["lower", "OBSERVATION_MODIFIER", 293, 298]]], ["29 When compared to other administrative data such as children in need data, which contains the rate of children on Child protection plans, GP recorded prevalence still remains low, which has also been shown in previous literature on maltreatment related concerns.", [["maltreatment", "DISEASE", 234, 246], ["children", "ORGANISM", 54, 62], ["children", "ORGANISM", 104, 112], ["children", "SPECIES", 54, 62], ["children", "SPECIES", 104, 112], ["Child protection plans", "TREATMENT", 116, 138], ["GP recorded prevalence", "TEST", 140, 162]]], ["30, 45 The low values of incidence and prevalence of childhood maltreatment and domestic abuse and other interesting findings resonate and build on known literature.", [["maltreatment", "DISEASE", 63, 75], ["domestic abuse", "DISEASE", 80, 94], ["childhood maltreatment", "PROBLEM", 53, 75], ["low values", "OBSERVATION_MODIFIER", 11, 21]]], ["There have been national policy reports highlighting inconsistencies in data collected relating domestic abuse and childhood maltreatment to poverty and ethnicity.", [["domestic abuse", "DISEASE", 96, 110], ["maltreatment", "DISEASE", 125, 137], ["poverty", "DISEASE", 141, 148]]], ["46, 47 However, we clearly demonstrate a linear relationship between IR and socio-economic deprivation following adjustment for ethnicity.", [["IR and socio-economic deprivation", "TREATMENT", 69, 102], ["ethnicity", "PROBLEM", 128, 137]]], ["When adjusting for deprivation, GP data still highlights the burden of maltreatment and abuse experienced in ethnic minorities (although South Asians were not at a higher risk of childhood maltreatment, and mixed raced individuals were not at a higher risk of either childhood maltreatment or domestic abuse).", [["maltreatment", "DISEASE", 71, 83], ["maltreatment", "DISEASE", 189, 201], ["maltreatment", "DISEASE", 277, 289], ["domestic abuse", "DISEASE", 293, 307], ["deprivation", "TREATMENT", 19, 30], ["GP data", "TEST", 32, 39], ["mixed raced individuals", "PROBLEM", 207, 230]]], ["It has been previously highlighted that black and minority ethnic children are over-represented in child protection records within the UK, but this may be related to poverty (a form of which we have been able to adjust for in our study), isolation and willingness to seek help due to stigma in some communities.", [["children", "ORGANISM", 66, 74], ["children", "SPECIES", 66, 74], ["our study", "TEST", 226, 235], ["stigma", "PROBLEM", 284, 290], ["black", "OBSERVATION_MODIFIER", 40, 45]]], ["48 In contrast to our findings, the prevalence reported for domestic abuse exposure CSEW was highest in those from a mixed race background, and lower in those from the South Asian, Black or Other community.", [["lower", "OBSERVATION_MODIFIER", 144, 149]]], ["26 There are clear messages that need to be taken from this study relating to the underrecording of domestic abuse and childhood maltreatment in GP records.", [["domestic abuse", "DISEASE", 100, 114], ["maltreatment", "DISEASE", 129, 141], ["this study", "TEST", 55, 65], ["clear", "OBSERVATION", 13, 18]]], ["Although approaches and intervention have been implemented and evaluated to record both of these traumatic experiences, more needs to be done.", [["intervention", "TREATMENT", 24, 36], ["traumatic", "OBSERVATION", 97, 106]]], ["24, 34 Healthcare professionals should be aware of the morbidity burden caused by such exposures and also the referral tools at their disposal highlighted in recent national guidelines.", [["the morbidity burden", "PROBLEM", 51, 71]]], ["18, 19 Attempts to overcome barriers in asking about domestic abuse and childhood maltreatment such as the use of short question proformas are options to be trialled more broadly.", [["domestic abuse", "DISEASE", 53, 67], ["maltreatment", "DISEASE", 82, 94]]], ["49 Although recording of domestic abuse and childhood maltreatment do not yet fall under the incentivised payment system for GPs, it should be strongly encouraged to improve our recording and implementation of appropriate referral mechanisms.", [["domestic abuse", "DISEASE", 25, 39], ["maltreatment", "DISEASE", 54, 66]]], ["50 Although this study was unable to explore the reasons for under-recording by GPs, there is substantial literature on reasons for the underrecording and under-reporting of maltreatment and abuse summarised in a recent review.", [["maltreatment", "DISEASE", 174, 186], ["this study", "TEST", 12, 22]]], ["51 Factors refer to either challenges in the recognition or reporting of maltreatment and abuse.", [["maltreatment", "DISEASE", 73, 85]]], ["Variables which may affect recognition include experience and knowledge levels of the treating clinician or variation in the threshold between clinicians as to what is reasonable suspicion of maltreatment or abuse.", [["maltreatment", "DISEASE", 192, 204]]], ["51, 52 Additionally, factors which affect the 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 F o r p e e r r e v i e w o n l y clinician reporting the maltreatment or abuse include; 1) knowledge of the family; 2) expected negative outcomes of reporting to child-protection services; 3) lack of confidence that reporting would improve patient outcomes and 4) damage to the patient-clinician relationship.", [["maltreatment", "DISEASE", 275, 287], ["patient", "ORGANISM", 458, 465], ["patient", "ORGANISM", 496, 503], ["patient", "SPECIES", 458, 465], ["patient", "SPECIES", 496, 503]]], ["51 Therefore, education approaches going beyond data improvement and screening are needed to improve not only recognition but reporting practices.Strengths and limitationsAlthough our data are derived from a large population-based cohort, the results demonstrate substantial under-recording of childhood maltreatment and domestic abuse.", [["maltreatment", "DISEASE", 304, 316], ["domestic abuse", "DISEASE", 321, 335], ["screening", "TEST", 69, 78], ["large", "OBSERVATION_MODIFIER", 208, 213], ["substantial", "OBSERVATION_MODIFIER", 263, 274]]], ["Therefore, our results are likely to underestimate the burden of childhood maltreatment and domestic abuse by GPs.", [["maltreatment", "DISEASE", 75, 87], ["domestic abuse", "DISEASE", 92, 106]]], ["The increasing trends in IR and prevalence suggest that recording is improving and with the introduction of national guidelines and standards, this will continue to improve.", [["increasing", "OBSERVATION_MODIFIER", 4, 14], ["trends", "OBSERVATION_MODIFIER", 15, 21]]], ["18, 19 Before this dataset can be used for surveillance purposes or tracking of long term trends in childhood maltreatment or domestic abuse, there need to be further improvements in the rate or recording and reporting.", [["maltreatment", "DISEASE", 110, 122], ["domestic abuse", "DISEASE", 126, 140], ["surveillance purposes", "TEST", 43, 64], ["the rate", "TEST", 183, 191], ["long term", "OBSERVATION_MODIFIER", 80, 89]]], ["Although this study was not designed to assess the impact of public policy or media attention at certain time points, it is also possible that spikes in IR seen in the dataset such as in 2012-2013 in the childhood maltreatment cohort may be related to high profile news events such as the exposure of Jimmy Savile which was shown to result in an increase of reports of childhood maltreatment to UK statutory bodies.", [["maltreatment", "DISEASE", 214, 226], ["maltreatment", "DISEASE", 379, 391], ["this study", "TEST", 9, 19], ["public policy", "TREATMENT", 61, 74], ["spikes", "PROBLEM", 143, 149], ["high profile news events", "PROBLEM", 252, 276], ["increase", "OBSERVATION_MODIFIER", 346, 354]]], ["53 Additionally, as time progress it may be possible to conduct an interrupted time series analysis to assess the impact of changes in the NICE guidance and whether this has led to improved recording and reporting.Strengths and limitationsIt is also important to note that the reliability of the findings are largely reliant on the accuracy of the coding practices by the GP.", [["an interrupted time series analysis", "TEST", 64, 99]]], ["As seen in this study, there are a wide variety of codes relating to childhood maltreatment and domestic abuse.", [["maltreatment", "DISEASE", 79, 91], ["domestic abuse", "DISEASE", 96, 110], ["this study", "TEST", 11, 21], ["wide", "OBSERVATION_MODIFIER", 35, 39], ["variety", "OBSERVATION_MODIFIER", 40, 47]]], ["It is possible that information relating to maltreatment and abuse is included in the free-text narrative during clinical consultation which is not accessible.", [["maltreatment", "DISEASE", 44, 56]]], ["Therefore, we advise that in future studies, that where possible, free text analysis is conducted on clinical records to assess if this increases the number of reported cases.Strengths and limitationsIn our IR subgroup analysis, we also have limitations in the recorded ethnicity of patients (highlighted in table 1).", [["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["future studies", "TEST", 29, 43], ["free text analysis", "TEST", 66, 84], ["our IR subgroup analysis", "TEST", 203, 227]]], ["Ethnicity recording has historically been poor, although improving in primary care data, with missing rates of around 50%.", [["poor", "OBSERVATION_MODIFIER", 42, 46]]], ["Another approach in future analyses, is if the dataset provides information on linked family members, it may be possible to infer the ethnicity if missing data is present.ConclusionIn conclusion, our study showed an in-depth exploration of the incidence rate and prevalence trends of childhood maltreatment and domestic abuse using UK primary care records.", [["maltreatment", "DISEASE", 294, 306], ["domestic abuse", "DISEASE", 311, 325], ["our study", "TEST", 196, 205], ["the incidence rate", "PROBLEM", 240, 258]]], ["It is clear that there is a severe under-reporting of both of these important exposures which relate to substantial morbidity and mortality burdens.", [["substantial morbidity", "PROBLEM", 104, 125], ["mortality burdens", "PROBLEM", 130, 147], ["clear", "OBSERVATION", 6, 11], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["substantial", "OBSERVATION_MODIFIER", 104, 115], ["morbidity", "OBSERVATION", 116, 125]]], ["Therefore,AcknowledgementsThe study team would like to thank Ms Anuradhaa Subramanian for her support with the statistical analysis.", [["the statistical analysis", "TEST", 107, 131]]], ["The team would also like to thank the University of Birmingham for supporting the open access fees.Data statementThe original data can be requested from the study team.", [["the open access fees", "TREATMENT", 78, 98]]], ["However, ethics approval may need to be sought by the data provider prior to release of data.Author contributionsThis study contributed to the PhD thesis for the main author JSC.", [["This study", "TEST", 113, 123]]], ["JSC, JT, SB and KN were responsible for initial conception of the study.", [["the study", "TEST", 62, 71], ["JT", "ANATOMY", 5, 7], ["SB", "ANATOMY", 9, 11]]], ["JSC and KG were responsible for data extraction, analysis and first draft of the manuscript.", [["JSC", "CELL", 0, 3], ["KG", "TREATMENT", 8, 10], ["data extraction", "TEST", 32, 47], ["analysis", "TEST", 49, 57]]], ["The final manuscript was authorised by all the authors with JT providing expert knowledge on childhood maltreatment, CBJ provided expertise on domestic abuse whereas SB and KN provided methodological expertise.", [["maltreatment", "DISEASE", 103, 115], ["CBJ", "DISEASE", 117, 120]]], ["All authors agree to be accountable for all aspects of the work.FundingThere is no funding to declare in this study.Declaration of InterestsAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.", [["this study", "TEST", 105, 115], ["no", "UNCERTAINTY", 80, 82]]], ["1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Neglected appearance R037.00References[D]Insufficient intake of food and water due to self neglect R2y3.", [["self neglect R2y3", "PROBLEM", 254, 271]]], ["11 [D] Self neglect Ry18.00References[D]Self neglect SN42000ReferencesDeprivation of food, unspecified SN43000ReferencesDeprivation of water SN55.00ReferencesChild maltreatment syndrome SN55000ReferencesEmotional maltreatment of child SN55011ReferencesEmotional deprivation of child SN55012ReferencesEmotional abuse of child SN55100ReferencesNutritional maltreatment of child SN55111ReferencesNutritional deprivation of child SN55112ReferencesMalnutrition in child maltreatment syndrome SN55200ReferencesNon-accidental injury to child SN55211ReferencesNAI -non-accidental injury to child SN55212ReferencesPhysical injury to child SN55300ReferencesBattered baby or child syndrome NOS SN55311ReferencesBattered baby syndrome NOS SN55312ReferencesBattered child syndrome NOS SN55400ReferencesMultiple deprivation of child SN55500ReferencesPhysical abuse of child SN55600ReferencesNon-accidental traumatic head injury to child SN55z00ReferencesChild maltreatment syndrome NOS SN55z11ReferencesChild abuse NEC SN55z12ReferencesChild deprivation syndrome SN55z13ReferencesNeglect Child abuse investigation Z787.00ReferencesSelf-neglect Z787200ReferencesNeglect of clothes Z787400ReferencesNeglect of personal hygiene Z787500ReferencesNeglect of physical health Z787600ReferencesNeglect of dental care Z787700ReferencesNeglect of physical illness Z787800ReferencesNeglect of common dangers ZV1B400References[V]Personal history of neglect ZV4H300References[V]Emotional neglect of child ZV4H400References[V]Other problems related to neglect in upbringing ZV61200References[V]Child abuse ZV61211References[V]Child battering ZV61212References[V]Child neglect ZV61213References[V]Parent -child conflict ZVu4B00References[X]Other problems related to neglect in upbringing 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Neglected appearance R037.00Childhood maltreatment-Prevalent codes[D]Insufficient intake of food and water due to self neglect R2y3.", [["head", "ANATOMY", 902, 906], ["maltreatment syndrome", "DISEASE", 164, 185], ["Emotional maltreatment", "DISEASE", 203, 225], ["Emotional abuse", "DISEASE", 300, 315], ["Nutritional maltreatment", "DISEASE", 342, 366], ["Malnutrition", "DISEASE", 443, 455], ["maltreatment syndrome", "DISEASE", 465, 486], ["Non-accidental injury", "DISEASE", 504, 525], ["SN55211ReferencesNAI", "CHEMICAL", 535, 555], ["accidental injury", "DISEASE", 561, 578], ["Physical injury", "DISEASE", 605, 620], ["Physical abuse", "DISEASE", 836, 850], ["traumatic head injury", "DISEASE", 892, 913], ["maltreatment syndrome", "DISEASE", 946, 967], ["abuse NEC", "DISEASE", 995, 1004], ["Child deprivation syndrome", "DISEASE", 1022, 1048], ["Neglect Child abuse", "DISEASE", 1066, 1085], ["Z787.00", "CHEMICAL", 1100, 1107], ["Neglect", "DISEASE", 1272, 1279], ["Neglect", "DISEASE", 1312, 1319], ["physical illness", "DISEASE", 1323, 1339], ["Neglect", "DISEASE", 1357, 1364], ["Emotional neglect", "DISEASE", 1451, 1468], ["neglect", "DISEASE", 1524, 1531], ["neglect", "DISEASE", 1737, 1744], ["maltreatment", "DISEASE", 1965, 1977], ["head", "ORGANISM_SUBDIVISION", 902, 906], ["Child maltreatment syndrome", "PROBLEM", 158, 185], ["Malnutrition", "PROBLEM", 443, 455], ["maltreatment syndrome", "PROBLEM", 465, 486], ["Non-accidental injury", "PROBLEM", 504, 525], ["accidental injury", "PROBLEM", 561, 578], ["Physical injury", "PROBLEM", 605, 620], ["child syndrome", "PROBLEM", 664, 678], ["NOS", "PROBLEM", 679, 682], ["Battered baby syndrome", "PROBLEM", 700, 722], ["Battered child syndrome", "PROBLEM", 744, 767], ["NOS", "PROBLEM", 768, 771], ["Non-accidental traumatic head injury", "PROBLEM", 877, 913], ["Child maltreatment syndrome", "PROBLEM", 940, 967], ["NEC", "PROBLEM", 1001, 1004], ["Child deprivation syndrome", "PROBLEM", 1022, 1048], ["ReferencesSelf", "TEST", 1107, 1121], ["neglect ZV4H300References", "PROBLEM", 1423, 1448], ["Other problems", "PROBLEM", 1498, 1512], ["neglect", "PROBLEM", 1524, 1531], ["ZV61211References", "TEST", 1578, 1595], ["ZV61212References", "TEST", 1614, 1631], ["ZV61213References", "TEST", 1648, 1665], ["Other problems", "PROBLEM", 1711, 1725], ["self neglect R2y3", "PROBLEM", 2041, 2058], ["head", "ANATOMY", 902, 906], ["neglect", "OBSERVATION", 1737, 1744]]], ["11 [D] Self neglect Ry18.00Childhood maltreatment-Prevalent codes[D]Self neglect SN42000Childhood maltreatment-Prevalent codesDeprivation of food, unspecified SN43000Childhood maltreatment-Prevalent codesDeprivation of water SN55.00Childhood maltreatment-Prevalent codesChild maltreatment syndrome SN55000Childhood maltreatment-Prevalent codesEmotional maltreatment of child SN55011Childhood maltreatment-Prevalent codesEmotional deprivation of child SN55012Childhood maltreatment-Prevalent codesEmotional abuse of child SN55100Childhood maltreatment-Prevalent codesNutritional maltreatment of child SN55111Childhood maltreatment-Prevalent codesNutritional deprivation of child SN55112Childhood maltreatment-Prevalent codesMalnutrition in child maltreatment syndrome SN55200Childhood maltreatment-Prevalent codesNon-accidental injury to child SN55211 NAI -non-accidental injury to child SN55212Childhood maltreatment-Prevalent codesPhysical injury to child 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Child abuse investigation Z787.00Childhood maltreatment-Prevalent codesSelf-neglect Z787200Childhood maltreatment-Prevalent codesNeglect of clothes Z787400Childhood maltreatment-Prevalent codesNeglect of personal hygiene Z787500Childhood maltreatment-Prevalent codesNeglect of physical health Z787600Childhood maltreatment-Prevalent codesNeglect of dental care 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Neglect of physical illness Z787800Childhood maltreatment-Prevalent codesNeglect of common dangers ZV1B400Childhood maltreatment-Prevalent codes[V]Personal history of neglect ZV4H300Childhood maltreatment-Prevalent codes[V]Emotional neglect of child ZV4H400Childhood maltreatment-Prevalent codes[V]Other problems related to neglect in upbringing ZV61200Childhood maltreatment-Prevalent codes[V]Child abuse ZV61211Childhood maltreatment-Prevalent codes[V]Child battering ZV61212Childhood maltreatment-Prevalent codes[V]Child neglect ZV61213Childhood maltreatment-Prevalent codes[V]Parent -child conflict ZVu4B00Childhood maltreatment-Prevalent codes[X]Other problems related to neglect in upbringing 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 F o r p e e r r e v i e w o n l y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60", [["maltreatment", "DISEASE", 37, 49], ["maltreatment", "DISEASE", 98, 110], ["maltreatment", "DISEASE", 176, 188], ["maltreatment", "DISEASE", 242, 254], ["maltreatment syndrome", "DISEASE", 276, 297], ["SN55000", "CHEMICAL", 298, 305], ["maltreatment", "DISEASE", 315, 327], ["Emotional maltreatment", "DISEASE", 343, 365], ["SN55011", "CHEMICAL", 375, 382], ["maltreatment", "DISEASE", 392, 404], ["SN55012Childhood maltreatment", "DISEASE", 451, 480], ["codesEmotional abuse", "DISEASE", 491, 511], ["SN55100", "CHEMICAL", 521, 528], ["maltreatment", "DISEASE", 538, 550], ["Nutritional maltreatment", "DISEASE", 566, 590], ["SN55111", "CHEMICAL", 600, 607], ["maltreatment", "DISEASE", 617, 629], ["SN55112", "CHEMICAL", 678, 685], ["maltreatment", "DISEASE", 695, 707], ["Malnutrition", "DISEASE", 723, 735], ["maltreatment syndrome", "DISEASE", 745, 766], ["SN55200", "CHEMICAL", 767, 774], ["maltreatment", "DISEASE", 784, 796], ["Non-accidental injury", "DISEASE", 812, 833], ["NAI", "CHEMICAL", 851, 854], ["non-accidental injury", "DISEASE", 856, 877], ["SN55212Childhood maltreatment", "DISEASE", 887, 916], ["Physical injury", "DISEASE", 932, 947], ["Z787.00", "CHEMICAL", 1151, 1158], ["maltreatment", "DISEASE", 1168, 1180], ["maltreatment", "DISEASE", 1226, 1238], ["Neglect", "DISEASE", 1254, 1261], ["Z787400", "CHEMICAL", 1273, 1280], ["maltreatment", "DISEASE", 1290, 1302], ["Neglect", "DISEASE", 1318, 1325], ["Z787500", "CHEMICAL", 1346, 1353], ["maltreatment", "DISEASE", 1363, 1375], ["Neglect", "DISEASE", 1391, 1398], ["maltreatment", "DISEASE", 1435, 1447], ["Neglect", "DISEASE", 1463, 1470], ["Neglect", "DISEASE", 1654, 1661], ["Z787800", "CHEMICAL", 1682, 1689], ["maltreatment", "DISEASE", 1699, 1711], ["Neglect", "DISEASE", 1727, 1734], ["neglect ZV4H300Childhood maltreatment", "DISEASE", 1821, 1858], ["Emotional neglect", "DISEASE", 1877, 1894], ["ZV4H400Childhood maltreatment", "DISEASE", 1904, 1933], ["neglect", "DISEASE", 1978, 1985], ["maltreatment", "DISEASE", 2017, 2029], ["ZV61211", "CHEMICAL", 2060, 2067], ["maltreatment", "DISEASE", 2077, 2089], ["ZV61212Childhood maltreatment", "DISEASE", 2124, 2153], ["ZV61213Childhood maltreatment", "DISEASE", 2186, 2215], ["ZVu4B00Childhood maltreatment", "DISEASE", 2257, 2286], ["neglect", "DISEASE", 2331, 2338], ["SN43000", "CHEMICAL", 159, 166], ["SN55112", "CHEMICAL", 678, 685], ["ZV61211", "CHEMICAL", 2060, 2067], ["50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14", "DNA", 2659, 3393], ["Self neglect Ry", "PROBLEM", 7, 22], ["Self neglect", "PROBLEM", 68, 80], ["Child maltreatment syndrome", "PROBLEM", 270, 297], ["Malnutrition", "PROBLEM", 723, 735], ["maltreatment syndrome", "PROBLEM", 745, 766], ["Non-accidental injury", "PROBLEM", 812, 833], ["NAI", "PROBLEM", 851, 854], ["non-accidental injury", "PROBLEM", 856, 877], ["neglect", "PROBLEM", 1201, 1208], ["neglect", "PROBLEM", 1821, 1828], ["Other problems", "PROBLEM", 1952, 1966], ["neglect", "PROBLEM", 1978, 1985], ["Other problems", "PROBLEM", 2305, 2319], ["p", "TEST", 3706, 3707], ["e", "TEST", 3708, 3709], ["e r r e v i e w o n l y", "TREATMENT", 3710, 3733], ["Malnutrition", "OBSERVATION", 723, 735], ["injury", "OBSERVATION", 941, 947], ["neglect", "OBSERVATION", 1201, 1208], ["neglect", "OBSERVATION", 1821, 1828], ["neglect", "OBSERVATION", 1978, 1985], ["neglect", "OBSERVATION", 2331, 2338]]]], "b3751edcd573ad46664235ecd8b63e9db99d4c09": [["IntroductionBlood meal digestion takes place in the midgut of hematophagous arthropods and provides the source of nutrients for vitellogenesis and oogenesis, as well as the entry point for pathogen transmission [1] .", [["Blood", "ANATOMY", 12, 17], ["midgut", "ANATOMY", 52, 58], ["Blood", "ORGANISM_SUBSTANCE", 12, 17], ["midgut", "ORGAN", 52, 58], ["IntroductionBlood meal digestion", "TREATMENT", 0, 32], ["hematophagous arthropods", "TREATMENT", 62, 86]]], ["Mosquito midgut epithelial cell ultrastructures have previously been characterized by electron microscopy in several species, including Aedes aegypti [2, 3, 4, 5] , Anopheles gambiae [6] , An. darlingi [7] , Culex quinquefasciatus [8] , and Cx. tarsalis [9] .", [["midgut epithelial cell", "ANATOMY", 9, 31], ["midgut epithelial cell", "CELL", 9, 31], ["Aedes aegypti", "ORGANISM", 136, 149], ["Anopheles gambiae [6]", "ORGANISM", 165, 186], ["An. darlingi", "ORGANISM", 189, 201], ["Culex quinquefasciatus", "ORGANISM", 208, 230], ["Aedes aegypti", "SPECIES", 136, 149], ["Anopheles gambiae", "SPECIES", 165, 182], ["An. darlingi", "SPECIES", 189, 201], ["Culex quinquefasciatus", "SPECIES", 208, 230], ["Cx. tarsalis", "SPECIES", 241, 253], ["Aedes aegypti", "SPECIES", 136, 149], ["Anopheles gambiae", "SPECIES", 165, 182], ["An. darlingi", "SPECIES", 189, 201], ["Culex quinquefasciatus", "SPECIES", 208, 230], ["Cx. tarsalis", "SPECIES", 241, 253], ["Mosquito midgut epithelial cell ultrastructures", "PROBLEM", 0, 47], ["electron microscopy", "TEST", 86, 105], ["Aedes aegypti", "TEST", 136, 149], ["Anopheles gambiae", "TEST", 165, 182], ["An. darlingi", "TEST", 189, 201], ["Culex quinquefasciatus", "TEST", 208, 230], ["epithelial cell", "OBSERVATION", 16, 31]]], ["One of the most striking findings from these studies was that the rough endoplasmic reticulum (RER) in midgut epithelial cells of adult female Aedes and Anopheles mosquitoes is organized into large whorl-like structures prior to blood feeding.", [["endoplasmic reticulum", "ANATOMY", 72, 93], ["RER", "ANATOMY", 95, 98], ["midgut epithelial cells", "ANATOMY", 103, 126], ["whorl-like structures", "ANATOMY", 198, 219], ["blood", "ANATOMY", 229, 234], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 72, 93], ["RER", "CELLULAR_COMPONENT", 95, 98], ["midgut epithelial cells", "CELL", 103, 126], ["adult female Aedes", "ORGANISM", 130, 148], ["Anopheles mosquitoes", "ORGANISM", 153, 173], ["whorl-like structures", "TISSUE", 198, 219], ["blood", "ORGANISM_SUBSTANCE", 229, 234], ["midgut epithelial cells", "CELL_TYPE", 103, 126], ["these studies", "TEST", 39, 52], ["the rough endoplasmic reticulum", "PROBLEM", 62, 93], ["Anopheles mosquitoes", "PROBLEM", 153, 173], ["blood feeding", "TREATMENT", 229, 242], ["most striking", "OBSERVATION_MODIFIER", 11, 24], ["endoplasmic reticulum", "OBSERVATION", 72, 93], ["midgut", "ANATOMY", 103, 109], ["epithelial cells", "OBSERVATION", 110, 126], ["large", "OBSERVATION_MODIFIER", 192, 197], ["whorl", "OBSERVATION_MODIFIER", 198, 203]]], ["With the onset of feeding, the RER whorls undergo a dramatic reorganization, presumably to facilitate the synthesis and secretion of digestive proteases and components of the peritrophic matrix [2, 3, 5, 7, 10, 11] .", [["RER whorls", "ANATOMY", 31, 41], ["digestive", "ANATOMY", 133, 142], ["peritrophic matrix", "ANATOMY", 175, 193], ["RER whorls", "MULTI-TISSUE_STRUCTURE", 31, 41], ["matrix", "CELLULAR_COMPONENT", 187, 193], ["digestive proteases", "PROTEIN", 133, 152], ["a dramatic reorganization", "TREATMENT", 50, 75], ["the synthesis", "TREATMENT", 102, 115], ["digestive proteases", "PROBLEM", 133, 152], ["the peritrophic matrix", "TREATMENT", 171, 193], ["dramatic", "OBSERVATION_MODIFIER", 52, 60], ["reorganization", "OBSERVATION", 61, 75], ["peritrophic matrix", "OBSERVATION", 175, 193]]], ["Interestingly, male mosquitoes, which do not blood feed, lack RER whorls in their midgut epithelial cells [12] .", [["blood", "ANATOMY", 45, 50], ["RER whorls", "ANATOMY", 62, 72], ["midgut epithelial cells", "ANATOMY", 82, 105], ["male mosquitoes", "ORGANISM", 15, 30], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["RER whorls", "CELLULAR_COMPONENT", 62, 72], ["midgut epithelial cells", "CELL", 82, 105], ["midgut epithelial cells", "CELL_TYPE", 82, 105]]], ["The identity and functional contribution of protein components localized to mosquito midgut RER whorls have not been investigated.IntroductionER whorls have been shown to form in vertebrate cells exposed to inducers of the ER stress response [10, 13] , and as a result of pathological conditions [14] .", [["midgut RER whorls", "ANATOMY", 85, 102], ["cells", "ANATOMY", 190, 195], ["midgut RER whorls", "MULTI-TISSUE_STRUCTURE", 85, 102], ["cells", "CELL", 190, 195], ["ER", "GENE_OR_GENE_PRODUCT", 223, 225], ["protein components", "PROTEIN", 44, 62], ["vertebrate cells", "CELL_TYPE", 179, 195], ["ER", "PROTEIN", 223, 225], ["protein components", "PROBLEM", 44, 62], ["pathological conditions", "PROBLEM", 272, 295]]], ["Whorl-like smooth ER structures have also been shown to form in mammalian tissue culture cells that over express transfected ER resident proteins or fluorescent protein gene fusions containing heterologous transmembrane domains [15, 16, 17] .", [["smooth ER structures", "ANATOMY", 11, 31], ["tissue culture cells", "ANATOMY", 74, 94], ["transmembrane", "ANATOMY", 206, 219], ["ER", "GENE_OR_GENE_PRODUCT", 18, 20], ["tissue culture cells", "CELL", 74, 94], ["ER", "GENE_OR_GENE_PRODUCT", 125, 127], ["fluorescent protein", "GENE_OR_GENE_PRODUCT", 149, 168], ["ER", "PROTEIN", 18, 20], ["mammalian tissue culture cells", "CELL_LINE", 64, 94], ["ER resident proteins", "PROTEIN", 125, 145], ["fluorescent protein gene fusions", "DNA", 149, 181], ["heterologous transmembrane domains", "PROTEIN", 193, 227], ["smooth ER structures", "PROBLEM", 11, 31], ["mammalian tissue culture cells", "PROBLEM", 64, 94], ["fluorescent protein gene fusions", "TREATMENT", 149, 181], ["heterologous transmembrane domains", "PROBLEM", 193, 227], ["smooth", "OBSERVATION_MODIFIER", 11, 17]]], ["Immunofluorescent staining has been used in these transfection experiments to show that weak proteinprotein interactions between the cytoplasmic domains of highly abundant ER imbedded proteins are sufficient to induce membrane stacking and whorl formation.", [["cytoplasmic", "ANATOMY", 133, 144], ["ER", "ANATOMY", 172, 174], ["membrane", "ANATOMY", 218, 226], ["whorl", "ANATOMY", 240, 245], ["proteinprotein", "GENE_OR_GENE_PRODUCT", 93, 107], ["cytoplasmic", "ORGANISM_SUBSTANCE", 133, 144], ["ER", "GENE_OR_GENE_PRODUCT", 172, 174], ["membrane", "CELLULAR_COMPONENT", 218, 226], ["whorl", "TISSUE", 240, 245], ["cytoplasmic domains", "PROTEIN", 133, 152], ["ER", "PROTEIN", 172, 174], ["Immunofluorescent staining", "TEST", 0, 26], ["these transfection experiments", "TEST", 44, 74], ["weak proteinprotein interactions", "PROBLEM", 88, 120], ["the cytoplasmic domains", "TEST", 129, 152], ["membrane stacking", "PROBLEM", 218, 235], ["whorl formation", "PROBLEM", 240, 255]]], ["The absence of some ER proteins can also induce whorl formation, suggesting that mechanisms are in place to prevent ER whorls from forming in most cell types [18] .IntroductionPlasma free amino acids and protein-bound amino acids in vertebrate blood provide the raw materials for energy conversion and reproduction [19, 20, 21] , and also function to initiate signaling through the target of rapamycin (TOR) signal transduction pathway [22, 23] .", [["whorl", "ANATOMY", 48, 53], ["ER whorls", "ANATOMY", 116, 125], ["cell", "ANATOMY", 147, 151], ["blood", "ANATOMY", 244, 249], ["amino acids", "CHEMICAL", 188, 199], ["amino acids", "CHEMICAL", 218, 229], ["rapamycin", "CHEMICAL", 392, 401], ["amino acids", "CHEMICAL", 188, 199], ["amino acids", "CHEMICAL", 218, 229], ["rapamycin", "CHEMICAL", 392, 401], ["ER", "GENE_OR_GENE_PRODUCT", 20, 22], ["whorl", "TISSUE", 48, 53], ["ER", "GENE_OR_GENE_PRODUCT", 116, 118], ["cell", "CELL", 147, 151], ["Plasma", "ORGANISM_SUBSTANCE", 176, 182], ["amino acids", "AMINO_ACID", 188, 199], ["amino acids", "AMINO_ACID", 218, 229], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["rapamycin", "GENE_OR_GENE_PRODUCT", 392, 401], ["TOR", "GENE_OR_GENE_PRODUCT", 403, 406], ["ER proteins", "PROTEIN", 20, 31], ["ER", "PROTEIN", 116, 118], ["TOR", "PROTEIN", 403, 406], ["some ER proteins", "PROBLEM", 15, 31], ["IntroductionPlasma free amino acids", "TEST", 164, 199], ["protein", "TEST", 204, 211], ["bound amino acids", "TEST", 212, 229], ["rapamycin", "TREATMENT", 392, 401], ["signal transduction pathway", "TEST", 408, 435], ["most cell", "OBSERVATION_MODIFIER", 142, 151]]], ["Moreover, an artificial amino acid meal is sufficient to induce translation of early trypsin mRNA using the TOR signaling pathway in midgut epithelial cells, however amino acids alone do not induce the transcription and translation of the late phase trypsin protein [24] .", [["midgut epithelial cells", "ANATOMY", 133, 156], ["amino acid", "CHEMICAL", 24, 34], ["amino acids", "CHEMICAL", 166, 177], ["amino acid", "CHEMICAL", 24, 34], ["amino acids", "CHEMICAL", 166, 177], ["amino acid", "AMINO_ACID", 24, 34], ["trypsin", "GENE_OR_GENE_PRODUCT", 85, 92], ["TOR", "GENE_OR_GENE_PRODUCT", 108, 111], ["midgut epithelial cells", "CELL", 133, 156], ["amino acids", "AMINO_ACID", 166, 177], ["trypsin", "GENE_OR_GENE_PRODUCT", 250, 257], ["early trypsin mRNA", "RNA", 79, 97], ["TOR", "PROTEIN", 108, 111], ["midgut epithelial cells", "CELL_TYPE", 133, 156], ["trypsin protein", "PROTEIN", 250, 265], ["an artificial amino acid meal", "TREATMENT", 10, 39], ["early trypsin mRNA", "PROBLEM", 79, 97], ["midgut epithelial cells", "PROBLEM", 133, 156], ["amino acids", "TREATMENT", 166, 177], ["the late phase trypsin protein", "TREATMENT", 235, 265], ["midgut epithelial", "ANATOMY", 133, 150]]], ["It is possible that amino acid signaling through the TOR pathway also stimulates RER reorganization in mosquito midgut epithelial cells.IntroductionIn order to investigate mechanisms controlling RER whorl unwinding and the initiation of blood meal digestion in female Ae. aegypti mosquitoes, we performed proteomic studies using mass spectrometry and identified midgut proteins associated with microsomal fractions in unfed and amino acid fed mosquitoes.", [["RER", "ANATOMY", 81, 84], ["midgut epithelial cells", "ANATOMY", 112, 135], ["RER whorl", "ANATOMY", 195, 204], ["blood", "ANATOMY", 237, 242], ["midgut", "ANATOMY", 362, 368], ["microsomal fractions", "ANATOMY", 394, 414], ["amino acid", "CHEMICAL", 20, 30], ["amino acid", "CHEMICAL", 428, 438], ["amino acid", "CHEMICAL", 20, 30], ["amino acid", "CHEMICAL", 428, 438], ["amino acid", "AMINO_ACID", 20, 30], ["TOR", "GENE_OR_GENE_PRODUCT", 53, 56], ["RER", "CELLULAR_COMPONENT", 81, 84], ["midgut epithelial cells", "CELL", 112, 135], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 195, 204], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["female", "ORGANISM", 261, 267], ["Ae. aegypti", "ORGANISM", 268, 279], ["mosquitoes", "ORGANISM", 280, 290], ["amino acid", "AMINO_ACID", 428, 438], ["TOR", "PROTEIN", 53, 56], ["mosquito midgut epithelial cells", "CELL_TYPE", 103, 135], ["midgut proteins", "PROTEIN", 362, 377], ["Ae. aegypti", "SPECIES", 268, 279], ["Ae. aegypti", "SPECIES", 268, 279], ["amino acid signaling", "PROBLEM", 20, 40], ["the TOR pathway", "PROBLEM", 49, 64], ["RER reorganization in mosquito midgut epithelial cells", "PROBLEM", 81, 135], ["RER whorl unwinding", "PROBLEM", 195, 214], ["blood meal digestion", "TREATMENT", 237, 257], ["proteomic studies", "TEST", 305, 322], ["mass spectrometry", "PROBLEM", 329, 346], ["midgut proteins", "PROBLEM", 362, 377], ["microsomal fractions", "PROBLEM", 394, 414], ["mosquito midgut epithelial cells", "OBSERVATION", 103, 135]]], ["The 139 kDa alpha subunit of the COPI coatomer complex was selected as one of eight candidate RER whorl-forming proteins based on bioinformatic analyses.", [["RER whorl", "ANATOMY", 94, 103], ["COPI", "GENE_OR_GENE_PRODUCT", 33, 37], ["139 kDa alpha subunit", "PROTEIN", 4, 25], ["COPI coatomer complex", "PROTEIN", 33, 54], ["RER whorl-forming proteins", "PROTEIN", 94, 120], ["the COPI coatomer complex", "PROBLEM", 29, 54], ["bioinformatic analyses", "TEST", 130, 152], ["coatomer complex", "OBSERVATION", 38, 54]]], ["We used RNAi-mediated knockdown to determine if loss of alpha-COPI expression had any effect on RER whorl formation in unfed mosquitoes or blood meal digestion in fed mosquitoes.", [["RER whorl", "ANATOMY", 96, 105], ["blood", "ANATOMY", 139, 144], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 56, 66], ["RER whorl", "TISSUE", 96, 105], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["alpha-COPI", "PROTEIN", 56, 66], ["RNAi-mediated knockdown", "TREATMENT", 8, 31], ["loss of alpha-COPI expression", "PROBLEM", 48, 77]]], ["Our data show that alpha-COPI functions are indeed required for RER whorl formation in unfed mosquitoes, and moreover, that a deficiency in alpha-COPI blocked the expression of three late phase midgut proteases in Figure 1 .", [["RER whorl", "ANATOMY", 64, 73], ["alpha-COPI", "CHEMICAL", 140, 150], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 19, 29], ["RER whorl", "TISSUE", 64, 73], ["alpha-COPI", "SIMPLE_CHEMICAL", 140, 150], ["alpha-COPI", "PROTEIN", 19, 29], ["alpha-COPI", "PROTEIN", 140, 150], ["late phase midgut proteases", "PROTEIN", 183, 210], ["Our data", "TEST", 0, 8], ["alpha-COPI functions", "PROBLEM", 19, 39], ["a deficiency in alpha-COPI", "PROBLEM", 124, 150]]], ["Amino acid feeding is sufficient to induce RER whorl unwinding.", [["RER whorl", "ANATOMY", 43, 52], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["Amino acid feeding", "TREATMENT", 0, 18], ["whorl unwinding", "OBSERVATION", 47, 62]]], ["Three-day-old Ae. aegypti females were kept unfed (sugar fed), or fed an amino acid meal for 30 min., and then sacrificed and dissected 30 min. or 120 min. later.", [["amino acid", "CHEMICAL", 73, 83], ["sugar", "CHEMICAL", 51, 56], ["amino acid", "CHEMICAL", 73, 83], ["Ae. aegypti", "ORGANISM", 14, 25], ["Ae. aegypti", "SPECIES", 14, 25], ["Ae. aegypti", "SPECIES", 14, 25], ["an amino acid meal", "TREATMENT", 70, 88]]], ["The dissected midguts were fixed for electron microscopy preparation as described in Materials and Methods and representative electron micrographs of midgut sections are shown here.", [["midguts", "ANATOMY", 14, 21], ["midgut sections", "ANATOMY", 150, 165], ["midgut sections", "MULTI-TISSUE_STRUCTURE", 150, 165], ["electron microscopy preparation", "TEST", 37, 68], ["midgut sections", "TEST", 150, 165]]], ["C) Amino acid fed mosquito dissected at 30 min. post-feeding (8,8006 magnification).", [["Amino acid", "CHEMICAL", 3, 13], ["Amino acid", "CHEMICAL", 3, 13], ["Amino acid", "SIMPLE_CHEMICAL", 3, 13], ["Amino acid fed mosquito", "TREATMENT", 3, 26]]], ["D) Amino acid fed mosquito dissected at 120 min. post-feeding (8,8006 magnification). doi:10.1371/journal.pone.0018150.g001 blood fed mosquitoes (AaSPVI, AaSPVII, AaLT).", [["blood", "ANATOMY", 124, 129], ["Amino acid", "CHEMICAL", 3, 13], ["Amino acid", "CHEMICAL", 3, 13], ["Amino acid", "SIMPLE_CHEMICAL", 3, 13], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["Amino acid fed mosquito", "TREATMENT", 3, 26], ["blood", "TEST", 124, 129], ["AaSPVI", "TEST", 146, 152]]], ["Interestingly, the early phase of blood meal digestion, which is characterized by the synthesis and secretion of the early trypsin protease (AaET), was not dependent on alpha-COPI expression.Amino acid feeding induces RER whorl unwindingTo determine if amino acids in the midgut lumen are sufficient to trigger RER whorl unwinding in midgut epithelial cells of Ae. aegypti mosquitoes, females were fed an artificial amino acid meal and dissected midguts were characterized for ultrastructural changes at the subcellular level using electron microscopy (EM).", [["blood", "ANATOMY", 34, 39], ["RER whorl", "ANATOMY", 218, 227], ["midgut lumen", "ANATOMY", 272, 284], ["RER whorl", "ANATOMY", 311, 320], ["midgut epithelial cells", "ANATOMY", 334, 357], ["midguts", "ANATOMY", 446, 453], ["subcellular", "ANATOMY", 508, 519], ["Amino acid", "CHEMICAL", 191, 201], ["amino acids", "CHEMICAL", 253, 264], ["amino acid", "CHEMICAL", 416, 426], ["Amino acid", "CHEMICAL", 191, 201], ["amino acids", "CHEMICAL", 253, 264], ["amino acid", "CHEMICAL", 416, 426], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["trypsin protease", "GENE_OR_GENE_PRODUCT", 123, 139], ["AaET", "GENE_OR_GENE_PRODUCT", 141, 145], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 169, 179], ["Amino acid", "AMINO_ACID", 191, 201], ["amino acids", "AMINO_ACID", 253, 264], ["midgut lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 272, 284], ["RER whorl", "CELLULAR_COMPONENT", 311, 320], ["midgut epithelial cells", "CELL", 334, 357], ["Ae. aegypti mosquitoes", "ORGANISM", 361, 383], ["amino acid", "AMINO_ACID", 416, 426], ["midguts", "ORGANISM_SUBSTANCE", 446, 453], ["trypsin protease", "PROTEIN", 123, 139], ["AaET", "PROTEIN", 141, 145], ["alpha-COPI", "PROTEIN", 169, 179], ["midgut epithelial cells", "CELL_TYPE", 334, 357], ["Ae. aegypti", "SPECIES", 361, 372], ["Ae. aegypti", "SPECIES", 361, 372], ["blood meal digestion", "PROBLEM", 34, 54], ["the synthesis", "PROBLEM", 82, 95], ["the early trypsin protease", "TREATMENT", 113, 139], ["Amino acid feeding", "TREATMENT", 191, 209], ["RER whorl unwinding", "PROBLEM", 218, 237], ["amino acids in the midgut lumen", "PROBLEM", 253, 284], ["an artificial amino acid meal", "TREATMENT", 402, 431], ["ultrastructural changes", "PROBLEM", 477, 500], ["electron microscopy", "TEST", 532, 551], ["early", "OBSERVATION_MODIFIER", 19, 24], ["phase", "OBSERVATION_MODIFIER", 25, 30], ["whorl unwinding", "OBSERVATION", 222, 237], ["midgut", "ANATOMY", 334, 340], ["epithelial cells", "OBSERVATION", 341, 357]]], ["As seen in representative electron micrographs (Figure 1 ), large whorls of stacked RER membranes were observed in midgut epithelial cells from unfed (sugar only) mosquitoes, with some RER whorls containing .50 stacked membranes.", [["RER membranes", "ANATOMY", 84, 97], ["midgut epithelial cells", "ANATOMY", 115, 138], ["RER whorls", "ANATOMY", 185, 195], ["membranes", "ANATOMY", 219, 228], ["sugar", "CHEMICAL", 151, 156], ["RER membranes", "CELLULAR_COMPONENT", 84, 97], ["midgut epithelial cells", "CELL", 115, 138], ["membranes", "CELLULAR_COMPONENT", 219, 228], ["midgut epithelial cells", "CELL_TYPE", 115, 138], ["representative electron micrographs", "TEST", 11, 46], ["large whorls of stacked RER membranes", "PROBLEM", 60, 97], ["large", "OBSERVATION_MODIFIER", 60, 65], ["whorls", "OBSERVATION_MODIFIER", 66, 72], ["RER membranes", "OBSERVATION", 84, 97], ["midgut", "ANATOMY", 115, 121], ["epithelial cells", "OBSERVATION", 122, 138], ["stacked membranes", "OBSERVATION", 211, 228]]], ["The whorls appeared to consist entirely of tightly packed RER membranes, with no evidence of a core lipid droplet as seen in other organisms [25] .", [["whorls", "ANATOMY", 4, 10], ["RER membranes", "ANATOMY", 58, 71], ["RER membranes", "CELLULAR_COMPONENT", 58, 71], ["tightly packed RER membranes", "PROBLEM", 43, 71], ["a core lipid droplet", "PROBLEM", 93, 113], ["no evidence of", "UNCERTAINTY", 78, 92]]], ["Quantitative measurements of whorl size in 20 randomly chosen EM fields revealed that the RER whorls ranged in size from ,5-35 mm 2 in unfed mosquitoes ( Figure 2 ).", [["whorl", "ANATOMY", 29, 34], ["RER whorls", "ANATOMY", 90, 100], ["RER whorls", "TISSUE", 90, 100], ["whorl size", "TEST", 29, 39], ["EM fields", "TEST", 62, 71], ["the RER whorls", "TEST", 86, 100], ["size", "TEST", 111, 115], ["whorl", "OBSERVATION_MODIFIER", 29, 34], ["size", "OBSERVATION_MODIFIER", 35, 39], ["whorls", "OBSERVATION_MODIFIER", 94, 100], ["ranged", "OBSERVATION_MODIFIER", 101, 107], ["size", "OBSERVATION_MODIFIER", 111, 115]]], ["However, following a 30 minute amino acid feeding period, and another 30 minutes of recovery, midgut epithelial cells were found to contain significantly fewer RER whorls of .5 membrane stacks (p,0.001) ( Figure 2 ).", [["midgut epithelial cells", "ANATOMY", 94, 117], ["RER whorls", "ANATOMY", 160, 170], ["membrane stacks", "ANATOMY", 177, 192], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "AMINO_ACID", 31, 41], ["midgut epithelial cells", "CELL", 94, 117], ["membrane stacks", "CELLULAR_COMPONENT", 177, 192], ["midgut epithelial cells", "CELL_TYPE", 94, 117], ["a 30 minute amino acid feeding period", "TREATMENT", 19, 56], ["midgut epithelial cells", "PROBLEM", 94, 117], [".5 membrane stacks", "TREATMENT", 174, 192], ["epithelial cells", "OBSERVATION", 101, 117]]], ["Moreover, most of the RER contained in the midgut epithelial cells of amino acid fed mosquitoes was arranged in short linear stacks ( Figure 1C ).", [["midgut epithelial cells", "ANATOMY", 43, 66], ["amino acid", "CHEMICAL", 70, 80], ["amino acid", "CHEMICAL", 70, 80], ["RER", "CELLULAR_COMPONENT", 22, 25], ["midgut epithelial cells", "CELL", 43, 66], ["amino acid", "AMINO_ACID", 70, 80], ["RER", "DNA", 22, 25], ["midgut epithelial cells", "CELL_TYPE", 43, 66], ["amino acid fed mosquitoes", "TREATMENT", 70, 95], ["midgut epithelial", "ANATOMY", 43, 60]]], ["Quantitative measurements of RER whorl size and number in midgut epithelial cells following a recovery period of 120 minutes after amino acid feeding gave similar results, suggesting that RER whorl unwinding is rapid and complete by 30 minutes post feeding ( Figures 1D and 2 ).Identification of candidate RER whorl-associated proteinsReorganization of the ER in midgut epithelial cells of amino acid fed mosquitoes may be associated with differential abundance of KDEL-containing ER resident proteins, which could provide a clue as to possible whorl-enriched proteins.", [["RER whorl", "ANATOMY", 29, 38], ["midgut epithelial cells", "ANATOMY", 58, 81], ["RER whorl", "ANATOMY", 188, 197], ["RER whorl", "ANATOMY", 306, 315], ["ER", "ANATOMY", 357, 359], ["midgut epithelial cells", "ANATOMY", 363, 386], ["amino acid", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 390, 400], ["amino acid", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 390, 400], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 29, 38], ["midgut epithelial cells", "CELL", 58, 81], ["amino acid", "AMINO_ACID", 131, 141], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 188, 197], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 306, 315], ["ER", "GENE_OR_GENE_PRODUCT", 357, 359], ["midgut epithelial cells", "CELL", 363, 386], ["amino acid", "AMINO_ACID", 390, 400], ["KDEL", "GENE_OR_GENE_PRODUCT", 465, 469], ["ER", "GENE_OR_GENE_PRODUCT", 481, 483], ["midgut epithelial cells", "CELL_TYPE", 58, 81], ["ER", "PROTEIN", 357, 359], ["midgut epithelial cells", "CELL_TYPE", 363, 386], ["KDEL", "PROTEIN", 465, 469], ["ER resident proteins", "PROTEIN", 481, 501], ["whorl-enriched proteins", "PROTEIN", 545, 568], ["amino acid feeding", "TREATMENT", 131, 149], ["RER whorl unwinding", "PROBLEM", 188, 207], ["amino acid fed mosquitoes", "PROBLEM", 390, 415], ["whorl-enriched proteins", "PROBLEM", 545, 568], ["whorl", "OBSERVATION_MODIFIER", 33, 38], ["size", "OBSERVATION_MODIFIER", 39, 43], ["number", "OBSERVATION_MODIFIER", 48, 54], ["midgut epithelial cells", "OBSERVATION", 58, 81], ["whorl unwinding", "OBSERVATION", 192, 207], ["proteinsReorganization", "OBSERVATION", 327, 349], ["midgut", "ANATOMY", 363, 369], ["epithelial cells", "OBSERVATION", 370, 386], ["amino acid", "OBSERVATION", 390, 400]]], ["To test this possibility, we prepared total protein extracts from midguts of unfed and amino acid fed (30 min and 120 min post feeding) mosquitoes, and analyzed the extracts by Western blotting using a KDELspecific antibody as shown in Figure 3 .", [["extracts", "ANATOMY", 52, 60], ["midguts", "ANATOMY", 66, 73], ["extracts", "ANATOMY", 165, 173], ["amino acid", "CHEMICAL", 87, 97], ["amino acid", "CHEMICAL", 87, 97], ["extracts", "ORGANISM_SUBSTANCE", 52, 60], ["midguts", "ORGANISM_SUBSTANCE", 66, 73], ["extracts", "ORGANISM_SUBSTANCE", 165, 173], ["KDELspecific antibody", "PROTEIN", 202, 223], ["total protein extracts", "TREATMENT", 38, 60], ["amino acid fed", "TREATMENT", 87, 101], ["a KDELspecific antibody", "TREATMENT", 200, 223]]], ["Four distinct protein bands were observed, two of which appeared to decrease in abundance after feeding (KDEL-2 and KDEL-4), relative to the internal control protein (GAPDH).", [["KDEL-2", "GENE_OR_GENE_PRODUCT", 105, 111], ["KDEL-4", "GENE_OR_GENE_PRODUCT", 116, 122], ["GAPDH", "GENE_OR_GENE_PRODUCT", 167, 172], ["KDEL", "PROTEIN", 105, 109], ["KDEL", "PROTEIN", 116, 120], ["internal control protein", "PROTEIN", 141, 165], ["GAPDH", "PROTEIN", 167, 172], ["Four distinct protein bands", "PROBLEM", 0, 27], ["KDEL", "TEST", 105, 109], ["KDEL", "TEST", 116, 120], ["distinct", "OBSERVATION_MODIFIER", 5, 13], ["protein bands", "OBSERVATION", 14, 27], ["decrease", "OBSERVATION_MODIFIER", 68, 76], ["abundance", "OBSERVATION_MODIFIER", 80, 89]]], ["The KDEL-1 protein was only present in the 30 min sample, whereas the KDEL-3 protein was present in all three protein samples.", [["sample", "ANATOMY", 50, 56], ["samples", "ANATOMY", 118, 125], ["KDEL-1", "GENE_OR_GENE_PRODUCT", 4, 10], ["KDEL-3", "GENE_OR_GENE_PRODUCT", 70, 76], ["KDEL", "PROTEIN", 4, 8], ["1 protein", "PROTEIN", 9, 18], ["KDEL", "PROTEIN", 70, 74], ["The KDEL", "TEST", 0, 8], ["the KDEL", "TEST", 66, 74]]], ["Since Ae. aegypti protein disulfide isomerase (PDI) has a predicted molecular mass of ,56 kDa, and is a KDEL-containing ER protein known to be expressed in Ae. aegypti midgut cells [26] , we analyzed these same protein extracts with a PDI antibody that recognizes Drosophila melanogaster PDI.", [["midgut cells", "ANATOMY", 168, 180], ["extracts", "ANATOMY", 219, 227], ["disulfide", "CHEMICAL", 26, 35], ["Ae. aegypti", "ORGANISM", 6, 17], ["protein disulfide isomerase", "GENE_OR_GENE_PRODUCT", 18, 45], ["PDI", "GENE_OR_GENE_PRODUCT", 47, 50], ["KDEL", "GENE_OR_GENE_PRODUCT", 104, 108], ["ER", "GENE_OR_GENE_PRODUCT", 120, 122], ["Ae", "CELL", 156, 158], ["aegypti", "ORGANISM", 160, 167], ["midgut cells", "CELL", 168, 180], ["extracts", "ORGANISM_SUBSTANCE", 219, 227], ["PDI", "GENE_OR_GENE_PRODUCT", 235, 238], ["Drosophila melanogaster", "ORGANISM", 264, 287], ["PDI", "GENE_OR_GENE_PRODUCT", 288, 291], ["Ae. aegypti protein disulfide isomerase", "PROTEIN", 6, 45], ["PDI", "PROTEIN", 47, 50], ["KDEL", "PROTEIN", 104, 108], ["ER protein", "PROTEIN", 120, 130], ["midgut cells", "CELL_TYPE", 168, 180], ["PDI antibody", "PROTEIN", 235, 247], ["Drosophila melanogaster PDI", "PROTEIN", 264, 291], ["aegypti", "SPECIES", 160, 167], ["Drosophila melanogaster", "SPECIES", 264, 287], ["Ae. aegypti", "SPECIES", 6, 17], ["aegypti", "SPECIES", 160, 167], ["Drosophila melanogaster", "SPECIES", 264, 287], ["Ae. aegypti protein disulfide isomerase", "TEST", 6, 45], ["a predicted molecular mass", "PROBLEM", 56, 82], ["a KDEL", "TEST", 102, 108], ["aegypti midgut cells", "PROBLEM", 160, 180], ["a PDI antibody", "TEST", 233, 247], ["Drosophila melanogaster PDI", "TREATMENT", 264, 291], ["mass", "OBSERVATION", 78, 82], ["Drosophila melanogaster", "OBSERVATION", 264, 287]]], ["Results from these experiments were negative (data not shown), however we could not rule out that antigenic differences between Drosophila and Aedes PDI proteins contributed to the negative result.Identification of candidate RER whorl-associated proteinsTo more directly identify midgut proteins that might be contributing to whorl formation in unfed adult female mosquitoes, we isolated microsomal proteins from midgut tissues of unfed and amino acid fed mosquitoes (30 min post-feeding) using a modified procedure that minimized protease activity in the sample and enriched for RER associated proteins (see Materials and Methods).", [["RER whorl", "ANATOMY", 225, 234], ["whorl", "ANATOMY", 326, 331], ["microsomal", "ANATOMY", 388, 398], ["midgut tissues", "ANATOMY", 413, 427], ["sample", "ANATOMY", 556, 562], ["amino acid", "CHEMICAL", 441, 451], ["amino acid", "CHEMICAL", 441, 451], ["Drosophila", "ORGANISM", 128, 138], ["Aedes", "ORGANISM", 143, 148], ["PDI", "GENE_OR_GENE_PRODUCT", 149, 152], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 225, 234], ["whorl", "TISSUE", 326, 331], ["female mosquitoes", "ORGANISM", 357, 374], ["midgut tissues", "TISSUE", 413, 427], ["amino acid", "AMINO_ACID", 441, 451], ["Drosophila and Aedes PDI proteins", "PROTEIN", 128, 161], ["RER whorl-associated proteins", "PROTEIN", 225, 254], ["midgut proteins", "PROTEIN", 280, 295], ["microsomal proteins", "PROTEIN", 388, 407], ["protease", "PROTEIN", 531, 539], ["RER associated proteins", "PROTEIN", 580, 603], ["Drosophila", "SPECIES", 128, 138], ["Drosophila", "SPECIES", 128, 138], ["these experiments", "TEST", 13, 30], ["antigenic differences between Drosophila", "PROBLEM", 98, 138], ["Aedes PDI proteins", "TEST", 143, 161], ["midgut proteins", "PROBLEM", 280, 295], ["whorl formation", "PROBLEM", 326, 341], ["isolated microsomal proteins", "PROBLEM", 379, 407], ["amino acid fed mosquitoes", "TREATMENT", 441, 466], ["a modified procedure", "TREATMENT", 495, 515], ["protease activity", "TREATMENT", 531, 548], ["RER associated proteins", "PROBLEM", 580, 603], ["might be contributing", "UNCERTAINTY", 301, 322], ["microsomal proteins", "OBSERVATION", 388, 407], ["midgut tissues", "ANATOMY", 413, 427]]], ["The protein samples were separated by molecular weight using SDS PAGE and four gel slices from each lane were processed for LC-MS/MS analysis and protein annotation ( Figure 4 ).", [["samples", "ANATOMY", 12, 19], ["The protein samples", "TEST", 0, 19], ["four gel slices", "TEST", 74, 89], ["LC", "TEST", 124, 126], ["MS/MS analysis", "TEST", 127, 141], ["protein annotation", "TEST", 146, 164]]], ["The SDS PAGE analysis revealed that intact proteins of up to ,130 kDa were present in both samples, suggesting that protease activity was minimal in the midgut protein sample from fed mosquitoes.", [["samples", "ANATOMY", 91, 98], ["midgut protein sample", "ANATOMY", 153, 174], ["midgut", "ORGANISM_SUBSTANCE", 153, 159], ["protease", "PROTEIN", 116, 124], ["The SDS PAGE analysis", "TEST", 0, 21], ["intact proteins", "PROBLEM", 36, 51], ["protease activity", "PROBLEM", 116, 133], ["protease activity", "OBSERVATION", 116, 133]]], ["Moreover, no major differences were observed in the distribution of proteins isolated from the unfed or amino acid fed mosquitoes, indicating that the 30 min time point preceded feeding-induced protein synthesis.Identification of candidate RER whorl-associated proteinsFollowing in-gel trypsin digestion, each of the eight protein samples was analyzed by LC-MS/MS. Bioinformatic analysis of the mass spectrometry data led to the identification of 127 proteins using the Ae. aegypti genome database in a Sequest-based search (Table S1 ).", [["RER whorl", "ANATOMY", 240, 249], ["samples", "ANATOMY", 331, 338], ["amino acid", "CHEMICAL", 104, 114], ["amino acid", "CHEMICAL", 104, 114], ["amino acid", "AMINO_ACID", 104, 114], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 240, 249], ["Ae. aegypti", "ORGANISM", 470, 481], ["RER whorl-associated proteins", "PROTEIN", 240, 269], ["trypsin", "PROTEIN", 286, 293], ["Ae. aegypti", "SPECIES", 470, 481], ["amino acid fed mosquitoes", "PROBLEM", 104, 129], ["induced protein synthesis", "PROBLEM", 186, 211], ["associated proteins", "PROBLEM", 250, 269], ["gel trypsin digestion", "TREATMENT", 282, 303], ["the eight protein samples", "TEST", 313, 338], ["Bioinformatic analysis", "TEST", 365, 387], ["the mass spectrometry data", "TEST", 391, 417], ["the identification", "TEST", 425, 443], ["no", "UNCERTAINTY", 10, 12], ["major", "OBSERVATION_MODIFIER", 13, 18], ["proteins isolated", "OBSERVATION", 68, 85], ["protein synthesis", "OBSERVATION", 194, 211]]], ["Gene Ontology (GO) analysis revealed that ,30% of Figure 2 .", [["analysis", "TEST", 19, 27]]], ["Quantitation of whorl size and number in unfed and amino acid fed mosquitoes.", [["whorl", "ANATOMY", 16, 21], ["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 51, 61], ["amino acid", "AMINO_ACID", 51, 61], ["whorl size", "PROBLEM", 16, 26], ["whorl", "OBSERVATION_MODIFIER", 16, 21], ["size", "OBSERVATION_MODIFIER", 22, 26], ["number", "OBSERVATION_MODIFIER", 31, 37]]], ["Whorls with a minimum of five stacked ER membranes were counted and the total area of each whorl was determined using NIH Image software.", [["ER membranes", "ANATOMY", 38, 50], ["whorl", "ANATOMY", 91, 96], ["ER", "GENE_OR_GENE_PRODUCT", 38, 40], ["membranes", "CELLULAR_COMPONENT", 41, 50], ["ER", "PROTEIN", 38, 40]]], ["Data are shown for whorl size and number in 20 random EM fields covering 3335 mm 2 of mosquito midgut epithelial cell area.", [["whorl", "ANATOMY", 19, 24], ["midgut epithelial cell area", "ANATOMY", 95, 122], ["midgut epithelial cell", "CELL", 95, 117], ["whorl size", "PROBLEM", 19, 29], ["mosquito midgut epithelial cell area", "PROBLEM", 86, 122], ["size", "OBSERVATION_MODIFIER", 25, 29], ["midgut", "ANATOMY", 95, 101], ["epithelial cell", "OBSERVATION", 102, 117]]], ["A) Size and number of RER whorls in 20 random fields from unfed and amino acid fed mosquitoes after 30 min. and 120 min.", [["RER whorls", "ANATOMY", 22, 32], ["amino acid", "CHEMICAL", 68, 78], ["amino acid", "CHEMICAL", 68, 78], ["amino acid", "AMINO_ACID", 68, 78], ["amino acid fed mosquitoes", "TREATMENT", 68, 93], ["Size", "OBSERVATION_MODIFIER", 3, 7], ["whorls", "OBSERVATION_MODIFIER", 26, 32]]], ["B) Total whorl in the same sample as shown in A. Statistical analysis using Pearson Chisquare test revealed that the total whorl area in amino acid fed mosquitoes at both 30 min and 120 min post-feeding was significantly less than the total whorl area in unfed mosquitoes (bars with different letters signify significance at p,0.001 comparing 30 min and 120 min to unfed mosquitoes). doi:10.1371/journal.pone.0018150.g002 the identified proteins could be assigned to microsomes (including ribosomal proteins and protein synthesis related proteins), ,19% were mitochondrial proteins, ,37% were cytoplasmic proteins, and ,14% were from other cellular fractions, including the nucleus.", [["sample", "ANATOMY", 27, 33], ["whorl area", "ANATOMY", 123, 133], ["whorl area", "ANATOMY", 241, 251], ["microsomes", "ANATOMY", 467, 477], ["ribosomal", "ANATOMY", 489, 498], ["mitochondrial", "ANATOMY", 559, 572], ["cytoplasmic", "ANATOMY", 593, 604], ["cellular fractions", "ANATOMY", 640, 658], ["nucleus", "ANATOMY", 674, 681], ["amino acid", "CHEMICAL", 137, 147], ["amino acid", "CHEMICAL", 137, 147], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["whorl area", "MULTI-TISSUE_STRUCTURE", 123, 133], ["amino acid", "AMINO_ACID", 137, 147], ["microsomes", "TISSUE", 467, 477], ["ribosomal proteins", "GENE_OR_GENE_PRODUCT", 489, 507], ["protein synthesis related proteins", "GENE_OR_GENE_PRODUCT", 512, 546], ["mitochondrial", "CELLULAR_COMPONENT", 559, 572], ["cytoplasmic", "ORGANISM_SUBSTANCE", 593, 604], ["cellular", "CELL", 640, 648], ["nucleus", "CELLULAR_COMPONENT", 674, 681], ["ribosomal proteins", "PROTEIN", 489, 507], ["protein synthesis related proteins", "PROTEIN", 512, 546], ["mitochondrial proteins", "PROTEIN", 559, 581], ["cytoplasmic proteins", "PROTEIN", 593, 613], ["Pearson Chisquare test", "TEST", 76, 98], ["microsomes", "TEST", 467, 477], ["ribosomal proteins", "TEST", 489, 507], ["protein synthesis", "TEST", 512, 529], ["proteins", "TEST", 538, 546], ["mitochondrial proteins", "TEST", 559, 581], ["cytoplasmic proteins", "TEST", 593, 613], ["cellular fractions", "OBSERVATION", 640, 658], ["nucleus", "ANATOMY", 674, 681]]], ["Eight of the microsomal proteins that were present in the protein sample from unfed mosquitoes, were chosen as candidate whorl-associated proteins based on their known role in ER or Golgi processes (Table 1 ).", [["sample", "ANATOMY", 66, 72], ["ER", "ANATOMY", 176, 178], ["Golgi", "ANATOMY", 182, 187], ["ER", "GENE_OR_GENE_PRODUCT", 176, 178], ["Golgi", "CELLULAR_COMPONENT", 182, 187], ["microsomal proteins", "PROTEIN", 13, 32], ["ER", "PROTEIN", 176, 178], ["the microsomal proteins", "TEST", 9, 32], ["the protein sample", "TEST", 54, 72], ["whorl-associated proteins", "PROBLEM", 121, 146]]], ["Based on peptide frequency, the most often represented protein was SND1 (Staphylococcal nuclease domain-containing protein 1), which is also known as Tudor domain-containing protein 11 [27] .", [["SND1", "GENE_OR_GENE_PRODUCT", 67, 71], ["Staphylococcal nuclease domain-containing protein 1", "GENE_OR_GENE_PRODUCT", 73, 124], ["Tudor domain-containing protein", "GENE_OR_GENE_PRODUCT", 150, 181], ["SND1", "PROTEIN", 67, 71], ["Staphylococcal nuclease domain-containing protein 1", "PROTEIN", 73, 124], ["Tudor domain-containing protein 11", "PROTEIN", 150, 184], ["protein", "TEST", 55, 62], ["Staphylococcal nuclease domain", "PROBLEM", 73, 103], ["protein", "TEST", 115, 122], ["protein", "TEST", 174, 181]]], ["Although SND1 is assigned to the Golgi apparatus cellular component by GO analysis, its primary function is gene regulation and RNA processing [28] .", [["Golgi apparatus cellular", "ANATOMY", 33, 57], ["SND1", "GENE_OR_GENE_PRODUCT", 9, 13], ["Golgi", "CELLULAR_COMPONENT", 33, 38], ["apparatus", "CELLULAR_COMPONENT", 39, 48], ["cellular component", "CELLULAR_COMPONENT", 49, 67], ["SND1", "PROTEIN", 9, 13], ["GO analysis", "TEST", 71, 82]]], ["The peptide frequency of SND1 was similar in protein samples from unfed and fed mosquitoes, even though EM analysis revealed that the majority of RER whorl unwinding had already occurred by 30 min post amino acid feeding ( Figure 1C ).", [["samples", "ANATOMY", 53, 60], ["RER whorl", "ANATOMY", 146, 155], ["amino acid", "CHEMICAL", 202, 212], ["amino acid", "CHEMICAL", 202, 212], ["SND1", "GENE_OR_GENE_PRODUCT", 25, 29], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 146, 155], ["amino acid", "AMINO_ACID", 202, 212], ["SND1", "PROTEIN", 25, 29], ["The peptide frequency of SND1", "PROBLEM", 0, 29], ["protein samples", "TEST", 45, 60], ["EM analysis", "TEST", 104, 115], ["RER whorl unwinding", "PROBLEM", 146, 165], ["amino acid feeding", "TREATMENT", 202, 220], ["whorl unwinding", "OBSERVATION", 150, 165]]], ["This result suggests that SND1 is most likely not associated with whorl maintenance since its presence in microsomal fractions is independent of whorl formation.Identification of candidate RER whorl-associated proteinsBesides PDI, we also identified three of the seven known coatomer subunits of the COPI vesicle transport system.", [["whorl", "ANATOMY", 66, 71], ["microsomal fractions", "ANATOMY", 106, 126], ["whorl", "ANATOMY", 145, 150], ["RER whorl", "ANATOMY", 189, 198], ["COPI vesicle", "ANATOMY", 300, 312], ["SND1", "GENE_OR_GENE_PRODUCT", 26, 30], ["whorl", "ORGANISM_SUBDIVISION", 66, 71], ["microsomal", "ORGANISM_SUBSTANCE", 106, 116], ["whorl", "TISSUE", 145, 150], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 189, 198], ["PDI", "GENE_OR_GENE_PRODUCT", 226, 229], ["coatomer", "GENE_OR_GENE_PRODUCT", 275, 283], ["COPI", "GENE_OR_GENE_PRODUCT", 300, 304], ["vesicle", "CELLULAR_COMPONENT", 305, 312], ["SND1", "PROTEIN", 26, 30], ["RER whorl-associated proteins", "PROTEIN", 189, 218], ["PDI", "PROTEIN", 226, 229], ["coatomer subunits", "PROTEIN", 275, 292], ["COPI", "PROTEIN", 300, 304], ["microsomal fractions", "PROBLEM", 106, 126], ["PDI", "PROBLEM", 226, 229], ["most likely not", "UNCERTAINTY", 34, 49], ["microsomal fractions", "OBSERVATION", 106, 126], ["whorl formation", "OBSERVATION", 145, 160], ["coatomer subunits", "OBSERVATION", 275, 292], ["COPI vesicle", "OBSERVATION", 300, 312], ["transport system", "OBSERVATION", 313, 329]]], ["As shown in Table 1 , more peptides corresponding to the alpha-COPI, beta-COPI, beta'-COPI, subunits were identified in the microsomal fractions isolated from unfed mosquitoes than fed mosquitoes ( Table 1 ), indicating that endosomal membranes in these fractions were depleted of COPI subunits.", [["microsomal fractions", "ANATOMY", 124, 144], ["endosomal membranes", "ANATOMY", 225, 244], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 57, 67], ["beta-COPI", "GENE_OR_GENE_PRODUCT", 69, 78], ["beta'-COPI", "GENE_OR_GENE_PRODUCT", 80, 90], ["microsomal", "ORGANISM_SUBSTANCE", 124, 134], ["endosomal membranes", "CELLULAR_COMPONENT", 225, 244], ["COPI", "GENE_OR_GENE_PRODUCT", 281, 285], ["alpha-COPI", "PROTEIN", 57, 67], ["beta-COPI", "PROTEIN", 69, 78], ["beta", "PROTEIN", 80, 84], ["COPI", "PROTEIN", 86, 90], ["COPI subunits", "PROTEIN", 281, 294], ["the alpha-COPI", "TEST", 53, 67], ["beta-COPI", "TREATMENT", 69, 78], ["beta'-COPI", "TREATMENT", 80, 90], ["subunits", "PROBLEM", 92, 100], ["the microsomal fractions", "TEST", 120, 144], ["endosomal membranes in these fractions", "PROBLEM", 225, 263], ["COPI subunits", "TREATMENT", 281, 294], ["endosomal membranes", "OBSERVATION", 225, 244], ["COPI subunits", "OBSERVATION", 281, 294]]], ["Since COPI subunits are soluble proteins that transiently cycle between vesicle membrane bound and unbound forms as a function of interactions with Arf proteins [29, 30] , the observed differential abundance of COPI subunits in the two midgut microsomal fractions suggests that they could be associated with RER whorls.", [["vesicle membrane", "ANATOMY", 72, 88], ["midgut microsomal fractions", "ANATOMY", 236, 263], ["RER whorls", "ANATOMY", 308, 318], ["COPI", "GENE_OR_GENE_PRODUCT", 6, 10], ["vesicle membrane", "CELLULAR_COMPONENT", 72, 88], ["Arf", "GENE_OR_GENE_PRODUCT", 148, 151], ["COPI", "GENE_OR_GENE_PRODUCT", 211, 215], ["COPI subunits", "PROTEIN", 6, 19], ["soluble proteins", "PROTEIN", 24, 40], ["vesicle membrane bound and unbound forms", "PROTEIN", 72, 112], ["Arf proteins", "PROTEIN", 148, 160], ["COPI subunits", "PROTEIN", 211, 224], ["COPI subunits", "TREATMENT", 6, 19], ["soluble proteins", "TREATMENT", 24, 40], ["vesicle membrane bound", "PROBLEM", 72, 94], ["Arf proteins", "TEST", 148, 160], ["COPI subunits", "PROBLEM", 211, 224], ["COPI subunits", "OBSERVATION", 211, 224]]], ["We tested this idea by knocking down alpha-COPI expression using RNAi to determine if this COPI coatomer subunit is required for RER whorl structures in mosquito midgut epithelial cells.alpha-COPI expression is required for RER whorl formation in midgut epithelial cellsIn order to test the role of alpha-COPI in RER whorl formation, we used an efficient dsRNA based RNAi protocol we previously developed for knocking down expression of abundant midgut proteases in Ae. aegypti [31] .", [["RER whorl structures", "ANATOMY", 129, 149], ["midgut epithelial cells", "ANATOMY", 162, 185], ["RER whorl", "ANATOMY", 224, 233], ["midgut epithelial cells", "ANATOMY", 247, 270], ["RER whorl", "ANATOMY", 313, 322], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 37, 47], ["COPI", "GENE_OR_GENE_PRODUCT", 91, 95], ["midgut epithelial cells", "CELL", 162, 185], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 186, 196], ["RER whorl", "TISSUE", 224, 233], ["midgut epithelial cells", "CELL", 247, 270], ["alpha-COPI", "SIMPLE_CHEMICAL", 299, 309], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 313, 322], ["Ae. aegypti", "ORGANISM", 466, 477], ["alpha-COPI", "PROTEIN", 37, 47], ["COPI coatomer subunit", "PROTEIN", 91, 112], ["mosquito midgut epithelial cells", "CELL_TYPE", 153, 185], ["alpha-COPI", "PROTEIN", 186, 196], ["midgut epithelial cells", "CELL_TYPE", 247, 270], ["alpha-COPI", "PROTEIN", 299, 309], ["midgut proteases", "PROTEIN", 446, 462], ["Ae. aegypti", "SPECIES", 466, 477], ["Ae. aegypti", "SPECIES", 466, 477], ["RNAi", "TREATMENT", 65, 69], ["this COPI coatomer subunit", "PROBLEM", 86, 112], ["RER whorl structures in mosquito midgut epithelial cells", "PROBLEM", 129, 185], ["alpha-COPI expression", "PROBLEM", 186, 207], ["RER whorl formation in midgut epithelial cells", "PROBLEM", 224, 270], ["an efficient dsRNA based RNAi protocol", "TREATMENT", 342, 380], ["abundant midgut proteases", "PROBLEM", 437, 462], ["mosquito midgut epithelial cells", "OBSERVATION", 153, 185], ["midgut epithelial", "ANATOMY", 247, 264], ["cells", "OBSERVATION", 265, 270]]], ["As shown in Figure 5 , the mean level of alpha-COPI transcripts in midguts of individual dsRNA-injected mosquitoes was .90% lower than the mean level in both uninjected mosquitoes and mosquitoes that had been injected with a control dsRNA from the firefly luciferase gene (Fluc).", [["midguts", "ANATOMY", 67, 74], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 41, 51], ["mosquitoes", "ORGANISM", 104, 114], ["luciferase", "GENE_OR_GENE_PRODUCT", 256, 266], ["Fluc", "GENE_OR_GENE_PRODUCT", 273, 277], ["alpha-COPI transcripts", "RNA", 41, 63], ["dsRNA", "RNA", 233, 238], ["firefly luciferase gene", "DNA", 248, 271], ["Fluc", "DNA", 273, 277], ["alpha-COPI transcripts", "TREATMENT", 41, 63], ["individual dsRNA", "PROBLEM", 78, 94], ["a control dsRNA", "TREATMENT", 223, 238], ["the firefly luciferase gene (Fluc", "TREATMENT", 244, 277]]], ["Since 100% of the alpha-COPI dsRNA injected mosquitoes we analyzed showed a similar decrease in alpha-COPI transcript levels ( Figure 5 ), we used this dsRNA injection protocol to knock down alpha-COPI expression in mosquitoes that were subsequently maintained on sugar alone (unfed), or fed an amino acid meal and sacrificed 120 min post-feeding.alpha-COPI expression is required for RER whorl formation in midgut epithelial cellsAs shown in Figure 6 , EM analysis of representative midguts from alpha-COPI and Fluc dsRNA injected mosquitoes showed that while large characteristic RER whorls were present in the midguts of unfed Fluc dsRNA injected mosquitoes ( Figures 6A, 6B) , the RER present in unfed alpha-COPI dsRNA injected mosquitoes was disorganized and RER whorl structures were absent ( Figures 6C, 6D) .", [["RER whorl", "ANATOMY", 385, 394], ["midgut epithelial cells", "ANATOMY", 408, 431], ["midguts", "ANATOMY", 484, 491], ["RER whorls", "ANATOMY", 582, 592], ["midguts", "ANATOMY", 613, 620], ["RER whorl structures", "ANATOMY", 764, 784], ["amino acid", "CHEMICAL", 295, 305], ["alpha-COPI", "CHEMICAL", 706, 716], ["sugar", "CHEMICAL", 264, 269], ["amino acid", "CHEMICAL", 295, 305], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 18, 28], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 96, 106], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 191, 201], ["mosquitoes", "ORGANISM", 216, 226], ["sugar", "SIMPLE_CHEMICAL", 264, 269], ["amino acid", "AMINO_ACID", 295, 305], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 347, 357], ["RER whorl", "TISSUE", 385, 394], ["midgut epithelial cells", "CELL", 408, 431], ["midguts", "ORGANISM", 484, 491], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 497, 507], ["Fluc dsRNA", "ORGANISM", 512, 522], ["RER whorls", "MULTI-TISSUE_STRUCTURE", 582, 592], ["Fluc dsRNA", "ORGANISM", 630, 640], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 706, 716], ["RER whorl structures", "TISSUE", 764, 784], ["alpha-COPI", "PROTEIN", 96, 106], ["alpha-COPI", "PROTEIN", 191, 201], ["alpha-COPI", "PROTEIN", 347, 357], ["midgut epithelial cells", "CELL_TYPE", 408, 431], ["the alpha-COPI dsRNA", "TREATMENT", 14, 34], ["a similar decrease in alpha-COPI transcript levels", "PROBLEM", 74, 124], ["this dsRNA injection protocol", "TREATMENT", 147, 176], ["an amino acid meal", "TREATMENT", 292, 310], ["alpha-COPI expression", "PROBLEM", 347, 368], ["RER whorl formation in midgut epithelial cells", "PROBLEM", 385, 431], ["EM analysis", "TEST", 454, 465], ["alpha-COPI", "TEST", 497, 507], ["Fluc dsRNA", "TREATMENT", 512, 522], ["large characteristic RER whorls", "PROBLEM", 561, 592], ["disorganized", "PROBLEM", 747, 759], ["similar", "OBSERVATION_MODIFIER", 76, 83], ["decrease", "OBSERVATION_MODIFIER", 84, 92], ["midgut epithelial", "ANATOMY", 408, 425], ["cells", "OBSERVATION", 426, 431]]], ["RER reorganization at 120 min post-feeding in Fluc dsRNA .", [["Fluc", "GENE_OR_GENE_PRODUCT", 46, 50], ["Fluc dsRNA", "DNA", 46, 56], ["Fluc dsRNA", "TREATMENT", 46, 56], ["Fluc dsRNA", "OBSERVATION", 46, 56]]], ["Western blot analysis using a KDEL-specific antibody shows differential expression of four ER resident midgut proteins in response to amino acid feeding in Ae. aegypti mosquitoes.", [["midgut", "ANATOMY", 103, 109], ["amino acid", "CHEMICAL", 134, 144], ["amino acid", "CHEMICAL", 134, 144], ["KDEL", "GENE_OR_GENE_PRODUCT", 30, 34], ["ER", "GENE_OR_GENE_PRODUCT", 91, 93], ["amino acid", "AMINO_ACID", 134, 144], ["aegypti mosquitoes", "ORGANISM", 160, 178], ["KDEL", "PROTEIN", 30, 34], ["ER resident midgut proteins", "PROTEIN", 91, 118], ["aegypti", "SPECIES", 160, 167], ["Ae.", "SPECIES", 156, 159], ["aegypti", "SPECIES", 160, 167], ["blot analysis", "TEST", 8, 21], ["a KDEL", "TEST", 28, 34], ["specific antibody", "TEST", 35, 52], ["amino acid feeding", "TREATMENT", 134, 152]]], ["Total midgut protein extracts were prepared from three day old female mosquitoes that were unfed, or amino acid fed and dissected at 30 min. or 120 min. post-feeding.", [["midgut", "ANATOMY", 6, 12], ["extracts", "ANATOMY", 21, 29], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "CHEMICAL", 101, 111], ["midgut protein extracts", "ORGANISM_SUBSTANCE", 6, 29], ["mosquitoes", "ORGANISM", 70, 80], ["amino acid", "AMINO_ACID", 101, 111], ["Total midgut protein extracts", "TREATMENT", 0, 29], ["amino acid fed", "TREATMENT", 101, 115]]], ["Proteins were resolved by 12% SDS-PAGE gel and Western blotted as described in Materials and Methods.", [["Proteins", "TEST", 0, 8], ["PAGE gel", "TREATMENT", 34, 42]]], ["The four unique protein bands were labeled KDEL-1 through KDEL-4 to denote their relative molecular weight, with KDEL-1 being the largest protein.", [["KDEL-1", "GENE_OR_GENE_PRODUCT", 43, 49], ["KDEL-4", "GENE_OR_GENE_PRODUCT", 58, 64], ["KDEL-1", "GENE_OR_GENE_PRODUCT", 113, 119], ["KDEL", "PROTEIN", 43, 47], ["KDEL-4", "PROTEIN", 58, 64], ["KDEL", "PROTEIN", 113, 117], ["The four unique protein bands", "TEST", 0, 29], ["KDEL", "TEST", 43, 47], ["KDEL", "TEST", 58, 62], ["KDEL", "TEST", 113, 117]]], ["Western blotting with an antibody that recognizes the ubiquitously expressed glyceraldehyde-3P dehydrogenase protein (GAPDH) was performed to control for equal protein loading. doi:10.1371/journal.pone.0018150.g003 injected mosquitoes looked similar to that of uninjected mosquitoes at the same time point, in that few if any whorls were present (compare Figures 7B and 1D ).", [["doi:10.1371/journal.pone.0018150.g003", "CHEMICAL", 177, 214], ["glyceraldehyde", "CHEMICAL", 77, 91], ["glyceraldehyde-3P dehydrogenase", "GENE_OR_GENE_PRODUCT", 77, 108], ["GAPDH", "GENE_OR_GENE_PRODUCT", 118, 123], ["glyceraldehyde-3P dehydrogenase protein", "PROTEIN", 77, 116], ["GAPDH", "PROTEIN", 118, 123], ["an antibody", "TEST", 22, 33], ["glyceraldehyde", "TEST", 77, 91], ["dehydrogenase protein", "TEST", 95, 116], ["GAPDH", "TEST", 118, 123], ["equal protein loading", "PROBLEM", 154, 175], ["protein loading", "OBSERVATION", 160, 175]]], ["As shown in Figure 8 , by quantitating the number and size of whorls in midgut epithelial cells from alpha-COPI and Fluc dsRNA injected mosquitoes, it is clear that loss of alpha-COPI expression in unfed mosquitoes was associated with a significant decrease in RER whorl formation.", [["midgut epithelial cells", "ANATOMY", 72, 95], ["RER whorl", "ANATOMY", 261, 270], ["midgut epithelial cells", "CELL", 72, 95], ["alpha-COPI", "CELL", 101, 111], ["Fluc", "GENE_OR_GENE_PRODUCT", 116, 120], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 173, 183], ["RER whorl", "TISSUE", 261, 270], ["midgut epithelial cells", "CELL_TYPE", 72, 95], ["alpha-COPI", "PROTEIN", 173, 183], ["whorls in midgut epithelial cells", "PROBLEM", 62, 95], ["alpha-COPI", "TREATMENT", 101, 111], ["Fluc dsRNA", "TREATMENT", 116, 126], ["loss of alpha-COPI expression in unfed mosquitoes", "PROBLEM", 165, 214], ["a significant decrease in RER whorl formation", "PROBLEM", 235, 280], ["size", "OBSERVATION_MODIFIER", 54, 58], ["midgut", "ANATOMY", 72, 78], ["epithelial cells", "OBSERVATION", 79, 95], ["Fluc dsRNA", "OBSERVATION", 116, 126], ["loss", "OBSERVATION_MODIFIER", 165, 169], ["alpha-COPI expression", "OBSERVATION", 173, 194], ["significant", "OBSERVATION_MODIFIER", 237, 248], ["decrease", "OBSERVATION_MODIFIER", 249, 257], ["whorl formation", "OBSERVATION", 265, 280]]], ["Moreover, a similar quantitative analysis of midgut epithelial cells from amino acid fed alpha-COPI dsRNA injected mosquitoes, showed highly disorganized endosomal structures and extended regions of swollen RER ( Figures 7C and 7D ).", [["midgut epithelial cells", "ANATOMY", 45, 68], ["endosomal structures", "ANATOMY", 154, 174], ["swollen RER", "ANATOMY", 199, 210], ["amino acid", "CHEMICAL", 74, 84], ["amino acid", "CHEMICAL", 74, 84], ["midgut epithelial cells", "CELL", 45, 68], ["amino acid", "AMINO_ACID", 74, 84], ["endosomal structures", "CELLULAR_COMPONENT", 154, 174], ["midgut epithelial cells", "CELL_TYPE", 45, 68], ["midgut epithelial cells", "PROBLEM", 45, 68], ["amino acid fed alpha-COPI dsRNA", "TREATMENT", 74, 105], ["highly disorganized endosomal structures", "PROBLEM", 134, 174], ["swollen RER", "PROBLEM", 199, 210], ["midgut epithelial cells", "OBSERVATION", 45, 68], ["highly", "OBSERVATION_MODIFIER", 134, 140], ["disorganized", "OBSERVATION_MODIFIER", 141, 153], ["endosomal structures", "OBSERVATION", 154, 174], ["swollen", "OBSERVATION_MODIFIER", 199, 206]]], ["Taken together, these data indicate that functional alpha-COPI protein is required for normal whorl formation in the midgut epithelial cells of unfed mosquitoes.Expression of late phase midgut proteases is inhibited in alpha-COPI deficient mosquitoesBlood meal digestion in Ae. aegpti mosquitoes requires the synthesis and secretion of numerous proteases, the best characterized of which are serine proteases.", [["whorl", "ANATOMY", 94, 99], ["midgut epithelial cells", "ANATOMY", 117, 140], ["Blood", "ANATOMY", 250, 255], ["serine", "CHEMICAL", 392, 398], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 52, 62], ["whorl", "TISSUE", 94, 99], ["midgut epithelial cells", "CELL", 117, 140], ["Blood", "ORGANISM_SUBSTANCE", 250, 255], ["Ae. aegpti mosquitoes", "ORGANISM", 274, 295], ["alpha-COPI protein", "PROTEIN", 52, 70], ["midgut epithelial cells", "CELL_TYPE", 117, 140], ["late phase midgut proteases", "PROTEIN", 175, 202], ["alpha-COPI", "PROTEIN", 219, 229], ["proteases", "PROTEIN", 345, 354], ["serine proteases", "PROTEIN", 392, 408], ["Ae. aegpti", "SPECIES", 274, 284], ["Ae. aegpti", "SPECIES", 274, 284], ["these data", "TEST", 16, 26], ["functional alpha-COPI protein", "PROBLEM", 41, 70], ["late phase midgut proteases", "PROBLEM", 175, 202], ["alpha-COPI deficient mosquitoes", "PROBLEM", 219, 250], ["Blood meal digestion", "PROBLEM", 250, 270], ["the synthesis", "TREATMENT", 305, 318], ["numerous proteases", "PROBLEM", 336, 354], ["serine proteases", "PROBLEM", 392, 408], ["midgut epithelial", "ANATOMY", 117, 134], ["cells", "OBSERVATION", 135, 140], ["late phase", "OBSERVATION_MODIFIER", 175, 185], ["meal digestion", "OBSERVATION", 256, 270]]], ["The early trypsin protease (AeET) is synthesized from pre-existing mRNA and secreted into the lumen within the first 6 hr PBM, whereas the late phase serine proteases AaSPVI, AaSPVII, and AaLT, are transcribed, translated, and secreted between 18-30 hr PBM [31] .", [["lumen", "ANATOMY", 94, 99], ["serine", "CHEMICAL", 150, 156], ["trypsin protease", "GENE_OR_GENE_PRODUCT", 10, 26], ["AeET", "GENE_OR_GENE_PRODUCT", 28, 32], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 99], ["AaSPVI", "GENE_OR_GENE_PRODUCT", 167, 173], ["AaSPVII", "GENE_OR_GENE_PRODUCT", 175, 182], ["AaLT", "GENE_OR_GENE_PRODUCT", 188, 192], ["early trypsin protease", "PROTEIN", 4, 26], ["AeET", "PROTEIN", 28, 32], ["pre-existing mRNA", "RNA", 54, 71], ["PBM", "CELL_TYPE", 122, 125], ["late phase serine proteases", "PROTEIN", 139, 166], ["AaSPVI", "PROTEIN", 167, 173], ["AaSPVII", "PROTEIN", 175, 182], ["AaLT", "PROTEIN", 188, 192], ["The early trypsin protease (AeET)", "TREATMENT", 0, 33], ["the first 6 hr PBM", "TREATMENT", 107, 125], ["lumen", "ANATOMY_MODIFIER", 94, 99]]], ["To determine if alpha-COPI functions are required for the synthesis and secretion of early and late phase serine proteases, we injected mosquitoes with Fluc and alpha-COPI dsRNA 3 days prior to blood feeding and used Western blotting to detect protease protein expression at 3 hr PBM (AeET) and 24 hr PBM (AaSPVI, AaSPVII, AaLT).", [["blood", "ANATOMY", 194, 199], ["serine", "CHEMICAL", 106, 112], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 16, 26], ["Fluc", "GENE_OR_GENE_PRODUCT", 152, 156], ["blood", "ORGANISM_SUBSTANCE", 194, 199], ["alpha-COPI", "PROTEIN", 16, 26], ["serine proteases", "PROTEIN", 106, 122], ["protease protein", "PROTEIN", 244, 260], ["PBM", "CELL_TYPE", 280, 283], ["alpha-COPI functions", "PROBLEM", 16, 36], ["the synthesis", "PROBLEM", 54, 67], ["early and late phase serine proteases", "PROBLEM", 85, 122], ["Fluc", "TREATMENT", 152, 156], ["alpha-COPI dsRNA", "TREATMENT", 161, 177], ["blood feeding", "TREATMENT", 194, 207], ["Western blotting", "TREATMENT", 217, 233], ["protease protein expression", "TREATMENT", 244, 271], ["AeET", "TEST", 285, 289], ["24 hr PBM", "TREATMENT", 295, 304], ["AaSPVI", "TEST", 306, 312]]], ["As shown in Figure 9A , the pattern of AeET protein expression is similar in Fluc and alpha-COPI dsRNA injected mosquitoes, suggesting that alpha-COPI functions are not required for early phase blood meal digestion.", [["blood", "ANATOMY", 194, 199], ["AeET", "GENE_OR_GENE_PRODUCT", 39, 43], ["Fluc", "GENE_OR_GENE_PRODUCT", 77, 81], ["alpha-COPI dsRNA", "ORGANISM", 86, 102], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 140, 150], ["blood", "ORGANISM_SUBSTANCE", 194, 199], ["AeET protein", "PROTEIN", 39, 51], ["AeET protein expression", "PROBLEM", 39, 62], ["Fluc", "TREATMENT", 77, 81], ["alpha-COPI dsRNA injected mosquitoes", "PROBLEM", 86, 122], ["alpha-COPI functions", "PROBLEM", 140, 160], ["early phase blood meal digestion", "PROBLEM", 182, 214]]], ["However, as shown in Figure 9B , 100-400 ng of alpha-COPI dsRNA blocks expression of all three abundant late phase proteases at 24 hr PBM in a dose-dependent manner.", [["alpha-COPI", "GENE_OR_GENE_PRODUCT", 47, 57], ["late phase proteases", "PROTEIN", 104, 124], ["PBM", "CELL_TYPE", 134, 137], ["alpha-COPI dsRNA blocks", "TREATMENT", 47, 70], ["abundant", "OBSERVATION_MODIFIER", 95, 103], ["late phase", "OBSERVATION_MODIFIER", 104, 114]]], ["Lack of late phase serine protease expression in alpha-COPI deficient mosquitoes was associated with ejection of the undigested blood meal between 12-30 hr PBM (data not shown).DiscussionBlood feeding is required by Ae. aegypti mosquitoes to obtain the necessary protein-derived nutrients for completion of the gonotrophic cycle [32] .", [["blood", "ANATOMY", 128, 133], ["Blood", "ANATOMY", 187, 192], ["serine", "CHEMICAL", 19, 25], ["late phase serine protease", "GENE_OR_GENE_PRODUCT", 8, 34], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 49, 59], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["Blood", "ORGANISM_SUBSTANCE", 187, 192], ["Ae. aegypti mosquitoes", "ORGANISM", 216, 238], ["alpha-COPI", "PROTEIN", 49, 59], ["PBM", "CELL_TYPE", 156, 159], ["Ae. aegypti", "SPECIES", 216, 227], ["Ae. aegypti", "SPECIES", 216, 227], ["late phase serine protease expression", "PROBLEM", 8, 45], ["alpha-COPI deficient mosquitoes", "PROBLEM", 49, 80], ["ejection of the undigested blood meal", "PROBLEM", 101, 138], ["Blood feeding", "TREATMENT", 187, 200], ["the necessary protein", "TREATMENT", 249, 270], ["the gonotrophic cycle", "TREATMENT", 307, 328], ["late phase", "OBSERVATION_MODIFIER", 8, 18]]], ["Understanding the biochemical and cellular regulation of blood meal metabolism will provide insights into this critical process in Ae. aegypti, as well as other blood-feeding arthropods that function as vectors of blood borne pathogens.", [["cellular", "ANATOMY", 34, 42], ["blood", "ANATOMY", 57, 62], ["blood", "ANATOMY", 161, 166], ["blood", "ANATOMY", 214, 219], ["cellular", "CELL", 34, 42], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["Ae. aegypti", "ORGANISM", 131, 142], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["blood", "ORGANISM_SUBSTANCE", 214, 219], ["Ae. aegypti", "SPECIES", 131, 142], ["Ae. aegypti", "SPECIES", 131, 142], ["blood-feeding arthropods", "TREATMENT", 161, 185], ["blood borne pathogens", "PROBLEM", 214, 235]]], ["Our objective in the studies reported here was to first determine if amino acids were sufficient to induce RER whorl unwinding, and if they were, to use a combination of proteomic and RNAi approaches to identify proteins that may be required for maintenance of RER whorls in midgut epithelial cells.", [["RER whorl", "ANATOMY", 107, 116], ["RER whorls", "ANATOMY", 261, 271], ["midgut epithelial cells", "ANATOMY", 275, 298], ["amino acids", "CHEMICAL", 69, 80], ["amino acids", "CHEMICAL", 69, 80], ["amino acids", "AMINO_ACID", 69, 80], ["RER whorls", "CELLULAR_COMPONENT", 261, 271], ["midgut epithelial cells", "CELL", 275, 298], ["midgut epithelial cells", "CELL_TYPE", 275, 298], ["the studies", "TEST", 17, 28], ["amino acids", "TEST", 69, 80], ["proteomic and RNAi approaches", "TREATMENT", 170, 199], ["RER whorls in midgut epithelial cells", "PROBLEM", 261, 298], ["midgut epithelial cells", "OBSERVATION", 275, 298]]], ["It is possible that RER whorls function by providing a mechanism to rapidly activate midgut secretion pathways upon feeding, rather than expend energy maintaining them in the absence of feeding.DiscussionBiochemical studies have shown that in addition to globin, albumin, and immunoglobulin proteins, which make up 80% of the soluble proteins in human blood, free amino acids are also present in blood [21] .", [["RER whorls", "ANATOMY", 20, 30], ["midgut", "ANATOMY", 85, 91], ["blood", "ANATOMY", 352, 357], ["blood", "ANATOMY", 396, 401], ["amino acids", "CHEMICAL", 364, 375], ["amino acids", "CHEMICAL", 364, 375], ["RER whorls", "TISSUE", 20, 30], ["globin", "GENE_OR_GENE_PRODUCT", 255, 261], ["albumin", "GENE_OR_GENE_PRODUCT", 263, 270], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 276, 290], ["human", "ORGANISM", 346, 351], ["blood", "ORGANISM_SUBSTANCE", 352, 357], ["amino acids", "AMINO_ACID", 364, 375], ["blood", "ORGANISM_SUBSTANCE", 396, 401], ["globin", "PROTEIN", 255, 261], ["albumin", "PROTEIN", 263, 270], ["immunoglobulin proteins", "PROTEIN", 276, 299], ["soluble proteins", "PROTEIN", 326, 342], ["human", "SPECIES", 346, 351], ["human", "SPECIES", 346, 351], ["midgut secretion pathways", "PROBLEM", 85, 110], ["DiscussionBiochemical studies", "TEST", 194, 223], ["globin", "TEST", 255, 261], ["albumin", "TEST", 263, 270], ["immunoglobulin proteins", "TEST", 276, 299], ["the soluble proteins", "TEST", 322, 342], ["human blood", "TEST", 346, 357], ["free amino acids", "TEST", 359, 375]]], ["Based on physiological studies showing that artificial amino acids meals are sufficient to induce early events in the blood digestion process [33] , it has been proposed that amino acids could play a signaling role by inducing protease expression [24] .", [["blood", "ANATOMY", 118, 123], ["amino acids", "CHEMICAL", 55, 66], ["amino acids", "CHEMICAL", 175, 186], ["amino acids", "CHEMICAL", 55, 66], ["amino acids", "CHEMICAL", 175, 186], ["amino acids", "AMINO_ACID", 55, 66], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["amino acids", "AMINO_ACID", 175, 186], ["protease", "PROTEIN", 227, 235], ["physiological studies", "TEST", 9, 30], ["artificial amino acids meals", "TREATMENT", 44, 72], ["early events", "PROBLEM", 98, 110], ["the blood digestion process", "PROBLEM", 114, 141], ["amino acids", "TREATMENT", 175, 186]]], ["Consistent with this idea, we have recently shown that amino acid feeding stimulates translation of pre-existing early trypsin mRNA through activation of the TOR signaling pathway [23] .", [["amino acid", "CHEMICAL", 55, 65], ["amino acid", "CHEMICAL", 55, 65], ["amino acid", "AMINO_ACID", 55, 65], ["trypsin", "GENE_OR_GENE_PRODUCT", 119, 126], ["TOR", "GENE_OR_GENE_PRODUCT", 158, 161], ["trypsin mRNA", "RNA", 119, 131], ["TOR", "PROTEIN", 158, 161], ["amino acid feeding", "TREATMENT", 55, 73], ["pre-existing early trypsin mRNA", "TREATMENT", 100, 131]]], ["Since large ER whorl structures have been shown to exist in the midgut of Ae. aegypti and other mosquito species [2,3,4,5,6,8,9], we used EM ultrastructural analysis to test if amino acid feeding induces ER whorl unwinding.", [["ER whorl structures", "ANATOMY", 12, 31], ["midgut", "ANATOMY", 64, 70], ["ER whorl", "ANATOMY", 204, 212], ["amino acid", "CHEMICAL", 177, 187], ["amino acid", "CHEMICAL", 177, 187], ["ER", "GENE_OR_GENE_PRODUCT", 12, 14], ["midgut", "ORGAN", 64, 70], ["aegypti", "ORGANISM", 78, 85], ["2,3,4,5,6,8,9", "SIMPLE_CHEMICAL", 114, 127], ["amino acid", "AMINO_ACID", 177, 187], ["ER", "GENE_OR_GENE_PRODUCT", 204, 206], ["ER", "PROTEIN", 12, 14], ["ER", "PROTEIN", 204, 206], ["aegypti", "SPECIES", 78, 85], ["Ae.", "SPECIES", 74, 77], ["aegypti", "SPECIES", 78, 85], ["large ER whorl structures", "PROBLEM", 6, 31], ["aegypti", "PROBLEM", 78, 85], ["EM ultrastructural analysis", "TEST", 138, 165], ["amino acid feeding", "TREATMENT", 177, 195], ["large", "OBSERVATION_MODIFIER", 6, 11], ["whorl", "ANATOMY_MODIFIER", 15, 20], ["midgut", "ANATOMY", 64, 70]]], ["As shown in Figures 1 and 2 , our data clearly demonstrate that amino acid feeding does induce ER whorl unwinding, and moreover, that the most abundant whorls consist of rough ER membranes based on the high density of ribosomal particles.DiscussionRecently, several studies have reported the presence of ER whorl-like structures in cultured cells following different treatment conditions.", [["ER whorl", "ANATOMY", 95, 103], ["whorls", "ANATOMY", 152, 158], ["ER membranes", "ANATOMY", 176, 188], ["ribosomal", "ANATOMY", 218, 227], ["ER whorl-like structures", "ANATOMY", 304, 328], ["cells", "ANATOMY", 341, 346], ["amino acid", "CHEMICAL", 64, 74], ["amino acid", "CHEMICAL", 64, 74], ["amino acid", "AMINO_ACID", 64, 74], ["ER", "GENE_OR_GENE_PRODUCT", 95, 97], ["ER", "GENE_OR_GENE_PRODUCT", 176, 178], ["membranes", "CELLULAR_COMPONENT", 179, 188], ["ribosomal", "CELLULAR_COMPONENT", 218, 227], ["ER", "GENE_OR_GENE_PRODUCT", 304, 306], ["cells", "CELL", 341, 346], ["ER", "PROTEIN", 95, 97], ["ER", "PROTEIN", 304, 306], ["cultured cells", "CELL_LINE", 332, 346], ["amino acid feeding", "TREATMENT", 64, 82], ["rough ER membranes", "PROBLEM", 170, 188], ["the high density of ribosomal particles", "PROBLEM", 198, 237], ["several studies", "TEST", 258, 273], ["ER whorl-like structures in cultured cells", "PROBLEM", 304, 346], ["different treatment conditions", "TREATMENT", 357, 387], ["high density", "OBSERVATION_MODIFIER", 202, 214], ["ribosomal particles", "OBSERVATION", 218, 237], ["cultured cells", "OBSERVATION", 332, 346]]], ["For example, treatment of mouse Leydig cells with the piperazine derivative diethylcarbamazine citrate (DEC), led to the appearance of large lipid droplets, degenerative mitochondria, and giant smooth ER whorls in some cells [25] .", [["Leydig cells", "ANATOMY", 32, 44], ["lipid droplets", "ANATOMY", 141, 155], ["mitochondria", "ANATOMY", 170, 182], ["giant smooth ER whorls", "ANATOMY", 188, 210], ["cells", "ANATOMY", 219, 224], ["piperazine", "CHEMICAL", 54, 64], ["diethylcarbamazine citrate", "CHEMICAL", 76, 102], ["DEC", "CHEMICAL", 104, 107], ["piperazine", "CHEMICAL", 54, 64], ["diethylcarbamazine citrate", "CHEMICAL", 76, 102], ["DEC", "CHEMICAL", 104, 107], ["mouse", "ORGANISM", 26, 31], ["Leydig cells", "CELL", 32, 44], ["piperazine derivative", "SIMPLE_CHEMICAL", 54, 75], ["diethylcarbamazine citrate", "SIMPLE_CHEMICAL", 76, 102], ["DEC", "SIMPLE_CHEMICAL", 104, 107], ["lipid droplets", "CELLULAR_COMPONENT", 141, 155], ["mitochondria", "CELLULAR_COMPONENT", 170, 182], ["ER", "GENE_OR_GENE_PRODUCT", 201, 203], ["cells", "CELL", 219, 224], ["mouse Leydig cells", "CELL_TYPE", 26, 44], ["mouse", "SPECIES", 26, 31], ["mouse", "SPECIES", 26, 31], ["treatment of mouse Leydig cells", "TREATMENT", 13, 44], ["the piperazine derivative diethylcarbamazine citrate", "TREATMENT", 50, 102], ["large lipid droplets", "PROBLEM", 135, 155], ["degenerative mitochondria", "PROBLEM", 157, 182], ["mouse Leydig cells", "OBSERVATION", 26, 44], ["large", "OBSERVATION_MODIFIER", 135, 140], ["lipid droplets", "OBSERVATION", 141, 155], ["degenerative mitochondria", "OBSERVATION", 157, 182], ["giant", "OBSERVATION_MODIFIER", 188, 193], ["smooth", "OBSERVATION_MODIFIER", 194, 200]]], ["Since DEC has been shown to disrupt ER and golgi vesicle transport processes, it could explain the formation of ER whorls.", [["ER", "ANATOMY", 36, 38], ["golgi vesicle", "ANATOMY", 43, 56], ["ER whorls", "ANATOMY", 112, 121], ["DEC", "CHEMICAL", 6, 9], ["DEC", "SIMPLE_CHEMICAL", 6, 9], ["ER", "GENE_OR_GENE_PRODUCT", 36, 38], ["golgi vesicle", "CELLULAR_COMPONENT", 43, 56], ["ER", "GENE_OR_GENE_PRODUCT", 112, 114], ["DEC", "PROTEIN", 6, 9], ["ER", "PROTEIN", 36, 38], ["ER", "PROTEIN", 112, 114]]], ["A similar loss of function study leading to the formation of ER whorls was seen in human HeLa cells in which expression of the ER protein Yip1A was knocked down by RNAi [18] .", [["ER whorls", "ANATOMY", 61, 70], ["HeLa cells", "ANATOMY", 89, 99], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["human", "ORGANISM", 83, 88], ["HeLa cells", "CELL", 89, 99], ["ER", "GENE_OR_GENE_PRODUCT", 127, 129], ["Yip1A", "GENE_OR_GENE_PRODUCT", 138, 143], ["ER", "PROTEIN", 61, 63], ["human HeLa cells", "CELL_LINE", 83, 99], ["ER protein", "PROTEIN", 127, 137], ["Yip1A", "PROTEIN", 138, 143], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["A similar loss of function study", "PROBLEM", 0, 32], ["human HeLa cells", "TREATMENT", 83, 99], ["the ER protein Yip1A", "TEST", 123, 143], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["loss", "OBSERVATION", 10, 14], ["HeLa cells", "OBSERVATION", 89, 99]]], ["Therefore one of the functions of Yip1A could be to maintain proper ER/golgi membrane networks under normal conditions, but when it is absent, ER membranes collapse into whorl structures.DiscussionAnother explanation for whorl formation is the presence of one or more abundant ER-associated proteins that stabilize stacked ER membranes in the absence of ongoing protein synthesis.", [["ER/golgi membrane networks", "ANATOMY", 68, 94], ["ER membranes", "ANATOMY", 143, 155], ["whorl structures", "ANATOMY", 170, 186], ["whorl", "ANATOMY", 221, 226], ["ER membranes", "ANATOMY", 323, 335], ["Yip1A", "GENE_OR_GENE_PRODUCT", 34, 39], ["ER", "GENE_OR_GENE_PRODUCT", 68, 70], ["ER", "GENE_OR_GENE_PRODUCT", 143, 145], ["membranes", "CELLULAR_COMPONENT", 146, 155], ["whorl structures", "MULTI-TISSUE_STRUCTURE", 170, 186], ["whorl", "TISSUE", 221, 226], ["ER", "GENE_OR_GENE_PRODUCT", 277, 279], ["ER membranes", "CELLULAR_COMPONENT", 323, 335], ["Yip1A", "PROTEIN", 34, 39], ["ER", "PROTEIN", 68, 70], ["ER", "PROTEIN", 143, 145], ["ER", "PROTEIN", 277, 279], ["associated proteins", "PROTEIN", 280, 299], ["ER", "PROTEIN", 323, 325], ["ER membranes collapse into whorl structures", "PROBLEM", 143, 186], ["stacked ER membranes", "PROBLEM", 315, 335], ["ongoing protein synthesis", "PROBLEM", 354, 379], ["golgi membrane", "OBSERVATION", 71, 85], ["normal conditions", "OBSERVATION", 101, 118], ["collapse", "OBSERVATION", 156, 164], ["protein synthesis", "OBSERVATION", 362, 379]]], ["Support for this model comes from studies in cultured cells showing that protein overexpression can induce ER whorl formation.", [["cells", "ANATOMY", 54, 59], ["ER whorl", "ANATOMY", 107, 115], ["cells", "CELL", 54, 59], ["ER", "GENE_OR_GENE_PRODUCT", 107, 109], ["cultured cells", "CELL_LINE", 45, 59], ["ER", "PROTEIN", 107, 109], ["studies in cultured cells", "TEST", 34, 59], ["protein overexpression", "PROBLEM", 73, 95], ["whorl formation", "OBSERVATION", 110, 125]]], ["Snapp et al. (2003) [15] reported that overexpression of cytochrome b5 induced the formation of smooth ER whorls, they called organized smooth ER (OSER), in transfected CV-1 cells.", [["smooth ER whorls", "ANATOMY", 96, 112], ["smooth ER", "ANATOMY", 136, 145], ["CV-1 cells", "ANATOMY", 169, 179], ["cytochrome b5", "GENE_OR_GENE_PRODUCT", 57, 70], ["ER", "GENE_OR_GENE_PRODUCT", 103, 105], ["smooth ER", "GENE_OR_GENE_PRODUCT", 136, 145], ["OSER", "GENE_OR_GENE_PRODUCT", 147, 151], ["CV-1 cells", "CELL", 169, 179], ["cytochrome b5", "PROTEIN", 57, 70], ["smooth ER", "PROTEIN", 136, 145], ["OSER", "PROTEIN", 147, 151], ["transfected CV-1 cells", "CELL_LINE", 157, 179], ["CV-1", "SPECIES", 169, 173], ["cytochrome b5", "PROBLEM", 57, 70], ["smooth", "OBSERVATION_MODIFIER", 96, 102]]], ["These same OSER structures could be observed when b5-GFP fusion proteins were over expressed, as long as they retained dimerization function in either the b5 or GFP protein domains.", [["b5-GFP", "GENE_OR_GENE_PRODUCT", 50, 56], ["b5", "GENE_OR_GENE_PRODUCT", 155, 157], ["GFP", "GENE_OR_GENE_PRODUCT", 161, 164], ["OSER", "PROTEIN", 11, 15], ["b5", "PROTEIN", 50, 52], ["GFP fusion proteins", "PROTEIN", 53, 72], ["b5 or GFP protein domains", "PROTEIN", 155, 180], ["b5-GFP fusion proteins", "TEST", 50, 72]]], ["The authors proposed that weak noncovalent interactions between ER resident proteins on apposing stacked membranes are sufficient to maintain smooth ER whorl structures.", [["membranes", "ANATOMY", 105, 114], ["ER whorl structures", "ANATOMY", 149, 168], ["ER", "GENE_OR_GENE_PRODUCT", 64, 66], ["membranes", "CELLULAR_COMPONENT", 105, 114], ["ER", "GENE_OR_GENE_PRODUCT", 149, 151], ["ER resident proteins", "PROTEIN", 64, 84], ["weak noncovalent interactions", "PROBLEM", 26, 55], ["apposing stacked membranes", "TREATMENT", 88, 114], ["weak", "OBSERVATION_MODIFIER", 26, 30], ["noncovalent", "OBSERVATION", 31, 42], ["smooth", "OBSERVATION_MODIFIER", 142, 148]]], ["Similar OSER structures were shown to form in HeLa cells that were infected with an adenovirus vector expressing the ER resident protein LAT linked to a heterologous protein dimerization domain [16] , or overexpression of a viral protein that associates with ER membranes in infected cells [17] .DiscussionIn order to identify candidate RER whorl forming proteins in Ae aegypti midgut epithelial cells, we took advantage of the fact that an amino acid meal is sufficient to induce whorl unwinding, which simplifies both EM analysis and protein identification by mass spectrometry because it eliminates interference from abundant blood meal proteins.", [["HeLa cells", "ANATOMY", 46, 56], ["ER membranes", "ANATOMY", 259, 271], ["cells", "ANATOMY", 284, 289], ["RER whorl", "ANATOMY", 337, 346], ["midgut epithelial cells", "ANATOMY", 378, 401], ["whorl", "ANATOMY", 481, 486], ["blood", "ANATOMY", 629, 634], ["amino acid", "CHEMICAL", 441, 451], ["amino acid", "CHEMICAL", 441, 451], ["HeLa cells", "CELL", 46, 56], ["adenovirus", "ORGANISM", 84, 94], ["ER", "GENE_OR_GENE_PRODUCT", 117, 119], ["LAT", "GENE_OR_GENE_PRODUCT", 137, 140], ["ER", "GENE_OR_GENE_PRODUCT", 259, 261], ["cells", "CELL", 284, 289], ["RER whorl", "TISSUE", 337, 346], ["Ae aegypti", "ORGANISM", 367, 377], ["midgut epithelial cells", "CELL", 378, 401], ["amino acid", "AMINO_ACID", 441, 451], ["blood", "ORGANISM_SUBSTANCE", 629, 634], ["OSER", "PROTEIN", 8, 12], ["HeLa cells", "CELL_LINE", 46, 56], ["ER resident protein", "PROTEIN", 117, 136], ["LAT", "PROTEIN", 137, 140], ["heterologous protein dimerization domain", "PROTEIN", 153, 193], ["viral protein", "PROTEIN", 224, 237], ["ER", "PROTEIN", 259, 261], ["infected cells", "CELL_TYPE", 275, 289], ["RER whorl forming proteins", "PROTEIN", 337, 363], ["Ae aegypti midgut epithelial cells", "CELL_TYPE", 367, 401], ["blood meal proteins", "PROTEIN", 629, 648], ["adenovirus", "SPECIES", 84, 94], ["Ae aegypti", "SPECIES", 367, 377], ["Similar OSER structures", "PROBLEM", 0, 23], ["HeLa cells", "PROBLEM", 46, 56], ["an adenovirus vector", "TREATMENT", 81, 101], ["a heterologous protein dimerization domain", "PROBLEM", 151, 193], ["a viral protein", "PROBLEM", 222, 237], ["ER membranes in infected cells", "PROBLEM", 259, 289], ["Ae aegypti midgut epithelial cells", "PROBLEM", 367, 401], ["an amino acid meal", "TREATMENT", 438, 456], ["whorl unwinding", "PROBLEM", 481, 496], ["both EM analysis", "TEST", 515, 531], ["protein identification", "TEST", 536, 558], ["mass spectrometry", "TEST", 562, 579], ["abundant blood meal proteins", "PROBLEM", 620, 648], ["HeLa cells", "OBSERVATION", 46, 56], ["viral protein", "OBSERVATION", 224, 237], ["infected cells", "OBSERVATION", 275, 289], ["epithelial cells", "OBSERVATION", 385, 401]]], ["Moreover, since we found that RER whorl unwinding occurs rapidly once feeding begins (Figure 1 ), we were able to use a short recovery time of only 30 min to enrich for microsomal proteins that are present in the mosquito midgut prior to feeding.", [["RER whorl", "ANATOMY", 30, 39], ["microsomal", "ANATOMY", 169, 179], ["midgut", "ANATOMY", 222, 228], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 30, 39], ["mosquito", "ORGANISM", 213, 221], ["midgut", "ORGAN", 222, 228], ["microsomal proteins", "PROTEIN", 169, 188], ["RER whorl unwinding", "PROBLEM", 30, 49], ["microsomal proteins", "TREATMENT", 169, 188], ["whorl", "OBSERVATION_MODIFIER", 34, 39], ["unwinding", "OBSERVATION", 40, 49], ["rapidly", "OBSERVATION_MODIFIER", 57, 64]]], ["The LC-MS/MS analysis identified 127 proteins using microsomal midgut protein samples from unfed and amino acid fed mosquitoes.", [["samples", "ANATOMY", 78, 85], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "AMINO_ACID", 101, 111], ["The LC-MS/MS analysis", "TEST", 0, 21], ["proteins", "TEST", 37, 45], ["microsomal midgut protein samples", "TEST", 52, 85], ["amino acid", "TEST", 101, 111]]], ["Eight proteins were considered candidate whorl associated proteins based on their known location and function in ER and Golgi membrane compartments (see Table 1 ).", [["whorl", "ANATOMY", 41, 46], ["ER", "ANATOMY", 113, 115], ["Golgi membrane compartments", "ANATOMY", 120, 147], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["Golgi membrane compartments", "CELLULAR_COMPONENT", 120, 147], ["whorl associated proteins", "PROTEIN", 41, 66], ["ER", "PROTEIN", 113, 115], ["whorl associated proteins", "PROBLEM", 41, 66]]], ["Since three of the candidate proteins encoded COPI coatomer subunits, and the peptide frequency was lower for each of the proteins in samples from fed mosquitoes compared to unfed mosquitoes, we chose alpha-COPI as a representative coatomer subunit and performed RNAi knockdown experiments.", [["samples", "ANATOMY", 134, 141], ["COPI", "GENE_OR_GENE_PRODUCT", 46, 50], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 201, 211], ["COPI coatomer subunits", "PROTEIN", 46, 68], ["alpha-COPI", "PROTEIN", 201, 211], ["coatomer subunit", "PROTEIN", 232, 248], ["COPI coatomer subunits", "TREATMENT", 46, 68], ["the peptide frequency", "PROBLEM", 74, 95], ["RNAi knockdown experiments", "TREATMENT", 263, 289], ["COPI", "OBSERVATION", 46, 50], ["coatomer subunits", "OBSERVATION", 51, 68]]], ["Data presented in Figures 6, 7 , and 8 show that loss of alpha-COPI expression is associated with the absence of RER whorls in unfed mosquitoes, as well as membrane disorganization and ER swelling in midgut epithelial cells of amino acid fed mosquitoes.", [["RER whorls", "ANATOMY", 113, 123], ["membrane", "ANATOMY", 156, 164], ["ER", "ANATOMY", 185, 187], ["midgut epithelial cells", "ANATOMY", 200, 223], ["amino acid", "CHEMICAL", 227, 237], ["amino acid", "CHEMICAL", 227, 237], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 57, 67], ["RER whorls", "CELLULAR_COMPONENT", 113, 123], ["membrane", "CELLULAR_COMPONENT", 156, 164], ["ER", "GENE_OR_GENE_PRODUCT", 185, 187], ["midgut epithelial cells", "CELL", 200, 223], ["amino acid", "AMINO_ACID", 227, 237], ["alpha-COPI", "PROTEIN", 57, 67], ["ER", "PROTEIN", 185, 187], ["midgut epithelial cells", "CELL_TYPE", 200, 223], ["loss of alpha-COPI expression", "PROBLEM", 49, 78], ["RER whorls in unfed mosquitoes", "PROBLEM", 113, 143], ["membrane disorganization", "PROBLEM", 156, 180], ["ER swelling", "PROBLEM", 185, 196], ["alpha-COPI expression", "OBSERVATION", 57, 78], ["unfed mosquitoes", "OBSERVATION", 127, 143], ["swelling", "OBSERVATION", 188, 196], ["midgut epithelial", "ANATOMY", 200, 217]]], ["These data suggest that alpha-COPI, and likely two or more of the other seven COPI coatomer subunits, are involved in RER whorl formation and maintenance in midgut epithelial cells of unfed female mosquitoes.", [["RER whorl", "ANATOMY", 118, 127], ["midgut epithelial cells", "ANATOMY", 157, 180], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 24, 34], ["COPI", "GENE_OR_GENE_PRODUCT", 78, 82], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 118, 127], ["midgut epithelial cells", "CELL", 157, 180], ["female mosquitoes", "ORGANISM", 190, 207], ["alpha-COPI", "PROTEIN", 24, 34], ["COPI coatomer subunits", "PROTEIN", 78, 100], ["midgut epithelial cells", "CELL_TYPE", 157, 180], ["alpha-COPI", "TEST", 24, 34], ["coatomer subunits", "OBSERVATION", 83, 100], ["whorl formation", "OBSERVATION", 122, 137], ["midgut epithelial cells", "OBSERVATION", 157, 180]]], ["Based on the association of RER whorls with untranslated AeET mRNA transcripts in unfed mosquitoes, we predicted that RER whorls inhibited the translation of AaET transcripts.", [["RER whorls", "ANATOMY", 28, 38], ["RER whorls", "ANATOMY", 118, 128], ["RER whorls", "MULTI-TISSUE_STRUCTURE", 28, 38], ["AeET", "GENE_OR_GENE_PRODUCT", 57, 61], ["RER whorls", "CELLULAR_COMPONENT", 118, 128], ["AaET", "GENE_OR_GENE_PRODUCT", 158, 162], ["untranslated AeET mRNA transcripts", "RNA", 44, 78], ["AaET transcripts", "RNA", 158, 174], ["AaET transcripts", "TREATMENT", 158, 174]]], ["However the data in Figure 9A clearly show that this is not the case since sugar fed alpha-COPI dsRNA injected mosquitoes lacked both RER whorls and AaET protein expression.", [["RER whorls", "ANATOMY", 134, 144], ["alpha-COPI", "CHEMICAL", 85, 95], ["sugar", "CHEMICAL", 75, 80], ["sugar", "SIMPLE_CHEMICAL", 75, 80], ["alpha-COPI", "SIMPLE_CHEMICAL", 85, 95], ["RER whorls", "TISSUE", 134, 144], ["AaET", "GENE_OR_GENE_PRODUCT", 149, 153], ["AaET protein", "PROTEIN", 149, 161], ["the data", "TEST", 8, 16], ["alpha-COPI dsRNA", "TREATMENT", 85, 101], ["protein expression", "OBSERVATION", 154, 172]]], ["Surprisingly, while synthesis and secretion of AeET was not altered in blood fed alpha-COPI deficient mosquitoes, expression of three abundant late phase proteases (AaSPVI, AaSPVII, AaLT) was inhibited ( Figure 9B ), indicating that COPI vesicle transport is required for later events in the blood digestion process.DiscussionThe COPI vesicle transport system has been shown to function in most cells as an retrograde transport mechanism that returns golgi-modified proteins back to the ER where they function in cell signaling and metabolism [29, 30] .", [["blood", "ANATOMY", 71, 76], ["COPI vesicle", "ANATOMY", 233, 245], ["blood", "ANATOMY", 292, 297], ["COPI vesicle", "ANATOMY", 330, 342], ["cells", "ANATOMY", 395, 400], ["ER", "ANATOMY", 487, 489], ["cell", "ANATOMY", 513, 517], ["AeET", "GENE_OR_GENE_PRODUCT", 47, 51], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["alpha-COPI deficient mosquitoes", "ORGANISM", 81, 112], ["late phase proteases", "GENE_OR_GENE_PRODUCT", 143, 163], ["AaSPVI", "GENE_OR_GENE_PRODUCT", 165, 171], ["AaSPVII", "GENE_OR_GENE_PRODUCT", 173, 180], ["AaLT", "GENE_OR_GENE_PRODUCT", 182, 186], ["COPI", "GENE_OR_GENE_PRODUCT", 233, 237], ["vesicle", "CELLULAR_COMPONENT", 238, 245], ["blood", "ORGANISM_SUBSTANCE", 292, 297], ["COPI", "GENE_OR_GENE_PRODUCT", 330, 334], ["cells", "CELL", 395, 400], ["ER", "GENE_OR_GENE_PRODUCT", 487, 489], ["cell", "CELL", 513, 517], ["AeET", "PROTEIN", 47, 51], ["late phase proteases", "PROTEIN", 143, 163], ["AaSPVI", "PROTEIN", 165, 171], ["AaSPVII", "PROTEIN", 173, 180], ["AaLT", "PROTEIN", 182, 186], ["COPI", "PROTEIN", 233, 237], ["COPI", "PROTEIN", 330, 334], ["golgi-modified proteins", "PROTEIN", 451, 474], ["ER", "PROTEIN", 487, 489], ["altered in blood fed alpha-COPI deficient mosquitoes", "PROBLEM", 60, 112], ["three abundant late phase proteases", "PROBLEM", 128, 163], ["AaSPVI", "TEST", 165, 171], ["AaSPVII", "TEST", 173, 180], ["COPI vesicle transport", "PROBLEM", 233, 255], ["the blood digestion process", "PROBLEM", 288, 315], ["late phase", "OBSERVATION_MODIFIER", 143, 153], ["COPI vesicle", "OBSERVATION", 233, 245]]], ["However, the COPI system has also been shown to function in anterograde transport in some secretory cells where it was found to be required for exocytosis of specific proteins [34] .", [["secretory cells", "ANATOMY", 90, 105], ["COPI", "GENE_OR_GENE_PRODUCT", 13, 17], ["secretory cells", "CELL", 90, 105], ["COPI", "PROTEIN", 13, 17], ["secretory cells", "CELL_TYPE", 90, 105], ["the COPI system", "TEST", 9, 24], ["exocytosis of specific proteins", "PROBLEM", 144, 175], ["secretory cells", "OBSERVATION", 90, 105]]], ["The COPI vesicle transport system consists of seven coatomer subunits (alpha, beta, beta', gamma, delta, epsilon, zeta), which function as structural components that promote vesicle formation, a G protein that facilitates coatomer assembly and membrane budding (Arf), guanine nucleotide exchange factors (GEFs) that activate Arf proteins and thereby initiate coatomer assembly, and GTPase activating proteins (ArfGAPs) that stimulate GTP hydrolysis in Arf proteins and induce coatomer disassembly, which is required for vesicle membrane fusion.", [["COPI vesicle", "ANATOMY", 4, 16], ["vesicle", "ANATOMY", 174, 181], ["coatomer", "ANATOMY", 222, 230], ["membrane", "ANATOMY", 244, 252], ["coatomer", "ANATOMY", 359, 367], ["coatomer", "ANATOMY", 476, 484], ["vesicle membrane", "ANATOMY", 520, 536], ["guanine nucleotide", "CHEMICAL", 268, 286], ["GTP", "CHEMICAL", 434, 437], ["guanine nucleotide", "CHEMICAL", 268, 286], ["GTP", "CHEMICAL", 434, 437], ["COPI", "GENE_OR_GENE_PRODUCT", 4, 8], ["alpha, beta", "GENE_OR_GENE_PRODUCT", 71, 82], ["beta'", "GENE_OR_GENE_PRODUCT", 84, 89], ["gamma", "GENE_OR_GENE_PRODUCT", 91, 96], ["delta", "GENE_OR_GENE_PRODUCT", 98, 103], ["epsilon", "GENE_OR_GENE_PRODUCT", 105, 112], ["zeta", "GENE_OR_GENE_PRODUCT", 114, 118], ["vesicle", "CELLULAR_COMPONENT", 174, 181], ["G protein", "GENE_OR_GENE_PRODUCT", 195, 204], ["coatomer", "GENE_OR_GENE_PRODUCT", 222, 230], ["membrane", "CELLULAR_COMPONENT", 244, 252], ["Arf", "GENE_OR_GENE_PRODUCT", 262, 265], ["guanine nucleotide exchange factors", "GENE_OR_GENE_PRODUCT", 268, 303], ["GEFs", "GENE_OR_GENE_PRODUCT", 305, 309], ["Arf", "GENE_OR_GENE_PRODUCT", 325, 328], ["coatomer", "GENE_OR_GENE_PRODUCT", 359, 367], ["GTPase activating proteins", "GENE_OR_GENE_PRODUCT", 382, 408], ["ArfGAPs", "GENE_OR_GENE_PRODUCT", 410, 417], ["GTP", "SIMPLE_CHEMICAL", 434, 437], ["Arf", "GENE_OR_GENE_PRODUCT", 452, 455], ["coatomer", "GENE_OR_GENE_PRODUCT", 476, 484], ["vesicle membrane", "CELLULAR_COMPONENT", 520, 536], ["COPI", "PROTEIN", 4, 8], ["coatomer subunits", "PROTEIN", 52, 69], ["alpha, beta, beta', gamma, delta, epsilon, zeta", "PROTEIN", 71, 118], ["G protein", "PROTEIN", 195, 204], ["Arf", "PROTEIN", 262, 265], ["guanine nucleotide exchange factors", "PROTEIN", 268, 303], ["GEFs", "PROTEIN", 305, 309], ["Arf proteins", "PROTEIN", 325, 337], ["GTPase activating proteins", "PROTEIN", 382, 408], ["ArfGAPs", "PROTEIN", 410, 417], ["Arf proteins", "PROTEIN", 452, 464], ["The COPI vesicle transport system", "TEST", 0, 33], ["seven coatomer subunits", "TREATMENT", 46, 69], ["alpha", "TEST", 71, 76], ["beta", "TEST", 78, 82], ["delta, epsilon, zeta", "TREATMENT", 98, 118], ["vesicle formation", "PROBLEM", 174, 191], ["a G protein", "TREATMENT", 193, 204], ["membrane budding (Arf", "PROBLEM", 244, 265], ["guanine nucleotide exchange factors", "TREATMENT", 268, 303], ["Arf proteins", "PROBLEM", 325, 337], ["GTPase activating proteins", "PROBLEM", 382, 408], ["GTP hydrolysis", "TREATMENT", 434, 448], ["Arf proteins", "PROBLEM", 452, 464], ["coatomer disassembly", "PROBLEM", 476, 496], ["vesicle membrane fusion", "TREATMENT", 520, 543], ["COPI vesicle", "OBSERVATION", 4, 16], ["vesicle formation", "OBSERVATION", 174, 191], ["coatomer disassembly", "OBSERVATION", 476, 496], ["membrane fusion", "OBSERVATION", 528, 543]]], ["Based on our finding that loss of alpha-COPI expression in midgut epithelial cells of unfed mosquitoes disrupts RER whorl formation, without decreasing the total amount of RER membrane in cells ( Figure 6C and 6D) , we propose that COPI coatomer proteins directly contribute to whorl formation through subunit assembly.", [["midgut epithelial cells", "ANATOMY", 59, 82], ["RER whorl", "ANATOMY", 112, 121], ["RER membrane", "ANATOMY", 172, 184], ["cells", "ANATOMY", 188, 193], ["whorl", "ANATOMY", 278, 283], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 34, 44], ["midgut epithelial cells", "CELL", 59, 82], ["RER whorl", "MULTI-TISSUE_STRUCTURE", 112, 121], ["RER membrane", "CELLULAR_COMPONENT", 172, 184], ["cells", "CELL", 188, 193], ["COPI", "GENE_OR_GENE_PRODUCT", 232, 236], ["whorl", "TISSUE", 278, 283], ["alpha-COPI", "PROTEIN", 34, 44], ["midgut epithelial cells", "CELL_TYPE", 59, 82], ["COPI coatomer proteins", "PROTEIN", 232, 254], ["loss of alpha-COPI expression", "PROBLEM", 26, 55], ["midgut epithelial cells", "PROBLEM", 59, 82], ["RER membrane in cells", "PROBLEM", 172, 193], ["COPI coatomer proteins", "TREATMENT", 232, 254], ["alpha-COPI expression", "OBSERVATION", 34, 55], ["midgut", "ANATOMY", 59, 65], ["epithelial cells", "OBSERVATION", 66, 82], ["whorl formation", "OBSERVATION", 116, 131], ["without", "UNCERTAINTY", 133, 140], ["decreasing", "OBSERVATION_MODIFIER", 141, 151], ["total", "OBSERVATION_MODIFIER", 156, 161], ["amount", "OBSERVATION_MODIFIER", 162, 168], ["RER membrane", "OBSERVATION", 172, 184]]], ["Further experiments are needed to directly test this idea, for example, by using immunogold EM analysis to determine if COPI coatomer proteins are tightly associated with RER whorls, and if so, which coatomer subunits are colocalized.MosquitoesAedes aegypti (L.)", [["RER whorls", "ANATOMY", 171, 181], ["COPI", "GENE_OR_GENE_PRODUCT", 120, 124], ["RER whorls", "CELLULAR_COMPONENT", 171, 181], ["coatomer", "GENE_OR_GENE_PRODUCT", 200, 208], ["MosquitoesAedes aegypti", "ORGANISM", 234, 257], ["COPI coatomer proteins", "PROTEIN", 120, 142], ["coatomer subunits", "PROTEIN", 200, 217], ["MosquitoesAedes aegypti", "SPECIES", 234, 257], ["MosquitoesAedes aegypti", "SPECIES", 234, 257], ["immunogold EM analysis", "TEST", 81, 103], ["COPI coatomer proteins", "PROBLEM", 120, 142]]], ["(Rockefeller strain) mosquitoes were used for all studies.", [["Rockefeller strain", "ORGANISM", 1, 19], ["all studies", "TEST", 46, 57]]], ["Larvae were maintained on a diet consisting of equal proportions of rat chow (Sunburst Pet Foods, Phoenix, AZ), lactalbumin hydrolysate (USB, Cleveland, OH), and yeast hydrolysate (USB, Cleveland, OH).", [["rat", "ORGANISM", 68, 71], ["chow", "ORGANISM_SUBDIVISION", 72, 76], ["AZ", "SIMPLE_CHEMICAL", 107, 109], ["lactalbumin hydrolysate", "SIMPLE_CHEMICAL", 112, 135], ["rat", "SPECIES", 68, 71], ["yeast", "SPECIES", 162, 167], ["rat", "SPECIES", 68, 71], ["yeast", "SPECIES", 162, 167], ["lactalbumin hydrolysate", "TREATMENT", 112, 135], ["yeast hydrolysate", "TREATMENT", 162, 179], ["USB", "TEST", 181, 184]]], ["Quantitation of whorl size and number in dsRNA injected unfed and amino acid fed mosquitoes.", [["whorl", "ANATOMY", 16, 21], ["amino acid", "CHEMICAL", 66, 76], ["amino acid", "CHEMICAL", 66, 76], ["amino acid", "AMINO_ACID", 66, 76], ["whorl size", "PROBLEM", 16, 26], ["number in dsRNA", "PROBLEM", 31, 46], ["amino acid fed mosquitoes", "TREATMENT", 66, 91], ["whorl", "OBSERVATION_MODIFIER", 16, 21], ["size", "OBSERVATION_MODIFIER", 22, 26], ["number", "OBSERVATION_MODIFIER", 31, 37]]], ["Whorls with a minimum of five stacked ER membranes were counted and the total area of each whorl was determined as described in figure 2 legend.", [["ER membranes", "ANATOMY", 38, 50], ["whorl", "ANATOMY", 91, 96], ["ER", "GENE_OR_GENE_PRODUCT", 38, 40], ["membranes", "CELLULAR_COMPONENT", 41, 50], ["ER", "PROTEIN", 38, 40]]], ["A) Size and number of RER whorls in 20 random fields from unfed and amino acid fed mosquitoes after 120 min. that were injected with Fluc or alpha-COPI dsRNA.", [["RER whorls", "ANATOMY", 22, 32], ["amino acid", "CHEMICAL", 68, 78], ["amino acid", "CHEMICAL", 68, 78], ["amino acid", "AMINO_ACID", 68, 78], ["Fluc", "GENE_OR_GENE_PRODUCT", 133, 137], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 141, 151], ["Fluc or alpha-COPI dsRNA", "DNA", 133, 157], ["amino acid fed mosquitoes", "TREATMENT", 68, 93], ["Fluc", "TREATMENT", 133, 137], ["alpha-COPI dsRNA", "PROBLEM", 141, 157], ["Size", "OBSERVATION_MODIFIER", 3, 7], ["whorls", "OBSERVATION_MODIFIER", 26, 32]]], ["B) Total whorl in the same sample as shown in A. Statistical analysis using Pearson Chi-square test revealed that the total whorl area in alpha-COPI dsRNA injected unfed and amino acid fed mosquitoes was significantly less than the total whorl area in Fluc dsRNA injected unfed mosquitoes (bars with different letters signify significance at p,0.001).", [["sample", "ANATOMY", 27, 33], ["whorl area", "ANATOMY", 124, 134], ["whorl area", "ANATOMY", 238, 248], ["alpha-COPI dsRNA", "CHEMICAL", 138, 154], ["amino acid", "CHEMICAL", 174, 184], ["amino acid", "CHEMICAL", 174, 184], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["whorl area", "MULTI-TISSUE_STRUCTURE", 124, 134], ["amino acid", "AMINO_ACID", 174, 184], ["Fluc", "GENE_OR_GENE_PRODUCT", 252, 256], ["alpha-COPI dsRNA", "RNA", 138, 154], ["Pearson Chi-square test", "TEST", 76, 99], ["the total whorl area", "PROBLEM", 114, 134], ["alpha-COPI dsRNA", "TREATMENT", 138, 154], ["amino acid fed mosquitoes", "PROBLEM", 174, 199], ["Fluc dsRNA", "TREATMENT", 252, 262], ["Fluc dsRNA", "OBSERVATION", 252, 262]]], ["In addition, the total whorl area in Fluc dsRNA injected fed mosquitoes was found to be significantly less than in Fluc dsRNA injected unfed mosquitoes using the Pearson Chi-square test (bars with different letters signify significance at p,0.001). doi:10.1371/journal.pone.0018150.g008 from males using a mosquito separator.", [["whorl area", "ANATOMY", 23, 33], ["whorl area", "MULTI-TISSUE_STRUCTURE", 23, 33], ["Fluc", "GENE_OR_GENE_PRODUCT", 37, 41], ["Fluc", "GENE_OR_GENE_PRODUCT", 115, 119], ["the total whorl area", "TREATMENT", 13, 33], ["Fluc dsRNA", "TREATMENT", 37, 47], ["Fluc dsRNA", "TREATMENT", 115, 125], ["the Pearson Chi-square test", "TEST", 158, 185], ["a mosquito separator", "TREATMENT", 304, 324], ["total", "OBSERVATION_MODIFIER", 17, 22], ["whorl", "OBSERVATION_MODIFIER", 23, 28], ["area", "OBSERVATION_MODIFIER", 29, 33], ["Fluc dsRNA", "OBSERVATION", 37, 47]]], ["Adult mosquitoes were routinely maintained at 28uC, 70-80% relative humidity and a photoperiod of 16:8 h (L:D), on 10% sucrose ad libitum.MosquitoesPreparation of amino acids meal or feeding buffer for mosquito feeding Amino acid meals was prepared according to Noriega et al. [33] with modifications.", [["sucrose", "CHEMICAL", 119, 126], ["amino acids", "CHEMICAL", 163, 174], ["Amino acid", "CHEMICAL", 219, 229], ["sucrose", "CHEMICAL", 119, 126], ["amino acids", "CHEMICAL", 163, 174], ["Amino acid", "CHEMICAL", 219, 229], ["mosquitoes", "ORGANISM", 6, 16], ["sucrose", "SIMPLE_CHEMICAL", 119, 126], ["amino acids", "AMINO_ACID", 163, 174], ["Amino acid", "SIMPLE_CHEMICAL", 219, 229], ["Adult mosquitoes", "TREATMENT", 0, 16], ["amino acids meal", "TREATMENT", 163, 179], ["feeding buffer", "TREATMENT", 183, 197], ["mosquito feeding Amino acid meals", "TREATMENT", 202, 235]]], ["Briefly, the amino acids meal consisted of 40 ml of amino acid-deficient M199 media (dM199) (Invitrogen Corporation, Carlsbad, CA), 1.6 ml of 1006 MEM nonessential amino acid solution (Mediatech, Inc., Herndon, VA), 3.2 ml of 506 MEM amino acid solution (Mediatech, Inc.), and 10 mg of HEPES (Sigma, St. Louis, MO) (pH 7.2), with a final concentration of 2.3 mg/ml total amino.", [["amino acids", "CHEMICAL", 13, 24], ["amino acid-deficient", "CHEMICAL", 52, 72], ["amino acid", "CHEMICAL", 164, 174], ["MEM amino acid", "CHEMICAL", 230, 244], ["amino", "CHEMICAL", 371, 376], ["amino acids", "CHEMICAL", 13, 24], ["amino", "CHEMICAL", 52, 57], ["amino acid", "CHEMICAL", 164, 174], ["amino acid", "CHEMICAL", 234, 244], ["HEPES", "CHEMICAL", 286, 291], ["amino", "CHEMICAL", 371, 376], ["amino acids", "AMINO_ACID", 13, 24], ["amino acid", "AMINO_ACID", 164, 174], ["the amino acids meal", "TREATMENT", 9, 29], ["amino acid-deficient M199 media", "TREATMENT", 52, 83], ["1006 MEM nonessential amino acid solution", "TREATMENT", 142, 183], ["506 MEM amino acid solution", "TREATMENT", 226, 253], ["HEPES", "TREATMENT", 286, 291], ["pH", "TEST", 316, 318]]], ["Just before feeding mosquitoes, ATP (Sigma) was added to the meal to a final concentration of 5 mM.", [["ATP", "CHEMICAL", 32, 35], ["ATP", "CHEMICAL", 32, 35], ["ATP", "SIMPLE_CHEMICAL", 32, 35], ["Sigma", "SIMPLE_CHEMICAL", 37, 42], ["ATP (Sigma)", "TREATMENT", 32, 43]]], ["The feeding buffer was composed of 100 mM NaHCO 3 and 150 mM NaCl, pH 7.2, as described by Kogan [35] .Preparation of midguts for transmission electron microscopyDissected midgets were fixed in 2.5% glutaraldehyde+2% formaldehyde in 0.1 M PIPES buffer (pH 7.4) for 1 hr at room temperature, washed in buffer, post-fixed in 1% osmium tetroxide in buffer for 1 hr, washed in deionized water, and stained with 2% aqueous uranyl acetate for 30 mins.", [["midguts", "ANATOMY", 118, 125], ["NaHCO", "CHEMICAL", 42, 47], ["NaCl", "CHEMICAL", 61, 65], ["glutaraldehyde", "CHEMICAL", 199, 213], ["formaldehyde", "CHEMICAL", 217, 229], ["osmium tetroxide", "CHEMICAL", 326, 342], ["uranyl acetate", "CHEMICAL", 418, 432], ["NaHCO", "CHEMICAL", 42, 47], ["NaCl", "CHEMICAL", 61, 65], ["glutaraldehyde", "CHEMICAL", 199, 213], ["formaldehyde", "CHEMICAL", 217, 229], ["PIPES", "CHEMICAL", 239, 244], ["osmium tetroxide", "CHEMICAL", 326, 342], ["uranyl acetate", "CHEMICAL", 418, 432], ["glutaraldehyde", "SIMPLE_CHEMICAL", 199, 213], ["formaldehyde", "SIMPLE_CHEMICAL", 217, 229], ["osmium tetroxide", "SIMPLE_CHEMICAL", 326, 342], ["aqueous uranyl acetate", "SIMPLE_CHEMICAL", 410, 432], ["The feeding buffer", "TREATMENT", 0, 18], ["100 mM NaHCO", "TREATMENT", 35, 47], ["pH", "TEST", 67, 69], ["pH", "TEST", 253, 255], ["1% osmium tetroxide", "TREATMENT", 323, 342], ["2% aqueous uranyl acetate", "TREATMENT", 407, 432]]], ["Specimens were dehydrated through an ethyl alcohol series, infiltrated with Spurr's resin and flat embedded at 60uC.", [["Specimens", "ANATOMY", 0, 9], ["ethyl alcohol", "CHEMICAL", 37, 50], ["ethyl alcohol", "CHEMICAL", 37, 50], ["ethyl alcohol", "SIMPLE_CHEMICAL", 37, 50], ["Specimens", "TEST", 0, 9], ["an ethyl alcohol series", "TREATMENT", 34, 57], ["Spurr's resin", "TREATMENT", 76, 89]]], ["Longitudinal sections (50 nm) were cut on a Leica UC2T ultramicrotome onto uncoated 150 mesh copper grids, counter-stained with lead citrate, and viewed in an FEI CM12S electron microscope operated at 80 kV.", [["sections", "ANATOMY", 13, 21], ["lead citrate", "CHEMICAL", 128, 140], ["copper", "CHEMICAL", 93, 99], ["citrate", "CHEMICAL", 133, 140], ["Longitudinal sections", "MULTI-TISSUE_STRUCTURE", 0, 21], ["citrate", "SIMPLE_CHEMICAL", 133, 140], ["Longitudinal sections", "TEST", 0, 21], ["a Leica UC2T ultramicrotome", "TREATMENT", 42, 69], ["uncoated 150 mesh copper grids", "TREATMENT", 75, 105], ["lead citrate", "TREATMENT", 128, 140]]], ["TIFF mages (8 bit) were collected via an AMT 4 M pixel camera and used for image analysis.Whorl quantitation and statistical analysisTwenty sequential and adjacent visual fields from each EM slide were imaged at a magnification of 8800.", [["TIFF mages", "TREATMENT", 0, 10], ["an AMT 4 M pixel camera", "TREATMENT", 38, 61], ["image analysis", "TEST", 75, 89], ["Whorl quantitation", "TEST", 90, 108], ["statistical analysis", "TEST", 113, 133], ["visual", "OBSERVATION_MODIFIER", 164, 170]]], ["Total area of the ER whorls in 20 visual fields of electron microscope was measured with ImageJ (NIH), which covered a total area of 3335 mm 2 .", [["ER whorls", "ANATOMY", 18, 27], ["ER", "GENE_OR_GENE_PRODUCT", 18, 20], ["ER", "PROTEIN", 18, 20], ["electron microscope", "TEST", 51, 70], ["whorls", "OBSERVATION_MODIFIER", 21, 27], ["total", "OBSERVATION_MODIFIER", 119, 124]]], ["Only ER membrane structures containing more than four membrane stacks were considered to be whorls and used for area measurements.", [["ER membrane structures", "ANATOMY", 5, 27], ["membrane stacks", "ANATOMY", 54, 69], ["ER", "GENE_OR_GENE_PRODUCT", 5, 7], ["ER", "PROTEIN", 5, 7], ["four membrane stacks", "TREATMENT", 49, 69], ["area measurements", "TEST", 112, 129], ["membrane", "ANATOMY_MODIFIER", 8, 16]]], ["The data were statistically analyzed as pixels per 20 visual fields using Pearson Chi-square test with SPSS for Windows (v11.5).Western BlotsWestern blots of early phase (AeET) and late phase (AaSPVI, AaSPVII, AaLT) protease expression in unfed and blood fed dsRNA injected mosquitoes were performed as previously described [31] .", [["blood", "ANATOMY", 249, 254], ["AaSPVII, AaLT) protease", "GENE_OR_GENE_PRODUCT", 201, 224], ["blood", "ORGANISM_SUBSTANCE", 249, 254], ["AaLT", "PROTEIN", 210, 214], ["protease", "PROTEIN", 216, 224], ["The data", "TEST", 0, 8], ["Pearson Chi-square test", "TEST", 74, 97], ["late phase", "TEST", 181, 191], ["AaSPVI", "TEST", 193, 199], ["AaSPVII", "TEST", 201, 208], ["protease expression", "TREATMENT", 216, 235]]], ["Analysis of KDEL containing proteins by Western blotting was done by dissecting fifty midguts from amino acid fed or unfed (sugar fed) female mosquitoes in pre-cold PBS buffer, dipped into 76Protease Inhibitor Cocktail in 100 mM phosphate buffer (pH 7.0) (Roche Applied Science, Germany) with a forceps, and transferred into an ice-cold 1.5-ml Eppendorf tube containing 60 ml of PBS/TDS buffer (1% Triton X-100, 12 mM Na deoxycholate, 0.2% SDS in PBS, and Protease Inhibitor Cocktail).", [["midguts", "ANATOMY", 86, 93], ["amino acid", "CHEMICAL", 99, 109], ["phosphate", "CHEMICAL", 229, 238], ["Triton X-100", "CHEMICAL", 398, 410], ["Na deoxycholate", "CHEMICAL", 418, 433], ["amino acid", "CHEMICAL", 99, 109], ["sugar", "CHEMICAL", 124, 129], ["phosphate", "CHEMICAL", 229, 238], ["Na deoxycholate", "CHEMICAL", 418, 433], ["SDS", "CHEMICAL", 440, 443], ["KDEL", "GENE_OR_GENE_PRODUCT", 12, 16], ["Triton X-100", "SIMPLE_CHEMICAL", 398, 410], ["Na deoxycholate", "SIMPLE_CHEMICAL", 418, 433], ["KDEL", "PROTEIN", 12, 16], ["KDEL containing proteins", "TREATMENT", 12, 36], ["Western blotting", "TEST", 40, 56], ["amino acid fed", "TREATMENT", 99, 113], ["pre-cold PBS buffer", "TREATMENT", 156, 175], ["dipped into 76Protease Inhibitor Cocktail", "TREATMENT", 177, 218], ["100 mM phosphate buffer", "TREATMENT", 222, 245], ["pH", "TEST", 247, 249], ["a forceps", "TREATMENT", 293, 302], ["Eppendorf tube", "TREATMENT", 344, 358], ["PBS/TDS buffer", "TREATMENT", 379, 393], ["12 mM Na deoxycholate", "TREATMENT", 412, 433], ["Protease Inhibitor Cocktail", "TREATMENT", 456, 483]]], ["The dissected midguts were homogenized using a blue Kontes pestle.", [["midguts", "ANATOMY", 14, 21], ["midguts", "ORGANISM", 14, 21], ["blue Kontes pestle", "SPECIES", 47, 65], ["a blue Kontes pestle", "TREATMENT", 45, 65]]], ["The homogenate was incubated on ice for 10 min and then spun at 10000 rpm for 10 min at 4uC.", [["homogenate", "ANATOMY", 4, 14], ["ice", "TREATMENT", 32, 35]]], ["The supernatant was transferred to a pre-chilled 1.5-ml tube and 56SDS sample loading buffer was added.", [["supernatant", "ANATOMY", 4, 15], ["sample", "ANATOMY", 71, 77], ["tube", "TISSUE", 56, 60], ["a pre-chilled 1.5-ml tube", "TREATMENT", 35, 60], ["56SDS sample loading buffer", "TREATMENT", 65, 92]]], ["The yielded supernatant was stored at 220uC for SDS-PAGE.Western BlotsProtein samples normalized to equal midgut equivalents were separated on 12% SDS-PAGE using standard procedures.", [["supernatant", "ANATOMY", 12, 23], ["samples", "ANATOMY", 78, 85], ["midgut", "ANATOMY", 106, 112], ["SDS", "CHEMICAL", 48, 51], ["BlotsProtein samples", "TEST", 65, 85], ["standard procedures", "TREATMENT", 162, 181]]], ["The membranes were dried in the air for 1 h and blocked at room temperature with 4% nonfat dry milk in 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 10% Tween-20 (TBST), and then incubated with mouse monoclonal antibody against the peptide sequence SEKDEL conjugated to KLH (Abcam Inc. Cambridge, MA, USA).", [["membranes", "ANATOMY", 4, 13], ["milk", "ANATOMY", 95, 99], ["Tris-HCl", "CHEMICAL", 109, 117], ["NaCl", "CHEMICAL", 134, 138], ["Tween-20", "CHEMICAL", 148, 156], ["Tris-HCl", "CHEMICAL", 109, 117], ["NaCl", "CHEMICAL", 134, 138], ["Tween-20", "CHEMICAL", 148, 156], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["milk", "ORGANISM_SUBSTANCE", 95, 99], ["Tris-HCl", "SIMPLE_CHEMICAL", 109, 117], ["Tween-20", "SIMPLE_CHEMICAL", 148, 156], ["mouse", "ORGANISM", 189, 194], ["mouse monoclonal antibody", "PROTEIN", 189, 214], ["KLH", "PROTEIN", 265, 268], ["Abcam", "PROTEIN", 270, 275], ["mouse", "SPECIES", 189, 194], ["mouse", "SPECIES", 189, 194], ["pH", "TEST", 119, 121], ["NaCl", "TEST", 134, 138], ["Tween", "TEST", 148, 153], ["TBST", "TEST", 158, 162], ["mouse monoclonal antibody", "TEST", 189, 214], ["the peptide sequence", "TEST", 223, 243], ["KLH", "TEST", 265, 268]]], ["Loading controls were performed using rabbit polyclonal antibody against full length native GAPDH protein from human erythrocytes (Abcam, USA) at 1:1000 dilution in 4% nonfat milk TBST solution at 4uC overnight.", [["erythrocytes", "ANATOMY", 117, 129], ["milk", "ANATOMY", 175, 179], ["rabbit", "ORGANISM", 38, 44], ["GAPDH", "GENE_OR_GENE_PRODUCT", 92, 97], ["human", "ORGANISM", 111, 116], ["erythrocytes", "CELL", 117, 129], ["Abcam", "GENE_OR_GENE_PRODUCT", 131, 136], ["milk", "ORGANISM_SUBSTANCE", 175, 179], ["rabbit polyclonal antibody", "PROTEIN", 38, 64], ["full length native GAPDH protein", "PROTEIN", 73, 105], ["human erythrocytes", "CELL_TYPE", 111, 129], ["Abcam", "PROTEIN", 131, 136], ["rabbit", "SPECIES", 38, 44], ["human", "SPECIES", 111, 116], ["rabbit", "SPECIES", 38, 44], ["human", "SPECIES", 111, 116], ["Loading controls", "TREATMENT", 0, 16], ["rabbit polyclonal antibody", "TEST", 38, 64], ["human erythrocytes", "TEST", 111, 129], ["GAPDH protein", "OBSERVATION", 92, 105]]], ["After washing with TBS containing 0.1% Tween-20 (TBST), the membranes were incubated with goat anti-rabbit IRDyeH 800CW or goat anti-mouse IRDyeH 800CW secondary antibody (LI-COR Biosciences, USA) at a dilution of 1:10000 in TBST/4% nonfat dry milk for 1 h at room temperature.", [["membranes", "ANATOMY", 60, 69], ["milk", "ANATOMY", 244, 248], ["Tween-20", "CHEMICAL", 39, 47], ["Tween-20", "CHEMICAL", 39, 47], ["TBS", "SIMPLE_CHEMICAL", 19, 22], ["Tween-20", "SIMPLE_CHEMICAL", 39, 47], ["membranes", "CELLULAR_COMPONENT", 60, 69], ["goat", "ORGANISM", 90, 94], ["goat", "ORGANISM", 123, 127], ["milk", "ORGANISM_SUBSTANCE", 244, 248], ["goat anti-rabbit IRDyeH 800CW", "PROTEIN", 90, 119], ["goat anti-mouse IRDyeH 800CW secondary antibody", "PROTEIN", 123, 170], ["goat", "SPECIES", 90, 94], ["anti-rabbit", "SPECIES", 95, 106], ["goat", "SPECIES", 123, 127], ["anti-mouse", "SPECIES", 128, 138], ["goat", "SPECIES", 90, 94], ["goat", "SPECIES", 123, 127], ["TBS", "TEST", 19, 22], ["goat anti-rabbit IRDyeH", "TREATMENT", 90, 113], ["goat anti-mouse IRDyeH", "TEST", 123, 145]]], ["Labeled proteins were visualized using Odyssey Infrared Imaging System (LI-COR Biosciences, USA).Microsomal midgut protein extractionAbout 40 midguts from the fed or unfed female mosquitoes were dissected with pre-cold PBS buffer, dipped into 76Protease Inhibitor Cocktail in 100 mM phosphate buffer (pH 7.0) (Roche Applied Science, Germany) with a forceps, and transferred into an Figure 9 .", [["Microsomal midgut", "ANATOMY", 97, 114], ["midguts", "ANATOMY", 142, 149], ["phosphate", "CHEMICAL", 283, 292], ["phosphate", "CHEMICAL", 283, 292], ["Microsomal midgut", "ORGANISM_SUBSTANCE", 97, 114], ["mosquitoes", "ORGANISM", 179, 189], ["Odyssey Infrared Imaging System", "TEST", 39, 70], ["Microsomal midgut protein extractionAbout", "TEST", 97, 138], ["pre-cold PBS buffer", "TREATMENT", 210, 229], ["100 mM phosphate buffer", "TREATMENT", 276, 299], ["pH", "TEST", 301, 303], ["a forceps", "TREATMENT", 347, 356]]], ["A deficiency in alpha-COPI inhibits feeding-induced expression of late phase midgut proteases.", [["alpha-COPI", "CHEMICAL", 16, 26], ["alpha-COPI", "CHEMICAL", 16, 26], ["alpha-COPI", "SIMPLE_CHEMICAL", 16, 26], ["alpha-COPI", "PROTEIN", 16, 26], ["late phase midgut proteases", "PROTEIN", 66, 93], ["A deficiency in alpha-COPI", "PROBLEM", 0, 26], ["late phase midgut proteases", "PROBLEM", 66, 93], ["deficiency", "OBSERVATION", 2, 12], ["late phase", "OBSERVATION_MODIFIER", 66, 76]]], ["A) Representative Western blot of AeET protein expression in the midguts of mosquitoes injected with 400 ng of Fluc or alpha-COPI dsRNA and maintained on sugar for 3 days and then dissected (unfed), or blood fed after 3 days of sugar feeding and dissected at 3 hr PBM (fed).", [["midguts", "ANATOMY", 65, 72], ["blood", "ANATOMY", 202, 207], ["sugar", "CHEMICAL", 154, 159], ["sugar", "CHEMICAL", 228, 233], ["AeET", "GENE_OR_GENE_PRODUCT", 34, 38], ["mosquitoes", "ORGANISM", 76, 86], ["Fluc", "GENE_OR_GENE_PRODUCT", 111, 115], ["sugar", "SIMPLE_CHEMICAL", 154, 159], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["AeET protein", "PROTEIN", 34, 46], ["PBM", "CELL_TYPE", 264, 267], ["AeET protein expression", "PROBLEM", 34, 57], ["Fluc", "TREATMENT", 111, 115], ["alpha-COPI dsRNA", "TREATMENT", 119, 135], ["sugar feeding", "TREATMENT", 228, 241]]], ["The GAPDH antibody was used as a protein loading control.", [["GAPDH antibody", "GENE_OR_GENE_PRODUCT", 4, 18], ["GAPDH antibody", "PROTEIN", 4, 18], ["The GAPDH antibody", "TEST", 0, 18], ["a protein loading control", "TREATMENT", 31, 56], ["GAPDH antibody", "OBSERVATION", 4, 18]]], ["Each lane contains the same midgut equivalents obtained from pooled mosquitoes.", [["midgut", "ANATOMY", 28, 34], ["midgut", "ORGANISM_SUBSTANCE", 28, 34]]], ["B) Representative Western blots of protein extracts prepared from pooled mosquito midguts dissected at 24 hr PBM and analyzed with antibodies against late phase serine proteases (AaSPVI, AaSPVII, AaLT) or GAPDH.", [["extracts", "ANATOMY", 43, 51], ["midguts", "ANATOMY", 82, 89], ["serine", "CHEMICAL", 161, 167], ["extracts", "ORGANISM_SUBSTANCE", 43, 51], ["late phase serine proteases", "GENE_OR_GENE_PRODUCT", 150, 177], ["AaSPVI", "GENE_OR_GENE_PRODUCT", 179, 185], ["AaSPVII", "GENE_OR_GENE_PRODUCT", 187, 194], ["AaLT", "GENE_OR_GENE_PRODUCT", 196, 200], ["GAPDH", "GENE_OR_GENE_PRODUCT", 205, 210], ["PBM", "CELL_TYPE", 109, 112], ["antibodies", "PROTEIN", 131, 141], ["late phase serine proteases", "PROTEIN", 150, 177], ["AaSPVI", "PROTEIN", 179, 185], ["AaSPVII", "PROTEIN", 187, 194], ["AaLT", "PROTEIN", 196, 200], ["GAPDH", "PROTEIN", 205, 210], ["protein extracts", "TREATMENT", 35, 51], ["pooled mosquito midguts", "PROBLEM", 66, 89], ["antibodies", "TEST", 131, 141], ["late phase serine proteases", "PROBLEM", 150, 177], ["AaSPVI", "TEST", 179, 185], ["AaSPVII", "TEST", 187, 194], ["GAPDH", "PROBLEM", 205, 210]]], ["Mosquitoes were injected with the indicated amount of dsRNA 3 days prior to blood feeding. doi:10.1371/journal.pone.0018150.g009Microsomal midgut protein extractionice-cold 1.5-ml Eppendorf tube containing 100 ml of 16Isotonic Extraction Buffer (5 mM HEPES;pH 7.8, 0.25 M sucrose, 1 mM EGTA, 25 mM KCl), and an appropriate amount of Protease Inhibitor Cocktail.", [["blood", "ANATOMY", 76, 81], ["sucrose", "CHEMICAL", 272, 279], ["EGTA", "CHEMICAL", 286, 290], ["KCl", "CHEMICAL", 298, 301], ["HEPES", "CHEMICAL", 251, 256], ["sucrose", "CHEMICAL", 272, 279], ["EGTA", "CHEMICAL", 286, 290], ["KCl", "CHEMICAL", 298, 301], ["Mosquitoes", "ORGANISM", 0, 10], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["EGTA", "SIMPLE_CHEMICAL", 286, 290], ["Protease Inhibitor Cocktail", "GENE_OR_GENE_PRODUCT", 333, 360], ["Mosquitoes", "TREATMENT", 0, 10], ["dsRNA", "TREATMENT", 54, 59], ["blood feeding", "TREATMENT", 76, 89], ["Eppendorf tube", "TREATMENT", 180, 194], ["16Isotonic Extraction Buffer", "TREATMENT", 216, 244], ["HEPES", "TEST", 251, 256], ["pH", "TEST", 257, 259], ["sucrose", "TEST", 272, 279], ["EGTA", "TEST", 286, 290], ["25 mM KCl)", "TREATMENT", 292, 302], ["Protease Inhibitor Cocktail", "TREATMENT", 333, 360]]], ["Mosquito midgut ER protein extraction was performed according using the Endoplasmic Reticulum Isolation kit (ER0100; Sigma, St. Louis, USA) with modification.", [["midgut", "ANATOMY", 9, 15], ["ER", "GENE_OR_GENE_PRODUCT", 16, 18], ["ER", "PROTEIN", 16, 18], ["Mosquito midgut ER protein extraction", "TREATMENT", 0, 37]]], ["Briefly, the dissected midguts were homogenized with a blue Kontes pestle and spun at 1000g for 10 min at 4uC.", [["midguts", "ANATOMY", 23, 30], ["midguts", "ORGANISM", 23, 30], ["blue Kontes pestle", "SPECIES", 55, 73], ["a blue Kontes pestle", "TREATMENT", 53, 73]]], ["The post nuclear supernatant was transferred into a clean 1.5-ml tube and spun at 12000g for 15 min at 4uC.", [["nuclear supernatant", "ANATOMY", 9, 28], ["tube", "TISSUE", 65, 69], ["a clean 1.5-ml tube", "TREATMENT", 50, 69]]], ["The post mitochondrial supernatant was transferred into a clean 1.5-ml tube and mixed with 7.5 volumes of 8 mM CaCl 2 by vortexing.", [["mitochondrial supernatant", "ANATOMY", 9, 34], ["CaCl 2", "CHEMICAL", 111, 117], ["CaCl 2", "CHEMICAL", 111, 117], ["mitochondrial", "CELLULAR_COMPONENT", 9, 22], ["tube", "TISSUE", 71, 75], ["a clean 1.5-ml tube", "TREATMENT", 56, 75], ["8 mM CaCl", "TREATMENT", 106, 115]]], ["The mixture was incubated on ice for 10 min and then spun at 8,000g for 10 minutes at 4uC.", [["ice", "TREATMENT", 29, 32]]], ["The supernatant was discarded, and the pellet containing the microsomal fraction, was resuspended in 20 ml of 16 Isotonic Extraction Buffer followed by a 10-min of incubation on ice.", [["supernatant", "ANATOMY", 4, 15], ["microsomal fraction", "ANATOMY", 61, 80], ["the microsomal fraction", "TREATMENT", 57, 80], ["Isotonic Extraction Buffer", "TREATMENT", 113, 139], ["ice", "TREATMENT", 178, 181]]], ["A 5 ml portion of the extracted ER protein fraction was used for measuring protein concentration with the BCA TM Protein Assay Kit (Pierce, USA).", [["ER", "ANATOMY", 32, 34], ["ER", "GENE_OR_GENE_PRODUCT", 32, 34], ["ER", "PROTEIN", 32, 34], ["the extracted ER protein fraction", "TREATMENT", 18, 51], ["measuring protein concentration", "TREATMENT", 65, 96], ["the BCA", "TEST", 102, 109]]], ["The remaining ER proteins were mixed with an appropriate amount of 56SDS sample loading buffer, boiled for 4 min, and spun at 130006 rpm for 5 min.", [["ER", "GENE_OR_GENE_PRODUCT", 14, 16], ["ER proteins", "PROTEIN", 14, 25]]], ["The supernatant was stored at 220C for SDS-PAGE.SDS-PAGE of ER proteins and in-gel digestionEqual amounts of ER proteins isolated from midguts of unfed and fed mosquitoes were separated by 12% SDS-PAGE and visualized using the GelCodeH Blue Staining Kit (Thermo Scientific, Rockford, IL, USA).", [["supernatant", "ANATOMY", 4, 15], ["midguts", "ANATOMY", 135, 142], ["GelCodeH Blue", "CHEMICAL", 227, 240], ["ER", "GENE_OR_GENE_PRODUCT", 60, 62], ["ER", "GENE_OR_GENE_PRODUCT", 109, 111], ["midguts", "ORGANISM_SUBSTANCE", 135, 142], ["ER proteins", "PROTEIN", 60, 71], ["ER proteins", "PROTEIN", 109, 120], ["SDS", "TEST", 48, 51], ["ER proteins", "TEST", 60, 71], ["ER proteins", "PROBLEM", 109, 120]]], ["Each gel lane was cut into 4 equal slices using a scalpel, and labeled as A, B, C, and D from high to low molecular weight regions.", [["slices", "ANATOMY", 35, 41], ["C", "SIMPLE_CHEMICAL", 80, 81], ["D", "SIMPLE_CHEMICAL", 87, 88], ["Each gel lane", "TREATMENT", 0, 13], ["a scalpel", "TREATMENT", 48, 57], ["scalpel", "ANATOMY", 50, 57]]], ["The gel slices were stored individually stored in a clean Eppendorf tube for in-gel digestion.", [["slices", "ANATOMY", 8, 14], ["The gel slices", "TREATMENT", 0, 14], ["a clean Eppendorf tube", "TREATMENT", 50, 72], ["Eppendorf tube", "OBSERVATION", 58, 72]]], ["Each gel slice was washed first with ddH 2 O for 15 min, then twice with 50% acetonitrile (ACN), and finally with 100 mM ammonium bicarbonate (Ambic, pH 8.0) containing 50% ACN for 15 min.", [["ddH 2 O", "CHEMICAL", 37, 44], ["acetonitrile", "CHEMICAL", 77, 89], ["ACN", "CHEMICAL", 91, 94], ["ammonium bicarbonate", "CHEMICAL", 121, 141], ["ACN", "CHEMICAL", 173, 176], ["acetonitrile", "CHEMICAL", 77, 89], ["ACN", "CHEMICAL", 91, 94], ["ammonium bicarbonate", "CHEMICAL", 121, 141], ["ACN", "CHEMICAL", 173, 176], ["acetonitrile", "SIMPLE_CHEMICAL", 77, 89], ["ACN", "SIMPLE_CHEMICAL", 91, 94], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 121, 141], ["Ambic", "SIMPLE_CHEMICAL", 143, 148], ["ACN", "SIMPLE_CHEMICAL", 173, 176], ["Each gel slice", "TREATMENT", 0, 14], ["50% acetonitrile (ACN", "TREATMENT", 73, 94], ["100 mM ammonium bicarbonate", "TREATMENT", 114, 141], ["pH", "TEST", 150, 152]]], ["After drying, the gel pieces were subjected to the standard in-gel digestion protocol.", [["the gel pieces", "TREATMENT", 14, 28], ["gel digestion protocol", "TREATMENT", 63, 85]]], ["Briefly, proteins were reduced by 10 mM DTT/100 mM Ambic at 56uC for 45 min., and alkylated by 55 mM iodoacetamide (IAA)/ 100 mM Ambic at room temperature in the dark for 30 min.", [["DTT", "CHEMICAL", 40, 43], ["56uC", "CHEMICAL", 60, 64], ["iodoacetamide", "CHEMICAL", 101, 114], ["IAA", "CHEMICAL", 116, 119], ["DTT", "CHEMICAL", 40, 43], ["iodoacetamide", "CHEMICAL", 101, 114], ["IAA", "CHEMICAL", 116, 119], ["DTT", "SIMPLE_CHEMICAL", 40, 43], ["iodoacetamide", "SIMPLE_CHEMICAL", 101, 114], ["IAA", "SIMPLE_CHEMICAL", 116, 119], ["Ambic", "TREATMENT", 51, 56]]], ["Gel pieces were washed with 100 mM Ambic dehydrated with ACN and dried.", [["ACN", "CHEMICAL", 57, 60], ["ACN", "CHEMICAL", 57, 60], ["ACN", "SIMPLE_CHEMICAL", 57, 60], ["Gel pieces", "TREATMENT", 0, 10], ["ACN", "TREATMENT", 57, 60]]], ["Proteolytic digestion was performed with 12.5 ng/ml trypsin dissolved in 100 mM Ambic and incubated on ice for 45 min.", [["trypsin", "GENE_OR_GENE_PRODUCT", 52, 59], ["trypsin", "PROTEIN", 52, 59], ["Proteolytic digestion", "PROBLEM", 0, 21]]], ["The digested mixture was acidified with 2% trifluoroacetic acid (TFA) in water for 1-2 minutes and then the supernatant was collected in a clean 1.5-ml tube.", [["supernatant", "ANATOMY", 108, 119], ["trifluoroacetic acid", "CHEMICAL", 43, 63], ["TFA", "CHEMICAL", 65, 68], ["trifluoroacetic acid", "CHEMICAL", 43, 63], ["TFA", "CHEMICAL", 65, 68], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 43, 63], ["TFA", "SIMPLE_CHEMICAL", 65, 68], ["tube", "TISSUE", 152, 156], ["The digested mixture", "TREATMENT", 0, 20], ["2% trifluoroacetic acid (TFA", "TREATMENT", 40, 68], ["a clean 1.5-ml tube", "TREATMENT", 137, 156], ["tube", "OBSERVATION", 152, 156]]], ["The peptides were extracted from the gel slice using 0.1% TFA in water, 0.1% TFA in 30% ACN, and 0.1% TFA in 60% ACN, respectively, with ultrasonication.", [["TFA", "CHEMICAL", 58, 61], ["TFA", "CHEMICAL", 77, 80], ["ACN", "CHEMICAL", 88, 91], ["TFA", "CHEMICAL", 102, 105], ["ACN", "CHEMICAL", 113, 116], ["TFA", "CHEMICAL", 58, 61], ["TFA", "CHEMICAL", 77, 80], ["ACN", "CHEMICAL", 88, 91], ["TFA", "CHEMICAL", 102, 105], ["ACN", "CHEMICAL", 113, 116], ["TFA", "SIMPLE_CHEMICAL", 58, 61], ["TFA", "SIMPLE_CHEMICAL", 77, 80], ["ACN", "SIMPLE_CHEMICAL", 88, 91], ["TFA", "SIMPLE_CHEMICAL", 102, 105], ["ACN", "SIMPLE_CHEMICAL", 113, 116], ["The peptides", "TREATMENT", 0, 12], ["the gel slice", "TREATMENT", 33, 46], ["0.1% TFA in water", "TREATMENT", 53, 70], ["ultrasonication", "TREATMENT", 137, 152]]], ["The peptides extracted in the four steps were combined together, concentrated by a SpeedVac to a desired volume and subjected to LC-MS/MS analysis.LC-MS/MS and data analysisMass spectrometry analysis was performed by the Chemistry & Biochemistry department proteomics core facility using in-house protocols.", [["The peptides", "TREATMENT", 0, 12], ["LC", "TEST", 129, 131], ["MS/MS analysis", "TEST", 132, 146], ["LC", "TEST", 147, 149], ["MS", "PROBLEM", 153, 155], ["data analysis", "TEST", 160, 173], ["Mass spectrometry analysis", "TEST", 173, 199]]], ["Briefly, trypsin digested protein samples were acidified with TFA and diluted to 20 ml prior to separation by C18 column (75 um61 mm, LC Packings, Amsterdam, Netherlands) at a flow rate of 30-500 nl/min and introduced into Finnigan LTQ (Thermo electron corporation) through nano spray (2.8 kV).", [["samples", "ANATOMY", 34, 41], ["TFA", "CHEMICAL", 62, 65], ["TFA", "CHEMICAL", 62, 65], ["trypsin", "GENE_OR_GENE_PRODUCT", 9, 16], ["TFA", "SIMPLE_CHEMICAL", 62, 65], ["trypsin", "PROTEIN", 9, 16], ["trypsin digested protein samples", "PROBLEM", 9, 41], ["TFA", "TREATMENT", 62, 65], ["a flow rate", "TEST", 174, 185], ["Finnigan LTQ (Thermo electron corporation", "TREATMENT", 223, 264], ["nano spray", "TREATMENT", 274, 284]]], ["Liquid chromatography mobile phases consisted of Solution A (90% water, 10%methonal, 0.5% formic acid, 0.01% TFA) and Solution B (98% methanol, 2% water, 0.5% formic acid, 0.01% TFA).", [["formic acid", "CHEMICAL", 90, 101], ["TFA", "CHEMICAL", 109, 112], ["Solution B", "CHEMICAL", 118, 128], ["formic acid", "CHEMICAL", 159, 170], ["formic acid", "CHEMICAL", 90, 101], ["TFA", "CHEMICAL", 109, 112], ["methanol", "CHEMICAL", 134, 142], ["formic acid", "CHEMICAL", 159, 170], ["TFA", "CHEMICAL", 178, 181], ["formic acid", "SIMPLE_CHEMICAL", 90, 101], ["TFA", "SIMPLE_CHEMICAL", 109, 112], ["Solution B", "SIMPLE_CHEMICAL", 118, 128], ["methanol", "SIMPLE_CHEMICAL", 134, 142], ["water", "SIMPLE_CHEMICAL", 147, 152], ["formic acid", "SIMPLE_CHEMICAL", 159, 170], ["TFA", "SIMPLE_CHEMICAL", 178, 181], ["Solution A (90% water", "TREATMENT", 49, 70], ["formic acid", "TREATMENT", 90, 101], ["Solution B", "TREATMENT", 118, 128], ["methanol", "TREATMENT", 134, 142], ["formic acid", "TREATMENT", 159, 170]]], ["A 120min linear gradient from 0 to 90% B was typically used.", [["A 120min linear gradient", "TEST", 0, 24], ["linear", "OBSERVATION_MODIFIER", 9, 15], ["gradient", "OBSERVATION_MODIFIER", 16, 24]]], ["Samples were subjected to nanoelectrospray mass spectrometry using standard procedures and data were analyzed using Sequest (ThermoFinnigan, San Jose, CA; version27, rev. 12) and X!", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["standard procedures", "TREATMENT", 67, 86]]], ["Tandem (www.thegpm.org; version 2007.01.01.1) using the Aedes aegypti database.", [["Aedes aegypti", "ORGANISM", 56, 69], ["Aedes aegypti", "SPECIES", 56, 69]]], ["Scaffold (Proteome Software Inc., Portland, OR) was used to validate MS/ MS based peptide and protein identifications.", [["MS", "TEST", 69, 71], ["protein identifications", "TEST", 94, 117]]], ["Sequest identifications required at least DCn scores of greater than 0.08 and XCorr scores of greater than 1.8, 2.5, 3.5 for singly, doubly, triply charged peptides.", [["DCn scores", "TEST", 42, 52], ["XCorr scores", "TEST", 78, 90], ["triply charged peptides", "TREATMENT", 141, 164]]], ["Tandem identifications required at least 2Log(Expect Scores) scores of greater than 3.0.Protein annotation analysisER proteins listed in Table 1 and Table S1were RNAi-mediated knockdown of alpha-COPI expression and validation by QRTPCR alpha-COPI gene was subjected to a RNAi according to our previous study [31] .", [["alpha-COPI", "GENE_OR_GENE_PRODUCT", 189, 199], ["QRTPCR alpha-COPI", "GENE_OR_GENE_PRODUCT", 229, 246], ["analysisER proteins", "PROTEIN", 107, 126], ["alpha-COPI", "DNA", 189, 199], ["QRTPCR alpha-COPI gene", "DNA", 229, 251], ["Scores) scores", "TEST", 53, 67], ["Protein annotation analysisER proteins", "TEST", 88, 126], ["alpha-COPI expression", "TREATMENT", 189, 210], ["our previous study", "TEST", 289, 307]]], ["Briefly, a DNA fragment of alpha-COPI gene was amplified by PCR (forward primer containing the T7 promoter sequence: 59 TAATACGACTCACTATAGGGAGA TGCTGACAAATTTCGAAACCAA 39; and reverse primers containing the T7 promoter sequence: 59 TAATACGACTCAC TATAGGGAGATCCGTCGCCGTAGGATTCTT 39) and cloned into the pGEM-T easy vector (Promega).", [["DNA", "CELLULAR_COMPONENT", 11, 14], ["alpha-COPI", "GENE_OR_GENE_PRODUCT", 27, 37], ["pGEM-T", "GENE_OR_GENE_PRODUCT", 300, 306], ["DNA fragment", "DNA", 11, 23], ["alpha-COPI gene", "DNA", 27, 42], ["forward primer", "DNA", 65, 79], ["T7 promoter sequence", "DNA", 95, 115], ["reverse primers", "DNA", 175, 190], ["T7 promoter sequence", "DNA", 206, 226], ["pGEM-T easy vector", "DNA", 300, 318], ["a DNA fragment of alpha-COPI gene", "PROBLEM", 9, 42], ["the T7 promoter sequence", "TREATMENT", 91, 115], ["TAATACGACTCACTATAGGGAGA TGCTGACAAATTTCGAAACCAA", "TEST", 120, 166], ["reverse primers", "TREATMENT", 175, 190], ["the T7 promoter sequence", "TREATMENT", 202, 226]]], ["Subsequently, a double-strand RNA (dsRNA) was synthesized in vitro transcription using the MEGAscript RNAi Kit (Ambion).", [["double-strand RNA", "RNA", 16, 33], ["a double-strand RNA (dsRNA", "TREATMENT", 14, 40], ["the MEGAscript RNAi Kit", "TREATMENT", 87, 110]]], ["Two-day old female mosquitoes were injected with 400 ng of dsRNA using a Nanoject II microinjector (Drummond Scientific).", [["Nanoject II", "CHEMICAL", 73, 84], ["mosquitoes", "ORGANISM", 19, 29], ["dsRNA", "TREATMENT", 59, 64], ["a Nanoject II microinjector", "TREATMENT", 71, 98]]], ["The knockdown efficiency of mRNA encoding alpha-COPI was determined using mosquitoes injected with Fluc (firefly luciferase) dsRNA as a control.", [["alpha-COPI", "GENE_OR_GENE_PRODUCT", 42, 52], ["Fluc", "GENE_OR_GENE_PRODUCT", 99, 103], ["luciferase", "GENE_OR_GENE_PRODUCT", 113, 123], ["mRNA", "RNA", 28, 32], ["alpha-COPI", "PROTEIN", 42, 52], ["Fluc (firefly luciferase) dsRNA", "DNA", 99, 130], ["mRNA encoding alpha-COPI", "TREATMENT", 28, 52], ["Fluc (firefly luciferase) dsRNA", "TREATMENT", 99, 130], ["knockdown efficiency", "OBSERVATION", 4, 24]]], ["QRT-PCR was performed using PerfeCTa SYBR Green FastMix (Quanta BioSciences) by Real-Time PCR (7300 Real-Time PCR System, Applied Biosystems) with alpha-COPI forward primer: 59 GTGTCCGCATCGTTGGATCA 39, alpha-COPI reverse primer: 59 ACAACAGCATCAGCTTGCCCAA 39.", [["alpha-COPI forward primer", "DNA", 147, 172], ["alpha-COPI reverse primer", "DNA", 202, 227], ["QRT-PCR", "TEST", 0, 7], ["alpha-COPI forward primer", "TEST", 147, 172], ["GTGTCCGCATCGTTGGATCA", "TEST", 177, 197], ["ACAACAGCATCAGCTTGCCCAA", "TEST", 232, 254]]], ["Ribosomal protein S7 mRNA levels were used as an internal control for normalization.", [["Ribosomal protein S7", "GENE_OR_GENE_PRODUCT", 0, 20], ["Ribosomal protein S7 mRNA", "RNA", 0, 25], ["Ribosomal protein S7 mRNA levels", "TEST", 0, 32], ["protein S7", "OBSERVATION", 10, 20]]], ["Statistical analysis of the gene expression was done by unpaired student t test using GraphPad Prism software (GraphPad Software, Inc.).Supporting InformationTable S1 Proteomic analysis of Ae. aegypti midgut microsomal proteins isolated from unfed (sugar fed) and amino acid fed (30 min. post-feeding).Supporting Information(DOC) paper: GZ JI RLM.", [["midgut microsomal", "ANATOMY", 201, 218], ["amino acid", "CHEMICAL", 264, 274], ["sugar", "CHEMICAL", 249, 254], ["amino acid", "CHEMICAL", 264, 274], ["Ae. aegypti", "ORGANISM", 189, 200], ["midgut microsomal", "ORGANISM", 201, 218], ["sugar", "SIMPLE_CHEMICAL", 249, 254], ["amino acid", "AMINO_ACID", 264, 274], ["Ae. aegypti midgut microsomal proteins", "PROTEIN", 189, 227], ["Ae. aegypti", "SPECIES", 189, 200], ["Ae. aegypti", "SPECIES", 189, 200], ["Statistical analysis", "TEST", 0, 20], ["Ae. aegypti midgut microsomal proteins", "TEST", 189, 227], ["amino acid fed", "TREATMENT", 264, 278]]]], "PMC7224015": [["IntroductionTo prevent tracheal injury and leakage, cuff pressure should be maintained between 25 and 30 cm H2O [1].", [["tracheal", "ANATOMY", 23, 31], ["cuff", "ANATOMY", 52, 56], ["tracheal injury", "DISEASE", 23, 38], ["H2O", "CHEMICAL", 108, 111], ["H2O", "CHEMICAL", 108, 111], ["tracheal", "MULTI-TISSUE_STRUCTURE", 23, 31], ["IntroductionTo", "TREATMENT", 0, 14], ["tracheal injury", "PROBLEM", 23, 38], ["leakage", "PROBLEM", 43, 50], ["cuff pressure", "TREATMENT", 52, 65], ["tracheal", "ANATOMY", 23, 31], ["injury", "OBSERVATION", 32, 38], ["leakage", "OBSERVATION", 43, 50], ["cuff pressure", "OBSERVATION", 52, 65]]], ["High pressures against the trachea may impede mucosal blood flow, resulting in mucosal ischaemia, necrosis [2], and tracheoesophageal fistula [3].", [["trachea", "ANATOMY", 27, 34], ["mucosal", "ANATOMY", 46, 53], ["blood", "ANATOMY", 54, 59], ["mucosal", "ANATOMY", 79, 86], ["tracheoesophageal fistula", "ANATOMY", 116, 141], ["ischaemia", "DISEASE", 87, 96], ["necrosis", "DISEASE", 98, 106], ["tracheoesophageal fistula", "DISEASE", 116, 141], ["trachea", "MULTI-TISSUE_STRUCTURE", 27, 34], ["mucosal blood", "MULTI-TISSUE_STRUCTURE", 46, 59], ["mucosal", "MULTI-TISSUE_STRUCTURE", 79, 86], ["High pressures against the trachea", "PROBLEM", 0, 34], ["mucosal blood flow", "PROBLEM", 46, 64], ["mucosal ischaemia", "PROBLEM", 79, 96], ["necrosis", "PROBLEM", 98, 106], ["tracheoesophageal fistula", "PROBLEM", 116, 141], ["pressures", "OBSERVATION_MODIFIER", 5, 14], ["trachea", "ANATOMY", 27, 34], ["mucosal blood flow", "OBSERVATION", 46, 64], ["mucosal", "ANATOMY", 79, 86], ["ischaemia", "OBSERVATION", 87, 96], ["necrosis", "OBSERVATION", 98, 106], ["tracheoesophageal", "ANATOMY", 116, 133], ["fistula", "OBSERVATION", 134, 141]]], ["Low pressures could increase the risk of leakage and pulmonary aspiration.", [["pulmonary", "ANATOMY", 53, 62], ["pulmonary", "ORGAN", 53, 62], ["Low pressures", "PROBLEM", 0, 13], ["leakage", "PROBLEM", 41, 48], ["pulmonary aspiration", "PROBLEM", 53, 73], ["pressures", "OBSERVATION", 4, 13], ["leakage", "OBSERVATION", 41, 48], ["pulmonary", "ANATOMY", 53, 62], ["aspiration", "OBSERVATION", 63, 73]]], ["Rello [4] showed that cuff pressure below 20 cm H2O was an independent risk factor for VAP (RR = 4.23).", [["cuff", "ANATOMY", 22, 26], ["H2O", "CHEMICAL", 48, 51], ["VAP", "DISEASE", 87, 90], ["H2O", "CHEMICAL", 48, 51], ["cuff", "TISSUE", 22, 26], ["cuff pressure", "TEST", 22, 35], ["VAP", "PROBLEM", 87, 90], ["RR", "TEST", 92, 94], ["pressure", "OBSERVATION_MODIFIER", 27, 35]]], ["Currently, the incidence of VAP in patients with mechanical ventilation is as high as 6\u201352% [5\u20137], which lead to the following serious consequences: VAP was associated with a 6.4-day extension of the duration of prior intubation [8], a 12.5-day extension of ICU stay [8], an average increase of $40,000 in hospital costs [5], and a 13% increase in attributable mortality [9].IntroductionHowever, the pilot balloon palpation (or \u2018finger-pressure\u2019) method is still widely used to assess endotracheal tube cuff inflation, which will lead to abnormal ETT cuff pressure [10\u201312].", [["finger", "ANATOMY", 429, 435], ["endotracheal tube", "ANATOMY", 485, 502], ["cuff", "ANATOMY", 551, 555], ["VAP", "DISEASE", 28, 31], ["VAP", "DISEASE", 149, 152], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["VAP", "PROBLEM", 28, 31], ["mechanical ventilation", "TREATMENT", 49, 71], ["VAP", "PROBLEM", 149, 152], ["prior intubation", "TREATMENT", 212, 228], ["the pilot balloon palpation", "TEST", 396, 423], ["\u2018finger-pressure\u2019) method", "TREATMENT", 428, 453], ["endotracheal tube cuff inflation", "TREATMENT", 485, 517], ["abnormal ETT cuff pressure", "PROBLEM", 538, 564], ["VAP", "OBSERVATION", 28, 31], ["mechanical ventilation", "OBSERVATION", 49, 71], ["VAP", "OBSERVATION", 149, 152], ["increase", "OBSERVATION_MODIFIER", 283, 291], ["tube cuff", "OBSERVATION", 498, 507], ["inflation", "OBSERVATION_MODIFIER", 508, 517], ["ETT cuff", "OBSERVATION", 547, 555], ["pressure", "OBSERVATION_MODIFIER", 556, 564]]], ["Nseir et al. measured cuff pressure every 8 h and found that cuff pressure was maintained within the recommended range in only 18% of patients [13].", [["cuff", "ANATOMY", 22, 26], ["cuff", "ANATOMY", 61, 65], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["cuff pressure", "TEST", 22, 35], ["cuff pressure", "TEST", 61, 74], ["pressure", "OBSERVATION_MODIFIER", 27, 35], ["cuff pressure", "OBSERVATION", 61, 74]]], ["Only a few large general hospitals in China have established a department of respiratory therapy [14], and the ETT cuff pressure is managed by the nurse.", [["respiratory", "ANATOMY", 77, 88], ["respiratory therapy", "TREATMENT", 77, 96], ["the ETT cuff pressure", "TREATMENT", 107, 128], ["few", "OBSERVATION_MODIFIER", 7, 10], ["large", "OBSERVATION_MODIFIER", 11, 16], ["pressure", "OBSERVATION_MODIFIER", 120, 128]]], ["Xiang et al. found that only 34.8% of nurses in a class III grade I hospital in Beijing used a manometer to assess cuff pressure scientifically [15].", [["cuff", "ANATOMY", 115, 119], ["a manometer", "TREATMENT", 93, 104], ["cuff pressure", "TEST", 115, 128]]], ["Fu et al. measured cuff pressure 812 times in 53 patients and found that 46.3% of pressure was not within the normal range [16].", [["cuff", "ANATOMY", 19, 23], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["cuff pressure", "TEST", 19, 32], ["pressure", "TEST", 82, 90], ["et al", "OBSERVATION", 3, 8], ["pressure", "OBSERVATION_MODIFIER", 24, 32]]], ["Therefore, it is necessary to improve the normative measurement of the ETT cuff pressure.", [["the ETT cuff pressure", "TEST", 67, 88], ["ETT cuff", "OBSERVATION", 71, 79], ["pressure", "OBSERVATION_MODIFIER", 80, 88]]], ["We studied the application of a mobile terminal application program in the execution of ETT cuff pressure measurement, which could ensure that only the manometer is allowed to assess cuff pressure, with the pressure measured at least three times a day, and provide convenient feedback to improve the execution of the normative measurement of the ETT cuff pressure.Study design and setting ::: MethodsThis prospective, experimental, before-after study that lasted for 18 months was undertaken in a 40-bed GICU of a class III grade I hospital in Zhejiang Province.", [["cuff", "ANATOMY", 92, 96], ["cuff", "ANATOMY", 183, 187], ["cuff", "MULTI-TISSUE_STRUCTURE", 183, 187], ["a mobile terminal application program", "TREATMENT", 30, 67], ["ETT cuff pressure measurement", "TEST", 88, 117], ["cuff pressure", "TEST", 183, 196], ["the pressure", "TEST", 203, 215], ["the ETT cuff pressure", "TEST", 342, 363], ["Methods", "TREATMENT", 393, 400], ["ETT cuff", "OBSERVATION", 88, 96], ["pressure", "OBSERVATION_MODIFIER", 97, 105], ["pressure", "OBSERVATION_MODIFIER", 188, 196], ["ETT cuff", "OBSERVATION", 346, 354], ["pressure", "OBSERVATION_MODIFIER", 355, 363]]], ["Training on cuff pressure measurement was provided according to the recommended method [1, 17] in July 2017 and followed by a 2-month wash-out period.", [["cuff", "ANATOMY", 12, 16], ["cuff", "MULTI-TISSUE_STRUCTURE", 12, 16], ["cuff pressure measurement", "TEST", 12, 37]]], ["Training on cuff pressure measurement methods applied by mobile terminal application program was provided in April 2018 and followed a 2-month wash-out period.", [["cuff", "ANATOMY", 12, 16], ["cuff", "MULTI-TISSUE_STRUCTURE", 12, 16], ["cuff pressure measurement methods", "TREATMENT", 12, 45]]], ["Cuff pressure was monitored and compared between baseline and intervention periods.", [["Cuff pressure", "TEST", 0, 13], ["intervention periods", "TREATMENT", 62, 82], ["pressure", "OBSERVATION_MODIFIER", 5, 13]]], ["All patients aged over 18 years who were receiving Mechanical Ventilation (MV) for 3\u201314 days with the endotracheal tube (COVIDIEN, size of ETT: 7.0\u20138.0) were included in the study.", [["endotracheal tube", "ANATOMY", 102, 119], ["patients", "ORGANISM", 4, 12], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 102, 119], ["patients", "SPECIES", 4, 12], ["MV", "SPECIES", 75, 77], ["Mechanical Ventilation", "TREATMENT", 51, 73], ["the endotracheal tube", "TREATMENT", 98, 119], ["ETT", "TEST", 139, 142], ["the study", "TEST", 170, 179], ["endotracheal tube", "OBSERVATION", 102, 119], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["We excluded patients receiving MV via a tracheostomy.The steps of ETT cuff pressure measurement ::: Interventions ::: MethodsThe researchers performed the following steps to measure cuff pressure in participants: (a) took the mobile terminal to the bedside of the patient, scanned the two-dimensional code of the patient's wrist band, and entered the interface for recording nursing operations of the current patient; (b) used the mobile terminal to scan the two-dimensional code on manometer and entered the interface for recording cuff pressure; (c) measured cuff pressure with the manometer; and (d) recorded the pressure before and after measurement on the interface of the mobile terminal.", [["cuff", "ANATOMY", 70, 74], ["cuff", "ANATOMY", 182, 186], ["wrist", "ANATOMY", 323, 328], ["cuff", "ANATOMY", 533, 537], ["cuff", "ANATOMY", 561, 565], ["patients", "ORGANISM", 12, 20], ["patient", "ORGANISM", 264, 271], ["patient", "ORGANISM", 313, 320], ["wrist", "ORGANISM_SUBDIVISION", 323, 328], ["patient", "ORGANISM", 409, 416], ["patients", "SPECIES", 12, 20], ["participants", "SPECIES", 199, 211], ["patient", "SPECIES", 264, 271], ["patient", "SPECIES", 313, 320], ["patient", "SPECIES", 409, 416], ["MV", "SPECIES", 31, 33], ["MV", "TREATMENT", 31, 33], ["a tracheostomy", "TREATMENT", 38, 52], ["ETT cuff pressure measurement", "TEST", 66, 95], ["Methods", "TREATMENT", 118, 125], ["cuff pressure", "TEST", 182, 195], ["the patient's wrist band", "TREATMENT", 309, 333], ["recording nursing operations", "TREATMENT", 365, 393], ["recording cuff pressure", "TEST", 523, 546], ["cuff pressure", "TEST", 561, 574], ["the pressure", "TEST", 612, 624], ["tracheostomy", "OBSERVATION", 40, 52], ["ETT cuff", "OBSERVATION", 66, 74], ["pressure", "OBSERVATION_MODIFIER", 75, 83], ["wrist", "ANATOMY", 323, 328], ["pressure", "OBSERVATION_MODIFIER", 538, 546], ["pressure", "OBSERVATION_MODIFIER", 566, 574], ["pressure", "OBSERVATION_MODIFIER", 616, 624], ["mobile", "OBSERVATION_MODIFIER", 678, 684], ["terminal", "OBSERVATION_MODIFIER", 685, 693]]], ["Note: when the cuff pressure was not measured and over 8 h had passed, the mobile terminal would display a message to remind the nurse to measure the pressure (Fig. 1).The mobile terminal application program has the function of ETT cuff pressure measurement feedback ::: Interventions ::: MethodsThe head nurse could glance at the cuff pressure measurement of each patient on the computer, including the frequency of cuff pressure measurement and the pressure value before and after each measurement.", [["cuff", "ANATOMY", 15, 19], ["cuff", "ANATOMY", 232, 236], ["head", "ANATOMY", 300, 304], ["cuff", "ANATOMY", 331, 335], ["cuff", "ANATOMY", 417, 421], ["cuff", "MULTI-TISSUE_STRUCTURE", 15, 19], ["head", "ORGAN", 300, 304], ["cuff", "TISSUE", 331, 335], ["patient", "ORGANISM", 365, 372], ["cuff", "MULTI-TISSUE_STRUCTURE", 417, 421], ["patient", "SPECIES", 365, 372], ["the cuff pressure", "TEST", 11, 28], ["The mobile terminal application program", "TREATMENT", 168, 207], ["ETT cuff pressure measurement", "TEST", 228, 257], ["Methods", "TREATMENT", 289, 296], ["the cuff pressure measurement", "TEST", 327, 356], ["cuff pressure measurement", "TEST", 417, 442], ["the pressure value", "TEST", 447, 465], ["each measurement", "TEST", 483, 499], ["ETT cuff", "OBSERVATION", 228, 236], ["head", "ANATOMY", 300, 304], ["cuff pressure", "OBSERVATION", 417, 430]]], ["In cases of failure to check the cuff pressure in accordance with the training method, the head nurse needed to determine the reason for this occurrence and try to resolve the issue.ETT cuff pressure measurement ::: MethodsCompared with intermittent measurement, a continuous ETT cuff pressure control system could better maintain the cuff pressure within the recommended range [18, 19].", [["cuff", "ANATOMY", 33, 37], ["head", "ANATOMY", 91, 95], ["cuff", "ANATOMY", 280, 284], ["cuff", "ANATOMY", 335, 339], ["head", "ORGANISM_SUBDIVISION", 91, 95], ["cuff", "ORGANISM_SUBDIVISION", 335, 339], ["failure", "PROBLEM", 12, 19], ["the cuff pressure", "TEST", 29, 46], ["the training method", "TREATMENT", 66, 85], ["ETT cuff pressure measurement", "TEST", 182, 211], ["intermittent measurement", "TEST", 237, 261], ["a continuous ETT cuff pressure control system", "TREATMENT", 263, 308], ["the cuff pressure", "TEST", 331, 348], ["failure", "OBSERVATION", 12, 19], ["pressure", "OBSERVATION_MODIFIER", 38, 46], ["cuff pressure", "OBSERVATION", 186, 199], ["cuff pressure", "OBSERVATION", 335, 348]]], ["However, we lack a continuous ETT cuff pressure control system, so we used the manometer to measure cuff pressure every 8 h and maintained the pressure at 30 cm H2O (the upper limit of the recommended range) for each cuff pressure measurement.ETT cuff pressure measurement ::: MethodsThe four nursing team leaders measured and recorded the cuff pressure once more at 14:00\u201316:00 every day during the baseline period and intervention period, and maintained cuff pressure at 30 cm H2O after measurement.", [["cuff", "ANATOMY", 100, 104], ["cuff", "ANATOMY", 217, 221], ["cuff", "ANATOMY", 340, 344], ["cuff", "ANATOMY", 456, 460], ["H2O", "CHEMICAL", 161, 164], ["H2O", "CHEMICAL", 479, 482], ["H2O", "CHEMICAL", 161, 164], ["H2O", "CHEMICAL", 479, 482], ["cuff", "ORGANISM_SUBDIVISION", 340, 344], ["cuff", "ORGANISM_SUBDIVISION", 456, 460], ["a continuous ETT cuff pressure control system", "TREATMENT", 17, 62], ["the manometer", "TREATMENT", 75, 88], ["cuff pressure", "TEST", 100, 113], ["the pressure", "TEST", 139, 151], ["each cuff pressure measurement", "TEST", 212, 242], ["ETT cuff pressure measurement", "TEST", 243, 272], ["Methods", "TREATMENT", 277, 284], ["the cuff pressure", "TEST", 336, 353], ["cuff pressure", "TEST", 456, 469], ["measurement", "TEST", 489, 500], ["pressure", "OBSERVATION_MODIFIER", 143, 151], ["upper limit", "OBSERVATION_MODIFIER", 170, 181], ["cuff pressure", "OBSERVATION", 217, 230], ["cuff pressure", "OBSERVATION", 247, 260], ["cuff", "ANATOMY", 340, 344], ["pressure", "OBSERVATION_MODIFIER", 345, 353], ["cuff pressure", "OBSERVATION", 456, 469]]], ["The nursing team leaders who were responsible for measuring the cuff pressure were blinded, as they were unaware of the study conditions.ETT cuff pressure measurement ::: MethodsBolzan et al. [20] showed that the cuff pressure drops by approximately 2 cm H2O (consistent with our monitoring results) when the manometer is connected to and disconnected from the cuff pressure valve during pressure checks.", [["cuff", "ANATOMY", 213, 217], ["cuff", "ANATOMY", 361, 365], ["H2O", "CHEMICAL", 255, 258], ["H2O", "CHEMICAL", 255, 258], ["cuff", "ORGANISM_SUBDIVISION", 213, 217], ["the cuff pressure", "TEST", 60, 77], ["the study conditions", "TEST", 116, 136], ["ETT cuff pressure measurement", "TEST", 137, 166], ["the cuff pressure", "TEST", 209, 226], ["the manometer", "TREATMENT", 305, 318], ["the cuff pressure valve", "TREATMENT", 357, 380], ["pressure checks", "TEST", 388, 403], ["cuff pressure", "OBSERVATION", 141, 154], ["pressure", "OBSERVATION_MODIFIER", 218, 226], ["cuff", "ANATOMY", 361, 365], ["pressure valve", "OBSERVATION", 366, 380], ["pressure", "OBSERVATION_MODIFIER", 388, 396]]], ["We also considered the loss of cuff pressure when the manometer was connected to and disconnected from the cuff pressure valve in our study.ETT cuff pressure measurement ::: MethodsThe manometer was a VBM (54-05-000) cuff pressure gauge that was made in Germany.Clinical criteria for VAP ::: MethodsClinical criteria for VAP include a new or persistent infiltration or progressive radiographic infiltrate in patients with mechanical ventilation for more than 48 h [21, 22], plus 2 or more of the following: (1) temperature > 38 \u00b0C; (2) purulent tracheal secretions; and (3) blood leukocyte count > 10 \u00d7 109/L or < 4 \u00d7 109/L [23].Variables recorded ::: MethodsThere were other factors contributing to abnormal cuff pressure, in addition to the method of cuff pressure measurement.", [["cuff", "ANATOMY", 31, 35], ["cuff", "ANATOMY", 107, 111], ["purulent tracheal secretions", "ANATOMY", 536, 564], ["blood leukocyte", "ANATOMY", 574, 589], ["cuff", "ANATOMY", 709, 713], ["cuff", "ANATOMY", 753, 757], ["VAP", "DISEASE", 284, 287], ["VAP", "DISEASE", 321, 324], ["cuff", "ORGANISM_SUBDIVISION", 31, 35], ["patients", "ORGANISM", 408, 416], ["blood", "ORGANISM_SUBSTANCE", 574, 579], ["leukocyte", "CELL", 580, 589], ["cuff", "MULTI-TISSUE_STRUCTURE", 709, 713], ["cuff", "ORGANISM_SUBDIVISION", 753, 757], ["patients", "SPECIES", 408, 416], ["the loss of cuff pressure", "PROBLEM", 19, 44], ["the manometer", "TREATMENT", 50, 63], ["the cuff pressure valve", "TREATMENT", 103, 126], ["our study", "TEST", 130, 139], ["ETT cuff pressure measurement", "TEST", 140, 169], ["Methods", "TREATMENT", 174, 181], ["The manometer", "TREATMENT", 181, 194], ["a VBM", "TREATMENT", 199, 204], ["cuff pressure gauge", "TREATMENT", 217, 236], ["VAP", "PROBLEM", 284, 287], ["VAP", "PROBLEM", 321, 324], ["a new or persistent infiltration", "PROBLEM", 333, 365], ["progressive radiographic infiltrate", "PROBLEM", 369, 404], ["mechanical ventilation", "TREATMENT", 422, 444], ["temperature", "TEST", 511, 522], ["purulent tracheal secretions", "PROBLEM", 536, 564], ["blood leukocyte count", "TEST", 574, 595], ["Methods", "TREATMENT", 652, 659], ["other factors", "PROBLEM", 670, 683], ["abnormal cuff pressure", "PROBLEM", 700, 722], ["cuff pressure measurement", "TEST", 753, 778], ["cuff pressure", "OBSERVATION", 31, 44], ["cuff", "OBSERVATION", 107, 111], ["pressure valve", "OBSERVATION", 112, 126], ["cuff pressure", "OBSERVATION", 144, 157], ["new", "OBSERVATION_MODIFIER", 335, 338], ["persistent", "OBSERVATION_MODIFIER", 342, 352], ["infiltration", "OBSERVATION", 353, 365], ["progressive", "OBSERVATION_MODIFIER", 369, 380], ["radiographic", "OBSERVATION_MODIFIER", 381, 393], ["infiltrate", "OBSERVATION", 394, 404], ["purulent", "OBSERVATION_MODIFIER", 536, 544], ["tracheal", "ANATOMY", 545, 553], ["secretions", "OBSERVATION", 554, 564], ["cuff pressure", "OBSERVATION", 709, 722], ["cuff pressure", "OBSERVATION", 753, 766]]], ["Nseir et al. [13] found that the risk factors for underinflation of the endotracheal cuff, including the absence of sedation and the duration of prior intubation by multivariate analysis, and no risk factors for the overinflation of the endotracheal cuff could be identified by univariate analysis.", [["endotracheal", "ANATOMY", 72, 84], ["endotracheal", "ANATOMY", 237, 249], ["endotracheal cuff", "MULTI-TISSUE_STRUCTURE", 72, 89], ["endotracheal cuff", "MULTI-TISSUE_STRUCTURE", 237, 254], ["the risk factors", "PROBLEM", 29, 45], ["underinflation of the endotracheal cuff", "PROBLEM", 50, 89], ["sedation", "TREATMENT", 116, 124], ["prior intubation", "TREATMENT", 145, 161], ["multivariate analysis", "TEST", 165, 186], ["risk factors", "PROBLEM", 195, 207], ["the overinflation of the endotracheal cuff", "PROBLEM", 212, 254], ["univariate analysis", "TEST", 278, 297], ["endotracheal cuff", "OBSERVATION", 72, 89], ["overinflation", "OBSERVATION", 216, 229], ["endotracheal cuff", "OBSERVATION", 237, 254]]], ["Therefore, we collected Richmond Agitation-Sedation Scale (RASS) scores [24] and information on the duration of prior intubation in addition to the cuff pressure of the baseline and intervention groups.", [["Richmond Agitation", "TREATMENT", 24, 42], ["Sedation Scale (RASS) scores", "TREATMENT", 43, 71], ["prior intubation", "TREATMENT", 112, 128], ["the cuff pressure", "TEST", 144, 161], ["intervention groups", "TREATMENT", 182, 201]]], ["Other data included gender, age, causes for ICU admission, size of ETT, and number of VAP patients.Sample size calculations ::: MethodsAccording to our pre-experiment, 55.2% of the cuff pressure was maintained within the recommended range in our GICU.", [["cuff", "ANATOMY", 181, 185], ["VAP", "DISEASE", 86, 89], ["patients", "ORGANISM", 90, 98], ["cuff", "MULTI-TISSUE_STRUCTURE", 181, 185], ["patients", "SPECIES", 90, 98], ["ETT", "TREATMENT", 67, 70], ["VAP patients", "TREATMENT", 86, 98], ["Sample size calculations", "TEST", 99, 123], ["the cuff pressure", "TEST", 177, 194], ["size", "OBSERVATION_MODIFIER", 59, 63], ["ETT", "OBSERVATION", 67, 70]]], ["It was assumed that the percentage of cuff pressure within the recommended range was increased by 10% after the intervention of the mobile terminal application program, which was considered to be effective.", [["cuff", "ANATOMY", 38, 42], ["cuff pressure", "TEST", 38, 51], ["the mobile terminal application program", "TREATMENT", 128, 167], ["cuff pressure", "OBSERVATION", 38, 51]]], ["Under the conditions of a 1:1 parallel design, a unilateral test, \u03b1 = 0.01, and power = 90%, the sample size during the study phase was at least 618, as calculated by Pass 11.", [["a unilateral test", "TEST", 47, 64], ["the sample size", "TEST", 93, 108], ["the study phase", "TEST", 116, 131], ["size", "OBSERVATION_MODIFIER", 104, 108]]], ["Because of operating errors or unpredictable factors, the sample size was expanded by 20%, and the final sample size at each study phase was 742.Statistical analysis ::: MethodsStatistical analyses were performed using SPSS 16.0.", [["operating errors", "PROBLEM", 11, 27], ["unpredictable factors", "PROBLEM", 31, 52], ["the sample size", "TEST", 54, 69], ["MethodsStatistical analyses", "TEST", 170, 197], ["SPSS", "TEST", 219, 223], ["unpredictable", "OBSERVATION_MODIFIER", 31, 44], ["size", "OBSERVATION_MODIFIER", 65, 69], ["size", "OBSERVATION_MODIFIER", 112, 116]]], ["Measurement data showing normal distributions were expressed as the mean \u00b1 standard deviation, and comparisons before and after interventions were performed using the t test.", [["Measurement data", "TEST", 0, 16], ["interventions", "TREATMENT", 128, 141], ["the t test", "TEST", 163, 173], ["normal", "OBSERVATION", 25, 31]]], ["Classification data were expressed as a percentage of the positive samples/total samples in one study period (%) and compared using the \u03c72 test.", [["samples", "ANATOMY", 67, 74], ["samples", "ANATOMY", 81, 88], ["Classification data", "TEST", 0, 19], ["the \u03c72 test", "TEST", 132, 143]]], ["All tests were 2-tailed.", [["All tests", "TEST", 0, 9]]], ["P < 0 0.05 was considered statistically significant.ResultsA total of 73 patients with mechanical ventilation support were monitored in the baseline group, and 102 patients were monitored in the intervention group.", [["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 164, 172], ["mechanical ventilation support", "TREATMENT", 87, 117]]], ["ETT cuff pressure was monitored 742 times in both the baseline group and the intervention group.ResultsThere was no statistical significance (P > 0.05) between the baseline group and the intervention group in terms of gender, age, basic disease, RASS score, duration of prior intubation and size of ETT (P > 0.05), and the detailed data are shown in Table 1.ResultsA total of 56.9% of cuff pressure measurements in the baseline group were within the recommended range, while 78.4% of measurements in the intervention group were within the recommended range, reflecting a statistically significant difference (P < 0.05).ResultsThe incidence of VAP was 13.7% in the baseline group and 11.9% in the intervention group.", [["cuff", "ANATOMY", 385, 389], ["VAP", "DISEASE", 643, 646], ["cuff", "MULTI-TISSUE_STRUCTURE", 385, 389], ["ETT cuff pressure", "TEST", 0, 17], ["the intervention group", "TREATMENT", 73, 95], ["P", "TEST", 142, 143], ["basic disease", "PROBLEM", 231, 244], ["RASS score", "TEST", 246, 256], ["prior intubation", "TREATMENT", 270, 286], ["ETT", "TEST", 299, 302], ["the detailed data", "TEST", 319, 336], ["ResultsA", "TEST", 358, 366], ["cuff pressure measurements", "TEST", 385, 411], ["VAP", "TEST", 643, 646], ["cuff pressure", "OBSERVATION", 4, 17], ["no", "UNCERTAINTY", 113, 115], ["size", "OBSERVATION_MODIFIER", 291, 295], ["pressure", "OBSERVATION_MODIFIER", 390, 398], ["significant", "OBSERVATION_MODIFIER", 585, 596], ["difference", "OBSERVATION_MODIFIER", 597, 607], ["VAP", "OBSERVATION", 643, 646]]], ["There was no significant difference between the two groups (P > 0.05), and the detailed data are shown in Table 1.DiscussionMaintaining cuff pressure in the recommended range can reduce related complications [1\u20139].", [["cuff", "ANATOMY", 136, 140], ["cuff", "MULTI-TISSUE_STRUCTURE", 136, 140], ["the detailed data", "TEST", 75, 92], ["cuff pressure", "TEST", 136, 149], ["related complications", "PROBLEM", 186, 207], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["cuff pressure", "OBSERVATION", 136, 149]]], ["However, it is common to use unscientific methods to assess cuff pressure in clinical practice [10\u201312, 15], and pressure cannot be maintained within the recommended range [13, 16].", [["cuff", "ANATOMY", 60, 64], ["cuff", "MULTI-TISSUE_STRUCTURE", 60, 64], ["unscientific methods", "TREATMENT", 29, 49], ["cuff pressure", "TEST", 60, 73], ["pressure", "TEST", 112, 120]]], ["In addition to the lack of training in cuff pressure measurement, these issues may be related to the following conditions.", [["cuff", "ANATOMY", 39, 43], ["cuff", "MULTI-TISSUE_STRUCTURE", 39, 43], ["cuff pressure measurement", "TEST", 39, 64], ["cuff pressure", "OBSERVATION", 39, 52]]], ["First, nurses may not use a manometer: The ratio of nurses to the number of beds as low as 1.91, which increases the nursing workload in the GICU of class III grade I hospitals in East China [25], and thus, nurses would use the pilot balloon palpation method to assess pressure because it saves more time.", [["the pilot balloon palpation method", "TREATMENT", 224, 258]]], ["However, the pilot balloon palpation method is less reliable in assessing pressure [10, 26].", [["the pilot balloon palpation method", "TREATMENT", 9, 43]]], ["Second, the head nurse could not obtain feedback information that the nurse measured cuff pressure using a method that was not recommended.DiscussionThe percentage of cuff pressure measurements falling within the recommended range increased from 56.9 to 78.4% in our study.", [["head", "ANATOMY", 12, 16], ["cuff", "ANATOMY", 85, 89], ["cuff", "ANATOMY", 167, 171], ["head", "ORGANISM_SUBDIVISION", 12, 16], ["cuff", "ORGANISM_SUBDIVISION", 85, 89], ["cuff", "MULTI-TISSUE_STRUCTURE", 167, 171], ["cuff pressure", "TEST", 85, 98], ["a method", "TREATMENT", 105, 113], ["cuff pressure measurements", "TEST", 167, 193], ["our study", "TEST", 263, 272], ["head", "ANATOMY", 12, 16], ["cuff pressure", "OBSERVATION", 167, 180]]], ["The main principles are as follows: (1) The use of the manometer must be ensured: after the intervention, the cuff pressure measurement required the mobile terminal to scan the two-dimensional code of the patient's wrist band and the two-dimensional code of the manometer, so the manometer must be used for the cuff pressure measurement; (2) The frequency of cuff pressure measurement was properly implemented: when the cuff pressure was not measured and over 8 h had passed, the mobile terminal would display a message to remind the nurse to measure the pressure; and (3) A convenient feedback channel must be provided: Step d required that the pressure values before and after measurement be recorded in the mobile terminal.", [["cuff", "ANATOMY", 110, 114], ["cuff", "ANATOMY", 311, 315], ["cuff", "ANATOMY", 359, 363], ["cuff", "ANATOMY", 420, 424], ["cuff", "MULTI-TISSUE_STRUCTURE", 110, 114], ["patient", "ORGANISM", 205, 212], ["wrist", "ORGANISM_SUBDIVISION", 215, 220], ["cuff", "ORGANISM_SUBDIVISION", 311, 315], ["cuff", "MULTI-TISSUE_STRUCTURE", 359, 363], ["cuff", "MULTI-TISSUE_STRUCTURE", 420, 424], ["patient", "SPECIES", 205, 212], ["the manometer", "TREATMENT", 51, 64], ["the intervention", "TREATMENT", 88, 104], ["the cuff pressure measurement", "TEST", 106, 135], ["the patient's wrist band", "TREATMENT", 201, 225], ["the manometer", "TREATMENT", 258, 271], ["the manometer", "TREATMENT", 276, 289], ["the cuff pressure measurement", "TEST", 307, 336], ["cuff pressure measurement", "TEST", 359, 384], ["the cuff pressure", "TEST", 416, 433], ["A convenient feedback channel", "TREATMENT", 573, 602], ["the pressure values", "TEST", 642, 661], ["main", "OBSERVATION_MODIFIER", 4, 8], ["wrist", "ANATOMY", 215, 220], ["cuff pressure", "OBSERVATION", 359, 372]]], ["The head nurse could glance at the cuff pressure measurement of each patient on the computer, including the frequency of cuff pressure measurement and the pressure values before and after measurement, which were used to supervise nurses and urge them to check cuff pressure using the recommended method.DiscussionThe maintenance of ETT cuff pressures within the recommended range could reduce the risk of the aspiration of subglottic secretions past the cuff and reduce the incidence of VAP.", [["head", "ANATOMY", 4, 8], ["cuff", "ANATOMY", 35, 39], ["cuff", "ANATOMY", 121, 125], ["cuff", "ANATOMY", 260, 264], ["cuff", "ANATOMY", 336, 340], ["subglottic secretions", "ANATOMY", 423, 444], ["VAP", "DISEASE", 487, 490], ["head", "ORGANISM_SUBDIVISION", 4, 8], ["cuff", "TISSUE", 35, 39], ["patient", "ORGANISM", 69, 76], ["cuff", "MULTI-TISSUE_STRUCTURE", 121, 125], ["cuff", "MULTI-TISSUE_STRUCTURE", 260, 264], ["subglottic secretions", "ORGANISM_SUBDIVISION", 423, 444], ["patient", "SPECIES", 69, 76], ["the cuff pressure measurement", "TEST", 31, 60], ["cuff pressure measurement", "TEST", 121, 146], ["the pressure values", "TEST", 151, 170], ["cuff pressure", "TEST", 260, 273], ["ETT cuff pressures", "TREATMENT", 332, 350], ["subglottic secretions", "PROBLEM", 423, 444], ["the cuff", "TREATMENT", 450, 458], ["VAP", "PROBLEM", 487, 490], ["head", "ANATOMY", 4, 8], ["cuff pressure", "OBSERVATION", 121, 134], ["ETT cuff", "OBSERVATION", 332, 340], ["pressures", "OBSERVATION_MODIFIER", 341, 350], ["aspiration", "OBSERVATION", 409, 419], ["subglottic", "ANATOMY", 423, 433], ["secretions", "OBSERVATION", 434, 444], ["cuff", "ANATOMY", 454, 458], ["VAP", "OBSERVATION", 487, 490]]], ["After the intervention, the incidence of VAP decreased, but there was no statistical significance (P > 0.05) between the baseline group and the intervention group.", [["VAP", "DISEASE", 41, 44], ["the intervention", "TREATMENT", 6, 22], ["VAP", "PROBLEM", 41, 44], ["P", "TEST", 99, 100], ["the intervention group", "TREATMENT", 140, 162], ["VAP", "OBSERVATION", 41, 44], ["no", "UNCERTAINTY", 70, 72]]], ["The main reason may be that the sample size of the study was not large enough (73 cases in the baseline group and 102 cases in the intervention group).", [["the study", "TEST", 47, 56], ["main reason may be", "UNCERTAINTY", 4, 22], ["size", "OBSERVATION_MODIFIER", 39, 43], ["large", "OBSERVATION_MODIFIER", 65, 70]]], ["If the sample size is increased, the incidence of VAP may be statistically significant.", [["VAP", "DISEASE", 50, 53], ["the sample size", "TEST", 3, 18], ["VAP", "PROBLEM", 50, 53], ["size", "OBSERVATION_MODIFIER", 14, 18], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["VAP", "OBSERVATION", 50, 53]]], ["And VAP can be reduced by some measures, such as novel multi-modal hand hygiene system [27], endotracheal tube with polyurethane cuff and subglottic secretion drainage [28], semirecumbent position (45-degree) [29], and duodenal versus gastric feeding [30].", [["hand", "ANATOMY", 67, 71], ["subglottic", "ANATOMY", 138, 148], ["duodenal", "ANATOMY", 219, 227], ["gastric", "ANATOMY", 235, 242], ["VAP", "DISEASE", 4, 7], ["polyurethane", "CHEMICAL", 116, 128], ["hand", "ORGANISM_SUBDIVISION", 67, 71], ["tube", "TISSUE", 106, 110], ["duodenal", "MULTI-TISSUE_STRUCTURE", 219, 227], ["gastric", "ORGAN", 235, 242], ["VAP", "TREATMENT", 4, 7], ["endotracheal tube", "TREATMENT", 93, 110], ["polyurethane cuff", "TREATMENT", 116, 133], ["subglottic secretion drainage", "TREATMENT", 138, 167], ["duodenal versus gastric feeding", "TREATMENT", 219, 250], ["VAP", "OBSERVATION", 4, 7], ["endotracheal tube", "OBSERVATION", 93, 110], ["polyurethane cuff", "OBSERVATION", 116, 133], ["subglottic", "ANATOMY", 138, 148], ["duodenal", "ANATOMY", 219, 227], ["gastric", "ANATOMY", 235, 242]]], ["However, the intervention measures in this study did not include these factors.DiscussionThere were still some shortcomings in this study: we could not collect and analyse all the factors that might affect the cuff pressure.", [["cuff", "ANATOMY", 210, 214], ["cuff", "ORGANISM_SUBDIVISION", 210, 214], ["this study", "TEST", 38, 48], ["this study", "TEST", 127, 137], ["the cuff pressure", "TEST", 206, 223], ["cuff pressure", "OBSERVATION", 210, 223]]], ["Further research is needed to determine whether the use of a mobile terminal application program for ETT cuff pressure measurement can significantly reduce the incidence of VAP.ConclusionThe application of the mobile terminal application program used for ETT cuff pressure measurement could improve the percentage of ETT cuff pressure measurements that fall within the recommended range.", [["cuff", "ANATOMY", 259, 263], ["cuff", "ANATOMY", 321, 325], ["VAP", "DISEASE", 173, 176], ["a mobile terminal application program", "TREATMENT", 59, 96], ["ETT cuff pressure measurement", "TEST", 101, 130], ["VAP", "PROBLEM", 173, 176], ["the mobile terminal application program", "TREATMENT", 206, 245], ["ETT cuff pressure measurement", "TEST", 255, 284], ["ETT cuff pressure measurements", "TEST", 317, 347], ["VAP", "OBSERVATION", 173, 176], ["ETT cuff", "OBSERVATION", 317, 325], ["pressure", "OBSERVATION_MODIFIER", 326, 334]]]], "337ca8723ce671a352029a6534a00bd125a54adf": [["Ocrelizumab zur Behandlung der Multiplen SkleroseHintergrund Die Multiple Sklerose (MS) ist mit weltweit ca.", [["Ocrelizumab zur Behandlung", "TREATMENT", 0, 26], ["Multiple Sklerose (MS) ist mit weltweit ca", "TREATMENT", 65, 107]]], ["Betroffenen die h\u00e4ufigste immunvermittelte, chronisch-entz\u00fcndliche Erkrankung des zentralen Nervensystems (ZNS).", [["Betroffenen", "TREATMENT", 0, 11], ["entz\u00fcndliche Erkrankung des zentralen Nervensystems", "TREATMENT", 54, 105]]], ["Der Krankheitsverlauf ist entweder schubf\u00f6rmig (RMS) -mehrheitlich im Verlauf mit \u00dcbergang in die sekund\u00e4r progrediente Form (SPMS) oder prim\u00e4r progredient [1] .", [["SPMS", "DISEASE", 126, 130], ["mehrheitlich im Verlauf mit \u00dcbergang", "TREATMENT", 54, 90]]], ["Trotz jahrzehntelanger Forschung sind die eigentlichen Ursachen der Erkrankung nicht gekl\u00e4rt.", [["Trotz", "TREATMENT", 0, 5]]], ["Derzeitigen Hypothesen zufolge handelt es sich um eine komplexe Genese, zu der sowohl genetische als auch immunologische und umweltbedingte Faktoren beitragen.", [["Derzeitigen", "TREATMENT", 0, 11]]], ["In den letzten zwei bis drei Dekaden gab es jedoch eine erfreuliche Entwicklung zahlreicher immunmodulatorischer Therapieoptionen [1] [2] [3] .", [["Dekaden gab es jedoch eine erfreuliche", "TREATMENT", 29, 67]]], ["Mechanistisch neuartig ist die Depletion von CD20-positiven Zellen, ein Therapieprinzip, das sich bei anderen Autoimmunerkrankungen in Form von Rituximab bereits l\u00e4nger bew\u00e4hrt hat [4, 5] .", [["CD20", "PROTEIN", 45, 49], ["Mechanistisch neuartig ist die Depletion", "TREATMENT", 0, 40], ["CD20", "TEST", 45, 49]]], ["Das CD20-Molek\u00fcl ist ein Mitglied der \"membrane spanning 4A family\" und wird vom MS4A1-Gen auf Chromosom 11 kodiert [6] .", [["CD20", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD20", "PROTEIN", 4, 8], ["MS4A1", "TEST", 81, 86]]], ["Mittels CD20-Depletion konnte nicht nur der schubf\u00f6rmige (RMS bzw.", [["CD20", "GENE_OR_GENE_PRODUCT", 8, 12], ["CD20", "PROTEIN", 8, 12], ["Mittels CD20", "TREATMENT", 0, 12]]], ["RRMS), sondern erstmals auch der prim\u00e4r chronischprogrediente Krankheitsverlauf (PPMS) positiv beeinflusst werden. .", [["RRMS", "DISEASE", 0, 4], ["RRMS", "PROBLEM", 0, 4]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["1 veranschaulicht die Entwicklungsstadien der B-Zell-Linie, die von einer gegen das CD20-Differenzierungsantigen gerichteten Therapie betroffen sind (adaptiert aus [7] ).", [["Entwicklungsstadien der B-Zell-Linie, die von einer gegen das CD20-Differenzierungsantigen gerichteten Therapie betroffen sind", "SPECIES", 22, 148], ["CD20", "TEST", 84, 88]]], ["B. der oral applizierte Bruton-Tyrosin-Kinase-Hemmer Evobrutinib [9] NCT04032158 und die monoklonalen Antik\u00f6rper Ofatumumab [10] NCT02792218 bzw.", [["Evobrutinib", "PROBLEM", 53, 64]]], ["NCT02792231, Ublituximab NCT03277261 bzw.", [["Ublituximab", "TEST", 13, 24]]], ["Die Ergebnisse der Ofatumumab-Zulassungsstudien wurden 2019 auf dem ECTRIMS-Kongress pr\u00e4sentiert.", [["Die Ergebnisse der Ofatumumab-Zulassungsstudien wurden 2019 auf dem ECTRIMS-Kongress pr\u00e4sentiert", "SPECIES", 0, 96]]], ["Ofatumumab f\u00fchrte zu einer relativen Risikoreduktion von 50,5 % (ASCLEPIOS I) bzw.", [["Ofatumumab f\u00fchrte zu einer relativen Risikoreduktion von 50,5", "SPECIES", 0, 61], ["Ofatumumab", "TREATMENT", 0, 10]]], ["58,5 % (ASCLEPIOS II) der auf ein Jahr umgerechneten Schubrate im Vergleich zu Teriflunomid [11] .", [["% (ASCLEPIOS II) der auf ein Jahr umgerechneten", "TREATMENT", 5, 52]]], ["Die Substanz wurde gut vertragen.Ocrelizumab zur Behandlung der Multiplen SkleroseInteressanterweise f\u00fchren niedrig dosierte intrathekale Gaben von Rituximab zu einer kompletten CD20-Depletion im peripheren Blut [12] , jedoch zu keiner vollst\u00e4ndigen CD20-Depletion im ZNS [13] .", [["Ocrelizumab", "CHEMICAL", 33, 44], ["CD20", "GENE_OR_GENE_PRODUCT", 250, 254], ["CD20", "PROTEIN", 178, 182], ["CD20", "PROTEIN", 250, 254], ["Ocrelizumab zur Behandlung der Multiplen Sklerose", "SPECIES", 33, 82], ["Interessanterweise f\u00fchren niedrig dosierte intrathekale Gaben von Rituximab zu einer kompletten CD20-Depletion im peripheren", "SPECIES", 82, 206], ["Interessanterweise f\u00fchren niedrig dosierte intrathekale", "TREATMENT", 82, 137], ["von Rituximab zu einer kompletten CD20", "TREATMENT", 144, 182], ["Depletion im peripheren Blut", "TREATMENT", 183, 211], ["jedoch zu keiner vollst\u00e4ndigen CD20-Depletion im ZNS", "TREATMENT", 219, 271]]], ["Diese therapeutischen Entwicklungen haben dazu beigetragen, unsere Konzepte der pathophysiologischen Rolle der Immunzellen in der MS wesentlich zu wandeln [14] .Ocrelizumab zur Behandlung der Multiplen SkleroseAktuell geht man davon aus, dass B-Zellen -und nicht mehr ausschlie\u00dflich oder dominant T-Zellen -eine zentrale Bedeutung in der MS zukommt (.", [["man", "SPECIES", 223, 226], ["Ocrelizumab zur Behandlung der Multiplen SkleroseAktuell geht man davon aus, dass B-Zellen -und nicht mehr ausschlie\u00dflich oder dominant T-Zellen -eine zentrale Bedeutung in der MS zukommt", "SPECIES", 161, 348], ["Diese therapeutischen", "TREATMENT", 0, 21]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Tab.", [["Tab", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["1 fasst die Rolle von B-Zellen in der Pathophysiologie der MS zusammen.Rituximab bei RRMS und PPMS: Fallberichte und -serienDie ersten Berichte \u00fcber den Einsatz von CD20-Depletion bei Patienten mit Multipler Sklerose stammen aus den Jahren 2005 und 2006.", [["Rituximab", "CHEMICAL", 71, 80], ["PPMS", "DISEASE", 94, 98], ["Fallberichte und -serienDie ersten Berichte \u00fcber den Einsatz von CD20-Depletion bei Patienten mit Multipler Sklerose stammen aus den Jahren 2005 und 2006", "SPECIES", 100, 253], ["Rituximab bei RRMS", "TREATMENT", 71, 89], ["Fallberichte und -serienDie ersten", "TREATMENT", 100, 134]]], ["In einer ersten Fallserie von PPMS-Patienten wurde zun\u00e4chst das B-Zell-Muster sowohl im peripheren Blut als auch im Liquor vor und nach Gabe von Rituximab untersucht.", [["einer ersten Fallserie von PPMS-Patienten wurde zun\u00e4chst das B-Zell-Muster sowohl im peripheren Blut als auch im Liquor vor und nach Gabe von Rituximab untersucht", "SPECIES", 3, 165], ["Muster sowohl", "TREATMENT", 71, 84], ["Rituximab untersucht", "TREATMENT", 145, 165]]], ["Erwartungsgem\u00e4\u00df depletierte Rituximab B-Zellen im peripheren Blut rasch, effektiv und l\u00e4ngerfristig, die Wirkung auf B-Zellen im Liquor war jedoch gering ausgepr\u00e4gt.", [["Erwartungsgem\u00e4\u00df depletierte Rituximab B-Zellen im peripheren Blut rasch, effektiv und l\u00e4ngerfristig, die Wirkung auf B-Zellen im Liquor war jedoch gering ausgepr\u00e4gt", "SPECIES", 0, 164], ["Erwartungsgem\u00e4\u00df", "TREATMENT", 0, 15], ["Rituximab B", "TREATMENT", 28, 39], ["Zellen im peripheren Blut rasch", "TREATMENT", 40, 71]]], ["Auch konnte gezeigt werden, dass die Kinetik der B-Zell-Repopulation individuell bei Patienten deutlich schwanken kann [15] .", [["Auch konnte gezeigt werden, dass die Kinetik der B-Zell-Repopulation individuell bei Patienten deutlich schwanken kann", "SPECIES", 0, 118]]], ["Diese Ergebnisse stehen teilweise im Widerspruch zu einer weiteren Fallserie, bei der Rituximab als Zusatztherapie bei RRMS-Patienten verabreicht wurde: Bei diesen Patienten zeigte sich ein Abfall von sowohl B-als auch T-Lymphozyten im Liquor [16] .", [["Diese Ergebnisse stehen teilweise im Widerspruch zu einer weiteren Fallserie, bei der Rituximab als Zusatztherapie bei RRMS-Patienten verabreicht wurde: Bei diesen Patienten zeigte sich ein Abfall von sowohl B-als auch T-Lymphozyten im Liquor [16", "SPECIES", 0, 246], ["bei der Rituximab als Zusatztherapie bei RRMS", "TREATMENT", 78, 123], ["Patienten verabreicht wurde", "TREATMENT", 124, 151]]], ["Bei einem anderen RRMS-Patienten mit fulminantem T T T T T T T T T T T T T T T T T T T T T T T T T T T T T reg g Anti-inflammatorische Makrophage T H H 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 17 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 T T T T T T T T T T T T T T T T T T T T T T T T T T H 1 1 Eine j\u00fcngst ver\u00f6ffentlichte Post-hoc-Analyse belegte eine best\u00e4tigte Verbesserung der Armfunktion, erfasst in 12w\u00f6chigen Abst\u00e4nden mit dem 9 Hole Peg Test (9HPT).", [["T T T T T T T T T T T T T T T T T T T T T T T T T", "CELL_TYPE", 281, 330], ["Bei einem anderen RRMS-Patienten mit fulminantem", "SPECIES", 0, 48], ["RRMS", "TEST", 18, 22], ["T", "TEST", 57, 58], ["T", "TEST", 59, 60], ["T", "TEST", 61, 62], ["T", "TEST", 63, 64], ["T", "TEST", 65, 66], ["T", "TEST", 67, 68], ["T", "TEST", 69, 70], ["T", "TEST", 71, 72], ["T", "TEST", 73, 74], ["T", "TEST", 75, 76], ["T", "TEST", 77, 78], ["T", "TEST", 79, 80], ["T", "TEST", 81, 82], ["T", "TEST", 83, 84], ["T", "TEST", 85, 86], ["T", "TEST", 87, 88], ["T", "TEST", 89, 90], ["T", "TEST", 91, 92], ["T", "TEST", 93, 94], ["T", "TEST", 95, 96], ["T", "TEST", 97, 98], ["T", "TEST", 99, 100], ["T", "TEST", 101, 102], ["T", "TEST", 103, 104], ["T", "TEST", 105, 106], ["reg", "TEST", 107, 110], ["Anti-inflammatorische", "TEST", 113, 134], ["Makrophage", "TEST", 135, 145], ["T H H", "TEST", 146, 151], ["T", "TEST", 283, 284], ["T", "TEST", 285, 286], ["T", "TEST", 287, 288], ["T", "TEST", 289, 290], ["T", "TEST", 291, 292], ["T", "TEST", 293, 294], ["T", "TEST", 295, 296], ["T", "TEST", 297, 298], ["T", "TEST", 299, 300], ["T", "TEST", 301, 302], ["T", "TEST", 303, 304], ["T", "TEST", 305, 306], ["T", "TEST", 307, 308], ["T", "TEST", 309, 310], ["T", "TEST", 311, 312], ["T", "TEST", 313, 314], ["T", "TEST", 315, 316], ["T", "TEST", 317, 318], ["T", "TEST", 319, 320], ["T", "TEST", 321, 322], ["T", "TEST", 323, 324], ["T", "TEST", 325, 326], ["T", "TEST", 327, 328], ["T", "TEST", 329, 330], ["T", "TEST", 331, 332], ["H", "TEST", 333, 334], ["ver\u00f6ffentlichte", "TEST", 351, 366], ["hoc", "TEST", 372, 375]]], ["In der Intention-to-treat-Analyse war auch der Anteil von Patienten mit best\u00e4tigter Verschlechterung im 9HPT geringer in der Ocrelizumabbehandelten Gruppe [27] .Rituximab bei RRMS und PPMS: Fallberichte und -serienIn einer k\u00fcrzlich ver\u00f6ffentlichen Analyse der Krankheitsprogression in den OPERA-Studien, zeigt sich, dass in der gesamten RMS-Population der gr\u00f6\u00dfte Anteil der erworben Behinderung schubunabh\u00e4ngig erfolgt [28] .Rituximab bei RRMS und PPMS: Fallberichte und -serienIn der 120-w\u00f6chigen PPMS-Studie ORATORIO erreichte Ocrelizumab sowohl den prim\u00e4ren Endpunkt (Reduktion des Risikos einer nach 12 Wochen best\u00e4tigten Behinderungsprogression) als auch die sekund\u00e4ren Endpunkte.", [["Rituximab", "CHEMICAL", 161, 170], ["PPMS", "DISEASE", 184, 188], ["Rituximab", "CHEMICAL", 425, 434], ["PPMS", "DISEASE", 448, 452], ["Fallberichte und -serienIn der 120-w\u00f6chigen PPMS-Studie ORATORIO erreichte Ocrelizumab sowohl den prim\u00e4ren Endpunkt (Reduktion des Risikos einer nach 12 Wochen best\u00e4tigten Behinderungsprogression) als auch die sekund\u00e4ren", "SPECIES", 454, 674], ["Rituximab", "TREATMENT", 161, 170], ["Fallberichte", "TEST", 190, 202], ["Rituximab", "TREATMENT", 425, 434], ["Fallberichte", "TEST", 454, 466], ["PPMS", "TEST", 498, 502], ["Studie", "TEST", 503, 509], ["ORATORIO", "TEST", 510, 518]]], ["Der Anteil der Patienten mit best\u00e4tigter Krankheitsprogression im EDSS-Score nach 12 Wochen war gegen\u00fcber Placebo um 24 % reduziert.", [["Der Anteil der Patienten mit best\u00e4tigter Krankheitsprogression im EDSS-Score nach 12 Wochen war gegen\u00fcber Placebo um 24 % reduziert", "SPECIES", 0, 131]]], ["Subanalysen der Handfunktion (9HPT) und Gehf\u00e4higkeit (T25FW) best\u00e4tigten die \u00dcberlegenheit von Ocrelizumab in diesen Teilbereichen der motorischen Funktion [26] .Rituximab bei RRMS und PPMS: Fallberichte und -serienEs ist zu erw\u00e4hnen, dass in der PPMS-Studie nur Patienten eingeschlossen wurden, die eine relativ kurze Erkrankungsdauer -definiert \u00fcber Alter (18 bis 55 Jahre) und Erkrankungsdauer (Symptomdauer <15 Jahre bei Patienten mit einem EDSS-Wert von >5,0 oder <10 Jahre bei Patienten mit einem EDSS von <5,0 zum Zeitpunkt des Screenings) -hatten.Rituximab bei RRMS und PPMS: Fallberichte und -serienDas Volumen von T2-Hirnl\u00e4sionen nahm in der Ocrelizumab-Gruppe um 3,4 % ab, w\u00e4hrend es unter Placebo um 7,4 % anstieg.", [["Rituximab", "CHEMICAL", 162, 171], ["PPMS", "DISEASE", 185, 189], ["Rituximab", "CHEMICAL", 555, 564], ["PPMS", "DISEASE", 578, 582], ["Fallberichte und -serienEs ist zu erw\u00e4hnen, dass in der PPMS-Studie nur Patienten eingeschlossen wurden, die eine relativ kurze Erkrankungsdauer -definiert \u00fcber Alter (18 bis 55 Jahre) und Erkrankungsdauer (Symptomdauer <15 Jahre bei Patienten mit einem EDSS-Wert von >5,0 oder <10 Jahre bei Patienten mit einem EDSS von <5,0 zum", "SPECIES", 191, 520], ["Fallberichte und -serienDas Volumen von T2-Hirnl\u00e4sionen nahm in der Ocrelizumab-Gruppe um 3,4 % ab, w\u00e4hrend es unter Placebo um 7,4 % anstieg", "SPECIES", 584, 725], ["Rituximab", "TREATMENT", 162, 171], ["Erkrankungsdauer", "TEST", 319, 335], ["Symptomdauer", "TEST", 398, 410], ["EDSS", "TEST", 445, 449], ["Rituximab", "TREATMENT", 555, 564], ["PPMS", "TEST", 578, 582], ["Fallberichte", "TEST", 584, 596], ["Hirnl\u00e4sionen nahm", "TREATMENT", 627, 644], ["Placebo um", "TREATMENT", 701, 711]]], ["Die Anzahl neuer T2-L\u00e4sionen war unter Ocrelizumab gegen\u00fcber Placebo um 92 % reduziert [26] .", [["Die Anzahl neuer T2-L\u00e4sionen war unter Ocrelizumab gegen\u00fcber Placebo um 92", "SPECIES", 0, 74]]], ["Subgruppenanalysen zufolge war das Ansprechen auf Ocrelizumab nicht von der Pr\u00e4senz gadoliniumaufnehmender L\u00e4sionen zu Beginn der Studie abh\u00e4ngig [26] .Rituximab bei RRMS und PPMS: Fallberichte und -serienBei Neuromyelitis-optica-Spektrumerkrankungen (NMOSD), einer Gruppe schubf\u00f6rmig verlaufender chronischentz\u00fcndlicher ZNS-Erkrankungen mit pathognomonischer Astrozytopathie, konnte gezeigt werden, dass eine B-Zell-Repopulation mit einem Anstieg der Schubrate assoziiert ist [29] .", [["Rituximab", "CHEMICAL", 152, 161], ["PPMS", "DISEASE", 175, 179], ["Neuromyelitis-optica-Spektrumerkrankungen", "DISEASE", 209, 250], ["Subgruppenanalysen zufolge war das Ansprechen auf Ocrelizumab nicht von der Pr\u00e4senz gadoliniumaufnehmender L\u00e4sionen zu Beginn der Studie abh\u00e4ngig", "SPECIES", 0, 145], ["Fallberichte und -serienBei Neuromyelitis-optica-Spektrumerkrankungen (NMOSD), einer Gruppe schubf\u00f6rmig verlaufender chronischentz\u00fcndlicher ZNS-Erkrankungen mit pathognomonischer Astrozytopathie, konnte gezeigt werden, dass eine B-Zell-Repopulation mit einem Anstieg der Schubrate assoziiert", "SPECIES", 181, 472], ["Subgruppenanalysen zufolge war das", "TREATMENT", 0, 34], ["Rituximab", "TREATMENT", 152, 161], ["PPMS", "TEST", 175, 179], ["Fallberichte", "TEST", 181, 193], ["Neuromyelitis", "PROBLEM", 209, 222], ["optica", "TEST", 223, 229], ["ZNS", "TEST", 321, 324], ["Erkrankungen mit pathognomonischer Astrozytopathie", "TREATMENT", 325, 375]]], ["Inwiefern sich dieser Zusammenhang auf die RMS \u00fcbertragen l\u00e4sst, ist bislang allerdings unklar.Rituximab bei RRMS und PPMS: Fallberichte und -serienIn den Zulassungsstudien kam es bei 20,7 % der RMS-Patienten und bei 26,3 % der PPMS-Patienten zu einem Abfall der absoluten Lymphozyten unterhalb des unteren Normalwertes [30] .", [["Rituximab", "CHEMICAL", 95, 104], ["PPMS", "DISEASE", 118, 122], ["Fallberichte und -serienIn den Zulassungsstudien kam es bei 20,7 % der RMS-Patienten und bei 26,3 % der PPMS-Patienten zu einem Abfall der absoluten Lymphozyten unterhalb des unteren", "SPECIES", 124, 306], ["Rituximab", "TREATMENT", 95, 104], ["Fallberichte", "TEST", 124, 136], ["Patienten zu einem", "TREATMENT", 233, 251]]], ["Die Mehrheit der Patienten entwickelte eine Grad-1-oder -2-Lymphopenie, die Rate der Grad-3-Lymphopenien lag bei 1 % und bereits nach 2 Wochen lie\u00dfen sich keine CD19-positiven Zellen mehr im Blut nachweisen [22, 26, 30] .", [["Die Mehrheit der Patienten entwickelte eine Grad-1-oder -2-Lymphopenie, die Rate der Grad-3-Lymphopenien lag bei 1 % und bereits nach 2 Wochen lie\u00dfen sich keine CD19-positiven Zellen mehr im Blut nachweisen", "SPECIES", 0, 206], ["Rate der Grad", "TEST", 76, 89], ["lag bei", "TEST", 105, 112], ["nach", "TEST", 129, 133], ["sich", "TEST", 150, 154], ["CD19", "TEST", 161, 165], ["Zellen", "TEST", 176, 182]]], ["Nach 2,5 Jahren (Median 72 Wochen) Ocrelizumab-Therapiepause hat sich bei 90 % der Patienten die Lymphozytenpopulation erholt [30] .", [["Nach 2,5 Jahren", "CHEMICAL", 0, 15], ["Nach", "TREATMENT", 0, 4], ["Ocrelizumab", "TREATMENT", 35, 46]]], ["Im Vergleich dazu hat sich die Lymphozytenpopulation in der Rituximab-Phase-2/3-Studie (OLYMPUS) nach 48 Wochen bei 35 % der Patienten erholt [22] .", [["Im Vergleich dazu hat sich die Lymphozytenpopulation in der Rituximab-Phase-2/3-Studie (OLYMPUS) nach 48 Wochen bei 35 % der Patienten erholt", "SPECIES", 0, 141], ["Phase", "TEST", 70, 75]]], ["Tab.", [["Tab", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Tab.", [["Tab", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["5) konnte der Nutzen von Ocrelizumab weiter best\u00e4tigt werden: 66,4 % der RMS-Patienten unter Ocrelizumab und 24,3 % der Patienten unter Interferon-\u03b21a zeigten keinen Hinweis f\u00fcr klinische oder radiologische Krankheitsaktivit\u00e4t (\"no evidence of disease activity\", NEDA; [31] ).", [["Interferon", "TREATMENT", 136, 146], ["disease activity", "PROBLEM", 244, 260], ["no evidence of", "UNCERTAINTY", 229, 243], ["disease", "OBSERVATION", 244, 251]]], ["Da direkte Vergleichsstudien von Ocrelizumab gegen andere MS-Therapien fehlen, wurde eine Metaanalyse durchgef\u00fchrt, die zeigte, dass der Nutzen einer Ocrelizumab-Therapie insbesondere bei Patienten mit hochaktiver RMS gegeben ist [32] .", [["Da direkte Vergleichsstudien von Ocrelizumab gegen andere MS-Therapien fehlen, wurde eine Metaanalyse durchgef\u00fchrt, die zeigte, dass der Nutzen einer Ocrelizumab-Therapie insbesondere bei Patienten mit hochaktiver RMS gegeben", "SPECIES", 0, 225], ["Therapien fehlen", "TREATMENT", 61, 77]]], ["Ferner lieferten zahlreiche retrospektive Analysen und eine Subgruppenanalyse Hinweise daf\u00fcr, dass Rituximab sowohl effektiv bei aggressiver RMS bzw. progressiver MS sein kann [33] [34] [35] [36] [37] [38] [39] als auch den MS-Therapien der 1.", [["33] [34] [35] [36] [37] [38] [39", "SIMPLE_CHEMICAL", 177, 209], ["Ferner lieferten zahlreiche retrospektive Analysen und eine Subgruppenanalyse Hinweise daf\u00fcr, dass Rituximab sowohl effektiv bei aggressiver RMS bzw", "SPECIES", 0, 148], ["dass Rituximab sowohl", "TREATMENT", 94, 115]]], ["Generation (i.e. Interferon-\u03b2 und Glatirameracetat) \u00fcberlegen ist [40, 41] .", [["Interferon", "PROTEIN", 17, 27], ["Interferon", "TREATMENT", 17, 27]]], ["Ob Rituximab allerdings eine gleichwertige Alternative zu Ocrelizumab darstellt, bleibt in Abwesenheit einer Kopf-an-Kopf-Phase-III-Studie Gegenstand von Diskussionen [42] [43] [44] [45] .", [["[42] [43] [44] [45", "SIMPLE_CHEMICAL", 167, 185], ["Abwesenheit einer Kopf-an-Kopf-Phase-III-Studie Gegenstand von Diskussionen", "SPECIES", 91, 166], ["Ob Rituximab", "TREATMENT", 0, 12], ["bleibt", "TEST", 81, 87], ["Abwesenheit", "TEST", 91, 102], ["Kopf", "TEST", 109, 113]]], ["Direkte Vergleichsstudien zwischen Rituximab und anderen Therapieoptionen w\u00e4ren sinnvoll, um diese Wissensl\u00fccken zu schlie\u00dfen [46] .Rituximab bei RRMS und PPMS: Fallberichte und -serienUm das Ansprechen der PPMS-Patienten auf eine Immuntherapie besser charakterisieren zu k\u00f6nnen, wird seit kurzem der Summenparameter mit dem Akronym NEPAD -\"no evidence of progression or active disease\" -verwendet.", [["Rituximab", "CHEMICAL", 132, 141], ["PPMS", "DISEASE", 155, 159], ["Direkte Vergleichsstudien zwischen Rituximab und anderen Therapieoptionen w\u00e4ren sinnvoll, um diese Wissensl\u00fccken zu schlie\u00dfen", "SPECIES", 0, 125], ["Fallberichte und -serienUm das Ansprechen der PPMS-Patienten auf eine Immuntherapie besser charakterisieren zu k\u00f6nnen, wird seit kurzem der Summenparameter mit dem Akronym NEPAD -\"", "SPECIES", 161, 341], ["Direkte Vergleichsstudien zwischen Rituximab und anderen Therapieoptionen", "TREATMENT", 0, 73], ["Rituximab", "TREATMENT", 132, 141], ["progression", "PROBLEM", 356, 367], ["active disease\"", "PROBLEM", 371, 386], ["no evidence of", "UNCERTAINTY", 341, 355], ["active", "OBSERVATION_MODIFIER", 371, 377], ["disease", "OBSERVATION", 378, 385]]], ["In der ORATORIO-Studie erh\u00f6hte Ocrelizumab den Anteil der PPMS-Patienten mit NEPAD nach 120 Wochen im Vergleich zu Placebo um das Drei- [53, 54] .Rituximab bei RRMS und PPMS: Fallberichte und -serienIn der 2:1 randomisierten Zulassungsstudie zur PPMS wurden unter Ocrelizumab (486 Patienten) in der placebokontrollierten Phase 11 Neoplasien verzeichnet, (Mammakarzinom 4, Basalzellkarzinom 3, endometrioides Adenokarzinom 1, anaplastisches gro\u00dfzelliges Lymphom 1, fibr\u00f6ses Histiozytom 1, Pankreaskarzinom 1), w\u00e4hrend in der Placebogruppe (239 Patienten) in der kontrollierte Studienphase 2 Neoplasien auftraten (Basalzellkarzinom 1, zervikales Adenokarzinom in situ 1; [26] ).Rituximab bei RRMS und PPMS: Fallberichte und -serienBei den RMS-Patienten unter Ocrelizumab traten in den 2-j\u00e4hrigen kontrollierten Phasen der OPERA-Studien insgesamt 4 maligne Erkrankungen auf (Mammakarzinom 2; Nierenzellkarzinom 1, malignes Melanom 1) und in der mit IFN-\u03b21a behandelten Gruppe 2 (Mantelzell-Lymphom 1 und pulmonales Plattenepithelkarzinom 1; [25] ).Rituximab bei RRMS und PPMS: Fallberichte und -serienJ\u00e4hrlich aktualisierte Analysen (aktueller Stand Januar 2019) zur Inzidenzrate von malignen Erkrankungen (ohne nichtmelanotische Hautmalignome) bei den weiter beobachteten Patienten des klinischen Studienprogramms zu Ocrelizumab zeigen, dass die alters-und geschlechtsstandardisierten Raten pro 100 Patientenjahre in der exponierten Population \u00fcber die Zeit stabil blieben und keinen zeitabh\u00e4ngigen Expositionseffekt zeigen.", [["Rituximab", "CHEMICAL", 146, 155], ["PPMS", "DISEASE", 169, 173], ["Rituximab", "CHEMICAL", 676, 685], ["PPMS", "DISEASE", 699, 703], ["Rituximab", "CHEMICAL", 1045, 1054], ["PPMS", "DISEASE", 1068, 1072], ["IFN", "PROTEIN", 946, 949], ["Ocrelizumab den Anteil der PPMS-Patienten mit NEPAD nach 120 Wochen im Vergleich zu Placebo um das Drei", "SPECIES", 31, 134], ["Fallberichte und -serienBei den RMS-Patienten unter Ocrelizumab traten in den 2-j\u00e4hrigen kontrollierten Phasen der OPERA-Studien insgesamt 4 maligne Erkrankungen auf", "SPECIES", 705, 870], ["Fallberichte und -serienJ\u00e4hrlich aktualisierte Analysen (aktueller Stand Januar 2019) zur Inzidenzrate von malignen Erkrankungen (ohne nichtmelanotische Hautmalignome) bei den weiter beobachteten Patienten des klinischen Studienprogramms zu Ocrelizumab zeigen, dass die alters-und geschlechtsstandardisierten Raten pro 100 Patientenjahre in der exponierten Population \u00fcber die Zeit stabil blieben und keinen zeitabh\u00e4ngigen Expositionseffekt zeigen", "SPECIES", 1074, 1521], ["Patienten mit NEPAD nach", "TREATMENT", 63, 87], ["Rituximab bei RRMS", "TREATMENT", 146, 164], ["der placebokontrollierten Phase", "TREATMENT", 295, 326], ["Neoplasien verzeichnet", "TREATMENT", 330, 352], ["Mammakarzinom", "TREATMENT", 355, 368], ["Basalzellkarzinom", "TREATMENT", 372, 389], ["endometrioides Adenokarzinom", "TREATMENT", 393, 421], ["anaplastisches gro\u00dfzelliges Lymphom", "TREATMENT", 425, 460], ["fibr\u00f6ses Histiozytom", "TREATMENT", 464, 484], ["der kontrollierte Studienphase", "TREATMENT", 557, 587], ["auftraten (Basalzellkarzinom", "TREATMENT", 601, 629], ["Rituximab", "TREATMENT", 676, 685], ["Fallberichte", "TEST", 705, 717], ["Erkrankungen auf (Mammakarzinom", "TREATMENT", 854, 885], ["Nierenzellkarzinom", "TREATMENT", 889, 907], ["IFN", "TEST", 946, 949], ["Mantelzell-Lymphom 1 und pulmonales Plattenepithelkarzinom", "TREATMENT", 976, 1034], ["Rituximab bei RRMS", "TREATMENT", 1045, 1063], ["Fallberichte", "TEST", 1074, 1086], ["Analysen (aktueller Stand Januar", "TREATMENT", 1121, 1153], ["zur Inzidenzrate von malignen Erkrankungen (ohne nichtmelanotische Hautmalignome", "TREATMENT", 1160, 1240]]], ["Des Weiteren ergaben Vergleiche der standardisierten Inzidenzraten f\u00fcr alle maligne Erkrankungen und f\u00fcr Mammakarzinome mit der US-amerikanischen SEER-Datenbank (Allgemeinbev\u00f6lkerung) und dem d\u00e4nischen MS-Register, dass die beobachteten Inzidenzraten im gesamten bisherigen Beobachtungszeitraum innerhalb der epidemiologischen Referenzbereiche lagen [55] .InfektionenFallberichte weisen auf das Risiko einer Hepatitisreaktivierung unter CD20-Depletion hin [56, 57] , daher ist eine Risikostratifizierung vor Therapiebeginn sinnvoll [58] .", [["Des Weiteren ergaben Vergleiche der standardisierten Inzidenzraten f\u00fcr alle maligne Erkrankungen und f\u00fcr Mammakarzinome mit der US-amerikanischen SEER-Datenbank (Allgemeinbev\u00f6lkerung) und dem d\u00e4nischen MS-Register, dass die beobachteten Inzidenzraten im gesamten bisherigen", "SPECIES", 0, 273], ["InfektionenFallberichte weisen auf das Risiko einer Hepatitisreaktivierung unter CD20-Depletion hin", "SPECIES", 356, 455], ["dass die beobachteten", "TREATMENT", 215, 236], ["Inzidenzraten", "TREATMENT", 237, 250]]], ["Ferner wurden als Risiken eine Late-onset-Neutropenie [59, 60] und das Auftreten tumefaktiver, demyelini-sierender L\u00e4sionen beschrieben [61] .", [["Ferner wurden als Risiken eine Late-onset-Neutropenie", "SPECIES", 0, 53], ["tumefaktiver", "TEST", 81, 93], ["demyelini", "TEST", 95, 104]]], ["Diese traten nach vorangegangener Therapie mit anderen Immunmodulatoren mit bekannt erh\u00f6htem PML-Risiko auf (7 F\u00e4lle Stand Ende 2019) [62, 63] .", [["Diese traten nach vorangegangener Therapie mit anderen Immunmodulatoren mit bekannt erh\u00f6htem PML-Risiko auf (7 F\u00e4lle Stand Ende 2019)", "SPECIES", 0, 133], ["PML", "PROBLEM", 93, 96]]], ["Aktuell ist eine nichtinterventionelle Studie geplant, die das Langzeitrisikoprofil von Ocrelizumab besser erfassen soll [64] .", [["Aktuell ist eine nichtinterventionelle Studie geplant, die das Langzeitrisikoprofil von Ocrelizumab besser erfassen soll", "SPECIES", 0, 120]]], ["Die Ergebnisse dieser Studie in Deutschland flie\u00dfen auch in globale Sicherheitsregister ein [65] .InfektionenDieser Kontext ist \u00e4hnlich wie bei den F\u00e4llen einer PML in Assoziation mit dem Vorl\u00e4uferpr\u00e4parat Rituximab in anderen Nicht-MS-Indikationen, wie z.", [["InfektionenDieser Kontext ist \u00e4hnlich wie bei den F\u00e4llen einer PML in Assoziation mit dem Vorl\u00e4uferpr\u00e4parat Rituximab in anderen Nicht-MS-Indikationen", "SPECIES", 98, 248], ["Infektionen", "PROBLEM", 98, 109], ["PML", "PROBLEM", 161, 164], ["Vorl\u00e4uferpr\u00e4parat Rituximab", "TREATMENT", 188, 215]]], ["B. rheumatoider Arthritis [66] .", [["Arthritis", "DISEASE", 16, 25], ["B. rheumatoider", "SPECIES", 0, 15], ["B. rheumatoider Arthritis", "PROBLEM", 0, 25], ["rheumatoider Arthritis", "OBSERVATION", 3, 25]]], ["Die Auswertung eines Rituximab-Therapieregisters ergab keine neuen Aspekte hinsichtlich des Nebenwirkungsprofils von CD20-Depletion [67] .", [["CD20", "GENE_OR_GENE_PRODUCT", 117, 121], ["CD20", "PROTEIN", 117, 121], ["Rituximab", "TREATMENT", 21, 30]]], ["Infektion unter Rituximab konnten jedoch keine klaren Risikofaktoren herausgearbeitet werden [69] .", [["Infektion", "TREATMENT", 0, 9], ["Rituximab konnten jedoch", "TREATMENT", 16, 40]]], ["Wie unter Rituximab sollte unter Ocrelizumab regelm\u00e4\u00dfig der IgG-Spiegel kontrolliert werden [70] .", [["Rituximab sollte", "TREATMENT", 10, 26], ["Spiegel kontrolliert werden", "TREATMENT", 64, 91]]], ["Dies ist insbesondere relevant, da die Infektionsrate unter CD20-Depletion bei MS-Patienten am h\u00f6chsten zu sein scheint [71] .InfektionenBei einer 78 Jahre alten Patientin, mit niedrigen CD4 + -und CD8 + -Lymphozytenzahlen vor Therapiebeginn und vermuteter Immunseneszenz wurde eine PML unter Ocrelizumab ohne Vorexposition gegen\u00fcber anderen immunologischen Therapien gemeldet [72] .InfektionenBez\u00fcglich anderer infekti\u00f6ser Komplikationen wurden einzelne Fallberichte von Patienten publiziert, die unter einer Ocrelizumab-Behandlung eine Herpes-simplex-Typ-2-Enzephalitis [73] , eine Parvovirus-B19-Infektion [74] und in 2 F\u00e4llen eine Meningitis entwickelten.", [["Herpes-simplex", "DISEASE", 538, 552], ["Parvovirus-B19", "DISEASE", 584, 598], ["Meningitis", "DISEASE", 635, 645], ["Herpes", "ORGANISM", 538, 544], ["simplex", "ORGANISM", 545, 552], ["eine", "ORGANISM", 579, 583], ["Parvovirus", "ORGANISM", 584, 594], ["B19", "ORGANISM", 595, 598], ["CD20", "PROTEIN", 60, 64], ["Herpes", "SPECIES", 538, 544], ["Dies ist insbesondere relevant, da die Infektionsrate unter CD20-Depletion bei MS-Patienten am h\u00f6chsten zu sein scheint", "SPECIES", 0, 119], ["InfektionenBei einer 78 Jahre alten Patientin, mit niedrigen CD4 + -und CD8 + -Lymphozytenzahlen vor Therapiebeginn und vermuteter Immunseneszenz wurde eine PML unter Ocrelizumab ohne Vorexposition gegen\u00fcber anderen immunologischen Therapien gemeldet", "SPECIES", 126, 376], ["Parvovirus-B19", "SPECIES", 584, 598], ["InfektionenBei", "TEST", 126, 140], ["CD4", "TEST", 187, 190], ["CD8", "TEST", 198, 201], ["Lymphozytenzahlen vor Therapiebeginn", "TREATMENT", 205, 241], ["Ocrelizumab", "TEST", 510, 521], ["eine Parvovirus", "TEST", 579, 594]]], ["In einem Fall verlief die Meningitis aseptisch, bei der anderen konnte eine vermutete Borreliengenese nicht verifiziert werden [75] .", [["Meningitis", "DISEASE", 26, 36], ["Meningitis", "PROBLEM", 26, 36]]], ["Ein Fallbericht legt nahe, dass Ocrelizumab zwar B-Zellen deple-tiert, jedoch nicht die T-Zell-Immunantwort auf Varizella Zoster beeinflusst [76] .InfektionenK\u00fcrzlich wurde unter Ocrelizumab das Auftreten einer Endokarditis berichtet [77] .InfektionenDie Therapie mit Ocrelizumab ist wahrscheinlich nicht mit einem erh\u00f6hten Risiko einer Tuberkuloseinfektion assoziiert [78] .InfektionenEs ist zu beachten, dass es bei RMS-Patienten unter Ocrelizumab im Vergleich zu Interferon-\u03b21a mehr Infektionen mit Varizella-Zoster-Viren (n = 17 vs. 8 [25] ) auftraten und bei PPMS-Patienten unter Ocrelizumab im Vergleich zu Placebo mehr Episoden mit oralem Herpes simplex (2,3 % vs. 0,4 %; [25] ).", [["Herpes simplex", "DISEASE", 646, 660], ["oralem Herpes simplex", "ORGANISM", 639, 660], ["dass Ocrelizumab zwar B-Zellen deple-tiert, jedoch nicht die T-Zell-Immunantwort auf Varizella Zoster beeinflusst", "SPECIES", 27, 140], ["InfektionenDie Therapie mit Ocrelizumab ist wahrscheinlich nicht mit einem erh\u00f6hten Risiko einer Tuberkuloseinfektion assoziiert", "SPECIES", 240, 368], ["InfektionenEs ist zu beachten, dass es bei RMS-Patienten unter Ocrelizumab im Vergleich zu Interferon-\u03b21a mehr Infektionen mit Varizella-Zoster-Viren", "SPECIES", 375, 524], ["Infektionen", "PROBLEM", 240, 251], ["Ocrelizumab im Vergleich zu Interferon", "TREATMENT", 438, 476], ["Varizella", "TEST", 502, 511], ["Zoster", "PROBLEM", 512, 518], ["Viren (n", "TREATMENT", 519, 527], ["auftraten und bei PPMS", "TREATMENT", 546, 568], ["mit oralem Herpes simplex", "PROBLEM", 635, 660]]], ["In der Zusammenschau sind regelm\u00e4\u00dfige Verlaufskontrollen bei MS-Patienten unter CD20-depletierendenTherapiensinnvoll [79] .InfektionenObwohl sowohl eine retrospektive Analyse von Patienten mit neuroimmunologischen Erkrankungen unter 7-j\u00e4hriger Rituximab-Therapie [80] als auch eine Metaanalyse von Patienten mit rheumatoider Arthritis [81] ein g\u00fcnstiges Sicherheitsprofil best\u00e4tigen konnten, ist der Einfluss einer Langzeit-B-Zell-Depletion auf Malignom-und Infektionsrisiken nicht vollst\u00e4ndig charakterisiert [82, 83] .", [["Zusammenschau sind regelm\u00e4\u00dfige Verlaufskontrollen bei MS-Patienten unter CD20-depletierenden", "SPECIES", 7, 99], ["Obwohl sowohl eine retrospektive Analyse von Patienten mit neuroimmunologischen Erkrankungen unter 7-j\u00e4hriger Rituximab-Therapie [80] als auch eine Metaanalyse von Patienten mit rheumatoider Arthritis [81] ein g\u00fcnstiges Sicherheitsprofil best\u00e4tigen konnten, ist der Einfluss einer Langzeit-B-Zell-Depletion auf Malignom-und Infektionsrisiken nicht vollst\u00e4ndig charakterisiert", "SPECIES", 134, 509], ["Infektionen", "TREATMENT", 123, 134], ["Erkrankungen", "TEST", 214, 226], ["j\u00e4hriger Rituximab", "TREATMENT", 235, 253], ["mit rheumatoider Arthritis", "PROBLEM", 308, 334], ["Langzeit", "TEST", 415, 423]]], ["F\u00fcr Ocrelizumab liegen aktuell aus klinischen Studien Daten von Patienten mit bis zu 6 Jahren Exposition vor, mit einer Gesamtexposition von \u00fcber 14.000 Patientenjahren (Stand Mai 2019; [55] ).Schwangerschaften unter CD20gerichteter TherapieEs zeigten sich keine klaren Sicherheitssignale (i.e. Spontanaborte oder kindliche Fehlbildungen) bei Schwangeren, die in den ersten 6 Schwangerschaftsmonaten eine CD20-Depletion mittels Rituximab erfahren haben [84] .", [["CD20", "GENE_OR_GENE_PRODUCT", 405, 409], ["CD20", "PROTEIN", 405, 409], ["F\u00fcr Ocrelizumab liegen aktuell aus klinischen Studien Daten von Patienten mit bis zu 6 Jahren Exposition vor, mit einer Gesamtexposition von \u00fcber 14.000 Patientenjahren (Stand Mai 2019", "SPECIES", 0, 184], ["Schwangerschaften", "TREATMENT", 193, 210], ["Spontanaborte oder kindliche Fehlbildungen", "TREATMENT", 295, 337], ["Schwangerschaftsmonaten eine CD20", "TREATMENT", 376, 409], ["Rituximab erfahren haben", "TREATMENT", 428, 452]]], ["Die Auswertung der bisher dokumentierten Schwangerschaften mit Ocrelizumab-Exposition ergab keine Auff\u00e4lligkeiten [85] .", [["Die Auswertung der bisher dokumentierten Schwangerschaften mit Ocrelizumab-Exposition ergab keine Auff\u00e4lligkeiten [85", "SPECIES", 0, 117]]], ["Weitere Daten werden im Ocrelizumab-Schwangerschaftsregister erhoben [86] .Schwangerschaften unter CD20gerichteter TherapieDie Datenlage bez\u00fcglich intrathekaler Applikation von CD20-depletierenden monoklonalen Antik\u00f6rpern ist gering [87] .", [["Weitere Daten werden im Ocrelizumab-Schwangerschaftsregister erhoben", "SPECIES", 0, 68], ["Schwangerschaften unter CD20gerichteter TherapieDie Datenlage bez\u00fcglich intrathekaler Applikation von CD20-depletierenden monoklonalen Antik\u00f6rpern ist gering", "SPECIES", 75, 232], ["Schwangerschaften", "TREATMENT", 75, 92]]], ["Ferner ist hervorzuheben, dass es bei RMS-Patienten unter Ocrelizumab im Vergleich zu Interferon-\u03b21a zu mehr Varizella-Zoster-Infektionen (17 vs. 8 [25] ) und bei PPMS-Patienten unter Ocrelizumab im Vergleich zu Placebo zu mehr oralen Herpesinfektionen (2,3 % vs. 0,4 %; [26] ) gekommen ist.Pathomechanistische Aspekte der Rolle von B-Zellen in der MSDie rasch einsetzenden tiefgreifenden Effekte einer CD20-B-Zell-gerichteten Therapie haben zu einer Neubewertung der humoralen Immunantwort bei MS gef\u00fchrt.", [["Ferner ist hervorzuheben, dass es bei RMS-Patienten unter Ocrelizumab im Vergleich zu Interferon-\u03b21a zu mehr Varizella-Zoster-Infektionen", "SPECIES", 0, 137], ["Pathomechanistische Aspekte der Rolle von B-Zellen in der MSDie rasch einsetzenden tiefgreifenden Effekte einer CD20-B-Zell-gerichteten Therapie haben zu einer Neubewertung der humoralen Immunantwort bei MS gef\u00fchrt", "SPECIES", 291, 505], ["Ocrelizumab im Vergleich zu Interferon", "TREATMENT", 58, 96], ["Ocrelizumab im Vergleich zu Placebo zu mehr oralen Herpesinfektionen", "TREATMENT", 184, 252], ["Pathomechanistische", "TEST", 291, 310], ["CD20", "TEST", 403, 407], ["Zell-gerichteten Therapie", "TREATMENT", 410, 435], ["Zoster", "OBSERVATION", 119, 125]]], ["Nach urspr\u00fcnglicher Vorstellung w\u00fcrde eine B-Zell-Depletion vermutlich wesentlich \u00fcber eine Verminderung der Produktion von Autoantik\u00f6rpern wirken.Pathomechanistische Aspekte der Rolle von B-Zellen in der MSDie Wirkungsweise von CD20-Depletion bei MS und den autoimmunen Tiermodellen ist allerdings bisher nicht vollst\u00e4ndig verstanden [88] .", [["Nach urspr\u00fcnglicher Vorstellung w\u00fcrde eine B-Zell-Depletion vermutlich wesentlich \u00fcber eine Verminderung der Produktion von Autoantik\u00f6rpern wirken", "SPECIES", 0, 146], ["Pathomechanistische Aspekte der Rolle von B-Zellen in der MSDie Wirkungsweise von CD20-Depletion bei MS und den autoimmunen Tiermodellen ist allerdings bisher nicht vollst\u00e4ndig verstanden", "SPECIES", 147, 334], ["Nach urspr\u00fcnglicher", "TREATMENT", 0, 19], ["Depletion vermutlich", "TREATMENT", 50, 70], ["Pathomechanistische", "TEST", 147, 166], ["Depletion bei MS", "TREATMENT", 234, 250]]], ["Die aktuelle Datenlage hinsichtlich der B-Zell-Rolle bei MS wurde rezent mehrfach zusammengefasst [7, 14, [89] [90] [91] [92] und die Interaktion von B-und T-Zellen diskutiert [93] .", [["Die aktuelle Datenlage hinsichtlich der B-Zell-Rolle bei MS wurde rezent mehrfach zusammengefasst", "SPECIES", 0, 97], ["Zell", "TEST", 42, 46], ["zusammengefasst", "TEST", 82, 97], ["von B", "TEST", 146, 151]]], ["Die Effektivit\u00e4t der B-Zell-Depletion bei MS unterst\u00fctzt die Hypothese, dass mit Epstein-Barr-Viren latent infizierte B-Zellen eine wichtige Rolle bei der Pathogenese der MS spielen k\u00f6nnten [94, 95] .", [["Die Effektivit\u00e4t der B-Zell-Depletion bei MS unterst\u00fctzt die Hypothese, dass mit Epstein-Barr-Viren latent infizierte B-Zellen eine wichtige Rolle bei der Pathogenese der MS spielen k\u00f6nnten", "SPECIES", 0, 189], ["Viren latent infizierte B", "TREATMENT", 94, 119]]], ["Aus tierexperimentellen Studien gibt es Hinweise, dass eine CD20-Depletion die Aktivierung von Mikrogliazellen und die Rekrutierung von T-Lymphozyten reduziert [96] .", [["Aus tierexperimentellen Studien gibt es Hinweise, dass eine CD20-Depletion die Aktivierung von Mikrogliazellen und die Rekrutierung von T-Lymphozyten reduziert [96", "SPECIES", 0, 163]]], ["Die pathogene CD40-vermittelte NF-\u03baB-Aktivierung in B-Zellen ist bei MS-Patienten verst\u00e4rkt [97] .", [["CD40", "GENE_OR_GENE_PRODUCT", 14, 18], ["CD40", "PROTEIN", 14, 18], ["vermittelte NF", "PROTEIN", 19, 33], ["\u03baB", "PROTEIN", 34, 36], ["B-Zellen ist bei MS-Patienten verst\u00e4rkt", "SPECIES", 52, 91], ["CD40", "TEST", 14, 18], ["NF", "TEST", 31, 33]]], ["Zus\u00e4tzlich werden B-Zell Aggregate in lymphfollikel\u00e4hnlichen Strukturen im Subarachnoidalraum, insbesondere bei Patienten mit sekund\u00e4r chronisch-progredienter Verlaufsform, als erkrankungsrelevant diskutiert [98, 99] .", [["Patienten mit sekund\u00e4r chronisch-progredienter Verlaufsform, als erkrankungsrelevant diskutiert", "SPECIES", 112, 207], ["Zus\u00e4tzlich", "TREATMENT", 0, 10]]], ["Eine tierexperimentelle Studie konnte diesbez\u00fcglich zeigen, dass eine intrathekale Gabe von Anti-CD20-Antik\u00f6rpern zu einer relevanten Depletion von B-Zellen in etablierten ZNS-L\u00e4sionen f\u00fchrt [100] .", [["Eine tierexperimentelle Studie konnte diesbez\u00fcglich zeigen, dass eine intrathekale Gabe von Anti-CD20-Antik\u00f6rpern zu einer relevanten Depletion von B-Zellen in etablierten ZNS-L\u00e4sionen f\u00fchrt", "SPECIES", 0, 190], ["Eine tierexperimentelle", "TREATMENT", 0, 23], ["von Anti-CD20", "TREATMENT", 88, 101], ["Antik\u00f6rpern zu einer relevanten Depletion von B", "TREATMENT", 102, 149], ["Zellen in etablierten ZNS", "TREATMENT", 150, 175]]], ["Des Weiteren gibt es Hinweise daf\u00fcr, dass es bei MS-Patienten einen Transit zwischen dem ZNS und der Peripherie von insbesondere immunaktiven B-Zellen gibt, die einen Immunglobulinklassenwechsel erfahren haben [101] , und dass B-Zellen von MS-Patienten vermehrt Antigene pr\u00e4sentieren [102] .", [["Des Weiteren gibt es Hinweise daf\u00fcr, dass es bei MS-Patienten einen Transit zwischen dem ZNS und der Peripherie von insbesondere immunaktiven B-Zellen gibt, die einen Immunglobulinklassenwechsel erfahren haben [101] , und dass B-Zellen von MS-Patienten vermehrt Antigene pr\u00e4sentieren", "SPECIES", 0, 283], ["Transit zwischen dem ZNS", "TREATMENT", 68, 92]]], ["Diese Immunzellen m\u00fcssen dabei mittels komplexer, mehrschrittiger Kaskaden Immunbarrieren \u00fcberwinden [103] , um dort klonal zu expandieren [104] und spezifische Immunglobuline zu produzieren [105] und Lymphangiogenese zu f\u00f6rdern [106] .", [["Diese Immunzellen m\u00fcssen dabei mittels komplexer, mehrschrittiger Kaskaden Immunbarrieren \u00fcberwinden [103] , um dort klonal zu expandieren [104] und spezifische Immunglobuline zu produzieren [105] und Lymphangiogenese zu f\u00f6rdern", "SPECIES", 0, 228], ["Diese", "TEST", 0, 5]]], ["Die Reifung der ZNS-st\u00e4ndigen B-Zellen bei MS-Patienten erfolgt nach aktuellem Wissenstand in den drainierenden zervikalen Lymphknoten [107] .", [["Die Reifung der ZNS-st\u00e4ndigen B-Zellen bei MS-Patienten erfolgt nach aktuellem Wissenstand in den drainierenden zervikalen", "SPECIES", 0, 122], ["ZNS", "TEST", 16, 19]]], ["B-Zellen von RRMS-Patienten sind in der Lage, komplement-und immunglobulinunabh\u00e4ngige Faktoren zu produzieren, die in vitro toxisch f\u00fcr Neurone und Oligodendrozyten sind [108] .", [["Zellen von RRMS", "PROBLEM", 2, 17]]], ["Bei Patienten mit Myelitis als klinisch isoliertem Syndrom, die sich somit im Anfangsstadium einer m\u00f6glichen MS befinden, konnte sowohl eine expandierte und mutierte Plasmablastensubgruppe [109] als auch eine bestimmte Verteilung von Interleukin-6/-10-produzierenden B-Lymphozyten differenziert werden [110] , was im Einklang mit dem aktuellen Verst\u00e4ndnis \u00fcber die Rolle der Zytokine bei autoimmunen Erkrankungen steht [111] .", [["Bei Patienten mit Myelitis als klinisch isoliertem Syndrom, die sich somit im Anfangsstadium einer m\u00f6glichen MS befinden, konnte sowohl eine expandierte und mutierte Plasmablastensubgruppe [109] als auch eine bestimmte Verteilung von Interleukin-6/-10-produzierenden B-Lymphozyten differenziert werden [110] , was im Einklang mit dem aktuellen Verst\u00e4ndnis \u00fcber die Rolle der Zytokine bei autoimmunen Erkrankungen steht", "SPECIES", 0, 418], ["mit Myelitis als klinisch isoliertem Syndrom", "PROBLEM", 14, 58], ["Plasmablastensubgruppe", "TEST", 166, 188], ["Interleukin", "TEST", 234, 245], ["produzierenden B-Lymphozyten differenziert werden", "TREATMENT", 252, 301]]], ["Somit scheint es, dass B-Zellen sowohl zu Beginn als auch bei der Aufrechterhaltung der MS-Erkrankung eine wichtige Rolle spielen [112] .", [["dass B-Zellen sowohl zu Beginn als auch bei der Aufrechterhaltung der MS-Erkrankung eine wichtige Rolle spielen [112", "SPECIES", 18, 134]]], ["Wichtig dabei scheint die Regulierung des \"Macrophage-migration-inhibitory-factor\"(MIF)-Signalwegs zu sein, da ein supprimiertes CD74 und ein hochreguliertes CXCR4 mit einer fr\u00fchen MS-Diagnose assoziiert sind [113] .", [["inhibitory-factor", "PROTEIN", 64, 81], ["MIF", "PROTEIN", 83, 86], ["MS", "TEST", 181, 183]]], ["Ferner wird diskutiert, dass nicht alle B-Lymphozyten pathophysiologisch relevant sind, sondern insbesondere eine bestimmte Subgruppe, und zwar \"Granulocyte-macrophage-colony-stimulatingfactor\"(GM-CSF)-exprimierende humane B-Ged\u00e4chtnis-Zellen [114] , bzw. verschiedene B-Lymphozyten-Subgruppen im Liquor entscheidend sind f\u00fcr den Erkrankungsph\u00e4notyp [115] .", [["GM", "CHEMICAL", 194, 196], ["macrophage", "CELL", 157, 167], ["verschiedene B-Lymphozyten-Subgruppen im Liquor entscheidend sind f\u00fcr den Erkrankungsph\u00e4notyp [115", "SPECIES", 256, 354], ["Granulocyte", "TEST", 145, 156], ["macrophage", "TEST", 157, 167], ["colony", "TEST", 168, 174], ["stimulatingfactor", "TEST", 175, 192], ["CSF", "TEST", 197, 200], ["verschiedene", "TEST", 256, 268], ["Lymphozyten", "TREATMENT", 271, 282]]], ["Basierend auf den Erkenntnissen \u00fcber die phasenabh\u00e4ngige Oberfl\u00e4chenexpression von Differenzierungsantigenen in der B-Zell-Reifung und der Diskussion einer aktuellen Phase-2/3-Studie von Inebilizumab, ein gegen CD19 gerichteter monoklonaler Antik\u00f6rper, bei NMOSD [116] muss zwischen CD20-und CD19-Depletion unterschieden werden (.", [["CD19", "GENE_OR_GENE_PRODUCT", 292, 296], ["CD20", "PROTEIN", 283, 287], ["CD19", "PROTEIN", 292, 296], ["Basierend auf den Erkenntnissen \u00fcber die phasenabh\u00e4ngige Oberfl\u00e4chenexpression von Differenzierungsantigenen in der B-Zell-Reifung und der Diskussion einer aktuellen Phase-2/3-Studie von Inebilizumab, ein gegen CD19 gerichteter monoklonaler Antik\u00f6rper, bei NMOSD [116] muss zwischen CD20-und CD19-Depletion unterschieden werden", "SPECIES", 0, 327], ["Phase", "TEST", 166, 171], ["zwischen", "TEST", 274, 282], ["CD20", "TEST", 283, 287]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["1): CD20 wird nicht auf der Oberfl\u00e4che von Plasmazellen exprimiert, wohingegen CD19 auf der Mehrheit von Plasmazellen in sekund\u00e4ren lymphatischen Organen (z.", [["CD20", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD20", "PROTEIN", 4, 8], ["CD20", "ANATOMY", 4, 8]]], ["B. Milz, Tonsillen), auf allen Plasmazellen im Blut und bei mehr als 50 % der Plasmazellen im Knochenmark nachgewiesen werden kann [117, 118] .", [["auf allen Plasmazellen im Blut und bei mehr als 50 % der Plasmazellen im Knochenmark nachgewiesen werden kann", "SPECIES", 21, 130], ["auf allen Plasmazellen im Blut und bei mehr als", "TREATMENT", 21, 68]]], ["Zus\u00e4tzlich muss beachtet werden, dass CD19 nur von Plasmazellen, CD20 jedoch auch von einer Untergruppe CDpositiver T-Zellen exprimiert wird [119] .", [["CD19", "PROTEIN", 38, 42], ["CD20", "PROTEIN", 65, 69], ["Zus\u00e4tzlich muss beachtet werden, dass CD19 nur von Plasmazellen, CD20 jedoch auch von einer Untergruppe CDpositiver T-Zellen exprimiert wird", "SPECIES", 0, 140]]], ["In der Zusammenschau sind B-Zellen allerdings nicht alleinig f\u00fcr die Entstehung und Aufrechterhaltung der MS verantwortlich: Es gibt Hinweise daf\u00fcr, dass (Ged\u00e4chtnis-)B-Zellen autoreaktive, autoproliferative [120] , proinflammatorische T-Zellen (u. a.", [["Zellen autoreaktive", "PROBLEM", 169, 188]]], ["TH17-Zellen) induzieren, die wiederum eine entscheidende Rolle in den Entz\u00fcndungskaskaden im ZNS spielen [121] [122] [123] , und dass \"polymorphonuclear myeloid-derived suppressor cells\" (PMN-MDSCs) selektiv die Akkumulierung von B-Zellen im ZNS kontrollieren [124] .", [["polymorphonuclear myeloid-derived suppressor cells", "ANATOMY", 135, 185], ["PMN", "ANATOMY", 188, 191], ["MDSCs", "ANATOMY", 192, 197], ["polymorphonuclear myeloid-derived suppressor cells", "CELL", 135, 185], ["PMN-MDSCs", "CELL", 188, 197], ["polymorphonuclear myeloid-derived suppressor cells", "CELL_TYPE", 135, 185], ["PMN", "CELL_TYPE", 188, 191], ["MDSCs", "CELL_TYPE", 192, 197], ["Akkumulierung von B-Zellen im ZNS kontrollieren", "SPECIES", 212, 259], ["polymorphonuclear myeloid", "TEST", 135, 160], ["derived suppressor cells", "TREATMENT", 161, 185], ["PMN", "TEST", 188, 191], ["Zellen im ZNS kontrollieren", "TREATMENT", 232, 259], ["polymorphonuclear myeloid", "OBSERVATION", 135, 160]]], ["Zus\u00e4tzlich ist bislang unklar, welche Rolle die kleine Subgruppe der CD20-positiven T-Zellen bei der MS spielt [126] .", [["Zus\u00e4tzlich ist bislang unklar, welche Rolle die kleine Subgruppe der CD20-positiven T-Zellen bei der MS spielt", "SPECIES", 0, 110], ["Zus\u00e4tzlich ist bislang unklar", "TREATMENT", 0, 29]]], ["So zeigte eine Phase-2a-Studie mit dem CD20depletierenden Antik\u00f6rper Ublituximab eine Ver\u00e4nderung des T-Zell-Profils bei MS-Patienten unter Therapie [127] .", [["So zeigte eine Phase-2a-Studie mit dem CD20depletierenden Antik\u00f6rper Ublituximab eine Ver\u00e4nderung des T-Zell-Profils bei MS-Patienten unter Therapie", "SPECIES", 0, 148], ["zeigte eine Phase", "TREATMENT", 3, 20]]], ["Die Schweizerische Multiple Sklerose Gesellschaft empfiehlt Ocrelizumab-Patienten in der Schweiz, die in einem Gebiet mit vielen SARS-CoV-2-F\u00e4llen leben, sich so weit wie m\u00f6glich zu isolieren, um ihr Infektionsrisiko zu verringern, und den Beginn einer Ocrelizumab-Therapie sorgsam abzuw\u00e4gen [138] .", [["Die Schweizerische Multiple Sklerose Gesellschaft empfiehlt Ocrelizumab-Patienten in der Schweiz, die in einem Gebiet mit vielen SARS-CoV-2-F\u00e4llen leben, sich so weit wie m\u00f6glich zu isolieren, um ihr Infektionsrisiko zu verringern, und den Beginn einer Ocrelizumab-Therapie sorgsam abzuw\u00e4gen", "SPECIES", 0, 291], ["CoV", "TEST", 134, 137]]], ["Die Multiple Sclerosis International Federation r\u00e4t Patienten unter Therapie, sich bei Verdacht auf, oder bei einer best\u00e4tigten Infektion mit SARS-CoV-2 nach vorheriger telefonischer Absprache, beim behandelnden Arzt vorzustellen.", [["Sclerosis", "DISEASE", 13, 22], ["Multiple Sclerosis", "PROBLEM", 4, 22], ["mit SARS", "PROBLEM", 138, 146], ["Sclerosis", "OBSERVATION", 13, 22]]], ["Das Risiko einer schwerwiegenden SARS-CoV-2-Infektion wird unter Glatirameracetat, Interferon-\u03b2 oder Natalizumab als am geringsten eingesch\u00e4tzt [139] .", [["Das Risiko einer schwerwiegenden SARS-CoV-2-Infektion wird unter Glatirameracetat, Interferon-\u03b2 oder Natalizumab als am geringsten eingesch\u00e4tzt", "SPECIES", 0, 143], ["CoV", "TEST", 38, 41], ["Infektion", "TREATMENT", 44, 53], ["Glatirameracetat", "TREATMENT", 65, 81], ["Interferon", "TREATMENT", 83, 93], ["Natalizumab", "TREATMENT", 101, 112]]], ["Eine verz\u00f6gerte Ocrelizumab-Gabe kann auch aus Sicht des Multiple Sclerosis Trust und der Association of British Neurologists erwogen werden, um ein Infektionsrisiko zu reduzieren [140, 141] .Ocrelizumab: Indikationen, praktische Aspekte und TherapiehinweiseUm Infektionskrankheiten vorzubeugen, sollten alle Patienten, die Ocrelizumab bekommen, vor Erstgabe nach den Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) f\u00fcr immunsupprimierte Patienten inkl. j\u00e4hrlicher Grippeschutz-und Pneumokokkenimpfung vakziniert werden.", [["Ocrelizumab", "CHEMICAL", 192, 203], ["Ocrelizumab", "CHEMICAL", 192, 203], ["Ocrelizumab", "SIMPLE_CHEMICAL", 192, 203], ["j\u00e4hrlicher Grippeschutz-und Pneumokokkenimpfung vakziniert werden", "SPECIES", 456, 521], ["Eine verz\u00f6gerte Ocrelizumab", "TREATMENT", 0, 27], ["Indikationen", "TREATMENT", 205, 217], ["praktische Aspekte", "TREATMENT", 219, 237], ["j\u00e4hrlicher", "TEST", 456, 466], ["Grippeschutz", "TEST", 467, 479], ["Sclerosis", "OBSERVATION", 66, 75]]], ["Zwischen Impfung und Ocrelizumab-Infusion sollte ein Abstand von 6 Wochen liegen, Lebendimpfungen sind unter Ocrelizumab kontraindiziert.Ocrelizumab: Indikationen, praktische Aspekte und TherapiehinweiseOcrelizumabdarfw\u00e4hrend derSchwangerschaft und Stillzeit nicht angewendet werden, weswegen eine wirksame Empf\u00e4ngnisverh\u00fctung unter Ocrelizumab f\u00fcr mindestens 12 Monate nach jeder Ocrelizumab-Gabe von der EMA empfohlen wird.", [["Ocrelizumab", "CHEMICAL", 137, 148], ["Ocrelizumab", "CHEMICAL", 137, 148], ["Ocrelizumab", "SIMPLE_CHEMICAL", 137, 148], ["Zwischen Impfung und Ocrelizumab-Infusion sollte ein Abstand von 6 Wochen liegen, Lebendimpfungen sind unter Ocrelizumab kontraindiziert", "SPECIES", 0, 136], ["praktische Aspekte und TherapiehinweiseOcrelizumabdarfw\u00e4hrend derSchwangerschaft und Stillzeit nicht angewendet werden, weswegen eine wirksame Empf\u00e4ngnisverh\u00fctung unter Ocrelizumab f\u00fcr mindestens 12 Monate nach jeder Ocrelizumab-Gabe von der EMA empfohlen wird", "SPECIES", 164, 424], ["Zwischen Impfung", "TREATMENT", 0, 16], ["Infusion sollte ein Abstand von", "TREATMENT", 33, 64], ["Indikationen", "TREATMENT", 150, 162], ["praktische", "TREATMENT", 164, 174]]], ["Neue Daten legen nahe, dass dieser Sicherheitsabstand in Zukunft m\u00f6glicherweise verk\u00fcrzt werden kann [85] .SchlussfolgerungIn der Zusammenschau hat man bei der Behandlung der Multiplen Sklerose in den letzten Jahren viel erreicht; die Zulassung von Ocrelizumab war ein weiterer wichtiger Schritt in die Richtung einer effektiven Behandlung von MS-Patienten.", [["man", "SPECIES", 148, 151], ["den letzten Jahren viel erreicht; die Zulassung von Ocrelizumab war ein weiterer wichtiger Schritt in die Richtung einer effektiven Behandlung von MS-Patienten", "SPECIES", 197, 356]]], ["Dieser humanisierte anti-CD20monoklonale Antik\u00f6rper, zweimal j\u00e4hrlich intraven\u00f6s verabreicht, z\u00e4hlt zu den Hochwirksamkeitsmedikamenten zur Behandlung der schubf\u00f6rmigen MS mit einem bislang guten Sicherheitsprofil bei halbj\u00e4hrlicher Anwendung.SchlussfolgerungHervorzuheben ist, dass Ocrelizumab das erste Medikament mit Wirksamkeit bei PPMS ist.", [["zweimal j\u00e4hrlich intraven\u00f6s verabreicht, z\u00e4hlt zu den Hochwirksamkeitsmedikamenten zur Behandlung der schubf\u00f6rmigen MS mit einem bislang guten Sicherheitsprofil bei halbj\u00e4hrlicher Anwendung", "SPECIES", 53, 242], ["Dieser humanisierte anti-CD20monoklonale Antik\u00f6rper", "TREATMENT", 0, 51], ["zweimal j\u00e4hrlich intraven\u00f6s verabreicht", "TREATMENT", 53, 92], ["mit einem bislang", "TREATMENT", 172, 189]]], ["Wichtig, wie bei jeder immunmodulierenden Substanz, sind eine rigorose Pharmakovigilanz, die Analyse von Registerdaten und die Ergebnisse von Phase-4-Studien (Beispiel die in Deutschland aktuell rekrutierende CONFIDENCE-Studie [64] Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt.", [["wie bei jeder immunmodulierenden Substanz, sind eine rigorose Pharmakovigilanz, die Analyse von Registerdaten und die Ergebnisse von Phase-4-Studien (Beispiel die in Deutschland aktuell rekrutierende CONFIDENCE-Studie [64] Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt", "SPECIES", 9, 421], ["Die", "PROBLEM", 232, 235], ["Artikel enthaltenen", "TREATMENT", 246, 265]]], ["Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist f\u00fcr die oben aufgef\u00fchrten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen.SchlussfolgerungWeitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/ licenses/by/4.0/deed.de.", [["by/4.0", "DNA", 414, 420], ["Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist f\u00fcr die oben aufgef\u00fchrten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen", "SPECIES", 0, 287]]]]}